{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 17 December 2008\nTarget: DATA PRIMEI AUTORIZĂRI SAU A REÎNNOIRII AUTORIZAȚIEI", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 17 December 2008\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 17 December 2008", "ro": "DATA PRIMEI AUTORIZĂRI SAU A REÎNNOIRII AUTORIZAȚIEI" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Overall response rate (complete remission [CR] + complete remission with incomplete blood count recovery [CRi]) as determined by the IRC was 27.8% in the Vidaza group and 25.1% in the combined CCR group (p = 0.5384).\nTarget: Răspunsul global (remisiune completă [CR] + remisiune completă cu recuperare incompletă a trombocitelor [CRi]) determinat de către CIE a fost de 27,8 % în grupul de tratament cu Vidaza și de 25,1 % în grupul de tratament cu RAC asociate (p = 0,5384).", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Overall response rate (complete remission [CR] + complete remission with incomplete blood count recovery [CRi]) as determined by the IRC was 27.8% in the Vidaza group and 25.1% in the combined CCR group (p = 0.5384).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Overall response rate (complete remission [CR] + complete remission with incomplete blood count recovery [CRi]) as determined by the IRC was 27.8% in the Vidaza group and 25.1% in the combined CCR group (p = 0.5384).", "ro": "Răspunsul global (remisiune completă [CR] + remisiune completă cu recuperare incompletă a trombocitelor [CRi]) determinat de către CIE a fost de 27,8 % în grupul de tratament cu Vidaza și de 25,1 % în grupul de tratament cu RAC asociate (p = 0,5384)." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Recovery* > 21 days *Recovery = counts ≥ nadir count + (0.5 x [baseline count - nadir count]) Following dose modifications, the cycle duration should return to 28 days.\nTarget: *Restabilire = număr ≥ numărul minim + (0,5 x [numărul inițial - numărul minim]) După modificările dozelor, durata ciclului trebuie să revină la 28 zile.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Recovery* > 21 days *Recovery = counts ≥ nadir count + (0.5 x [baseline count - nadir count]) Following dose modifications, the cycle duration should return to 28 days.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Recovery* > 21 days *Recovery = counts ≥ nadir count + (0.5 x [baseline count - nadir count]) Following dose modifications, the cycle duration should return to 28 days.", "ro": "*Restabilire = număr ≥ numărul minim + (0,5 x [numărul inițial - numărul minim]) După modificările dozelor, durata ciclului trebuie să revină la 28 zile." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: The most commonly reported (≥ 10%) haematological adverse reactions associated with azacitidine treatment include anaemia, thrombocytopenia, neutropenia, febrile neutropenia and leukopenia, and were usually Grade 3 or 4.\nTarget: Reacțiile adverse hematologice asociate cu tratamentul cu azacitidină raportate cel mai frecvent (≥10 %) includ anemie, trombocitopenie, neutropenie, neutropenie febrilă și leucopenie, de regulă de grad 3 sau 4.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: The most commonly reported (≥ 10%) haematological adverse reactions associated with azacitidine treatment include anaemia, thrombocytopenia, neutropenia, febrile neutropenia and leukopenia, and were usually Grade 3 or 4.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "The most commonly reported (≥ 10%) haematological adverse reactions associated with azacitidine treatment include anaemia, thrombocytopenia, neutropenia, febrile neutropenia and leukopenia, and were usually Grade 3 or 4.", "ro": "Reacțiile adverse hematologice asociate cu tratamentul cu azacitidină raportate cel mai frecvent (≥10 %) includ anemie, trombocitopenie, neutropenie, neutropenie febrilă și leucopenie, de regulă de grad 3 sau 4." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: • acute myeloid leukaemia (AML) with 20-30 % blasts and multi-lineage dysplasia, according to\nTarget: • leucemie acută mieloidă (LAM) cu 20-30 % blaști și linii multiple de diferențiere a displaziei,", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: • acute myeloid leukaemia (AML) with 20-30 % blasts and multi-lineage dysplasia, according to\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "• acute myeloid leukaemia (AML) with 20-30 % blasts and multi-lineage dysplasia, according to", "ro": "• leucemie acută mieloidă (LAM) cu 20-30 % blaști și linii multiple de diferențiere a displaziei," } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: OTHER SPECIAL WARNING(S), IF NECESSARY Cytotoxic EXPIRY DATE\nTarget: ALTĂ(E) ATENȚIONARE(ĂRI) SPECIALĂ(E), DACĂ ESTE(SUNT) NECESARĂ(E)", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: OTHER SPECIAL WARNING(S), IF NECESSARY Cytotoxic EXPIRY DATE\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "OTHER SPECIAL WARNING(S), IF NECESSARY Cytotoxic EXPIRY DATE", "ro": "ALTĂ(E) ATENȚIONARE(ĂRI) SPECIALĂ(E), DACĂ ESTE(SUNT) NECESARĂ(E)" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: • intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International\nTarget: • sindroame mielodisplazice (SMD) cu risc intermediar-2 și mare, conform Sistemului", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: • intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "• intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International", "ro": "• sindroame mielodisplazice (SMD) cu risc intermediar-2 și mare, conform Sistemului" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Such as blood in the stools due to bleeding in the stomach or gut, or such as bleeding inside your head.\nTarget: • Sângerare - cum sunt prezența sânge în scaun, din cauza unei sângerări de la nivelul stomacului sau intestinului sau hemoragia în interiorul craniului.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Such as blood in the stools due to bleeding in the stomach or gut, or such as bleeding inside your head.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Such as blood in the stools due to bleeding in the stomach or gut, or such as bleeding inside your head.", "ro": "• Sângerare - cum sunt prezența sânge în scaun, din cauza unei sângerări de la nivelul stomacului sau intestinului sau hemoragia în interiorul craniului." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Vidaza therapy should be discontinued in patients who develop necrotising fasciitis and appropriate treatment should be promptly initiated.\nTarget: La pacienții care dezvoltă fasceită necrozantă, tratamentul cu Vidaza trebuie întrerupt și trebuie inițiat în cel mai scurt timp tratamentul adecvat.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Vidaza therapy should be discontinued in patients who develop necrotising fasciitis and appropriate treatment should be promptly initiated.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Vidaza therapy should be discontinued in patients who develop necrotising fasciitis and appropriate treatment should be promptly initiated.", "ro": "La pacienții care dezvoltă fasceită necrozantă, tratamentul cu Vidaza trebuie întrerupt și trebuie inițiat în cel mai scurt timp tratamentul adecvat." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Azacitidine undergoes spontaneous hydrolysis and deamination mediated by cytidine deaminase.\nTarget: Azacitidina este supusă hidrolizei spontane și dezaminării mediate de citidin-dezaminază.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Azacitidine undergoes spontaneous hydrolysis and deamination mediated by cytidine deaminase.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Azacitidine undergoes spontaneous hydrolysis and deamination mediated by cytidine deaminase.", "ro": "Azacitidina este supusă hidrolizei spontane și dezaminării mediate de citidin-dezaminază." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Use an effective method of contraception during and up to 3 months after treatment.\nTarget: Utilizați o metodă contraceptivă eficace pe perioada tratamentului și până la 3 luni după oprirea tratamentului.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Use an effective method of contraception during and up to 3 months after treatment.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Use an effective method of contraception during and up to 3 months after treatment.", "ro": "Utilizați o metodă contraceptivă eficace pe perioada tratamentului și până la 3 luni după oprirea tratamentului." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: • Chest pain, being short of breath.\nTarget: • Durere în piept, dificultăți în respirație.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: • Chest pain, being short of breath.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "• Chest pain, being short of breath.", "ro": "• Durere în piept, dificultăți în respirație." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: • acute myeloid leukaemia (AML).\nTarget: • leucemia acută mieloidă (LAM).", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: • acute myeloid leukaemia (AML).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "• acute myeloid leukaemia (AML).", "ro": "• leucemia acută mieloidă (LAM)." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Following removal of the syringe and needle, the vial should be vigorously shaken until a uniform cloudy suspension is achieved.\nTarget: După scoaterea seringii și a acului, se agită energic flaconul până la obținerea unei suspensii uniforme, opalescente.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Following removal of the syringe and needle, the vial should be vigorously shaken until a uniform cloudy suspension is achieved.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Following removal of the syringe and needle, the vial should be vigorously shaken until a uniform cloudy suspension is achieved.", "ro": "După scoaterea seringii și a acului, se agită energic flaconul până la obținerea unei suspensii uniforme, opalescente." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: These may be symptoms of having low levels of platelets in your blood.\nTarget: Acestea pot fi simptome ale numărului scăzut de trombocite din sânge.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: These may be symptoms of having low levels of platelets in your blood.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "These may be symptoms of having low levels of platelets in your blood.", "ro": "Acestea pot fi simptome ale numărului scăzut de trombocite din sânge." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Musculoskeletal and connective tissue disorders arthralgia, musculoskeletal pain (includes back, bone and pain in extremity)\nTarget: Tulburări musculoscheletice și ale țesutului conjunctiv artralgie, durere musculoscheletică (inclusiv durere la nivelul spatelui, oaselor și extremităților)", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Musculoskeletal and connective tissue disorders arthralgia, musculoskeletal pain (includes back, bone and pain in extremity)\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Musculoskeletal and connective tissue disorders arthralgia, musculoskeletal pain (includes back, bone and pain in extremity)", "ro": "Tulburări musculoscheletice și ale țesutului conjunctiv artralgie, durere musculoscheletică (inclusiv durere la nivelul spatelui, oaselor și extremităților)" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: These include swelling, a hard lump, bruising,\nTarget: Acestea includ umflături, un nodul de consistență tare,", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: These include swelling, a hard lump, bruising,\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "These include swelling, a hard lump, bruising,", "ro": "Acestea includ umflături, un nodul de consistență tare," } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: • Tiredness (fatigue).\nTarget: • Oboseală (fatigabilitate).", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: • Tiredness (fatigue).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "• Tiredness (fatigue).", "ro": "• Oboseală (fatigabilitate)." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: This may be due to low levels of white cells in your blood.\nTarget: Aceasta se poate datora numărului scăzut de globule albe din sânge.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: This may be due to low levels of white cells in your blood.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "This may be due to low levels of white cells in your blood.", "ro": "Aceasta se poate datora numărului scăzut de globule albe din sânge." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: bleeding into your skin (haematoma), rash, itching and changes in the skin colour.\nTarget: vânătaie (echimoză), sângerare în piele (hematom), erupții trecătoare pe piele, mâncărime și modificări ale culorii pielii.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: bleeding into your skin (haematoma), rash, itching and changes in the skin colour.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "bleeding into your skin (haematoma), rash, itching and changes in the skin colour.", "ro": "vânătaie (echimoză), sângerare în piele (hematom), erupții trecătoare pe piele, mâncărime și modificări ale culorii pielii." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: • Fluid around the lungs (pleural effusion).\nTarget: • Lichid în jurul plămânilor (efuziune pleurală).", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: • Fluid around the lungs (pleural effusion).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "• Fluid around the lungs (pleural effusion).", "ro": "• Lichid în jurul plămânilor (efuziune pleurală)." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: • Loss of appetite.\nTarget: • Pierderea poftei de mâncare.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: • Loss of appetite.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "• Loss of appetite.", "ro": "• Pierderea poftei de mâncare." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Special populations Elderly patients\nTarget: Grupe speciale de pacienți", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Special populations Elderly patients\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Special populations Elderly patients", "ro": "Grupe speciale de pacienți" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: A fresh subcutaneous needle (recommended 25-gauge) should then be firmly attached to the syringe.\nTarget: Se ia un ac nou pentru injectare subcutanată (se recomandă un ac de calibrul 25) și se atașază ferm la seringă.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: A fresh subcutaneous needle (recommended 25-gauge) should then be firmly attached to the syringe.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "A fresh subcutaneous needle (recommended 25-gauge) should then be firmly attached to the syringe.", "ro": "Se ia un ac nou pentru injectare subcutanată (se recomandă un ac de calibrul 25) și se atașază ferm la seringă." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: • Headache.\nTarget: • Durere de cap.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: • Headache.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "• Headache.", "ro": "• Durere de cap." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: (% of recommended starting dose)\nTarget: Doza mg/m (% din doza inițială recomandată)", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: (% of recommended starting dose)\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "(% of recommended starting dose)", "ro": "Doza mg/m (% din doza inițială recomandată)" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Vidaza is contraindicated in patients with advanced malignant hepatic tumours (see sections 4.3 and 4.4).\nTarget: Vidaza este contraindicat la pacienții cu tumori hepatice maligne avansate (vezi pct. 4.3 și 4.4).", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Vidaza is contraindicated in patients with advanced malignant hepatic tumours (see sections 4.3 and 4.4).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Vidaza is contraindicated in patients with advanced malignant hepatic tumours (see sections 4.3 and 4.4).", "ro": "Vidaza este contraindicat la pacienții cu tumori hepatice maligne avansate (vezi pct. 4.3 și 4.4)." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: What Vidaza is used for\nTarget: Pentru ce se utilizează Vidaza", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: What Vidaza is used for\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "What Vidaza is used for", "ro": "Pentru ce se utilizează Vidaza" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Vascular disorders hypotension*, hypertension, orthostatic hypotension, haematoma\nTarget: Tulburări vasculare hipotensiune arterială*, hipertensiune arterială, hipotensiune arterială ortostatică, hematom", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Vascular disorders hypotension*, hypertension, orthostatic hypotension, haematoma\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Vascular disorders hypotension*, hypertension, orthostatic hypotension, haematoma", "ro": "Tulburări vasculare hipotensiune arterială*, hipertensiune arterială, hipotensiune arterială ortostatică, hematom" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: For later use\nTarget: Pentru utilizare ulterioară", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: For later use\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "For later use", "ro": "Pentru utilizare ulterioară" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: • Muscle spasms.\nTarget: • Spasme musculare.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: • Muscle spasms.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "• Muscle spasms.", "ro": "• Spasme musculare." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: The results presented below represent the intent-to-treat population studied in AZA-AML-001 (see section 4.1 for the approved indication).\nTarget: Populație adultă cu vârsta de 65 de ani sau peste cu LAM cu > 30 % blaști medulari Rezultatele prezentate mai jos se referă la populația în intenție de tratament inclusă în cadrul studiului AZA-AML-001 (vezi pct. 4.1 pentru indicația aprobată).", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: The results presented below represent the intent-to-treat population studied in AZA-AML-001 (see section 4.1 for the approved indication).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "The results presented below represent the intent-to-treat population studied in AZA-AML-001 (see section 4.1 for the approved indication).", "ro": "Populație adultă cu vârsta de 65 de ani sau peste cu LAM cu > 30 % blaști medulari Rezultatele prezentate mai jos se referă la populația în intenție de tratament inclusă în cadrul studiului AZA-AML-001 (vezi pct. 4.1 pentru indicația aprobată)." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: • Sore nose and throat.\nTarget: • Inflamația nasului și gâtului.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: • Sore nose and throat.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "• Sore nose and throat.", "ro": "• Inflamația nasului și gâtului." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: When Vidaza is reconstituted using refrigerated (2 °C to 8 °C) water for injections, the chemical and physical in-use stability of the reconstituted medicinal product has been demonstrated at 2 °C to 8 °C for 22 hours.\nTarget: Când Vidaza este reconstituit cu apă pentru preparate injectabile de la frigider (2 °C până la 8 °C), stabilitatea chimică și fizică în timpul utilizării a medicamentului reconstituit a fost demonstrată la 2 °C până la 8 °C timp de 22 ore.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: When Vidaza is reconstituted using refrigerated (2 °C to 8 °C) water for injections, the chemical and physical in-use stability of the reconstituted medicinal product has been demonstrated at 2 °C to 8 °C for 22 hours.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "When Vidaza is reconstituted using refrigerated (2 °C to 8 °C) water for injections, the chemical and physical in-use stability of the reconstituted medicinal product has been demonstrated at 2 °C to 8 °C for 22 hours.", "ro": "Când Vidaza este reconstituit cu apă pentru preparate injectabile de la frigider (2 °C până la 8 °C), stabilitatea chimică și fizică în timpul utilizării a medicamentului reconstituit a fost demonstrată la 2 °C până la 8 °C timp de 22 ore." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: The most commonly reported adverse reactions with azacitidine treatment were haematological reactions (71.4 %) including thrombocytopenia, neutropenia and leukopenia (usually Grade 3-4), gastrointestinal events (60.6 %) including nausea, vomiting (usually Grade 1-2) or injection site reactions (77.1 %; usually Grade 1-2).\nTarget: Reacțiile adverse raportate cel mai frecvent în cadrul tratamentului cu azacitidină au fost reacții adverse hematologice (71,4 %), inclusiv trombocitopenie, neutropenie și leucopenie (de regulă, de grad 3-4), evenimente adverse gastrointestinale (60,6 %), inclusiv greață, vărsături (de regulă, de grad 1-2) sau reacții la locul injectării 77,1 %; de regulă de grad 1-2).", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: The most commonly reported adverse reactions with azacitidine treatment were haematological reactions (71.4 %) including thrombocytopenia, neutropenia and leukopenia (usually Grade 3-4), gastrointestinal events (60.6 %) including nausea, vomiting (usually Grade 1-2) or injection site reactions (77.1 %; usually Grade 1-2).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "The most commonly reported adverse reactions with azacitidine treatment were haematological reactions (71.4 %) including thrombocytopenia, neutropenia and leukopenia (usually Grade 3-4), gastrointestinal events (60.6 %) including nausea, vomiting (usually Grade 1-2) or injection site reactions (77.1 %; usually Grade 1-2).", "ro": "Reacțiile adverse raportate cel mai frecvent în cadrul tratamentului cu azacitidină au fost reacții adverse hematologice (71,4 %), inclusiv trombocitopenie, neutropenie și leucopenie (de regulă, de grad 3-4), evenimente adverse gastrointestinale (60,6 %), inclusiv greață, vărsături (de regulă, de grad 1-2) sau reacții la locul injectării 77,1 %; de regulă de grad 1-2)." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Of the patients in the azacitidine group who were RBC transfusion dependent at baseline, 45.0 % of these patients became RBC transfusion independent during the treatment period, compared with 11.4 % of the patients in the combined CCR groups (a statistically significant (p < 0.0001) difference of 33.6 % (95 % CI: 22.4, 44.6).\nTarget: 45,0 % dintre pacienții inițial dependenți de transfuzia cu eritrocite din grupul cu azacitidină au devenit independenți față de transfuzia cu eritrocite în timpul tratamentului, în comparație cu 11,4 % dintre pacienți în grupele RAC asociate (o diferență semnificativă statistic (p < 0,0001) de 33,6 % (IÎ 95 %: 22,4; 44,6).", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Of the patients in the azacitidine group who were RBC transfusion dependent at baseline, 45.0 % of these patients became RBC transfusion independent during the treatment period, compared with 11.4 % of the patients in the combined CCR groups (a statistically significant (p < 0.0001) difference of 33.6 % (95 % CI: 22.4, 44.6).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Of the patients in the azacitidine group who were RBC transfusion dependent at baseline, 45.0 % of these patients became RBC transfusion independent during the treatment period, compared with 11.4 % of the patients in the combined CCR groups (a statistically significant (p < 0.0001) difference of 33.6 % (95 % CI: 22.4, 44.6).", "ro": "45,0 % dintre pacienții inițial dependenți de transfuzia cu eritrocite din grupul cu azacitidină au devenit independenți față de transfuzia cu eritrocite în timpul tratamentului, în comparație cu 11,4 % dintre pacienți în grupele RAC asociate (o diferență semnificativă statistic (p < 0,0001) de 33,6 % (IÎ 95 %: 22,4; 44,6)." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Other medicines and Vidaza\nTarget: Vidaza împreună cu alte medicamente", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Other medicines and Vidaza\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Other medicines and Vidaza", "ro": "Vidaza împreună cu alte medicamente" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: CCR consisted of BSC alone (n=45), lowdose cytarabine plus BSC (n=158), or standard intensive chemotherapy with cytarabine and anthracycline plus BSC (n=44).\nTarget: RAC au cuprins CMBTS în monoterapie (n=45), citarabină în doză mică în asociere cu CMBTS (n=158) sau chimioterapie intensivă standard cu citarabină și antraciclină în asociere cu CMBTS (n=44).", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: CCR consisted of BSC alone (n=45), lowdose cytarabine plus BSC (n=158), or standard intensive chemotherapy with cytarabine and anthracycline plus BSC (n=44).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "CCR consisted of BSC alone (n=45), lowdose cytarabine plus BSC (n=158), or standard intensive chemotherapy with cytarabine and anthracycline plus BSC (n=44).", "ro": "RAC au cuprins CMBTS în monoterapie (n=45), citarabină în doză mică în asociere cu CMBTS (n=158) sau chimioterapie intensivă standard cu citarabină și antraciclină în asociere cu CMBTS (n=44)." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: In addition, renal tubular acidosis, defined as a fall in serum bicarbonate to < 20 mmol/L in association with an alkaline urine and hypokalaemia (serum potassium < 3 mmol/L) developed in 5 subjects with chronic myelogenous leukaemia (CML) treated with azacitidine and etoposide.\nTarget: În plus, 5 pacienți cu leucemie mieloidă cronică (LMC) cărora li s-au administrat azacitidină și etopozidă au prezentat acidoză tubulară renală, definită prin scăderea valorilor bicarbonatului seric < 20 mmol/l în asociere cu alcalinizarea urinii și hipokaliemie (potasiu seric < 3 mmol/l).", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: In addition, renal tubular acidosis, defined as a fall in serum bicarbonate to < 20 mmol/L in association with an alkaline urine and hypokalaemia (serum potassium < 3 mmol/L) developed in 5 subjects with chronic myelogenous leukaemia (CML) treated with azacitidine and etoposide.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "In addition, renal tubular acidosis, defined as a fall in serum bicarbonate to < 20 mmol/L in association with an alkaline urine and hypokalaemia (serum potassium < 3 mmol/L) developed in 5 subjects with chronic myelogenous leukaemia (CML) treated with azacitidine and etoposide.", "ro": "În plus, 5 pacienți cu leucemie mieloidă cronică (LMC) cărora li s-au administrat azacitidină și etopozidă au prezentat acidoză tubulară renală, definită prin scăderea valorilor bicarbonatului seric < 20 mmol/l în asociere cu alcalinizarea urinii și hipokaliemie (potasiu seric < 3 mmol/l)." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Grounds for the variation to the terms of the marketing authorisation(s)\nTarget: Motive pentru modificarea condițiilor autorizației/autorizațiilor de punere pe piață", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Grounds for the variation to the terms of the marketing authorisation(s)\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Grounds for the variation to the terms of the marketing authorisation(s)", "ro": "Motive pentru modificarea condițiilor autorizației/autorizațiilor de punere pe piață" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Vidaza plus BSC (n=241) was compared to CCR.\nTarget: Administrarea de Vidaza în asociere cu cel mai bun tratament de susținere (CMBTS) (n=241) a fost comparată cu regimurile de asistență convențională (RAC).", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Vidaza plus BSC (n=241) was compared to CCR.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Vidaza plus BSC (n=241) was compared to CCR.", "ro": "Administrarea de Vidaza în asociere cu cel mai bun tratament de susținere (CMBTS) (n=241) a fost comparată cu regimurile de asistență convențională (RAC)." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: • An infection in your urine.\nTarget: • Infecție urinară.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: • An infection in your urine.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "• An infection in your urine.", "ro": "• Infecție urinară." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: UNIQUE IDENTIFIER - 2D BARCODE 2 D bar code carrying the unique identifier 18.\nTarget: IDENTIFICATOR UNIC - COD DE BARE BIDIMENSIONAL", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: UNIQUE IDENTIFIER - 2D BARCODE 2 D bar code carrying the unique identifier 18.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "UNIQUE IDENTIFIER - 2D BARCODE 2 D bar code carrying the unique identifier 18.", "ro": "IDENTIFICATOR UNIC - COD DE BARE BIDIMENSIONAL" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Bleeding may occur with patients receiving azacitidine.\nTarget: La pacienții cărora li se administrează azacitidină pot apărea hemoragii.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Bleeding may occur with patients receiving azacitidine.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Bleeding may occur with patients receiving azacitidine.", "ro": "La pacienții cărora li se administrează azacitidină pot apărea hemoragii." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: The syringe filled with reconstituted suspension should be allowed up to 30 minutes prior to administration to reach a temperature of approximately 20 °C-25 °C.\nTarget: Înaintea administrării, seringa umplută cu soluția reconstituită trebuie lăsată la temperatura camerei cel mult 30 minute, pentru a atinge o temperatură de aproximativ 20 °C-25 °C.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: The syringe filled with reconstituted suspension should be allowed up to 30 minutes prior to administration to reach a temperature of approximately 20 °C-25 °C.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "The syringe filled with reconstituted suspension should be allowed up to 30 minutes prior to administration to reach a temperature of approximately 20 °C-25 °C.", "ro": "Înaintea administrării, seringa umplută cu soluția reconstituită trebuie lăsată la temperatura camerei cel mult 30 minute, pentru a atinge o temperatură de aproximativ 20 °C-25 °C." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Complete blood counts should be performed prior to initiation of therapy and as needed to monitor response and toxicity, but at a minimum, prior to each treatment cycle.\nTarget: Hemoleucograma completă trebuie efectuată înaintea inițierii tratamentului și de câte ori este necesar pentru monitorizarea răspunsului și toxicității, dar cel puțin înaintea fiecărui ciclu terapeutic.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Complete blood counts should be performed prior to initiation of therapy and as needed to monitor response and toxicity, but at a minimum, prior to each treatment cycle.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Complete blood counts should be performed prior to initiation of therapy and as needed to monitor response and toxicity, but at a minimum, prior to each treatment cycle.", "ro": "Hemoleucograma completă trebuie efectuată înaintea inițierii tratamentului și de câte ori este necesar pentru monitorizarea răspunsului și toxicității, dar cel puțin înaintea fiecărui ciclu terapeutic." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Azacitidine is contraindicated in patients with advanced malignant hepatic tumours (see section 4.3).\nTarget: Azacitidina este contraindicată la pacienții cu tumori hepatice maligne avansate (vezi pct. 4.3).", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Azacitidine is contraindicated in patients with advanced malignant hepatic tumours (see section 4.3).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Azacitidine is contraindicated in patients with advanced malignant hepatic tumours (see section 4.3).", "ro": "Azacitidina este contraindicată la pacienții cu tumori hepatice maligne avansate (vezi pct. 4.3)." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Blood and lymphatic system disorders febrile neutropenia*, neutropenia, leukopenia, thrombocytopenia, anaemia pancytopenia*, bone marrow failure\nTarget: Tulburări hematologice și limfatice neutropenie febrilă*, neutropenie, leucopenie, trombocitopenie, anemie pancitopenie*, insuficiență medulară", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Blood and lymphatic system disorders febrile neutropenia*, neutropenia, leukopenia, thrombocytopenia, anaemia pancytopenia*, bone marrow failure\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Blood and lymphatic system disorders febrile neutropenia*, neutropenia, leukopenia, thrombocytopenia, anaemia pancytopenia*, bone marrow failure", "ro": "Tulburări hematologice și limfatice neutropenie febrilă*, neutropenie, leucopenie, trombocitopenie, anemie pancitopenie*, insuficiență medulară" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Uncommon Rare\nTarget: Cu frecvență necunoscută", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Uncommon Rare\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Uncommon Rare", "ro": "Cu frecvență necunoscută" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: You are more prone to bleeding and bruising.\nTarget: Sunteți predispus la sângerări și vânătăi (echimoze).", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: You are more prone to bleeding and bruising.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "You are more prone to bleeding and bruising.", "ro": "Sunteți predispus la sângerări și vânătăi (echimoze)." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: In patients who were RBC transfusion dependent at baseline and became independent, the median duration of RBC transfusion independence was 13 months in the azacitidine group.\nTarget: La pacienții care la momentul inițial erau dependenți de transfuzia cu eritrocite și au devenit independenți, durata mediană a independenței față de transfuzia cu eritrocite a fost de 13 luni în grupul cu azacitidină.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: In patients who were RBC transfusion dependent at baseline and became independent, the median duration of RBC transfusion independence was 13 months in the azacitidine group.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "In patients who were RBC transfusion dependent at baseline and became independent, the median duration of RBC transfusion independence was 13 months in the azacitidine group.", "ro": "La pacienții care la momentul inițial erau dependenți de transfuzia cu eritrocite și au devenit independenți, durata mediană a independenței față de transfuzia cu eritrocite a fost de 13 luni în grupul cu azacitidină." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Renal and urinary disorders renal failure*, haematuria, elevated serum creatinine renal tubular acidosis\nTarget: Tulburări renale și ale căilor urinare insuficiență renală*, hematurie, valori crescute ale creatininemiei acidoză tubulară renală", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Renal and urinary disorders renal failure*, haematuria, elevated serum creatinine renal tubular acidosis\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Renal and urinary disorders renal failure*, haematuria, elevated serum creatinine renal tubular acidosis", "ro": "Tulburări renale și ale căilor urinare insuficiență renală*, hematurie, valori crescute ale creatininemiei acidoză tubulară renală" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: ANC (x 109/l)\nTarget: NAN (x 10", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: ANC (x 109/l)\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "ANC (x 109/l)", "ro": "NAN (x 10" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: • Dry cough.\nTarget: • Tuse seacă.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: • Dry cough.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "• Dry cough.", "ro": "• Tuse seacă." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Rare side effects (may affect up to 1 in 1,000 people)\nTarget: Reacții adverse rare (pot afecta cel mult 1 din 1.000 persoane)", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Rare side effects (may affect up to 1 in 1,000 people)\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Rare side effects (may affect up to 1 in 1,000 people)", "ro": "Reacții adverse rare (pot afecta cel mult 1 din 1.000 persoane)" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: • Being short of breath when you move.\nTarget: • Probleme de respirație la deplasare.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: • Being short of breath when you move.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "• Being short of breath when you move.", "ro": "• Probleme de respirație la deplasare." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Very common side effects (may affect more than 1 in 10 people)\nTarget: Reacții adverse foarte frecvente (pot afecta mai mult de 1 din 10 persoane)", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Very common side effects (may affect more than 1 in 10 people)\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Very common side effects (may affect more than 1 in 10 people)", "ro": "Reacții adverse foarte frecvente (pot afecta mai mult de 1 din 10 persoane)" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: One case of overdose with azacitidine was reported during clinical trials.\nTarget: În timpul studiilor clinice s-a raportat un caz de supradozaj cu azacitidină.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: One case of overdose with azacitidine was reported during clinical trials.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "One case of overdose with azacitidine was reported during clinical trials.", "ro": "În timpul studiilor clinice s-a raportat un caz de supradozaj cu azacitidină." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: • Drowsiness, shaking, jaundice, abdominal bloating and easy bruising.\nTarget: • Somnolență, tremurături, icter, balonare și învinețire cu ușurință.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: • Drowsiness, shaking, jaundice, abdominal bloating and easy bruising.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "• Drowsiness, shaking, jaundice, abdominal bloating and easy bruising.", "ro": "• Somnolență, tremurături, icter, balonare și învinețire cu ușurință." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Azacitidine induces both gene mutations and chromosomal aberrations in bacterial and mammalian cell systems in vitro.\nTarget: În sistemele celulare bacteriene și de mamifere, in vitro, azacitidina induce atât mutații genetice cât și aberații cromozomiale.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Azacitidine induces both gene mutations and chromosomal aberrations in bacterial and mammalian cell systems in vitro.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Azacitidine induces both gene mutations and chromosomal aberrations in bacterial and mammalian cell systems in vitro.", "ro": "În sistemele celulare bacteriene și de mamifere, in vitro, azacitidina induce atât mutații genetice cât și aberații cromozomiale." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: • Reduced white blood cell count.\nTarget: • Număr scăzut de globule albe sanguine.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: • Reduced white blood cell count.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "• Reduced white blood cell count.", "ro": "• Număr scăzut de globule albe sanguine." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Bleeding\nTarget: Hemoragii", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Bleeding\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Bleeding", "ro": "Hemoragii" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: These may be symptoms of kidney failure and can be life-threatening.\nTarget: Acestea pot fi simptome ale insuficienței renale și pot pune viața în pericol.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: These may be symptoms of kidney failure and can be life-threatening.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "These may be symptoms of kidney failure and can be life-threatening.", "ro": "Acestea pot fi simptome ale insuficienței renale și pot pune viața în pericol." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: • White coating covering tongue, inner cheeks, and sometimes on the roof of your mouth, gums and tonsils (oral fungal infection).\nTarget: • Depozite albicioase pe limbă, interiorul obrajilor și uneori cerul gurii, gingii și amigdale", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: • White coating covering tongue, inner cheeks, and sometimes on the roof of your mouth, gums and tonsils (oral fungal infection).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "• White coating covering tongue, inner cheeks, and sometimes on the roof of your mouth, gums and tonsils (oral fungal infection).", "ro": "• Depozite albicioase pe limbă, interiorul obrajilor și uneori cerul gurii, gingii și amigdale" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: - If you have any further questions, ask your doctor, pharmacist or nurse.\nTarget: - Dacă aveți orice întrebări suplimentare, adresați-vă medicului dumneavoastră, farmacistului sau asistentei medicale.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: - If you have any further questions, ask your doctor, pharmacist or nurse.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "- If you have any further questions, ask your doctor, pharmacist or nurse.", "ro": "- Dacă aveți orice întrebări suplimentare, adresați-vă medicului dumneavoastră, farmacistului sau asistentei medicale." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: APPROPRIATE\nTarget: Azacitidină", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: APPROPRIATE\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "APPROPRIATE", "ro": "Azacitidină" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Liver function tests, serum creatinine and serum bicarbonate should be determined prior to initiation of therapy and prior to each treatment cycle.\nTarget: Înaintea inițierii tratamentului și înaintea fiecărui ciclu terapeutic trebuie investigată funcția hepatică, creatinina serică și bicarbonatul seric.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Liver function tests, serum creatinine and serum bicarbonate should be determined prior to initiation of therapy and prior to each treatment cycle.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Liver function tests, serum creatinine and serum bicarbonate should be determined prior to initiation of therapy and prior to each treatment cycle.", "ro": "Înaintea inițierii tratamentului și înaintea fiecărui ciclu terapeutic trebuie investigată funcția hepatică, creatinina serică și bicarbonatul seric." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Log-Rank p = 0.0001 HR = 0.58 [95% CI: 0.43-0.77]\nTarget: RR 0,58 [IÎ 95 %: 0,43-0,77] Decese:", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Log-Rank p = 0.0001 HR = 0.58 [95% CI: 0.43-0.77]\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Log-Rank p = 0.0001 HR = 0.58 [95% CI: 0.43-0.77]", "ro": "RR 0,58 [IÎ 95 %: 0,43-0,77] Decese:" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: These may be symptoms of liver failure and can be life-threatening.\nTarget: Acestea pot fi simptome ale insuficienței hepatice și pot pune viața în pericol.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: These may be symptoms of liver failure and can be life-threatening.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "These may be symptoms of liver failure and can be life-threatening.", "ro": "Acestea pot fi simptome ale insuficienței hepatice și pot pune viața în pericol." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: ANNEX III LABELLING AND PACKAGE LEAFLET\nTarget: ETICHETAREA ȘI PROSPECTUL", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: ANNEX III LABELLING AND PACKAGE LEAFLET\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "ANNEX III LABELLING AND PACKAGE LEAFLET", "ro": "ETICHETAREA ȘI PROSPECTUL" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Developmental abnormalities in the brain have been detected in mice given azacitidine on or before closure of the hard palate.\nTarget: La șoarecii cărora li s-a administrat azacitidină în momentul sau înaintea închiderii palatului dur, s-au înregistrat anomalii de dezvoltare ale sistemului nervos central (SNC).", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Developmental abnormalities in the brain have been detected in mice given azacitidine on or before closure of the hard palate.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Developmental abnormalities in the brain have been detected in mice given azacitidine on or before closure of the hard palate.", "ro": "La șoarecii cărora li s-a administrat azacitidină în momentul sau înaintea închiderii palatului dur, s-au înregistrat anomalii de dezvoltare ale sistemului nervos central (SNC)." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Not known (frequency cannot be estimated from the available data) Infection of the deeper layers of skin, which spreads quickly, damaging the skin and tissue, which can be life-threatening (necrotizing fasciitis).\nTarget: • Infecție a straturilor profunde ale pielii, care se răspândește rapid, afectând pielea și țesuturile și care poate pune viața în pericol (fasceită necrozantă).", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Not known (frequency cannot be estimated from the available data) Infection of the deeper layers of skin, which spreads quickly, damaging the skin and tissue, which can be life-threatening (necrotizing fasciitis).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Not known (frequency cannot be estimated from the available data) Infection of the deeper layers of skin, which spreads quickly, damaging the skin and tissue, which can be life-threatening (necrotizing fasciitis).", "ro": "• Infecție a straturilor profunde ale pielii, care se răspândește rapid, afectând pielea și țesuturile și care poate pune viața în pericol (fasceită necrozantă)." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: • Difficulty breathing, swelling of the lips, itching or rash.\nTarget: • Dificultate în a respira, umflarea buzelor, mâncărime (prurit) sau erupții trecătoare pe piele.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: • Difficulty breathing, swelling of the lips, itching or rash.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "• Difficulty breathing, swelling of the lips, itching or rash.", "ro": "• Dificultate în a respira, umflarea buzelor, mâncărime (prurit) sau erupții trecătoare pe piele." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON\nTarget: INFORMAȚII CARE TREBUIE SĂ APARĂ PE AMBALAJUL SECUNDAR", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON", "ro": "INFORMAȚII CARE TREBUIE SĂ APARĂ PE AMBALAJUL SECUNDAR" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: The efficacy and safety of Vidaza were studied in an international, multicenter, controlled, open-label, randomised, parallel-group, Phase 3 comparative study (AZA PH GL 2003 CL 001) in adult patients with: intermediate-2 and high-risk MDS according to the International Prognostic Scoring System (IPSS), refractory anaemia with excess blasts (RAEB), refractory anaemia with excess blasts in transformation (RAEB-T) and modified chronic myelomonocytic leukaemia (mCMML) according to the French American British (FAB) classification system.\nTarget: SMD cu risc intermediar-2 și mare, conform Sistemului Internațional de Punctaj referitor la Prognostic (SIPP), anemie refractară cu exces de blaști (AREB), anemie refractară cu exces de blaști în transformare (AREB-T) și leucemie mielomonocitară cronică modificată (LMMCm), conform sistemului de clasificare Francez, American, Britanic (FAB).", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: The efficacy and safety of Vidaza were studied in an international, multicenter, controlled, open-label, randomised, parallel-group, Phase 3 comparative study (AZA PH GL 2003 CL 001) in adult patients with: intermediate-2 and high-risk MDS according to the International Prognostic Scoring System (IPSS), refractory anaemia with excess blasts (RAEB), refractory anaemia with excess blasts in transformation (RAEB-T) and modified chronic myelomonocytic leukaemia (mCMML) according to the French American British (FAB) classification system.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "The efficacy and safety of Vidaza were studied in an international, multicenter, controlled, open-label, randomised, parallel-group, Phase 3 comparative study (AZA PH GL 2003 CL 001) in adult patients with: intermediate-2 and high-risk MDS according to the International Prognostic Scoring System (IPSS), refractory anaemia with excess blasts (RAEB), refractory anaemia with excess blasts in transformation (RAEB-T) and modified chronic myelomonocytic leukaemia (mCMML) according to the French American British (FAB) classification system.", "ro": "SMD cu risc intermediar-2 și mare, conform Sistemului Internațional de Punctaj referitor la Prognostic (SIPP), anemie refractară cu exces de blaști (AREB), anemie refractară cu exces de blaști în transformare (AREB-T) și leucemie mielomonocitară cronică modificată (LMMCm), conform sistemului de clasificare Francez, American, Britanic (FAB)." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: • A low blood platelet count (thrombocytopenia).\nTarget: • Număr scăzut de trombocite sanguine (trombocitopenie).", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: • A low blood platelet count (thrombocytopenia).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "• A low blood platelet count (thrombocytopenia).", "ro": "• Număr scăzut de trombocite sanguine (trombocitopenie)." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: • Dizziness.\nTarget: • Amețeală.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: • Dizziness.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "• Dizziness.", "ro": "• Amețeală." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: • Lethargy.\nTarget: • Letargie.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: • Lethargy.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "• Lethargy.", "ro": "• Letargie." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: How Vidaza works\nTarget: Cum acționează Vidaza", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: How Vidaza works\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "How Vidaza works", "ro": "Cum acționează Vidaza" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: • Redness of your skin.\nTarget: • Erupții trecătoare pe piele.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: • Redness of your skin.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "• Redness of your skin.", "ro": "• Erupții trecătoare pe piele." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Haematological toxicity is defined as the lowest count reached in a given cycle (nadir) if platelets ≤ 50.0 x 109/l and/or absolute neutrophil count (ANC) ≤ 1 x 109/l.\nTarget: Ajustarea dozei ca urmare a toxicității hematologice Toxicitatea hematologică este definită ca fiind cel mai mic număr de leucocite/neutrofile obținut într-un anumit ciclu (limita inferioară (minim)), dacă numărul trombocitelor este ≤ 50,0 x 10", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Haematological toxicity is defined as the lowest count reached in a given cycle (nadir) if platelets ≤ 50.0 x 109/l and/or absolute neutrophil count (ANC) ≤ 1 x 109/l.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Haematological toxicity is defined as the lowest count reached in a given cycle (nadir) if platelets ≤ 50.0 x 109/l and/or absolute neutrophil count (ANC) ≤ 1 x 109/l.", "ro": "Ajustarea dozei ca urmare a toxicității hematologice Toxicitatea hematologică este definită ca fiind cel mai mic număr de leucocite/neutrofile obținut într-un anumit ciclu (limita inferioară (minim)), dacă numărul trombocitelor este ≤ 50,0 x 10" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: • higher-risk myelodysplastic syndromes (MDS).\nTarget: • sindroamelor mielodisplazice (SMD) cu risc crescut.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: • higher-risk myelodysplastic syndromes (MDS).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "• higher-risk myelodysplastic syndromes (MDS).", "ro": "• sindroamelor mielodisplazice (SMD) cu risc crescut." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: • Collection of fluid around the heart (pericardial effusion)..\nTarget: • Acumulare de lichid în jurul inimii (efuziune pericardică).", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: • Collection of fluid around the heart (pericardial effusion)..\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "• Collection of fluid around the heart (pericardial effusion)..", "ro": "• Acumulare de lichid în jurul inimii (efuziune pericardică)." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: • Feeling generally unwell.\nTarget: • Stare generală de rău.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: • Feeling generally unwell.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "• Feeling generally unwell.", "ro": "• Stare generală de rău." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: If the Vidaza suspension is prepared using water for injections that has been stored in the refrigerator (2 °C - 8 °C), the suspension must be placed in the refrigerator (2 °C - 8 °C) immediately after it is prepared and kept refrigerated for up to a maximum of 22 hours.\nTarget: Dacă suspensia Vidaza este preparată utilizând apă pentru preparate injectabile care a fost păstrată la frigider (2 °C - 8 °C), suspensia trebuie pusă la frigider (2 °C - 8 °C) imediat după ce este preparată și ținută la frigider timp de maxim 22 de ore.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: If the Vidaza suspension is prepared using water for injections that has been stored in the refrigerator (2 °C - 8 °C), the suspension must be placed in the refrigerator (2 °C - 8 °C) immediately after it is prepared and kept refrigerated for up to a maximum of 22 hours.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "If the Vidaza suspension is prepared using water for injections that has been stored in the refrigerator (2 °C - 8 °C), the suspension must be placed in the refrigerator (2 °C - 8 °C) immediately after it is prepared and kept refrigerated for up to a maximum of 22 hours.", "ro": "Dacă suspensia Vidaza este preparată utilizând apă pentru preparate injectabile care a fost păstrată la frigider (2 °C - 8 °C), suspensia trebuie pusă la frigider (2 °C - 8 °C) imediat după ce este preparată și ținută la frigider timp de maxim 22 de ore." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Patients with reduced baseline blood counts (i.e. WBC < 3.0 x 109/l or ANC < 1.5 x 109/l or platelets < 75.0 x 109/l) prior to the first treatment\nTarget: 9/l sau NAN <1,5 x 10 9/l sau trombocite < 75,0 x 10", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Patients with reduced baseline blood counts (i.e. WBC < 3.0 x 109/l or ANC < 1.5 x 109/l or platelets < 75.0 x 109/l) prior to the first treatment\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Patients with reduced baseline blood counts (i.e. WBC < 3.0 x 109/l or ANC < 1.5 x 109/l or platelets < 75.0 x 109/l) prior to the first treatment", "ro": "9/l sau NAN <1,5 x 10 9/l sau trombocite < 75,0 x 10" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: System Organ Class\nTarget: Clasificarea pe aparate, sisteme și organe", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: System Organ Class\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "System Organ Class", "ro": "Clasificarea pe aparate, sisteme și organe" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: If the Vidaza suspension is prepared using water for injections that has not been refrigerated, the suspension must be placed in the refrigerator (2 °C - 8 °C) immediately after it is prepared and kept refrigerated for up to a maximum of 8 hours.\nTarget: Dacă suspensia Vidaza este preparată utilizând apă pentru preparate injectabile care nu a fost păstrată la frigider, suspensia trebuie pusă la frigider (2 °C - 8 °C) imediat după ce este preparată și trebuie ținută la frigider timp de maxim 8 ore.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: If the Vidaza suspension is prepared using water for injections that has not been refrigerated, the suspension must be placed in the refrigerator (2 °C - 8 °C) immediately after it is prepared and kept refrigerated for up to a maximum of 8 hours.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "If the Vidaza suspension is prepared using water for injections that has not been refrigerated, the suspension must be placed in the refrigerator (2 °C - 8 °C) immediately after it is prepared and kept refrigerated for up to a maximum of 8 hours.", "ro": "Dacă suspensia Vidaza este preparată utilizând apă pentru preparate injectabile care nu a fost păstrată la frigider, suspensia trebuie pusă la frigider (2 °C - 8 °C) imediat după ce este preparată și trebuie ținută la frigider timp de maxim 8 ore." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Patients without reduced baseline blood counts (i.e. White Blood Cells (WBC) ≥ 3.0 x 109/l and ANC ≥ 1.5 x 109/l, and platelets ≥ 75.0 x 109/l) prior to the first treatment\nTarget: Pacienții fără număr inițial redus de celule sanguine (adică, celule albe sanguine (CAS) ≥ 3,0 x 10", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Patients without reduced baseline blood counts (i.e. White Blood Cells (WBC) ≥ 3.0 x 109/l and ANC ≥ 1.5 x 109/l, and platelets ≥ 75.0 x 109/l) prior to the first treatment\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Patients without reduced baseline blood counts (i.e. White Blood Cells (WBC) ≥ 3.0 x 109/l and ANC ≥ 1.5 x 109/l, and platelets ≥ 75.0 x 109/l) prior to the first treatment", "ro": "Pacienții fără număr inițial redus de celule sanguine (adică, celule albe sanguine (CAS) ≥ 3,0 x 10" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Haematologic adverse reactions\nTarget: Reacții adverse hematologice", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Haematologic adverse reactions\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Haematologic adverse reactions", "ro": "Reacții adverse hematologice" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: • Shaking.\nTarget: • Leșin.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: • Shaking.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "• Shaking.", "ro": "• Leșin." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Pregnancy\nTarget: Alăptarea", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Pregnancy\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Pregnancy", "ro": "Alăptarea" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Necrotising fasciitis\nTarget: Flacoanele sigilate", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Necrotising fasciitis\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Necrotising fasciitis", "ro": "Flacoanele sigilate" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: • Kidney failure.\nTarget: • Insuficiență renală.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: • Kidney failure.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "• Kidney failure.", "ro": "• Insuficiență renală." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Talk to your doctor, pharmacist or nurse before using Vidaza:\nTarget: Înainte să utilizați Vidaza, adresați-vă medicului dumneavoastră, farmacistului sau asistentei medicale:", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Talk to your doctor, pharmacist or nurse before using Vidaza:\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Talk to your doctor, pharmacist or nurse before using Vidaza:", "ro": "Înainte să utilizați Vidaza, adresați-vă medicului dumneavoastră, farmacistului sau asistentei medicale:" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: • Shivering (chills).\nTarget: • Tremur (frisoane).", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: • Shivering (chills).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "• Shivering (chills).", "ro": "• Tremur (frisoane)." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: OTHER\nTarget: vaa", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: OTHER\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "OTHER", "ro": "vaa" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: Vidaza treatment led to a reduced need for red blood cell (RBC) and platelet transfusions.\nTarget: Tratamentul cu Vidaza a dus la o scădere a necesarului de transfuzii de eritrocite și trombocite.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: Vidaza treatment led to a reduced need for red blood cell (RBC) and platelet transfusions.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "Vidaza treatment led to a reduced need for red blood cell (RBC) and platelet transfusions.", "ro": "Tratamentul cu Vidaza a dus la o scădere a necesarului de transfuzii de eritrocite și trombocite." } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 100 mg\nTarget: CONȚINUTUL PE MASĂ, VOLUM SAU UNITATEA DE DOZĂ", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 100 mg\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 100 mg", "ro": "CONȚINUTUL PE MASĂ, VOLUM SAU UNITATEA DE DOZĂ" } }
{ "translation": { "text": "Translate the source text from English to Romanian.\nSource: If you get any side effects, talk to your doctor, pharmacist or nurse.\nTarget: Dacă manifestați orice reacții adverse, adresați-vă medicului dumneavoastră, farmacistului sau asistentei medicale.", "en_prompt": "<|im_start|>user\nTranslate the source text from English to Romanian.\nEnglish: If you get any side effects, talk to your doctor, pharmacist or nurse.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "", "en": "If you get any side effects, talk to your doctor, pharmacist or nurse.", "ro": "Dacă manifestați orice reacții adverse, adresați-vă medicului dumneavoastră, farmacistului sau asistentei medicale." } }
{ "translation": { "text": "Glossary:\n\"hypersensitivity\" -> \"hipersensibilitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the SC Study 5.8% [3/52] developed positive neutralizing anti-tocilizumab antibodies without developing a serious or clinically significant hypersensitivity reaction.\nRomanian: În studiul privind administrarea SC, 5,8% [3/52] dintre pacienţi au dezvoltat anticorpi anti-tocilizumab neutralizanţi, fără a manifesta vreo reacţie de hipersensibilitate gravă sau semnificativă clinic.", "en_prompt": "<|im_start|>user\nGlossary:\n\"hypersensitivity\" -> \"hipersensibilitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the SC Study 5.8% [3/52] developed positive neutralizing anti-tocilizumab antibodies without developing a serious or clinically significant hypersensitivity reaction.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "hypersensitivity|||hipersensibilitate", "en": "In the SC Study 5.8% [3/52] developed positive neutralizing anti-tocilizumab antibodies without developing a serious or clinically significant hypersensitivity reaction.", "ro": "În studiul privind administrarea SC, 5,8% [3/52] dintre pacienţi au dezvoltat anticorpi anti-tocilizumab neutralizanţi, fără a manifesta vreo reacţie de hipersensibilitate gravă sau semnificativă clinic." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The total patient years duration in the RoActemra all exposure population was 138.5 patient years during the 12 month double blind, placebo controlled phase of the study.\nRomanian: Durata totală a expunerii în pacienţi-ani la nivelul întregii populaţii tratate cu RoActemra a fost de 138,5 pacienţi-ani pe parcursul fazei placebo-controlate, cu protocol dublu-orb, cu durata de 12 luni, a studiului.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The total patient years duration in the RoActemra all exposure population was 138.5 patient years during the 12 month double blind, placebo controlled phase of the study.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "The total patient years duration in the RoActemra all exposure population was 138.5 patient years during the 12 month double blind, placebo controlled phase of the study.", "ro": "Durata totală a expunerii în pacienţi-ani la nivelul întregii populaţii tratate cu RoActemra a fost de 138,5 pacienţi-ani pe parcursul fazei placebo-controlate, cu protocol dublu-orb, cu durata de 12 luni, a studiului." } }
{ "translation": { "text": "Glossary:\n\"fever\" -> \"febră\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • fever and chills\nRomanian: • febră şi frisoane", "en_prompt": "<|im_start|>user\nGlossary:\n\"fever\" -> \"febră\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • fever and chills\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "fever|||febră", "en": "• fever and chills", "ro": "• febră şi frisoane" } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Patients randomized to tocilizumab had fewer ACR30 flares and higher overall ACR responses than patients receiving placebo regardless of a history of prior biologic use.\nRomanian: Pacienţii randomizaţi pentru a li se administra tocilizumab au prezentat mai puţine acutizări ale bolii conform ACR 30 şi răspunsuri globale ACR mai mari, comparativ cu pacienţii cărora li s-a administrat placebo, indiferent dacă au urmat anterior un tratament biologic.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Patients randomized to tocilizumab had fewer ACR30 flares and higher overall ACR responses than patients receiving placebo regardless of a history of prior biologic use.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "Patients randomized to tocilizumab had fewer ACR30 flares and higher overall ACR responses than patients receiving placebo regardless of a history of prior biologic use.", "ro": "Pacienţii randomizaţi pentru a li se administra tocilizumab au prezentat mai puţine acutizări ale bolii conform ACR 30 şi răspunsuri globale ACR mai mari, comparativ cu pacienţii cărora li s-a administrat placebo, indiferent dacă au urmat anterior un tratament biologic." } }
{ "translation": { "text": "Glossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Each patient continued in Part II of the study until Week 40 or until the patient satisfied JIA ACR30 flare criteria (relative to Week 16) and qualified for escape to tocilizumab therapy (same dose received in Part I).\nRomanian: Fiecare pacient a continuat în Partea a II-a a studiului clinic până la săptămâna 40 sau până la o acutizare a bolii conform criteriului AIJ ACR30 (comparativ cu săptămâna 16) şi s-a calificat pentru terapia de salvare cu tocilizumab (aceeaşi doză administrată şi în Partea I).", "en_prompt": "<|im_start|>user\nGlossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Each patient continued in Part II of the study until Week 40 or until the patient satisfied JIA ACR30 flare criteria (relative to Week 16) and qualified for escape to tocilizumab therapy (same dose received in Part I).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||doză", "en": "Each patient continued in Part II of the study until Week 40 or until the patient satisfied JIA ACR30 flare criteria (relative to Week 16) and qualified for escape to tocilizumab therapy (same dose received in Part I).", "ro": "Fiecare pacient a continuat în Partea a II-a a studiului clinic până la săptămâna 40 sau până la o acutizare a bolii conform criteriului AIJ ACR30 (comparativ cu săptămâna 16) şi s-a calificat pentru terapia de salvare cu tocilizumab (aceeaşi doză administrată şi în Partea I)." } }
{ "translation": { "text": "Glossary:\n\"body weight\" -> \"greutate corporală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Patients with sJIA must have a minimum body weight of 10 kg when receiving RoActemra subcutaneously (see section 4.2).\nRomanian: Pacienții cu AIJs trebuie să aibă o greutate corporală de cel puțin 10 kg când li se administrează subcutanat RoActemra (vezi pct. 4.2).", "en_prompt": "<|im_start|>user\nGlossary:\n\"body weight\" -> \"greutate corporală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Patients with sJIA must have a minimum body weight of 10 kg when receiving RoActemra subcutaneously (see section 4.2).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "body weight|||greutate corporală", "en": "Patients with sJIA must have a minimum body weight of 10 kg when receiving RoActemra subcutaneously (see section 4.2).", "ro": "Pacienții cu AIJs trebuie să aibă o greutate corporală de cel puțin 10 kg când li se administrează subcutanat RoActemra (vezi pct. 4.2)." } }
{ "translation": { "text": "Glossary:\n\"fatigue\" -> \"oboseală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Symptoms include headache, fatigue and jaw pain.\nRomanian: Simptomele includ dureri de cap, oboseală şi dureri la nivelul maxilarului.", "en_prompt": "<|im_start|>user\nGlossary:\n\"fatigue\" -> \"oboseală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Symptoms include headache, fatigue and jaw pain.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "fatigue|||oboseală", "en": "Symptoms include headache, fatigue and jaw pain.", "ro": "Simptomele includ dureri de cap, oboseală şi dureri la nivelul maxilarului." } }
{ "translation": { "text": "Glossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The data available so far does not suggest any effect on fertility from this treatment.\nRomanian: Datele disponibile până în prezent nu sugerează niciun efect al acestui tratament asupra fertilităţii.", "en_prompt": "<|im_start|>user\nGlossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The data available so far does not suggest any effect on fertility from this treatment.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratament", "en": "The data available so far does not suggest any effect on fertility from this treatment.", "ro": "Datele disponibile până în prezent nu sugerează niciun efect al acestui tratament asupra fertilităţii." } }
{ "translation": { "text": "Glossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Thereafter, neutrophils recovered towards baseline in a dose dependent manner.\nRomanian: Ulterior, numărul de neutrofile a revenit aproape la valorile iniţiale în mod dependent de doză.", "en_prompt": "<|im_start|>user\nGlossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Thereafter, neutrophils recovered towards baseline in a dose dependent manner.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||doză", "en": "Thereafter, neutrophils recovered towards baseline in a dose dependent manner.", "ro": "Ulterior, numărul de neutrofile a revenit aproape la valorile iniţiale în mod dependent de doză." } }
{ "translation": { "text": "Glossaries:\n\"treatment\" -> \"tratament\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The adjusted mean change in the pain VAS after 12 weeks of tocilizumab treatment was a reduction of 41 points on a scale of 0 - 100 compared to a reduction of 1 for placebo patients (p<0.0001).\nRomanian: Modificarea medie ajustată a durerii pe scala VAS după 12 săptămâni de tratament cu tocilizumab a fost o reducere de 41 de puncte pe o scală de la 0 - 100 comparativ cu o reducere de 1 punct pentru pacienţii trataţi cu placebo (p<0,0001).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"treatment\" -> \"tratament\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The adjusted mean change in the pain VAS after 12 weeks of tocilizumab treatment was a reduction of 41 points on a scale of 0 - 100 compared to a reduction of 1 for placebo patients (p<0.0001).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratament\tplacebo|||placebo", "en": "The adjusted mean change in the pain VAS after 12 weeks of tocilizumab treatment was a reduction of 41 points on a scale of 0 - 100 compared to a reduction of 1 for placebo patients (p<0.0001).", "ro": "Modificarea medie ajustată a durerii pe scala VAS după 12 săptămâni de tratament cu tocilizumab a fost o reducere de 41 de puncte pe o scală de la 0 - 100 comparativ cu o reducere de 1 punct pentru pacienţii trataţi cu placebo (p<0,0001)." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: RoActemra is usually given in combination with another medicine for RA called methotrexate.\nRomanian: RoActemra este administrat de obicei în asociere cu alt medicament pentru PR numit metotrexat.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: RoActemra is usually given in combination with another medicine for RA called methotrexate.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "RoActemra is usually given in combination with another medicine for RA called methotrexate.", "ro": "RoActemra este administrat de obicei în asociere cu alt medicament pentru PR numit metotrexat." } }
{ "translation": { "text": "Glossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: A median of 1 dose of tocilizumab (range, 1-4 doses) was administered.\nRomanian: Mediana dozelor de tocilizumab administrate (interval, 1-4 doze) a fost de 1 doză.", "en_prompt": "<|im_start|>user\nGlossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: A median of 1 dose of tocilizumab (range, 1-4 doses) was administered.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||doză", "en": "A median of 1 dose of tocilizumab (range, 1-4 doses) was administered.", "ro": "Mediana dozelor de tocilizumab administrate (interval, 1-4 doze) a fost de 1 doză." } }
{ "translation": { "text": "Glossary:\n\"hypersensitivity\" -> \"hipersensibilitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • allergic (hypersensitivity) reactions\nRomanian: • reacţii alergice (de hipersensibilitate)", "en_prompt": "<|im_start|>user\nGlossary:\n\"hypersensitivity\" -> \"hipersensibilitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • allergic (hypersensitivity) reactions\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "hypersensitivity|||hipersensibilitate", "en": "• allergic (hypersensitivity) reactions", "ro": "• reacţii alergice (de hipersensibilitate)" } }
{ "translation": { "text": "Glossaries:\n\"infusion\" -> \"perfuzie\"\n\"body weight\" -> \"greutate corporală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: For individuals whose body weight is more than 100 kg, doses exceeding 800 mg per infusion are not recommended (see section 5.2).\nRomanian: Pentru persoanele cu greutate corporală peste 100 kg, nu sunt recomandate doze mai mari de 800 mg per perfuzie (vezi pct. 5.2).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"infusion\" -> \"perfuzie\"\n\"body weight\" -> \"greutate corporală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: For individuals whose body weight is more than 100 kg, doses exceeding 800 mg per infusion are not recommended (see section 5.2).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "infusion|||perfuzie\tbody weight|||greutate corporală", "en": "For individuals whose body weight is more than 100 kg, doses exceeding 800 mg per infusion are not recommended (see section 5.2).", "ro": "Pentru persoanele cu greutate corporală peste 100 kg, nu sunt recomandate doze mai mari de 800 mg per perfuzie (vezi pct. 5.2)." } }
{ "translation": { "text": "Glossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The all control population includes all patients from the double-blind phases of each core study from randomization until either the first change in the treatment regimen, or two years is reached.\nRomanian: Populaţia de control include toţi pacienţii din perioada controlată dublu-orb a fiecărui studiu, de la randomizare şi până la prima modificare a schemei de tratament sau până când perioada de 2 ani a fost atinsă.", "en_prompt": "<|im_start|>user\nGlossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The all control population includes all patients from the double-blind phases of each core study from randomization until either the first change in the treatment regimen, or two years is reached.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratament", "en": "The all control population includes all patients from the double-blind phases of each core study from randomization until either the first change in the treatment regimen, or two years is reached.", "ro": "Populaţia de control include toţi pacienţii din perioada controlată dublu-orb a fiecărui studiu, de la randomizare şi până la prima modificare a schemei de tratament sau până când perioada de 2 ani a fost atinsă." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The safety profile of tocilizumab has been studied in 4 placebo-controlled studies (studies II, III, IV and V), 1 MTX-controlled study (study I) and their extension periods (see section 5.1).\nRomanian: Profilul de siguranţă al administrării tocilizumabului a fost studiat în cadrul a 4 studii placebo controlate (studiile II, III, IV şi V), un studiu MTX controlat (studiul I) şi perioadele lor de extensie (vezi pct. 5.1).", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The safety profile of tocilizumab has been studied in 4 placebo-controlled studies (studies II, III, IV and V), 1 MTX-controlled study (study I) and their extension periods (see section 5.1).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "The safety profile of tocilizumab has been studied in 4 placebo-controlled studies (studies II, III, IV and V), 1 MTX-controlled study (study I) and their extension periods (see section 5.1).", "ro": "Profilul de siguranţă al administrării tocilizumabului a fost studiat în cadrul a 4 studii placebo controlate (studiile II, III, IV şi V), un studiu MTX controlat (studiul I) şi perioadele lor de extensie (vezi pct. 5.1)." } }
{ "translation": { "text": "Glossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The proportion of patients with serious adverse events was balanced between the treatment groups (RoActemra 11.7% vs. adalimumab 9.9%).\nRomanian: Procentul pacienţilor la care au apărut reacţii adverse grave a fost echilibrat între grupurile de tratament (RoActemra 11,7% comparativ cu adalimumab 9,9%).", "en_prompt": "<|im_start|>user\nGlossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The proportion of patients with serious adverse events was balanced between the treatment groups (RoActemra 11.7% vs. adalimumab 9.9%).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratament", "en": "The proportion of patients with serious adverse events was balanced between the treatment groups (RoActemra 11.7% vs. adalimumab 9.9%).", "ro": "Procentul pacienţilor la care au apărut reacţii adverse grave a fost echilibrat între grupurile de tratament (RoActemra 11,7% comparativ cu adalimumab 9,9%)." } }
{ "translation": { "text": "Glossaries:\n\"infusion\" -> \"perfuzie\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the 12 week controlled phase, 16% of patients in the tocilizumab group and 5.4% of patients in the placebo group experienced an event within 24 hours of infusion.\nRomanian: În faza controlată a studiului cu durata de 12 săptămâni, 16% din pacienţii din grupul tratat cu tocilizumab şi 5,4% din pacienţii din grupul care a primit placebo au prezentat un eveniment în decurs de 24 de ore de la perfuzie.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"infusion\" -> \"perfuzie\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the 12 week controlled phase, 16% of patients in the tocilizumab group and 5.4% of patients in the placebo group experienced an event within 24 hours of infusion.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "infusion|||perfuzie\tplacebo|||placebo", "en": "In the 12 week controlled phase, 16% of patients in the tocilizumab group and 5.4% of patients in the placebo group experienced an event within 24 hours of infusion.", "ro": "În faza controlată a studiului cu durata de 12 săptămâni, 16% din pacienţii din grupul tratat cu tocilizumab şi 5,4% din pacienţii din grupul care a primit placebo au prezentat un eveniment în decurs de 24 de ore de la perfuzie." } }
{ "translation": { "text": "Glossaries:\n\"treatment\" -> \"tratament\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The adjusted mean change in the pain VAS after 40 weeks of tocilizumab treatment was 32.4 mm on a 0-100 mm scale compared to a reduction of 22.3 mm for placebo patients (highly statistically significant; p=0.0076).\nRomanian: Modificarea medie ajustată a durerii pe scala VAS după 40 de săptămâni de tratament cu tocilizumab a fost de 32,4 mm pe o scală de la 0-100 mm, comparativ cu o reducere de 22,3 mm la pacienţii trataţi cu placebo (extrem de semnificativ statistic; p = 0,0076).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"treatment\" -> \"tratament\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The adjusted mean change in the pain VAS after 40 weeks of tocilizumab treatment was 32.4 mm on a 0-100 mm scale compared to a reduction of 22.3 mm for placebo patients (highly statistically significant; p=0.0076).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratament\tplacebo|||placebo", "en": "The adjusted mean change in the pain VAS after 40 weeks of tocilizumab treatment was 32.4 mm on a 0-100 mm scale compared to a reduction of 22.3 mm for placebo patients (highly statistically significant; p=0.0076).", "ro": "Modificarea medie ajustată a durerii pe scala VAS după 40 de săptămâni de tratament cu tocilizumab a fost de 32,4 mm pe o scală de la 0-100 mm, comparativ cu o reducere de 22,3 mm la pacienţii trataţi cu placebo (extrem de semnificativ statistic; p = 0,0076)." } }
{ "translation": { "text": "Glossary:\n\"body weight\" -> \"greutate corporală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Patients must have a minimum body weight of 10 kg when receiving RoActemra subcutaneously.\nRomanian: Pacienții trebuie să aibă o greutate corporală de cel puțin 10 kg când li se administrează subcutanat", "en_prompt": "<|im_start|>user\nGlossary:\n\"body weight\" -> \"greutate corporală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Patients must have a minimum body weight of 10 kg when receiving RoActemra subcutaneously.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "body weight|||greutate corporală", "en": "Patients must have a minimum body weight of 10 kg when receiving RoActemra subcutaneously.", "ro": "Pacienții trebuie să aibă o greutate corporală de cel puțin 10 kg când li se administrează subcutanat" } }
{ "translation": { "text": "Glossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Suitability of the patient or parent/guardian for subcutaneous home use should be assessed and patients or parent/guardian instructed to inform a healthcare professional before administering the next dose if they experience symptoms of an allergic reaction.\nRomanian: Trebuie evaluat dacă administrarea subcutanată acasă este adecvată pentru pacient sau părinte/reprezentantul legal al pacientului, iar pacienţii sau părinţii/reprezentanţii legali ai pacienţilor instruiţi să informeze un profesionist din domeniul sănătăţii înainte de a administra următoarea doză dacă prezintă simptome ale unei reacţii alergice.", "en_prompt": "<|im_start|>user\nGlossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Suitability of the patient or parent/guardian for subcutaneous home use should be assessed and patients or parent/guardian instructed to inform a healthcare professional before administering the next dose if they experience symptoms of an allergic reaction.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||doză", "en": "Suitability of the patient or parent/guardian for subcutaneous home use should be assessed and patients or parent/guardian instructed to inform a healthcare professional before administering the next dose if they experience symptoms of an allergic reaction.", "ro": "Trebuie evaluat dacă administrarea subcutanată acasă este adecvată pentru pacient sau părinte/reprezentantul legal al pacientului, iar pacienţii sau părinţii/reprezentanţii legali ai pacienţilor instruiţi să informeze un profesionist din domeniul sănătăţii înainte de a administra următoarea doză dacă prezintă simptome ale unei reacţii alergice." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: 1p<0.0001, tocilizumab vs. placebo\nRomanian: 1p<0,0001, tocilizumab comparativ cu placebo", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: 1p<0.0001, tocilizumab vs. placebo\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "1p<0.0001, tocilizumab vs. placebo", "ro": "1p<0,0001, tocilizumab comparativ cu placebo" } }
{ "translation": { "text": "Glossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Patients (which includes younger children with sJIA or pJIA who may be less able to communicate their symptoms) and parents/guardians of sJIA or pJIA patients, should be instructed to contact their healthcare professional immediately when any symptoms suggesting infection appear, in order to assure rapid evaluation and appropriate treatment.\nRomanian: Pacienţii (incluzând copiii mai mici cu AIJs sau AIJp care pot să comunice mai greu simptomele lor) şi părinţii/reprezentanţi legali ai pacienţilor cu AIJs sau AIJp, trebuie să fie instruiţi să contacteze imediat personalul medical atunci când apar orice simptome ce sugerează o infecţie, pentru a se asigura o evaluare promptă şi iniţierea unui tratament adecvat.", "en_prompt": "<|im_start|>user\nGlossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Patients (which includes younger children with sJIA or pJIA who may be less able to communicate their symptoms) and parents/guardians of sJIA or pJIA patients, should be instructed to contact their healthcare professional immediately when any symptoms suggesting infection appear, in order to assure rapid evaluation and appropriate treatment.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratament", "en": "Patients (which includes younger children with sJIA or pJIA who may be less able to communicate their symptoms) and parents/guardians of sJIA or pJIA patients, should be instructed to contact their healthcare professional immediately when any symptoms suggesting infection appear, in order to assure rapid evaluation and appropriate treatment.", "ro": "Pacienţii (incluzând copiii mai mici cu AIJs sau AIJp care pot să comunice mai greu simptomele lor) şi părinţii/reprezentanţi legali ai pacienţilor cu AIJs sau AIJp, trebuie să fie instruiţi să contacteze imediat personalul medical atunci când apar orice simptome ce sugerează o infecţie, pentru a se asigura o evaluare promptă şi iniţierea unui tratament adecvat." } }
{ "translation": { "text": "Glossaries:\n\"dosing interval\" -> \"interval\"\n\"interval\" -> \"interval\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: At steady-state following a dose of 8 mg/kg every 4 weeks, the effective t1/2 decreased with decreasing concentrations within a dosing interval from 18 days to 6 days.\nRomanian: La starea de echilibru, după administrarea unei doze de 8 mg/kg la interval de 4 săptămâni, t1/2 efectiv scade cu diminuarea concentraţiilor dintr-un interval de dozare, de la 18 până la 6 zile.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dosing interval\" -> \"interval\"\n\"interval\" -> \"interval\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: At steady-state following a dose of 8 mg/kg every 4 weeks, the effective t1/2 decreased with decreasing concentrations within a dosing interval from 18 days to 6 days.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "dosing interval|||interval\tinterval|||interval", "en": "At steady-state following a dose of 8 mg/kg every 4 weeks, the effective t1/2 decreased with decreasing concentrations within a dosing interval from 18 days to 6 days.", "ro": "La starea de echilibru, după administrarea unei doze de 8 mg/kg la interval de 4 săptămâni, t1/2 efectiv scade cu diminuarea concentraţiilor dintr-un interval de dozare, de la 18 până la 6 zile." } }
{ "translation": { "text": "Glossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: After 2 years of treatment with RoActemra plus MTX, 14% of patients achieved a major clinical response (maintenance of an ACR70 response for 24 weeks or more).\nRomanian: După 2 ani de tratament cu RoActemra în asociere cu MTX, 14% dintre pacienţi au obţinut un răspuns clinic important (menţinerea unui răspuns ACR 70 timp de 24 de săptămâni sau mai mult).", "en_prompt": "<|im_start|>user\nGlossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: After 2 years of treatment with RoActemra plus MTX, 14% of patients achieved a major clinical response (maintenance of an ACR70 response for 24 weeks or more).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratament", "en": "After 2 years of treatment with RoActemra plus MTX, 14% of patients achieved a major clinical response (maintenance of an ACR70 response for 24 weeks or more).", "ro": "După 2 ani de tratament cu RoActemra în asociere cu MTX, 14% dintre pacienţi au obţinut un răspuns clinic important (menţinerea unui răspuns ACR 70 timp de 24 de săptămâni sau mai mult)." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Forty (80%) of these patients had an increase in their haemoglobin to within the normal range at week 12, in comparison to 2 out of 29 (7%) of placebo treated patients with haemoglobin < LLN at baseline (p<0.0001).\nRomanian: Patruzeci din aceşti pacienţi (80%) au avut o creştere până la o valoare a hemoglobinei cuprinsă în limite normale în săptămâna 12, în comparaţie cu 2 din cei 29 pacienţi (7%) trataţi cu placebo, având valoarea hemoglobinei < LIN, la începutul tratamentului sub limita inferioară a valorii normale (p<0,0001).", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Forty (80%) of these patients had an increase in their haemoglobin to within the normal range at week 12, in comparison to 2 out of 29 (7%) of placebo treated patients with haemoglobin < LLN at baseline (p<0.0001).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "Forty (80%) of these patients had an increase in their haemoglobin to within the normal range at week 12, in comparison to 2 out of 29 (7%) of placebo treated patients with haemoglobin < LLN at baseline (p<0.0001).", "ro": "Patruzeci din aceşti pacienţi (80%) au avut o creştere până la o valoare a hemoglobinei cuprinsă în limite normale în săptămâna 12, în comparaţie cu 2 din cei 29 pacienţi (7%) trataţi cu placebo, având valoarea hemoglobinei < LIN, la începutul tratamentului sub limita inferioară a valorii normale (p<0,0001)." } }
{ "translation": { "text": "Glossary:\n\"clearance\" -> \"clearance\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Mild renal impairment (estimated creatinine clearance based on Cockcroft-Gault formula) did not impact the pharmacokinetics of RoActemra.\nRomanian: Insuficienţa renală uşoară (clearance-ul creatininei estimat pe baza formulei Cockcroft-Gault <) nu influenţează farmacocinetica RoActemra.", "en_prompt": "<|im_start|>user\nGlossary:\n\"clearance\" -> \"clearance\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Mild renal impairment (estimated creatinine clearance based on Cockcroft-Gault formula) did not impact the pharmacokinetics of RoActemra.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "clearance|||clearance", "en": "Mild renal impairment (estimated creatinine clearance based on Cockcroft-Gault formula) did not impact the pharmacokinetics of RoActemra.", "ro": "Insuficienţa renală uşoară (clearance-ul creatininei estimat pe baza formulei Cockcroft-Gault <) nu influenţează farmacocinetica RoActemra." } }
{ "translation": { "text": "Glossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The proportion of patients with serious adverse events was balanced between the treatment groups (tocilizumab 11.7% vs. adalimumab 9.9%).\nRomanian: Procentul pacienţilor la care au apărut reacţii adverse grave a fost echilibrat între grupurile de tratament (tocilizumab 11,7% comparativ cu adalimumab 9,9%).", "en_prompt": "<|im_start|>user\nGlossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The proportion of patients with serious adverse events was balanced between the treatment groups (tocilizumab 11.7% vs. adalimumab 9.9%).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratament", "en": "The proportion of patients with serious adverse events was balanced between the treatment groups (tocilizumab 11.7% vs. adalimumab 9.9%).", "ro": "Procentul pacienţilor la care au apărut reacţii adverse grave a fost echilibrat între grupurile de tratament (tocilizumab 11,7% comparativ cu adalimumab 9,9%)." } }
{ "translation": { "text": "Glossaries:\n\"treatment\" -> \"tratament\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Patients (treated with or without MTX) were randomised (tocilizumab:placebo = 2:1) to one of two treatment groups, 75 patients received tocilizumab infusions every two weeks, either 8 mg/kg for patients ≥ 30 kg or 12 mg/kg for patients < 30 kg and 37 patients were assigned to receiving placebo infusions every two weeks.\nRomanian: Pacienţii (trataţi cu sau fără MTX) au fost randomizaţi (tocilizumab:placebo = 2:1) în unul sau două grupuri de tratament, 75 de pacienţi au primit perfuzie cu tocilizumab la interval de două săptămâni, 8 mg/kg pentru pacienţii ≥ 30 kg sau 12 mg/kg pentru pacienţii < 30 kg şi 37 de pacienţi au fost repartizaţi pentru a primi perfuzie cu placebo la interval de două săptămâni.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"treatment\" -> \"tratament\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Patients (treated with or without MTX) were randomised (tocilizumab:placebo = 2:1) to one of two treatment groups, 75 patients received tocilizumab infusions every two weeks, either 8 mg/kg for patients ≥ 30 kg or 12 mg/kg for patients < 30 kg and 37 patients were assigned to receiving placebo infusions every two weeks.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratament\tplacebo|||placebo", "en": "Patients (treated with or without MTX) were randomised (tocilizumab:placebo = 2:1) to one of two treatment groups, 75 patients received tocilizumab infusions every two weeks, either 8 mg/kg for patients ≥ 30 kg or 12 mg/kg for patients < 30 kg and 37 patients were assigned to receiving placebo infusions every two weeks.", "ro": "Pacienţii (trataţi cu sau fără MTX) au fost randomizaţi (tocilizumab:placebo = 2:1) în unul sau două grupuri de tratament, 75 de pacienţi au primit perfuzie cu tocilizumab la interval de două săptămâni, 8 mg/kg pentru pacienţii ≥ 30 kg sau 12 mg/kg pentru pacienţii < 30 kg şi 37 de pacienţi au fost repartizaţi pentru a primi perfuzie cu placebo la interval de două săptămâni." } }
{ "translation": { "text": "Glossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The majority of ISRs reported were Grade 1 events and all ISRs reported were non-serious and none required patient withdrawal from treatment or dose interruption.\nRomanian: Majoritatea RLI raportate au fost evenimente de Gradul 1 și toate RLI raportate au fost evenimente lipsite de gravitate, niciuna dintre RLI nu a necesitat retragerea pacientului din tratament sau întreruperea administrării dozei.", "en_prompt": "<|im_start|>user\nGlossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The majority of ISRs reported were Grade 1 events and all ISRs reported were non-serious and none required patient withdrawal from treatment or dose interruption.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratament", "en": "The majority of ISRs reported were Grade 1 events and all ISRs reported were non-serious and none required patient withdrawal from treatment or dose interruption.", "ro": "Majoritatea RLI raportate au fost evenimente de Gradul 1 și toate RLI raportate au fost evenimente lipsite de gravitate, niciuna dintre RLI nu a necesitat retragerea pacientului din tratament sau întreruperea administrării dozei." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: A higher frequency of injection site reactions was observed in the subcutaneous arms compared with placebo subcutaneous injections in the intravenous arms.\nRomanian: O frecvenţă mai mare a reacţiilor la nivelul locului de injectare a fost observată în braţele în care s-a administrat forma farmaceutică cu utilizare subcutanată, comparativ cu braţele în care s-a administrat placebo subcutanat şi forma farmaceutică cu utilizare intravenoasă.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: A higher frequency of injection site reactions was observed in the subcutaneous arms compared with placebo subcutaneous injections in the intravenous arms.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "A higher frequency of injection site reactions was observed in the subcutaneous arms compared with placebo subcutaneous injections in the intravenous arms.", "ro": "O frecvenţă mai mare a reacţiilor la nivelul locului de injectare a fost observată în braţele în care s-a administrat forma farmaceutică cu utilizare subcutanată, comparativ cu braţele în care s-a administrat placebo subcutanat şi forma farmaceutică cu utilizare intravenoasă." } }
{ "translation": { "text": "Glossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: After 2 years of treatment with tocilizumab plus MTX, 14% of patients achieved a major clinical response (maintenance of an ACR70 response for 24 weeks or more).\nRomanian: După 2 ani de tratament cu tocilizumab în asociere cu MTX, 14% dintre pacienţi au obţinut un răspuns clinic important (menţinerea unui răspuns ACR 70 timp de 24 de săptămâni sau mai mult).", "en_prompt": "<|im_start|>user\nGlossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: After 2 years of treatment with tocilizumab plus MTX, 14% of patients achieved a major clinical response (maintenance of an ACR70 response for 24 weeks or more).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratament", "en": "After 2 years of treatment with tocilizumab plus MTX, 14% of patients achieved a major clinical response (maintenance of an ACR70 response for 24 weeks or more).", "ro": "După 2 ani de tratament cu tocilizumab în asociere cu MTX, 14% dintre pacienţi au obţinut un răspuns clinic important (menţinerea unui răspuns ACR 70 timp de 24 de săptămâni sau mai mult)." } }
{ "translation": { "text": "Glossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The majority was resolved without any treatment and none necessitated drug discontinuation.\nRomanian: Majoritatea reacţiilor s-au remis fără administrarea unui tratament şi niciuna dintre reacţii nu a necesitat întreruperea administrării medicamentului.", "en_prompt": "<|im_start|>user\nGlossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The majority was resolved without any treatment and none necessitated drug discontinuation.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratament", "en": "The majority was resolved without any treatment and none necessitated drug discontinuation.", "ro": "Majoritatea reacţiilor s-au remis fără administrarea unui tratament şi niciuna dintre reacţii nu a necesitat întreruperea administrării medicamentului." } }
{ "translation": { "text": "Glossary:\n\"swelling\" -> \"umflare\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • rash, itching, hives, swelling of the lips, tongue or face If you notice any of these, tell your doctor immediately.\nRomanian: • erupţie pe piele, mâncărime, urticarie, umflare a buzelor, limbii sau a feţei Dacă observaţi oricare dintre acestea, adresaţi-vă medicului dumneavoastră imediat.", "en_prompt": "<|im_start|>user\nGlossary:\n\"swelling\" -> \"umflare\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • rash, itching, hives, swelling of the lips, tongue or face If you notice any of these, tell your doctor immediately.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "swelling|||umflare", "en": "• rash, itching, hives, swelling of the lips, tongue or face If you notice any of these, tell your doctor immediately.", "ro": "• erupţie pe piele, mâncărime, urticarie, umflare a buzelor, limbii sau a feţei Dacă observaţi oricare dintre acestea, adresaţi-vă medicului dumneavoastră imediat." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: A decrease in platelet count below 100 × 103 / μL was not observed in either of the placebo plus prednisone taper groups.\nRomanian: Scăderea numărului de trombocite sub 100 × 103/μl nu a fost observată în niciunul dintre grupurile cu administrare de placebo plus prednison în doze scăzute progresiv.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: A decrease in platelet count below 100 × 103 / μL was not observed in either of the placebo plus prednisone taper groups.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "A decrease in platelet count below 100 × 103 / μL was not observed in either of the placebo plus prednisone taper groups.", "ro": "Scăderea numărului de trombocite sub 100 × 103/μl nu a fost observată în niciunul dintre grupurile cu administrare de placebo plus prednison în doze scăzute progresiv." } }
{ "translation": { "text": "Glossary:\n\"body weight\" -> \"greutate corporală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The usual dose of RoActemra is 8 mg for every kg of body weight if you weigh 30 kg or more.\nRomanian: Doza uzuală de RoActemra este de 8 mg pentru fiecare kg de greutate corporală, în cazul în care aceasta este de 30 kg sau mai mult.", "en_prompt": "<|im_start|>user\nGlossary:\n\"body weight\" -> \"greutate corporală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The usual dose of RoActemra is 8 mg for every kg of body weight if you weigh 30 kg or more.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "body weight|||greutate corporală", "en": "The usual dose of RoActemra is 8 mg for every kg of body weight if you weigh 30 kg or more.", "ro": "Doza uzuală de RoActemra este de 8 mg pentru fiecare kg de greutate corporală, în cazul în care aceasta este de 30 kg sau mai mult." } }
{ "translation": { "text": "Glossary:\n\"tuberculosis\" -> \"tuberculoză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • If you have had tuberculosis, tell your doctor.\nRomanian: • Dacă aţi avut tuberculoză, spuneţi medicului dumneavoastră.", "en_prompt": "<|im_start|>user\nGlossary:\n\"tuberculosis\" -> \"tuberculoză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • If you have had tuberculosis, tell your doctor.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "tuberculosis|||tuberculoză", "en": "• If you have had tuberculosis, tell your doctor.", "ro": "• Dacă aţi avut tuberculoză, spuneţi medicului dumneavoastră." } }
{ "translation": { "text": "Glossary:\n\"swelling\" -> \"umflare\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If you develop symptoms such as, but not limited to skin rash, itching, chills, swelling of face, lips, tongue or throat, chest pain, wheezing, difficulty breathing or swallowing or feeling dizzy or faint at any time while not at the clinic during or following an RoACTEMRA injection you should seek emergency care immediately.\nRomanian: Dacă manifestaţi simptome cum ar fi, dar fără a fi limitate la, erupţie trecătoare pe piele, mâncărime, frisoane, umflare a feţei, buzelor, limbii sau a gâtului, durere la nivelul pieptului, respiraţie şuierătoare, dificultate la respiraţie sau la înghiţire sau dacă aveţi senzaţie de ameţeală sau de leşin în orice moment în timpul sau după administrarea injecţiei de RoActemra şi nu vă aflaţi într-o unitate sanitară, trebuie să solicitaţi imediat îngrijire medicală de urgenţă.", "en_prompt": "<|im_start|>user\nGlossary:\n\"swelling\" -> \"umflare\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If you develop symptoms such as, but not limited to skin rash, itching, chills, swelling of face, lips, tongue or throat, chest pain, wheezing, difficulty breathing or swallowing or feeling dizzy or faint at any time while not at the clinic during or following an RoACTEMRA injection you should seek emergency care immediately.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "swelling|||umflare", "en": "If you develop symptoms such as, but not limited to skin rash, itching, chills, swelling of face, lips, tongue or throat, chest pain, wheezing, difficulty breathing or swallowing or feeling dizzy or faint at any time while not at the clinic during or following an RoACTEMRA injection you should seek emergency care immediately.", "ro": "Dacă manifestaţi simptome cum ar fi, dar fără a fi limitate la, erupţie trecătoare pe piele, mâncărime, frisoane, umflare a feţei, buzelor, limbii sau a gâtului, durere la nivelul pieptului, respiraţie şuierătoare, dificultate la respiraţie sau la înghiţire sau dacă aveţi senzaţie de ameţeală sau de leşin în orice moment în timpul sau după administrarea injecţiei de RoActemra şi nu vă aflaţi într-o unitate sanitară, trebuie să solicitaţi imediat îngrijire medicală de urgenţă." } }
{ "translation": { "text": "Glossary:\n\"IgE\" -> \"IgE\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the RoActemra subcutaneous weekly group, one patient (1.1%, 1/95) developed positive neutralizing anti-RoActemra antibodies, though not of the IgE isotype.\nRomanian: Imunogenitate În grupul cu RoActemra administrat subcutanat în fiecare săptămână, un pacient (1,1%, 1/95) a dezvoltat anticorpi anti-RoActemra neutralizanţi, care nu corespundeau însă izotipului IgE.", "en_prompt": "<|im_start|>user\nGlossary:\n\"IgE\" -> \"IgE\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the RoActemra subcutaneous weekly group, one patient (1.1%, 1/95) developed positive neutralizing anti-RoActemra antibodies, though not of the IgE isotype.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "IgE|||IgE", "en": "In the RoActemra subcutaneous weekly group, one patient (1.1%, 1/95) developed positive neutralizing anti-RoActemra antibodies, though not of the IgE isotype.", "ro": "Imunogenitate În grupul cu RoActemra administrat subcutanat în fiecare săptămână, un pacient (1,1%, 1/95) a dezvoltat anticorpi anti-RoActemra neutralizanţi, care nu corespundeau însă izotipului IgE." } }
{ "translation": { "text": "Glossaries:\n\"corticosteroid\" -> \"corticosteroid\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Seventeen (24%) tocilizumab treated patients versus 1 (3%) placebo patient were able to reduce their dose of corticosteroid by at least 20% without experiencing a subsequent JIA ACR30 flare or occurrence of systemic symptoms to week 12 (p=0.028).\nRomanian: Şaptesprezece pacienţi (24%) trataţi cu tocilizumab comparativ cu 1 pacient (3%) tratat cu placebo au reuşit să reducă doza lor de corticosteroid cu cel puţin 20%, fără a experimenta o acutizare ulterioară a bolii conform ACR30 în AIJ sau apariţia simptomelor sistemice în săptămâna 12", "en_prompt": "<|im_start|>user\nGlossaries:\n\"corticosteroid\" -> \"corticosteroid\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Seventeen (24%) tocilizumab treated patients versus 1 (3%) placebo patient were able to reduce their dose of corticosteroid by at least 20% without experiencing a subsequent JIA ACR30 flare or occurrence of systemic symptoms to week 12 (p=0.028).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "corticosteroid|||corticosteroid\tplacebo|||placebo", "en": "Seventeen (24%) tocilizumab treated patients versus 1 (3%) placebo patient were able to reduce their dose of corticosteroid by at least 20% without experiencing a subsequent JIA ACR30 flare or occurrence of systemic symptoms to week 12 (p=0.028).", "ro": "Şaptesprezece pacienţi (24%) trataţi cu tocilizumab comparativ cu 1 pacient (3%) tratat cu placebo au reuşit să reducă doza lor de corticosteroid cu cel puţin 20%, fără a experimenta o acutizare ulterioară a bolii conform ACR30 în AIJ sau apariţia simptomelor sistemice în săptămâna 12" } }
{ "translation": { "text": "Glossary:\n\"cytokine\" -> \"citokine\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Thus, CYP450 expression may be reversed when potent cytokine inhibitory therapy, such as tocilizumab, is introduced.\nRomanian: Astfel, exprimarea CYP450 poate fi restabilită atunci când se administrează un tratament cu inhibitori potenţi de citokine, cum este tocilizumab.", "en_prompt": "<|im_start|>user\nGlossary:\n\"cytokine\" -> \"citokine\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Thus, CYP450 expression may be reversed when potent cytokine inhibitory therapy, such as tocilizumab, is introduced.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "cytokine|||citokine", "en": "Thus, CYP450 expression may be reversed when potent cytokine inhibitory therapy, such as tocilizumab, is introduced.", "ro": "Astfel, exprimarea CYP450 poate fi restabilită atunci când se administrează un tratament cu inhibitori potenţi de citokine, cum este tocilizumab." } }
{ "translation": { "text": "Glossary:\n\"cough\" -> \"tuse\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • cough, shortness of breath\nRomanian: • tuse, scurtare a respiraţiei", "en_prompt": "<|im_start|>user\nGlossary:\n\"cough\" -> \"tuse\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • cough, shortness of breath\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "cough|||tuse", "en": "• cough, shortness of breath", "ro": "• tuse, scurtare a respiraţiei" } }
{ "translation": { "text": "Glossary:\n\"cough\" -> \"tuse\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • cough, chest discomfort/tightness, shortness of breath\nRomanian: • tuse, disconfort/senzaţie de apăsare la nivelul pieptului, scurtare a respiraţiei", "en_prompt": "<|im_start|>user\nGlossary:\n\"cough\" -> \"tuse\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • cough, chest discomfort/tightness, shortness of breath\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "cough|||tuse", "en": "• cough, chest discomfort/tightness, shortness of breath", "ro": "• tuse, disconfort/senzaţie de apăsare la nivelul pieptului, scurtare a respiraţiei" } }
{ "translation": { "text": "Glossary:\n\"hypersensitivity\" -> \"hipersensibilitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Two patients developed positive anti-tocilizumab antibodies with one of these patients having a hypersensitivity reaction leading to withdrawal.\nRomanian: Doi pacienţi au dezvoltat anticorpi anti-tocilizumab iar unul dintre aceşti pacienţi a prezentat o reacţie de hipersensibilitate care a determinat retragerea acestuia din studiul clinic.", "en_prompt": "<|im_start|>user\nGlossary:\n\"hypersensitivity\" -> \"hipersensibilitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Two patients developed positive anti-tocilizumab antibodies with one of these patients having a hypersensitivity reaction leading to withdrawal.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "hypersensitivity|||hipersensibilitate", "en": "Two patients developed positive anti-tocilizumab antibodies with one of these patients having a hypersensitivity reaction leading to withdrawal.", "ro": "Doi pacienţi au dezvoltat anticorpi anti-tocilizumab iar unul dintre aceşti pacienţi a prezentat o reacţie de hipersensibilitate care a determinat retragerea acestuia din studiul clinic." } }
{ "translation": { "text": "Glossary:\n\"arthritis\" -> \"artrită\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Reported serious infections, some with fatal outcome, included pneumonia, cellulitis, herpes zoster, gastroenteritis, diverticulitis, sepsis, bacterial arthritis.\nRomanian: Infecţiile grave raportate, unele cu efect letal, au inclus pneumonie, celulită, herpes zoster, gastroenterită, diverticulită, sepsis, artrită bacteriană.", "en_prompt": "<|im_start|>user\nGlossary:\n\"arthritis\" -> \"artrită\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Reported serious infections, some with fatal outcome, included pneumonia, cellulitis, herpes zoster, gastroenteritis, diverticulitis, sepsis, bacterial arthritis.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "arthritis|||artrită", "en": "Reported serious infections, some with fatal outcome, included pneumonia, cellulitis, herpes zoster, gastroenteritis, diverticulitis, sepsis, bacterial arthritis.", "ro": "Infecţiile grave raportate, unele cu efect letal, au inclus pneumonie, celulită, herpes zoster, gastroenterită, diverticulită, sepsis, artrită bacteriană." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • if you are allergic to tocilizumab or any of the other ingredients of this medicine (listed in Section 6).\nRomanian: • dacă sunteţi alergic la tocilizumab sau la oricare dintre celelalte componente ale acestui medicament (enumerate la punctul 6).", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • if you are allergic to tocilizumab or any of the other ingredients of this medicine (listed in Section 6).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "• if you are allergic to tocilizumab or any of the other ingredients of this medicine (listed in Section 6).", "ro": "• dacă sunteţi alergic la tocilizumab sau la oricare dintre celelalte componente ale acestui medicament (enumerate la punctul 6)." } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"doză\"\n\"single dose\" -> \"doză unică\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: One case of accidental overdose was reported in which a patient with multiple myeloma received a single dose of 40 mg/kg administered intravenously.\nRomanian: A fost raportat un caz de supradozare accidentală la un pacient cu mielom multiplu la care s-a administrat intravenos o doză unică de 40 mg/kg.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"doză\"\n\"single dose\" -> \"doză unică\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: One case of accidental overdose was reported in which a patient with multiple myeloma received a single dose of 40 mg/kg administered intravenously.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||doză\tsingle dose|||doză unică", "en": "One case of accidental overdose was reported in which a patient with multiple myeloma received a single dose of 40 mg/kg administered intravenously.", "ro": "A fost raportat un caz de supradozare accidentală la un pacient cu mielom multiplu la care s-a administrat intravenos o doză unică de 40 mg/kg." } }
{ "translation": { "text": "Glossary:\n\"cytokine\" -> \"citokine\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Thus, CYP450 expression may be reversed when potent cytokine inhibitory therapy, such as RoActemra, is introduced.\nRomanian: Astfel, exprimarea CYP450 poate fi restabilită atunci când se administrează un tratament cu inhibitori potenţi de citokine, cum este RoActemra .", "en_prompt": "<|im_start|>user\nGlossary:\n\"cytokine\" -> \"citokine\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Thus, CYP450 expression may be reversed when potent cytokine inhibitory therapy, such as RoActemra, is introduced.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "cytokine|||citokine", "en": "Thus, CYP450 expression may be reversed when potent cytokine inhibitory therapy, such as RoActemra, is introduced.", "ro": "Astfel, exprimarea CYP450 poate fi restabilită atunci când se administrează un tratament cu inhibitori potenţi de citokine, cum este RoActemra ." } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"doză\"\n\"single dose\" -> \"doză unică\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: One case of accidental overdose was reported in which a patient with multiple myeloma received a single dose of 40 mg/kg.\nRomanian: A fost raportat un caz de supradozare accidentală la un pacient cu mielom multiplu la care s-a administrat o doză unică de 40 mg/kg.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"doză\"\n\"single dose\" -> \"doză unică\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: One case of accidental overdose was reported in which a patient with multiple myeloma received a single dose of 40 mg/kg.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||doză\tsingle dose|||doză unică", "en": "One case of accidental overdose was reported in which a patient with multiple myeloma received a single dose of 40 mg/kg.", "ro": "A fost raportat un caz de supradozare accidentală la un pacient cu mielom multiplu la care s-a administrat o doză unică de 40 mg/kg." } }
{ "translation": { "text": "Glossary:\n\"background\" -> \"fond\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: All patients received background non-biologic DMARD(s).\nRomanian: La toţi pacienţii s-au administrat, ca tratament de fond, DMARD non-biologice.", "en_prompt": "<|im_start|>user\nGlossary:\n\"background\" -> \"fond\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: All patients received background non-biologic DMARD(s).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "background|||fond", "en": "All patients received background non-biologic DMARD(s).", "ro": "La toţi pacienţii s-au administrat, ca tratament de fond, DMARD non-biologice." } }
{ "translation": { "text": "Glossary:\n\"exposure\" -> \"expunere\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the long-term exposure population, the overall rate of infections with RoActemra was 108 events per 100 patient years exposure.\nRomanian: În cadrul expunerii pe termen lung a populaţiei, incidenţa generală a infecţiilor în grupul tratat cu RoActemra a fost de 108 evenimente per 100 pacienţi-ani expunere.", "en_prompt": "<|im_start|>user\nGlossary:\n\"exposure\" -> \"expunere\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the long-term exposure population, the overall rate of infections with RoActemra was 108 events per 100 patient years exposure.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "exposure|||expunere", "en": "In the long-term exposure population, the overall rate of infections with RoActemra was 108 events per 100 patient years exposure.", "ro": "În cadrul expunerii pe termen lung a populaţiei, incidenţa generală a infecţiilor în grupul tratat cu RoActemra a fost de 108 evenimente per 100 pacienţi-ani expunere." } }
{ "translation": { "text": "Glossaries:\n\"disease\" -> \"boală\"\n\"arthritis\" -> \"artrită\"\n\"fever\" -> \"febră\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • children and adolescents, aged 1 year and over, with active systemic juvenile idiopathic arthritis (sJIA), an inflammatory disease that causes pain and swelling in one or more joints as well as fever and rash.\nRomanian: • copii și adolescenți, cu vârsta de 1 an și peste, cu artrită idiopatică juvenilă sistemică (AIJs) activă, o boală inflamatorie care cauzează durere şi inflamaţie în una sau mai multe articulaţii, precum și febră și erupție trecătoare pe piele.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"disease\" -> \"boală\"\n\"arthritis\" -> \"artrită\"\n\"fever\" -> \"febră\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • children and adolescents, aged 1 year and over, with active systemic juvenile idiopathic arthritis (sJIA), an inflammatory disease that causes pain and swelling in one or more joints as well as fever and rash.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "disease|||boală\tarthritis|||artrită\tfever|||febră", "en": "• children and adolescents, aged 1 year and over, with active systemic juvenile idiopathic arthritis (sJIA), an inflammatory disease that causes pain and swelling in one or more joints as well as fever and rash.", "ro": "• copii și adolescenți, cu vârsta de 1 an și peste, cu artrită idiopatică juvenilă sistemică (AIJs) activă, o boală inflamatorie care cauzează durere şi inflamaţie în una sau mai multe articulaţii, precum și febră și erupție trecătoare pe piele." } }
{ "translation": { "text": "Glossary:\n\"hypersensitivity\" -> \"hipersensibilitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Of the 46 patients (1.6%) who developed anti-tocilizumab antibodies, 6 had an associated medically significant hypersensitivity reaction, of which 5 led to permanent discontinuation of treatment.\nRomanian: Din 46 de pacienţi (1,6%) care au dezvoltat anticorpi anti-tocilizumab, 6 au prezentat reacţii de hipersensibilitate asociate, semnificative din punct de vedere medical, din care 5 au întrerupt tratamentul permanent.", "en_prompt": "<|im_start|>user\nGlossary:\n\"hypersensitivity\" -> \"hipersensibilitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Of the 46 patients (1.6%) who developed anti-tocilizumab antibodies, 6 had an associated medically significant hypersensitivity reaction, of which 5 led to permanent discontinuation of treatment.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "hypersensitivity|||hipersensibilitate", "en": "Of the 46 patients (1.6%) who developed anti-tocilizumab antibodies, 6 had an associated medically significant hypersensitivity reaction, of which 5 led to permanent discontinuation of treatment.", "ro": "Din 46 de pacienţi (1,6%) care au dezvoltat anticorpi anti-tocilizumab, 6 au prezentat reacţii de hipersensibilitate asociate, semnificative din punct de vedere medical, din care 5 au întrerupt tratamentul permanent." } }
{ "translation": { "text": "Glossary:\n\"hypersensitivity\" -> \"hipersensibilitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Such reactions may be more severe, and potentially fatal in patients who have experienced hypersensitivity reactions during previous treatment with RoActemra even if they have received premedication with steroids and antihistamines.\nRomanian: Astfel de reacţii pot fi mai severe şi potenţial letale la pacienţii care au prezentat reacţii de hipersensibilitate în timpul tratamentului anterior cu RoActemra, chiar dacă li s-a administrat premedicaţie cu steroizi şi antihistaminice.", "en_prompt": "<|im_start|>user\nGlossary:\n\"hypersensitivity\" -> \"hipersensibilitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Such reactions may be more severe, and potentially fatal in patients who have experienced hypersensitivity reactions during previous treatment with RoActemra even if they have received premedication with steroids and antihistamines.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "hypersensitivity|||hipersensibilitate", "en": "Such reactions may be more severe, and potentially fatal in patients who have experienced hypersensitivity reactions during previous treatment with RoActemra even if they have received premedication with steroids and antihistamines.", "ro": "Astfel de reacţii pot fi mai severe şi potenţial letale la pacienţii care au prezentat reacţii de hipersensibilitate în timpul tratamentului anterior cu RoActemra, chiar dacă li s-a administrat premedicaţie cu steroizi şi antihistaminice." } }
{ "translation": { "text": "Glossary:\n\"fever\" -> \"febră\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Systemic Effects In the tocilizumab treated patients, 85% who had fever due to sJIA at baseline were free of fever (no temperature recording ≥ 37.5°C in the preceding 14 days) at week 12 versus 21% of placebo patients\nRomanian: La pacienţii trataţi cu tocilizumab, 85% dintre pacienţii care au avut febră iniţial din cauza AIJs, nu au mai avut febră (nicio înregistrare a temperaturii ≥ 37,5°C în ultimele 14 zile) în săptămâna 12,", "en_prompt": "<|im_start|>user\nGlossary:\n\"fever\" -> \"febră\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Systemic Effects In the tocilizumab treated patients, 85% who had fever due to sJIA at baseline were free of fever (no temperature recording ≥ 37.5°C in the preceding 14 days) at week 12 versus 21% of placebo patients\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "fever|||febră", "en": "Systemic Effects In the tocilizumab treated patients, 85% who had fever due to sJIA at baseline were free of fever (no temperature recording ≥ 37.5°C in the preceding 14 days) at week 12 versus 21% of placebo patients", "ro": "La pacienţii trataţi cu tocilizumab, 85% dintre pacienţii care au avut febră iniţial din cauza AIJs, nu au mai avut febră (nicio înregistrare a temperaturii ≥ 37,5°C în ultimele 14 zile) în săptămâna 12," } }
{ "translation": { "text": "Glossaries:\n\"sepsis\" -> \"septicemie\"\n\"arthritis\" -> \"artrită\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Reported serious infections, some with fatal outcome, included active tuberculosis, which may present with intrapulmonary or extrapulmonary disease, invasive pulmonary infections, including candidiasis, aspergillosis, coccidioidomycosis and pneumocystis jirovecii, pneumonia, cellulitis, herpes zoster, gastroenteritis, diverticulitis, sepsis and bacterial arthritis.\nRomanian: Infecţiile grave raportate, unele cu evoluţie letală, includ tuberculoza activă, care poate apărea cu boala intrapulmonară sau extrapulmonară, infecţii pulmonare invazive, incluzând candidoza, aspergiloza, coccidiodomicoza şi infecţia cu Pneumocystis jiroveci, pneumonie, celulită, herpes zoster, gastroenterită, diverticulită, septicemie şi artrită bacteriană.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"sepsis\" -> \"septicemie\"\n\"arthritis\" -> \"artrită\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Reported serious infections, some with fatal outcome, included active tuberculosis, which may present with intrapulmonary or extrapulmonary disease, invasive pulmonary infections, including candidiasis, aspergillosis, coccidioidomycosis and pneumocystis jirovecii, pneumonia, cellulitis, herpes zoster, gastroenteritis, diverticulitis, sepsis and bacterial arthritis.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "sepsis|||septicemie\tarthritis|||artrită", "en": "Reported serious infections, some with fatal outcome, included active tuberculosis, which may present with intrapulmonary or extrapulmonary disease, invasive pulmonary infections, including candidiasis, aspergillosis, coccidioidomycosis and pneumocystis jirovecii, pneumonia, cellulitis, herpes zoster, gastroenteritis, diverticulitis, sepsis and bacterial arthritis.", "ro": "Infecţiile grave raportate, unele cu evoluţie letală, includ tuberculoza activă, care poate apărea cu boala intrapulmonară sau extrapulmonară, infecţii pulmonare invazive, incluzând candidoza, aspergiloza, coccidiodomicoza şi infecţia cu Pneumocystis jiroveci, pneumonie, celulită, herpes zoster, gastroenterită, diverticulită, septicemie şi artrită bacteriană." } }
{ "translation": { "text": "Glossary:\n\"dexamethasone\" -> \"dexametazonă\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: methylprednisolone, dexamethasone, (with the possibility for oral glucocorticoid withdrawal syndrome), atorvastatin, calcium channel blockers, theophylline, warfarin, phenprocoumon, phenytoin, ciclosporin, or benzodiazepines) should be monitored as doses may need to be increased to maintain therapeutic effect.\nRomanian: (cum sunt metilprednisolon, dexametazonă (cu posibilitatea apariţiei sindromului de întrerupere în cazul glucocorticoizilor cu administrare orală), atorvastatină, blocante ale canalelor de calciu, teofilină, warfarină, fenprocumonă, fenitoină, ciclosporină, sau benzodiazepine) trebuie monitorizaţi, deoarece poate fi necesară creşterea dozelor pentru menţinerea efectului terapeutic.", "en_prompt": "<|im_start|>user\nGlossary:\n\"dexamethasone\" -> \"dexametazonă\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: methylprednisolone, dexamethasone, (with the possibility for oral glucocorticoid withdrawal syndrome), atorvastatin, calcium channel blockers, theophylline, warfarin, phenprocoumon, phenytoin, ciclosporin, or benzodiazepines) should be monitored as doses may need to be increased to maintain therapeutic effect.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "dexamethasone|||dexametazonă", "en": "methylprednisolone, dexamethasone, (with the possibility for oral glucocorticoid withdrawal syndrome), atorvastatin, calcium channel blockers, theophylline, warfarin, phenprocoumon, phenytoin, ciclosporin, or benzodiazepines) should be monitored as doses may need to be increased to maintain therapeutic effect.", "ro": "(cum sunt metilprednisolon, dexametazonă (cu posibilitatea apariţiei sindromului de întrerupere în cazul glucocorticoizilor cu administrare orală), atorvastatină, blocante ale canalelor de calciu, teofilină, warfarină, fenprocumonă, fenitoină, ciclosporină, sau benzodiazepine) trebuie monitorizaţi, deoarece poate fi necesară creşterea dozelor pentru menţinerea efectului terapeutic." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The safety of RoActemra has been studied in 4 placebo-controlled studies (studies II, III, IV and V), 1 MTX-controlled study (study I) and their extension periods (see section 5.1).\nRomanian: Siguranţa administrării RoActemra a fost studiată în 4 studii clinice controlate cu placebo (studiile II, III, IV şi V), un studiu clinic controlat cu MTX (studiul I) şi perioadele de extensie ale acestora (vezi pct. 5.1).", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The safety of RoActemra has been studied in 4 placebo-controlled studies (studies II, III, IV and V), 1 MTX-controlled study (study I) and their extension periods (see section 5.1).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "The safety of RoActemra has been studied in 4 placebo-controlled studies (studies II, III, IV and V), 1 MTX-controlled study (study I) and their extension periods (see section 5.1).", "ro": "Siguranţa administrării RoActemra a fost studiată în 4 studii clinice controlate cu placebo (studiile II, III, IV şi V), un studiu clinic controlat cu MTX (studiul I) şi perioadele de extensie ale acestora (vezi pct. 5.1)." } }
{ "translation": { "text": "Glossary:\n\"test\" -> \"test\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Your doctor will perform a blood test before you receive RoActemra, to determine if you have a low white blood cell count, low platelet count or high liver enzymes.\nRomanian: Înainte de a începe tratamentul cu RoActemra, medicul dumneavoastră vă va efectua un test de sânge pentru a determina dacă aveţi un număr scăzut de celule albe ale sângelui, un număr scăzut de trombocite sau valori crescute ale enzimelor ficatului.", "en_prompt": "<|im_start|>user\nGlossary:\n\"test\" -> \"test\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Your doctor will perform a blood test before you receive RoActemra, to determine if you have a low white blood cell count, low platelet count or high liver enzymes.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "test|||test", "en": "Your doctor will perform a blood test before you receive RoActemra, to determine if you have a low white blood cell count, low platelet count or high liver enzymes.", "ro": "Înainte de a începe tratamentul cu RoActemra, medicul dumneavoastră vă va efectua un test de sânge pentru a determina dacă aveţi un număr scăzut de celule albe ale sângelui, un număr scăzut de trombocite sau valori crescute ale enzimelor ficatului." } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"doză\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In Part II, patients were randomized to tocilizumab (same dose received in Part I) or placebo in a 1:1 ratio, stratified by concurrent MTX use and concurrent corticosteroid use.\nRomanian: În Partea a II-a, pacienţii au fost randomizaţi în raport 1:1 pentru a li se administra tocilizumab (aceeaşi doză administrată și în Partea I) sau placebo şi au fost distribuiţi în funcţie de administrarea concomitentă de MTX şi de corticosteroizi.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"doză\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In Part II, patients were randomized to tocilizumab (same dose received in Part I) or placebo in a 1:1 ratio, stratified by concurrent MTX use and concurrent corticosteroid use.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||doză\tplacebo|||placebo", "en": "In Part II, patients were randomized to tocilizumab (same dose received in Part I) or placebo in a 1:1 ratio, stratified by concurrent MTX use and concurrent corticosteroid use.", "ro": "În Partea a II-a, pacienţii au fost randomizaţi în raport 1:1 pentru a li se administra tocilizumab (aceeaşi doză administrată și în Partea I) sau placebo şi au fost distribuiţi în funcţie de administrarea concomitentă de MTX şi de corticosteroizi." } }
{ "translation": { "text": "Glossary:\n\"necrosis\" -> \"necroză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more diseasemodifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.\nRomanian: • tratamentul pacienţilor adulţi cu PR activă, moderată până la severă, care au avut fie un răspuns inadecvat, fie nu au tolerat tratamentul cu unul sau mai multe medicamente antireumatice modificatoare ale bolii (DMARD) sau cu inhibitori ai factorului de necroză tumorală (TNF).", "en_prompt": "<|im_start|>user\nGlossary:\n\"necrosis\" -> \"necroză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more diseasemodifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "necrosis|||necroză", "en": "• the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more diseasemodifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.", "ro": "• tratamentul pacienţilor adulţi cu PR activă, moderată până la severă, care au avut fie un răspuns inadecvat, fie nu au tolerat tratamentul cu unul sau mai multe medicamente antireumatice modificatoare ale bolii (DMARD) sau cu inhibitori ai factorului de necroză tumorală (TNF)." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: This was not observed in either of the placebo plus prednisone taper groups.\nRomanian: Aceste modificări nu au fost observate în niciunul dintre grupurile cu administrare de placebo plus prednison în doze scăzute progresiv.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: This was not observed in either of the placebo plus prednisone taper groups.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "This was not observed in either of the placebo plus prednisone taper groups.", "ro": "Aceste modificări nu au fost observate în niciunul dintre grupurile cu administrare de placebo plus prednison în doze scăzute progresiv." } }
{ "translation": { "text": "Glossary:\n\"hypersensitivity\" -> \"hipersensibilitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Of the 46 patients (1.6%) who developed anti-RoActemra antibodies, 6 had an associated medically significant hypersensitivity reaction, of which 5 led to permanent discontinuation of treatment.\nRomanian: Din 46 de pacienţi (1,6%) care au dezvoltat anticorpi anti-RoActemra, 6 au prezentat reacţii de hipersensibilitate asociate, semnificative din punct de vedere medical, din care 5 au întrerupt tratamentul permanent.", "en_prompt": "<|im_start|>user\nGlossary:\n\"hypersensitivity\" -> \"hipersensibilitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Of the 46 patients (1.6%) who developed anti-RoActemra antibodies, 6 had an associated medically significant hypersensitivity reaction, of which 5 led to permanent discontinuation of treatment.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "hypersensitivity|||hipersensibilitate", "en": "Of the 46 patients (1.6%) who developed anti-RoActemra antibodies, 6 had an associated medically significant hypersensitivity reaction, of which 5 led to permanent discontinuation of treatment.", "ro": "Din 46 de pacienţi (1,6%) care au dezvoltat anticorpi anti-RoActemra, 6 au prezentat reacţii de hipersensibilitate asociate, semnificative din punct de vedere medical, din care 5 au întrerupt tratamentul permanent." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: An elevation in AST > 3 ULN occurred in 1% of patients in the RoActemra subcutaneous weekly group, compared to no patients in either of the placebo plus prednisone taper groups.\nRomanian: O creştere a AST la valori > 3 LSN a fost observată la 1% dintre pacienţii grupului cu RoActemra administrat subcutanat în fiecare săptămână, comparativ cu niciun pacient în grupurile cu administrare de placebo plus prednison în doze scăzute progresiv.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: An elevation in AST > 3 ULN occurred in 1% of patients in the RoActemra subcutaneous weekly group, compared to no patients in either of the placebo plus prednisone taper groups.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "An elevation in AST > 3 ULN occurred in 1% of patients in the RoActemra subcutaneous weekly group, compared to no patients in either of the placebo plus prednisone taper groups.", "ro": "O creştere a AST la valori > 3 LSN a fost observată la 1% dintre pacienţii grupului cu RoActemra administrat subcutanat în fiecare săptămână, comparativ cu niciun pacient în grupurile cu administrare de placebo plus prednison în doze scăzute progresiv." } }
{ "translation": { "text": "Glossaries:\n\"antigen\" -> \"antigen\"\n\"receptor\" -> \"receptor\"\n\"cytokine\" -> \"citokine\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: RoActemra is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.\nRomanian: RoActemra este indicat pentru tratamentul sindromului de eliberare de citokine (SEC) indus de terapia pe bază de limfocite T cu receptor chimeric pentru antigen (chimeric antigen receptor T cell, CAR-T), sever sau care pune viaţa în pericol, la pacienţi adulţi sau copii şi adolescenţi cu vârsta de 2 ani sau peste.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"antigen\" -> \"antigen\"\n\"receptor\" -> \"receptor\"\n\"cytokine\" -> \"citokine\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: RoActemra is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "antigen|||antigen\treceptor|||receptor\tcytokine|||citokine", "en": "RoActemra is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.", "ro": "RoActemra este indicat pentru tratamentul sindromului de eliberare de citokine (SEC) indus de terapia pe bază de limfocite T cu receptor chimeric pentru antigen (chimeric antigen receptor T cell, CAR-T), sever sau care pune viaţa în pericol, la pacienţi adulţi sau copii şi adolescenţi cu vârsta de 2 ani sau peste." } }
{ "translation": { "text": "Glossary:\n\"body weight\" -> \"greutate corporală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Exploratory efficacy results showed that RoActemra SC improved median Juvenile Arthritis Disease Activity Score (JADAS)-71 for RoActemra naïve patients and maintained the median JADAS-71 for patients who switched from IV to SC RoActemra treatment over the entire course of the study for patients in both body weight groups (below 30 kg and ≥ 30 kg).\nRomanian: Rezultatele analizei exploratorii privind eficacitatea au evidenţiat faptul că RoActemra administrat subcutanat a îmbunătăţit scorul de activitate a bolii în artrita juvenilă, evaluat pe 71 de articulaţii (Juvenile Arthritis Activity Score, JADAS -71) în cazul pacienţilor netrataţi anterior şi a menţinut valoarea mediană a scorului JADAS-71 în cazul pacienţilor care au trecut de la tratamentul cu RoActemra pe cale intravenoasă la cel administrat subcutanat, pe durata întregului studiu, pentru pacienţii din ambele grupe de greutate corporală (mai mică de 30 kg şi ≥ 30 kg).", "en_prompt": "<|im_start|>user\nGlossary:\n\"body weight\" -> \"greutate corporală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Exploratory efficacy results showed that RoActemra SC improved median Juvenile Arthritis Disease Activity Score (JADAS)-71 for RoActemra naïve patients and maintained the median JADAS-71 for patients who switched from IV to SC RoActemra treatment over the entire course of the study for patients in both body weight groups (below 30 kg and ≥ 30 kg).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "body weight|||greutate corporală", "en": "Exploratory efficacy results showed that RoActemra SC improved median Juvenile Arthritis Disease Activity Score (JADAS)-71 for RoActemra naïve patients and maintained the median JADAS-71 for patients who switched from IV to SC RoActemra treatment over the entire course of the study for patients in both body weight groups (below 30 kg and ≥ 30 kg).", "ro": "Rezultatele analizei exploratorii privind eficacitatea au evidenţiat faptul că RoActemra administrat subcutanat a îmbunătăţit scorul de activitate a bolii în artrita juvenilă, evaluat pe 71 de articulaţii (Juvenile Arthritis Activity Score, JADAS -71) în cazul pacienţilor netrataţi anterior şi a menţinut valoarea mediană a scorului JADAS-71 în cazul pacienţilor care au trecut de la tratamentul cu RoActemra pe cale intravenoasă la cel administrat subcutanat, pe durata întregului studiu, pentru pacienţii din ambele grupe de greutate corporală (mai mică de 30 kg şi ≥ 30 kg)." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Each of the RoActemra-treated groups and one of the placebo-treated groups followed a pre-specified prednisone-taper regimen over 26 weeks, while the second placebo-treated group followed a pre-specified prednisone-taper regimen over 52 weeks, designed to be more in keeping with standard practice.\nRomanian: Fiecare dintre grupurile tratate cu RoActemra şi unul dintre grupurile la care s-a administrat placebo au urmat o schemă pre-specificată de tratament cu prednison administrat în doze scăzute treptat pe parcursul a 26 de săptămâni, în timp ce al doilea grup la care s-a administrat placebo a urmat o schemă de tratament pre-specificată, mai apropiată de practica standard, cu prednison în doze scăzute treptat pe parcursul a 52 de săptămâni.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Each of the RoActemra-treated groups and one of the placebo-treated groups followed a pre-specified prednisone-taper regimen over 26 weeks, while the second placebo-treated group followed a pre-specified prednisone-taper regimen over 52 weeks, designed to be more in keeping with standard practice.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "Each of the RoActemra-treated groups and one of the placebo-treated groups followed a pre-specified prednisone-taper regimen over 26 weeks, while the second placebo-treated group followed a pre-specified prednisone-taper regimen over 52 weeks, designed to be more in keeping with standard practice.", "ro": "Fiecare dintre grupurile tratate cu RoActemra şi unul dintre grupurile la care s-a administrat placebo au urmat o schemă pre-specificată de tratament cu prednison administrat în doze scăzute treptat pe parcursul a 26 de săptămâni, în timp ce al doilea grup la care s-a administrat placebo a urmat o schemă de tratament pre-specificată, mai apropiată de practica standard, cu prednison în doze scăzute treptat pe parcursul a 52 de săptămâni." } }
{ "translation": { "text": "Glossary:\n\"arthritis\" -> \"artrită\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The linear clearance was estimated as a parameter in the population pharmacokinetic analysis and was 5.7 mL/h in paediatric patients with systemic juvenile idiopathic arthritis.\nRomanian: Clearance-ul linear a fost estimat ca parametru în cadrul analizei farmacocinetice a populaţiei şi a fost de 5,7 mL/h la pacienţii copii și adolescenți cu artrită idiopatică juvenilă sistemică.", "en_prompt": "<|im_start|>user\nGlossary:\n\"arthritis\" -> \"artrită\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The linear clearance was estimated as a parameter in the population pharmacokinetic analysis and was 5.7 mL/h in paediatric patients with systemic juvenile idiopathic arthritis.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "arthritis|||artrită", "en": "The linear clearance was estimated as a parameter in the population pharmacokinetic analysis and was 5.7 mL/h in paediatric patients with systemic juvenile idiopathic arthritis.", "ro": "Clearance-ul linear a fost estimat ca parametru în cadrul analizei farmacocinetice a populaţiei şi a fost de 5,7 mL/h la pacienţii copii și adolescenți cu artrită idiopatică juvenilă sistemică." } }
{ "translation": { "text": "Glossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The dose-response curve for tocilizumab flattens at higher exposure, resulting in smaller efficacy gains for each incremental increase in RoActemra concentration such that clinically meaningful increases in efficacy were not demonstrated in patients treated with > 800 mg of RoActemra.\nRomanian: Curba doză-răspuns pentru tocilizumab se aplatizează la expuneri mai mari, determinând creşteri ale eficacităţii mai mici pentru fiecare creştere incrementală a concentraţiei de RoActemra, astfel încât la pacienţii trataţi cu doze > 800 mg de RoActemra nu au fost demonstrate creşteri semnificative clinic ale eficacităţii.", "en_prompt": "<|im_start|>user\nGlossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The dose-response curve for tocilizumab flattens at higher exposure, resulting in smaller efficacy gains for each incremental increase in RoActemra concentration such that clinically meaningful increases in efficacy were not demonstrated in patients treated with > 800 mg of RoActemra.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||doză", "en": "The dose-response curve for tocilizumab flattens at higher exposure, resulting in smaller efficacy gains for each incremental increase in RoActemra concentration such that clinically meaningful increases in efficacy were not demonstrated in patients treated with > 800 mg of RoActemra.", "ro": "Curba doză-răspuns pentru tocilizumab se aplatizează la expuneri mai mari, determinând creşteri ale eficacităţii mai mici pentru fiecare creştere incrementală a concentraţiei de RoActemra, astfel încât la pacienţii trataţi cu doze > 800 mg de RoActemra nu au fost demonstrate creşteri semnificative clinic ale eficacităţii." } }
{ "translation": { "text": "Glossary:\n\"practice\" -> \"practică\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In sJIA and pJIA patients, neutrophils and platelets should be monitored at the time of the second administration and thereafter according to good clinical practice (see section 4.2).\nRomanian: La pacienţii cu AIJs și AIJp, neutrofilele şi trombocitele trebuie monitorizate în momentul celei de-a doua administrări şi ulterior, conform regulilor de bună practică clinică (vezi pct. 4.2).", "en_prompt": "<|im_start|>user\nGlossary:\n\"practice\" -> \"practică\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In sJIA and pJIA patients, neutrophils and platelets should be monitored at the time of the second administration and thereafter according to good clinical practice (see section 4.2).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "practice|||practică", "en": "In sJIA and pJIA patients, neutrophils and platelets should be monitored at the time of the second administration and thereafter according to good clinical practice (see section 4.2).", "ro": "La pacienţii cu AIJs și AIJp, neutrofilele şi trombocitele trebuie monitorizate în momentul celei de-a doua administrări şi ulterior, conform regulilor de bună practică clinică (vezi pct. 4.2)." } }
{ "translation": { "text": "Glossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Patients transitioning from intravenous to subcutaneous formulation should administer their first subcutaneous dose instead of the next scheduled intravenous dose under the supervision of a qualified healthcare professional.\nRomanian: Pacienţii care au trecut de la forma farmaceutică intravenoasă la cea subcutanată trebuie să-şi administreze subcutanat prima doză care înlocuieşte următoarea doză programată a fi administrată intravenos, sub supravegherea unui profesionist în domeniul sănătăţii calificat.", "en_prompt": "<|im_start|>user\nGlossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Patients transitioning from intravenous to subcutaneous formulation should administer their first subcutaneous dose instead of the next scheduled intravenous dose under the supervision of a qualified healthcare professional.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||doză", "en": "Patients transitioning from intravenous to subcutaneous formulation should administer their first subcutaneous dose instead of the next scheduled intravenous dose under the supervision of a qualified healthcare professional.", "ro": "Pacienţii care au trecut de la forma farmaceutică intravenoasă la cea subcutanată trebuie să-şi administreze subcutanat prima doză care înlocuieşte următoarea doză programată a fi administrată intravenos, sub supravegherea unui profesionist în domeniul sănătăţii calificat." } }
{ "translation": { "text": "Glossary:\n\"clearance\" -> \"clearance\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Once the non-linear clearance pathway is saturated, at higher RoActemra concentrations, clearance is mainly determined by the linear clearance.\nRomanian: Imediat ce calea clearance-ului non-linear este saturată, la concentraţii ridicate de RoActemra, clearance-ul este în principal determinat de clearance-ul linear.", "en_prompt": "<|im_start|>user\nGlossary:\n\"clearance\" -> \"clearance\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Once the non-linear clearance pathway is saturated, at higher RoActemra concentrations, clearance is mainly determined by the linear clearance.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "clearance|||clearance", "en": "Once the non-linear clearance pathway is saturated, at higher RoActemra concentrations, clearance is mainly determined by the linear clearance.", "ro": "Imediat ce calea clearance-ului non-linear este saturată, la concentraţii ridicate de RoActemra, clearance-ul este în principal determinat de clearance-ul linear." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The key secondary efficacy endpoint also based on the proportion of patients achieving sustained remission at week 52, comparing tocilizumab plus 26 weeks prednisone taper with placebo plus 52 weeks prednisone taper, was also met (Table 4).\nRomanian: Criteriul secundar de eficacitate bazat, de asemenea, pe proporţia pacienţilor care au obţinut o remisiune durabilă la săptămâna 52, comparând tocilizumab plus prednison în doze scăzute treptat pe parcursul a 26 săptămâni cu placebo plus prednison în doze scăzute treptat pe parcursul a 52 săptămâni a fost, de asemenea, îndeplinit (Tabelul 4).", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The key secondary efficacy endpoint also based on the proportion of patients achieving sustained remission at week 52, comparing tocilizumab plus 26 weeks prednisone taper with placebo plus 52 weeks prednisone taper, was also met (Table 4).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "The key secondary efficacy endpoint also based on the proportion of patients achieving sustained remission at week 52, comparing tocilizumab plus 26 weeks prednisone taper with placebo plus 52 weeks prednisone taper, was also met (Table 4).", "ro": "Criteriul secundar de eficacitate bazat, de asemenea, pe proporţia pacienţilor care au obţinut o remisiune durabilă la săptămâna 52, comparând tocilizumab plus prednison în doze scăzute treptat pe parcursul a 26 săptămâni cu placebo plus prednison în doze scăzute treptat pe parcursul a 52 săptămâni a fost, de asemenea, îndeplinit (Tabelul 4)." } }
{ "translation": { "text": "Glossary:\n\"infusion\" -> \"perfuzie\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Therefore, tocilizumab doses exceeding 800 mg per infusion are not recommended (see section 4.2).\nRomanian: Prin urmare, nu se recomandă administrarea unor doze de tocilizumab mai mari de 800 mg per perfuzie (vezi pct. 4.2).", "en_prompt": "<|im_start|>user\nGlossary:\n\"infusion\" -> \"perfuzie\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Therefore, tocilizumab doses exceeding 800 mg per infusion are not recommended (see section 4.2).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "infusion|||perfuzie", "en": "Therefore, tocilizumab doses exceeding 800 mg per infusion are not recommended (see section 4.2).", "ro": "Prin urmare, nu se recomandă administrarea unor doze de tocilizumab mai mari de 800 mg per perfuzie (vezi pct. 4.2)." } }
{ "translation": { "text": "Glossary:\n\"disease\" -> \"boală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: RoActemra has been shown to slow the damage to the cartilage and bone of the joints caused by the disease and to improve your ability to do normal daily activities.\nRomanian: S-a demonstrat că RoActemra încetineşte distrucţia cartilajelor şi a oaselor la nivelul articulaţiilor cauzată de boală şi vă îmbunătăţeşte capacitatea de desfăşurare a activităţilor zilnice obişnuite.", "en_prompt": "<|im_start|>user\nGlossary:\n\"disease\" -> \"boală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: RoActemra has been shown to slow the damage to the cartilage and bone of the joints caused by the disease and to improve your ability to do normal daily activities.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "disease|||boală", "en": "RoActemra has been shown to slow the damage to the cartilage and bone of the joints caused by the disease and to improve your ability to do normal daily activities.", "ro": "S-a demonstrat că RoActemra încetineşte distrucţia cartilajelor şi a oaselor la nivelul articulaţiilor cauzată de boală şi vă îmbunătăţeşte capacitatea de desfăşurare a activităţilor zilnice obişnuite." } }
{ "translation": { "text": "Glossaries:\n\"infusion\" -> \"perfuzie\"\n\"intravenous infusion\" -> \"perfuzie intravenoasă\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: After dilution, RoActemra for RA, sJIA, pJIA, and CRS patients should be administered as an intravenous infusion over 1 hour.\nRomanian: La pacienţii cu PR, AIJs, AIJp și SEC, după diluare, RoActemra trebuie administrat sub formă de perfuzie intravenoasă în decurs de 1 oră.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"infusion\" -> \"perfuzie\"\n\"intravenous infusion\" -> \"perfuzie intravenoasă\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: After dilution, RoActemra for RA, sJIA, pJIA, and CRS patients should be administered as an intravenous infusion over 1 hour.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "infusion|||perfuzie\tintravenous infusion|||perfuzie intravenoasă", "en": "After dilution, RoActemra for RA, sJIA, pJIA, and CRS patients should be administered as an intravenous infusion over 1 hour.", "ro": "La pacienţii cu PR, AIJs, AIJp și SEC, după diluare, RoActemra trebuie administrat sub formă de perfuzie intravenoasă în decurs de 1 oră." } }
{ "translation": { "text": "Glossaries:\n\"disability\" -> \"dizabilitate\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In patients treated with tocilizumab 8 mg/kg, significant improvements were noted on all individual components of the ACR response including: tender and swollen joint counts; patients and physician global assessment; disability index scores; pain assessment and CRP compared to patients receiving placebo plus MTX or other DMARDs in all studies.\nRomanian: În toate studiile, la pacienţii trataţi cu tocilizumab 8 mg/kg, au fost observate îmbunătăţiri semnificative ale tuturor componentelor individuale ale răspunsului ACR care includ: numărul de articulaţii inflamate şi sensibile; evaluarea globală a pacientului şi medicului; scorul indexului de dizabilitate; evaluarea durerii şi a PCR comparativ cu pacienţii la care se administrează placebo plus", "en_prompt": "<|im_start|>user\nGlossaries:\n\"disability\" -> \"dizabilitate\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In patients treated with tocilizumab 8 mg/kg, significant improvements were noted on all individual components of the ACR response including: tender and swollen joint counts; patients and physician global assessment; disability index scores; pain assessment and CRP compared to patients receiving placebo plus MTX or other DMARDs in all studies.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "disability|||dizabilitate\tplacebo|||placebo", "en": "In patients treated with tocilizumab 8 mg/kg, significant improvements were noted on all individual components of the ACR response including: tender and swollen joint counts; patients and physician global assessment; disability index scores; pain assessment and CRP compared to patients receiving placebo plus MTX or other DMARDs in all studies.", "ro": "În toate studiile, la pacienţii trataţi cu tocilizumab 8 mg/kg, au fost observate îmbunătăţiri semnificative ale tuturor componentelor individuale ale răspunsului ACR care includ: numărul de articulaţii inflamate şi sensibile; evaluarea globală a pacientului şi medicului; scorul indexului de dizabilitate; evaluarea durerii şi a PCR comparativ cu pacienţii la care se administrează placebo plus" } }
{ "translation": { "text": "Glossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The overall safety profile observed in the RoActemra treatment groups was consistent with the known safety profile of RoActemra (see Table 1).\nRomanian: Profilul general de siguranţă observat în grupurile de tratament cu RoActemra a fost în concordanţă cu profilul de siguranţă cunoscut al RoActemra (vezi", "en_prompt": "<|im_start|>user\nGlossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The overall safety profile observed in the RoActemra treatment groups was consistent with the known safety profile of RoActemra (see Table 1).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratament", "en": "The overall safety profile observed in the RoActemra treatment groups was consistent with the known safety profile of RoActemra (see Table 1).", "ro": "Profilul general de siguranţă observat în grupurile de tratament cu RoActemra a fost în concordanţă cu profilul de siguranţă cunoscut al RoActemra (vezi" } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If you have any further questions on the use of this medicine, ask your doctor or nurse.\nRomanian: Dacă aveţi orice întrebări suplimentare cu privire la utilizarea acestui medicament, adresaţi-vă medicului dumneavoastră sau asistentei medicale.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If you have any further questions on the use of this medicine, ask your doctor or nurse.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "If you have any further questions on the use of this medicine, ask your doctor or nurse.", "ro": "Dacă aveţi orice întrebări suplimentare cu privire la utilizarea acestui medicament, adresaţi-vă medicului dumneavoastră sau asistentei medicale." } }
{ "translation": { "text": "Glossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Patients who transition from tocilizumab IV therapy to SC administration should administer the first SC dose at the time of the next scheduled IV dose under the supervision of a qualified health care professional.\nRomanian: Pacienţii care trec de la terapia cu tocilizumab pe cale intravenoasă la administrarea pe cale subcutanată trebuie să-şi administreze prima doză subcutanată la momentul următoarei doze intravenoase programate, sub supravegherea unui profesionist în domeniul sănătăţii calificat.", "en_prompt": "<|im_start|>user\nGlossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Patients who transition from tocilizumab IV therapy to SC administration should administer the first SC dose at the time of the next scheduled IV dose under the supervision of a qualified health care professional.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||doză", "en": "Patients who transition from tocilizumab IV therapy to SC administration should administer the first SC dose at the time of the next scheduled IV dose under the supervision of a qualified health care professional.", "ro": "Pacienţii care trec de la terapia cu tocilizumab pe cale intravenoasă la administrarea pe cale subcutanată trebuie să-şi administreze prima doză subcutanată la momentul următoarei doze intravenoase programate, sub supravegherea unui profesionist în domeniul sănătăţii calificat." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In study SC-II, mean decrease in HAQ-DI from baseline to week 24 was significantly greater for patients treated with RoActemra subcutaneous every other week (0.4) versus placebo (0.3).\nRomanian: În Studiul SC-II, scăderea medie a HAQ-DI de la momentul iniţial la săptămâna 24, a fost semnificativ mai mare la pacienţii trataţi cu RoActemra administrat subcutanat la interval de 2 săptămâni (0,4), comparativ cu placebo (0,3).", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In study SC-II, mean decrease in HAQ-DI from baseline to week 24 was significantly greater for patients treated with RoActemra subcutaneous every other week (0.4) versus placebo (0.3).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "In study SC-II, mean decrease in HAQ-DI from baseline to week 24 was significantly greater for patients treated with RoActemra subcutaneous every other week (0.4) versus placebo (0.3).", "ro": "În Studiul SC-II, scăderea medie a HAQ-DI de la momentul iniţial la săptămâna 24, a fost semnificativ mai mare la pacienţii trataţi cu RoActemra administrat subcutanat la interval de 2 săptămâni (0,4), comparativ cu placebo (0,3)." } }
{ "translation": { "text": "Glossaries:\n\"disease\" -> \"boală\"\n\"diabetes\" -> \"diabet\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Healthcare professionals should exercise caution when considering the use of RoActemra in patients with a history of recurring or chronic infections or with underlying conditions (e.g.) diverticulitis, diabetes and interstitial lung disease which may predispose patients to infections.\nRomanian: Medicii trebuie să fie precauţi când au în vedere administrarea RoActemra la pacienţii cu antecedente de infecţii recurente sau cronice sau cu afecţiuni asociate (de exemplu diverticulită, diabet zaharat şi boală pulmonară interstiţială), care îi pot predispune la infecţii.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"disease\" -> \"boală\"\n\"diabetes\" -> \"diabet\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Healthcare professionals should exercise caution when considering the use of RoActemra in patients with a history of recurring or chronic infections or with underlying conditions (e.g.) diverticulitis, diabetes and interstitial lung disease which may predispose patients to infections.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "disease|||boală\tdiabetes|||diabet", "en": "Healthcare professionals should exercise caution when considering the use of RoActemra in patients with a history of recurring or chronic infections or with underlying conditions (e.g.) diverticulitis, diabetes and interstitial lung disease which may predispose patients to infections.", "ro": "Medicii trebuie să fie precauţi când au în vedere administrarea RoActemra la pacienţii cu antecedente de infecţii recurente sau cronice sau cu afecţiuni asociate (de exemplu diverticulită, diabet zaharat şi boală pulmonară interstiţială), care îi pot predispune la infecţii." } }
{ "translation": { "text": "Glossary:\n\"hypersensitivity\" -> \"hipersensibilitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Such reactions may be more severe, and potentially fatal in patients who have experienced hypersensitivity reactions during previous infusions even if they have received premedication with steroids and antihistamines.\nRomanian: Astfel de reacţii pot fi mai severe şi potenţial letale la pacienţii care au prezentat reacţii de hipersensibilitate în timpul perfuziilor administrate anterior, chiar dacă li s-a administrat premedicaţie cu steroizi şi antihistaminice.", "en_prompt": "<|im_start|>user\nGlossary:\n\"hypersensitivity\" -> \"hipersensibilitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Such reactions may be more severe, and potentially fatal in patients who have experienced hypersensitivity reactions during previous infusions even if they have received premedication with steroids and antihistamines.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "hypersensitivity|||hipersensibilitate", "en": "Such reactions may be more severe, and potentially fatal in patients who have experienced hypersensitivity reactions during previous infusions even if they have received premedication with steroids and antihistamines.", "ro": "Astfel de reacţii pot fi mai severe şi potenţial letale la pacienţii care au prezentat reacţii de hipersensibilitate în timpul perfuziilor administrate anterior, chiar dacă li s-a administrat premedicaţie cu steroizi şi antihistaminice." } }
{ "translation": { "text": "Glossary:\n\"body weight\" -> \"greutate corporală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • If you weigh 30 kg or more, the dose is 8 mg for every kilogram of body weight The dose is calculated based on your body weight at each administration.\nRomanian: • Dacă aveţi greutatea de 30 kg sau mai mare, doza este de 8 mg pentru fiecare kilogram de greutate corporală Doza este calculată pe baza greutăţii corporale a pacientului la fiecare administrare.", "en_prompt": "<|im_start|>user\nGlossary:\n\"body weight\" -> \"greutate corporală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • If you weigh 30 kg or more, the dose is 8 mg for every kilogram of body weight The dose is calculated based on your body weight at each administration.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "body weight|||greutate corporală", "en": "• If you weigh 30 kg or more, the dose is 8 mg for every kilogram of body weight The dose is calculated based on your body weight at each administration.", "ro": "• Dacă aveţi greutatea de 30 kg sau mai mare, doza este de 8 mg pentru fiecare kilogram de greutate corporală Doza este calculată pe baza greutăţii corporale a pacientului la fiecare administrare." } }
{ "translation": { "text": "Glossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: At week 24, a significant reduction in DAS28 from baseline (mean improvement) of 3.5 was observed on both treatment arms, and a comparable proportion of patients had achieved DAS28 clinical remission (DAS28 < 2.6) on the subcutaneous (38.4%) and IV (36.9%) arms.\nRomanian: La săptămâna 24, a fost observată o scădere semnificativă a DAS28 faţă de momentul iniţial (îmbunătăţire medie) de 3,5, în ambele braţe de tratament, iar un procent comparabil de pacienţi au atins remisiunea clinică conform DAS28 (DAS28 < 2,6) în braţul cu administrare subcutantă (38,4%) şi în braţul cu administrare intravenoasă (36,9%).", "en_prompt": "<|im_start|>user\nGlossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: At week 24, a significant reduction in DAS28 from baseline (mean improvement) of 3.5 was observed on both treatment arms, and a comparable proportion of patients had achieved DAS28 clinical remission (DAS28 < 2.6) on the subcutaneous (38.4%) and IV (36.9%) arms.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratament", "en": "At week 24, a significant reduction in DAS28 from baseline (mean improvement) of 3.5 was observed on both treatment arms, and a comparable proportion of patients had achieved DAS28 clinical remission (DAS28 < 2.6) on the subcutaneous (38.4%) and IV (36.9%) arms.", "ro": "La săptămâna 24, a fost observată o scădere semnificativă a DAS28 faţă de momentul iniţial (îmbunătăţire medie) de 3,5, în ambele braţe de tratament, iar un procent comparabil de pacienţi au atins remisiunea clinică conform DAS28 (DAS28 < 2,6) în braţul cu administrare subcutantă (38,4%) şi în braţul cu administrare intravenoasă (36,9%)." } }
{ "translation": { "text": "Glossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The long-term exposure population includes all patients who received at least one dose of tocilizumab either in the double-blind control period or open label extension phase in the studies.\nRomanian: Populaţia expusă pe termen lung a inclus toţi pacienţii cărora li s-a administrat cel puţin o doză de tocilizumab, fie în perioada controlată dublu-orb, fie în faza de extensie deschisă a studiilor.", "en_prompt": "<|im_start|>user\nGlossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The long-term exposure population includes all patients who received at least one dose of tocilizumab either in the double-blind control period or open label extension phase in the studies.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||doză", "en": "The long-term exposure population includes all patients who received at least one dose of tocilizumab either in the double-blind control period or open label extension phase in the studies.", "ro": "Populaţia expusă pe termen lung a inclus toţi pacienţii cărora li s-a administrat cel puţin o doză de tocilizumab, fie în perioada controlată dublu-orb, fie în faza de extensie deschisă a studiilor." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Study WA28119 was a randomized, multi-center, double-blind placebo-controlled Phase III superiority study conducted to assess the efficacy and safety of RoActemra in patients with GCA.\nRomanian: Studiul WA28119 a fost un studiu randomizat, multicentric, dublu-orb, placebo-controlat, de fază III,", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Study WA28119 was a randomized, multi-center, double-blind placebo-controlled Phase III superiority study conducted to assess the efficacy and safety of RoActemra in patients with GCA.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "Study WA28119 was a randomized, multi-center, double-blind placebo-controlled Phase III superiority study conducted to assess the efficacy and safety of RoActemra in patients with GCA.", "ro": "Studiul WA28119 a fost un studiu randomizat, multicentric, dublu-orb, placebo-controlat, de fază III," } }
{ "translation": { "text": "Glossary:\n\"clearance\" -> \"clearance\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Once the non-linear clearance pathway is saturated, at higher tocilizumab concentrations, clearance is mainly determined by the linear clearance.\nRomanian: Imediat ce calea clearance-ului non-linear este saturată, la concentraţii ridicate de tocilizumab, clearance-ul este în principal determinat de clearance-ul linear.", "en_prompt": "<|im_start|>user\nGlossary:\n\"clearance\" -> \"clearance\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Once the non-linear clearance pathway is saturated, at higher tocilizumab concentrations, clearance is mainly determined by the linear clearance.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "clearance|||clearance", "en": "Once the non-linear clearance pathway is saturated, at higher tocilizumab concentrations, clearance is mainly determined by the linear clearance.", "ro": "Imediat ce calea clearance-ului non-linear este saturată, la concentraţii ridicate de tocilizumab, clearance-ul este în principal determinat de clearance-ul linear." } }
{ "translation": { "text": "Glossaries:\n\"disability\" -> \"dizabilitate\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In patients treated with RoActemra 8 mg/kg, significant improvements were noted on all individual components of the ACR response including: tender and swollen joint counts; patients and physician global assessment; disability index scores; pain assessment and CRP compared to patients receiving placebo plus MTX or other DMARDs in all studies.\nRomanian: În toate studiile clinice, la pacienţii trataţi cu RoActemra 8 mg/kg, au fost observate îmbunătăţiri semnificative ale tuturor componentelor individuale ale răspunsului ACR care includ: numărul de articulaţii inflamate şi sensibile; evaluarea globală a pacientului şi a medicului; scorul indexului de dizabilitate; evaluarea durerii şi a PCR comparativ cu pacienţii la care se administrează placebo plus", "en_prompt": "<|im_start|>user\nGlossaries:\n\"disability\" -> \"dizabilitate\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In patients treated with RoActemra 8 mg/kg, significant improvements were noted on all individual components of the ACR response including: tender and swollen joint counts; patients and physician global assessment; disability index scores; pain assessment and CRP compared to patients receiving placebo plus MTX or other DMARDs in all studies.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "disability|||dizabilitate\tplacebo|||placebo", "en": "In patients treated with RoActemra 8 mg/kg, significant improvements were noted on all individual components of the ACR response including: tender and swollen joint counts; patients and physician global assessment; disability index scores; pain assessment and CRP compared to patients receiving placebo plus MTX or other DMARDs in all studies.", "ro": "În toate studiile clinice, la pacienţii trataţi cu RoActemra 8 mg/kg, au fost observate îmbunătăţiri semnificative ale tuturor componentelor individuale ale răspunsului ACR care includ: numărul de articulaţii inflamate şi sensibile; evaluarea globală a pacientului şi a medicului; scorul indexului de dizabilitate; evaluarea durerii şi a PCR comparativ cu pacienţii la care se administrează placebo plus" } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The rate of infection/serious infection events was balanced between the RoActemra weekly group (200.2/9.7 events per 100 patient years) vs. placebo plus 26 weeks prednisone taper (156.0/4.2 events per 100 patient years) and placebo plus 52 weeks taper (210.2/12.5 events per 100 patient years) groups.\nRomanian: Infecţii Incidenţa infecţiilor/infecţiilor grave a fost echilibrată între grupul cu RoActemra administrat săptămânal (200,2/9,7 evenimente per 100 de pacienţi-ani) şi cel la care s-a administrat placebo plus prednison în doze scăzute progresiv în decurs de 26 săptămâni (156,0/4,2 evenimente per 100 pacienţiani), respectiv cel la care s-a administrat placebo plus prednison în doze scăzute treptat pe parcursul a", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The rate of infection/serious infection events was balanced between the RoActemra weekly group (200.2/9.7 events per 100 patient years) vs. placebo plus 26 weeks prednisone taper (156.0/4.2 events per 100 patient years) and placebo plus 52 weeks taper (210.2/12.5 events per 100 patient years) groups.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "The rate of infection/serious infection events was balanced between the RoActemra weekly group (200.2/9.7 events per 100 patient years) vs. placebo plus 26 weeks prednisone taper (156.0/4.2 events per 100 patient years) and placebo plus 52 weeks taper (210.2/12.5 events per 100 patient years) groups.", "ro": "Infecţii Incidenţa infecţiilor/infecţiilor grave a fost echilibrată între grupul cu RoActemra administrat săptămânal (200,2/9,7 evenimente per 100 de pacienţi-ani) şi cel la care s-a administrat placebo plus prednison în doze scăzute progresiv în decurs de 26 săptămâni (156,0/4,2 evenimente per 100 pacienţiani), respectiv cel la care s-a administrat placebo plus prednison în doze scăzute treptat pe parcursul a" } }
{ "translation": { "text": "Glossary:\n\"vial\" -> \"flacon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Each 400 mg vial contains 0.39 mmol (8.85 mg) sodium.\nRomanian: Fiecare flacon a 400 mg conţine sodiu 0,39 mmoli (8,85 mg).", "en_prompt": "<|im_start|>user\nGlossary:\n\"vial\" -> \"flacon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Each 400 mg vial contains 0.39 mmol (8.85 mg) sodium.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "vial|||flacon", "en": "Each 400 mg vial contains 0.39 mmol (8.85 mg) sodium.", "ro": "Fiecare flacon a 400 mg conţine sodiu 0,39 mmoli (8,85 mg)." } }
{ "translation": { "text": "Glossary:\n\"hypersensitivity\" -> \"hipersensibilitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Clinically significant hypersensitivity reactions associated with tocilizumab and requiring treatment discontinuation, were reported in 1 out of 112 patients (< 1%) treated with tocilizumab during the controlled and up to and including the open label clinical trial.\nRomanian: Au fost raportate reacţii de hipersensibilitate semnificative clinic asociate cu administrarea de tocilizumab care au necesitat întreruperea tratamentului la 1 pacient din cei 112 pacienţi (< 1%) trataţi cu tocilizumab în timpul perioadei controlate şi până la includerea în studiul clinic deschis.", "en_prompt": "<|im_start|>user\nGlossary:\n\"hypersensitivity\" -> \"hipersensibilitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Clinically significant hypersensitivity reactions associated with tocilizumab and requiring treatment discontinuation, were reported in 1 out of 112 patients (< 1%) treated with tocilizumab during the controlled and up to and including the open label clinical trial.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "hypersensitivity|||hipersensibilitate", "en": "Clinically significant hypersensitivity reactions associated with tocilizumab and requiring treatment discontinuation, were reported in 1 out of 112 patients (< 1%) treated with tocilizumab during the controlled and up to and including the open label clinical trial.", "ro": "Au fost raportate reacţii de hipersensibilitate semnificative clinic asociate cu administrarea de tocilizumab care au necesitat întreruperea tratamentului la 1 pacient din cei 112 pacienţi (< 1%) trataţi cu tocilizumab în timpul perioadei controlate şi până la includerea în studiul clinic deschis." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The number of active joints was significantly reduced compared to baseline in patients receiving tocilizumab compared to placebo (adjusted mean changes of -14.3 vs -11.4, p=0.0435).\nRomanian: * p< 0,01, tocilizumab comparativ cu placebo Comparativ cu placebo, numărul articulaţiilor active s-a redus semnificativ la pacienţii cărora li s-a administrat tocilizumab (modificări medii ajustate de -14,3 comparativ cu -11,4, p = 0,0435).", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The number of active joints was significantly reduced compared to baseline in patients receiving tocilizumab compared to placebo (adjusted mean changes of -14.3 vs -11.4, p=0.0435).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "The number of active joints was significantly reduced compared to baseline in patients receiving tocilizumab compared to placebo (adjusted mean changes of -14.3 vs -11.4, p=0.0435).", "ro": "* p< 0,01, tocilizumab comparativ cu placebo Comparativ cu placebo, numărul articulaţiilor active s-a redus semnificativ la pacienţii cărora li s-a administrat tocilizumab (modificări medii ajustate de -14,3 comparativ cu -11,4, p = 0,0435)." } }
{ "translation": { "text": "Glossary:\n\"toxicity\" -> \"toxicitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Effects on endocrine active and reproductive system organs were not observed in a chronic cynomolgus monkey toxicity study and reproductive performance was not affected in IL-6 deficient mice.\nRomanian: Într-un studiu de toxicitate cronică efectuat la maimuţa cynomolgus nu au fost observate efecte asupra sistemului endocrin activ şi aparatului reproducător, iar la şoarecele cu deficit de IL-6 nu s-au observat efecte asupra funcţiei de reproducere a şoarecelui.", "en_prompt": "<|im_start|>user\nGlossary:\n\"toxicity\" -> \"toxicitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Effects on endocrine active and reproductive system organs were not observed in a chronic cynomolgus monkey toxicity study and reproductive performance was not affected in IL-6 deficient mice.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "toxicity|||toxicitate", "en": "Effects on endocrine active and reproductive system organs were not observed in a chronic cynomolgus monkey toxicity study and reproductive performance was not affected in IL-6 deficient mice.", "ro": "Într-un studiu de toxicitate cronică efectuat la maimuţa cynomolgus nu au fost observate efecte asupra sistemului endocrin activ şi aparatului reproducător, iar la şoarecele cu deficit de IL-6 nu s-au observat efecte asupra funcţiei de reproducere a şoarecelui." } }
{ "translation": { "text": "Glossary:\n\"hypersensitivity\" -> \"hipersensibilitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If an anaphylactic reaction or other serious hypersensitivity / serious infusion related reaction occurs, administration of RoActemra should be stopped immediately and RoActemra should be permanently discontinued.\nRomanian: Dacă apare o reacţie anafilactică sau alte reacţii de hipersensibilitate grave/reacţii grave asociate perfuziei, administrarea de RoActemra trebuie oprită imediat şi tratamentul cu RoActemra trebuie întrerupt definitiv.", "en_prompt": "<|im_start|>user\nGlossary:\n\"hypersensitivity\" -> \"hipersensibilitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If an anaphylactic reaction or other serious hypersensitivity / serious infusion related reaction occurs, administration of RoActemra should be stopped immediately and RoActemra should be permanently discontinued.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "hypersensitivity|||hipersensibilitate", "en": "If an anaphylactic reaction or other serious hypersensitivity / serious infusion related reaction occurs, administration of RoActemra should be stopped immediately and RoActemra should be permanently discontinued.", "ro": "Dacă apare o reacţie anafilactică sau alte reacţii de hipersensibilitate grave/reacţii grave asociate perfuziei, administrarea de RoActemra trebuie oprită imediat şi tratamentul cu RoActemra trebuie întrerupt definitiv." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: During the 6-month controlled period, in SC-I, the frequency of injection site reactions was 10.1% (64/631) and 2.4% (15/631) for the subcutaneous RoActemra and the subcutaneous placebo (intravenous group) weekly injections, respectively.\nRomanian: În timpul perioadei controlate de 6 luni, în studiul clinic SC-I, frecvenţa reacţiilor la locul de injectare a fost de 10,1% (64/631) în cazul administrării subcutanate de RoActemra şi de 2,4% (15/631) în cazul administrării subcutanate de placebo (grupul în care a fost administrată forma farmaceutică cu utilizare intravenoasă), intervalul de administrare în ambele cazuri fiind o dată la o săptămână.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: During the 6-month controlled period, in SC-I, the frequency of injection site reactions was 10.1% (64/631) and 2.4% (15/631) for the subcutaneous RoActemra and the subcutaneous placebo (intravenous group) weekly injections, respectively.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "During the 6-month controlled period, in SC-I, the frequency of injection site reactions was 10.1% (64/631) and 2.4% (15/631) for the subcutaneous RoActemra and the subcutaneous placebo (intravenous group) weekly injections, respectively.", "ro": "În timpul perioadei controlate de 6 luni, în studiul clinic SC-I, frecvenţa reacţiilor la locul de injectare a fost de 10,1% (64/631) în cazul administrării subcutanate de RoActemra şi de 2,4% (15/631) în cazul administrării subcutanate de placebo (grupul în care a fost administrată forma farmaceutică cu utilizare intravenoasă), intervalul de administrare în ambele cazuri fiind o dată la o săptămână." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: At week 24, a significant reduction in DAS28 from baseline of 3.1 was observed on subcutaneous and 1.7 on placebo arm, and for DAS28 < 2.6, 32.0% was observed on subcutaneous and 4.0% on placebo arm.\nRomanian: La săptămâna 24, a fost observată o scădere semnificativă a DAS28 de la momentul iniţial, de 3,1 în braţul cu administrare subcutanată, comparativ cu 1,7 în braţul cu administrare de placebo, iar DAS28 < 26 a fost observat la 32% dintre pacienţii din braţul cu administrare subcutanată şi la 4%", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: At week 24, a significant reduction in DAS28 from baseline of 3.1 was observed on subcutaneous and 1.7 on placebo arm, and for DAS28 < 2.6, 32.0% was observed on subcutaneous and 4.0% on placebo arm.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "At week 24, a significant reduction in DAS28 from baseline of 3.1 was observed on subcutaneous and 1.7 on placebo arm, and for DAS28 < 2.6, 32.0% was observed on subcutaneous and 4.0% on placebo arm.", "ro": "La săptămâna 24, a fost observată o scădere semnificativă a DAS28 de la momentul iniţial, de 3,1 în braţul cu administrare subcutanată, comparativ cu 1,7 în braţul cu administrare de placebo, iar DAS28 < 26 a fost observat la 32% dintre pacienţii din braţul cu administrare subcutanată şi la 4%" } }
{ "translation": { "text": "Glossaries:\n\"disease\" -> \"boală\"\n\"autoimmune disease\" -> \"boală autoimună\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • adults with moderate to severe active rheumatoid arthritis (RA), an autoimmune disease, if previous therapies did not work well enough.\nRomanian: • pacienţilor adulţi cu poliartrită reumatoidă (PR) activă, moderată până la severă, o boală autoimună, dacă tratamentele anterioare nu au acţionat eficient.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"disease\" -> \"boală\"\n\"autoimmune disease\" -> \"boală autoimună\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • adults with moderate to severe active rheumatoid arthritis (RA), an autoimmune disease, if previous therapies did not work well enough.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "disease|||boală\tautoimmune disease|||boală autoimună", "en": "• adults with moderate to severe active rheumatoid arthritis (RA), an autoimmune disease, if previous therapies did not work well enough.", "ro": "• pacienţilor adulţi cu poliartrită reumatoidă (PR) activă, moderată până la severă, o boală autoimună, dacă tratamentele anterioare nu au acţionat eficient." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Do not use this medicine after the expiry date which is stated on the pre-filled syringe label and carton (EXP).\nRomanian: Nu utilizaţi acest medicament după data de expirare înscrisă pe eticheta seringii preumplute şi pe cutie după EXP.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Do not use this medicine after the expiry date which is stated on the pre-filled syringe label and carton (EXP).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "Do not use this medicine after the expiry date which is stated on the pre-filled syringe label and carton (EXP).", "ro": "Nu utilizaţi acest medicament după data de expirare înscrisă pe eticheta seringii preumplute şi pe cutie după EXP." } }
{ "translation": { "text": "Glossaries:\n\"infusion\" -> \"perfuzie\"\n\"intravenous infusion\" -> \"perfuzie intravenoasă\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Children with sJIA will be given RoActemra once every 2 weeks through a drip in the vein (intravenous infusion) over one hour.\nRomanian: Copiilor cu AIJs li se va administra RoActemra o dată la interval de 2 săptămâni, prin picurare, într-una din vene (perfuzie intravenoasă), în decurs de o oră.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"infusion\" -> \"perfuzie\"\n\"intravenous infusion\" -> \"perfuzie intravenoasă\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Children with sJIA will be given RoActemra once every 2 weeks through a drip in the vein (intravenous infusion) over one hour.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "infusion|||perfuzie\tintravenous infusion|||perfuzie intravenoasă", "en": "Children with sJIA will be given RoActemra once every 2 weeks through a drip in the vein (intravenous infusion) over one hour.", "ro": "Copiilor cu AIJs li se va administra RoActemra o dată la interval de 2 săptămâni, prin picurare, într-una din vene (perfuzie intravenoasă), în decurs de o oră." } }
{ "translation": { "text": "Glossary:\n\"vial\" -> \"flacon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Each 200 mg vial contains 0.20 mmol (4.43 mg) sodium.\nRomanian: Fiecare flacon a 200 mg conţine sodiu 0,20 mmoli (4,43 mg).", "en_prompt": "<|im_start|>user\nGlossary:\n\"vial\" -> \"flacon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Each 200 mg vial contains 0.20 mmol (4.43 mg) sodium.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "vial|||flacon", "en": "Each 200 mg vial contains 0.20 mmol (4.43 mg) sodium.", "ro": "Fiecare flacon a 200 mg conţine sodiu 0,20 mmoli (4,43 mg)." } }
{ "translation": { "text": "Glossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: After week 52, all patients could receive open-label treatment with tocilizumab 8 mg/kg.\nRomanian: După săptămâna 52, tuturor pacienţilor li s-a putut administra tratament deschis cu tocilizumab", "en_prompt": "<|im_start|>user\nGlossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: After week 52, all patients could receive open-label treatment with tocilizumab 8 mg/kg.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratament", "en": "After week 52, all patients could receive open-label treatment with tocilizumab 8 mg/kg.", "ro": "După săptămâna 52, tuturor pacienţilor li s-a putut administra tratament deschis cu tocilizumab" } }
{ "translation": { "text": "Glossary:\n\"body weight\" -> \"greutate corporală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Exploratory efficacy results showed that RoActemra SC improved all exploratory efficacy parameters including Juvenile Arthritis Disease Activity Score (JADAS)-71, for TCZ naïve patients and maintained all exploratory efficacy parameters for patients who switched from RoActemra IV to RoActemra SC treatment over the entire course of the study for patients in both body weight groups\nRomanian: Rezultatele analizei exploratorii privind eficacitatea au evidenţiat faptul că RoActemra administrat subcutanat a îmbunătăţit toți parametrii analizei exploratorii privind eficacitatea, incluzând scorul de activitate a bolii în artrita juvenilă, evaluat pe 71 de articulaţii (JADAS)-71, pentru pacienții netratați anterior cu TCZ, și a menținut toți parametrii exploratorii privind eficacitatea pentru pacienții care au trecut de la tratamentul cu RoActemra IV la cel cu RoActemra subcutanat pe toată durata studiului pentru pacienții din ambele grupe de greutate corporală (sub 30 kg și ≥30 kg).", "en_prompt": "<|im_start|>user\nGlossary:\n\"body weight\" -> \"greutate corporală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Exploratory efficacy results showed that RoActemra SC improved all exploratory efficacy parameters including Juvenile Arthritis Disease Activity Score (JADAS)-71, for TCZ naïve patients and maintained all exploratory efficacy parameters for patients who switched from RoActemra IV to RoActemra SC treatment over the entire course of the study for patients in both body weight groups\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "body weight|||greutate corporală", "en": "Exploratory efficacy results showed that RoActemra SC improved all exploratory efficacy parameters including Juvenile Arthritis Disease Activity Score (JADAS)-71, for TCZ naïve patients and maintained all exploratory efficacy parameters for patients who switched from RoActemra IV to RoActemra SC treatment over the entire course of the study for patients in both body weight groups", "ro": "Rezultatele analizei exploratorii privind eficacitatea au evidenţiat faptul că RoActemra administrat subcutanat a îmbunătăţit toți parametrii analizei exploratorii privind eficacitatea, incluzând scorul de activitate a bolii în artrita juvenilă, evaluat pe 71 de articulaţii (JADAS)-71, pentru pacienții netratați anterior cu TCZ, și a menținut toți parametrii exploratorii privind eficacitatea pentru pacienții care au trecut de la tratamentul cu RoActemra IV la cel cu RoActemra subcutanat pe toată durata studiului pentru pacienții din ambele grupe de greutate corporală (sub 30 kg și ≥30 kg)." } }
{ "translation": { "text": "Glossary:\n\"infusion\" -> \"perfuzie\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Doses exceeding 800 mg per infusion are not recommended in CRS patients.\nRomanian: Nu se recomandă administrarea de doze care depăşesc 800 mg de perfuzie la pacienţii cu SEC.", "en_prompt": "<|im_start|>user\nGlossary:\n\"infusion\" -> \"perfuzie\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Doses exceeding 800 mg per infusion are not recommended in CRS patients.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "infusion|||perfuzie", "en": "Doses exceeding 800 mg per infusion are not recommended in CRS patients.", "ro": "Nu se recomandă administrarea de doze care depăşesc 800 mg de perfuzie la pacienţii cu SEC." } }
{ "translation": { "text": "Glossaries:\n\"exposure\" -> \"expunere\"\n\"systemic exposure\" -> \"expunere sistemică\"\n\"abortion\" -> \"avort\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: However, a slight increase in abortion/embryonal-foetal death was observed with high systemic exposure (> 100 x human exposure) in the 50 mg/kg/day high-dose group compared to placebo and other low-dose groups.\nRomanian: Totuşi, la o expunere sistemică mare (> 100 x expunerea la om), la grupul tratat cu doze mari de 50 mg/kg/zi, a fost observată o uşoară creştere a ratei de avort/moarte embrio-fetală, comparativ cu placebo sau cu alte grupuri tratate cu doze scăzute.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"exposure\" -> \"expunere\"\n\"systemic exposure\" -> \"expunere sistemică\"\n\"abortion\" -> \"avort\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: However, a slight increase in abortion/embryonal-foetal death was observed with high systemic exposure (> 100 x human exposure) in the 50 mg/kg/day high-dose group compared to placebo and other low-dose groups.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "exposure|||expunere\tsystemic exposure|||expunere sistemică\tabortion|||avort\tplacebo|||placebo", "en": "However, a slight increase in abortion/embryonal-foetal death was observed with high systemic exposure (> 100 x human exposure) in the 50 mg/kg/day high-dose group compared to placebo and other low-dose groups.", "ro": "Totuşi, la o expunere sistemică mare (> 100 x expunerea la om), la grupul tratat cu doze mari de 50 mg/kg/zi, a fost observată o uşoară creştere a ratei de avort/moarte embrio-fetală, comparativ cu placebo sau cu alte grupuri tratate cu doze scăzute." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Patients had mean DAS28 at baseline of 6.7 on subcutaneous and 6.6 on placebo arms.\nRomanian: Pacienţii din braţul cu administrare subcutanată au avut o valoare medie a DAS28 la momentul iniţial de 6,7, comparativ cu 6,6 la cei din braţul cu administrare de placebo.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Patients had mean DAS28 at baseline of 6.7 on subcutaneous and 6.6 on placebo arms.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "Patients had mean DAS28 at baseline of 6.7 on subcutaneous and 6.6 on placebo arms.", "ro": "Pacienţii din braţul cu administrare subcutanată au avut o valoare medie a DAS28 la momentul iniţial de 6,7, comparativ cu 6,6 la cei din braţul cu administrare de placebo." } }
{ "translation": { "text": "Glossaries:\n\"infusion\" -> \"perfuzie\"\n\"intravenous infusion\" -> \"perfuzie intravenoasă\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Children with pJIA will be given RoActemra once every 4 weeks through a drip in the vein (intravenous infusion) over one hour.\nRomanian: Copiilor cu AIJp li se va administra RoActemra o dată la interval de 4 săptămâni, prin picurare, într-una din vene (perfuzie intravenoasă), în decurs de o oră.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"infusion\" -> \"perfuzie\"\n\"intravenous infusion\" -> \"perfuzie intravenoasă\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Children with pJIA will be given RoActemra once every 4 weeks through a drip in the vein (intravenous infusion) over one hour.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "infusion|||perfuzie\tintravenous infusion|||perfuzie intravenoasă", "en": "Children with pJIA will be given RoActemra once every 4 weeks through a drip in the vein (intravenous infusion) over one hour.", "ro": "Copiilor cu AIJp li se va administra RoActemra o dată la interval de 4 săptămâni, prin picurare, într-una din vene (perfuzie intravenoasă), în decurs de o oră." } }
{ "translation": { "text": "Glossaries:\n\"dosing interval\" -> \"interval\"\n\"interval\" -> \"interval\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: After subcutaneous administration, the effective t1/2 of RoActemra in pJIA patients is up to 10 days for patients < 30 kg (162 mg SC Q3W) and up to 7 days for patients >= 30 kg (162 mg SC Q2W) during a dosing interval at steady state.\nRomanian: După administrarea subcutanată, t1/2 efectiv la RoActemra la pacienții cu AIJp este de până la 10 zile pentru pacienții < 30 kg (162 mg subcutanat la interval de 3 săptămâni) și de până la 7 zile pentru pacienții >= 30 kg (162 mg subcutanat la interval de 2 săptămâni) pe durata unui interval de dozare în starea de echilibru.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dosing interval\" -> \"interval\"\n\"interval\" -> \"interval\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: After subcutaneous administration, the effective t1/2 of RoActemra in pJIA patients is up to 10 days for patients < 30 kg (162 mg SC Q3W) and up to 7 days for patients >= 30 kg (162 mg SC Q2W) during a dosing interval at steady state.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "dosing interval|||interval\tinterval|||interval", "en": "After subcutaneous administration, the effective t1/2 of RoActemra in pJIA patients is up to 10 days for patients < 30 kg (162 mg SC Q3W) and up to 7 days for patients >= 30 kg (162 mg SC Q2W) during a dosing interval at steady state.", "ro": "După administrarea subcutanată, t1/2 efectiv la RoActemra la pacienții cu AIJp este de până la 10 zile pentru pacienții < 30 kg (162 mg subcutanat la interval de 3 săptămâni) și de până la 7 zile pentru pacienții >= 30 kg (162 mg subcutanat la interval de 2 săptămâni) pe durata unui interval de dozare în starea de echilibru." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Forty eight percent (48.1%, 39/81) of the patients treated with placebo flared compared with 25.6% (21/82) of tocilizumab treated patients.\nRomanian: 39/81) dintre pacienţii cărora li s-a administrat placebo au prezentat o acutizare a bolii, comparativ cu 25,6% (21/82) dintre pacienţii cărora li s-a administrat tocilizumab.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Forty eight percent (48.1%, 39/81) of the patients treated with placebo flared compared with 25.6% (21/82) of tocilizumab treated patients.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "Forty eight percent (48.1%, 39/81) of the patients treated with placebo flared compared with 25.6% (21/82) of tocilizumab treated patients.", "ro": "39/81) dintre pacienţii cărora li s-a administrat placebo au prezentat o acutizare a bolii, comparativ cu 25,6% (21/82) dintre pacienţii cărora li s-a administrat tocilizumab." } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"doză\"\n\"exposure\" -> \"expunere\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The long-term exposure population includes all patients who received at least one dose of RoActemra either in the double-blind control period or open label extension phase in the studies.\nRomanian: Populaţia cu expunere pe termen lung include toţi pacienţii cărora li s-a administrat cel puţin o doză de RoActemra, fie în perioada controlată dublu-orb, fie în faza de extensie deschisă a studiilor clinice.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"doză\"\n\"exposure\" -> \"expunere\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The long-term exposure population includes all patients who received at least one dose of RoActemra either in the double-blind control period or open label extension phase in the studies.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||doză\texposure|||expunere", "en": "The long-term exposure population includes all patients who received at least one dose of RoActemra either in the double-blind control period or open label extension phase in the studies.", "ro": "Populaţia cu expunere pe termen lung include toţi pacienţii cărora li s-a administrat cel puţin o doză de RoActemra, fie în perioada controlată dublu-orb, fie în faza de extensie deschisă a studiilor clinice." } }
{ "translation": { "text": "Glossaries:\n\"disease\" -> \"boală\"\n\"arthritis\" -> \"artrită\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: RoActemra is used for children aged 2 years and over with active polyarticular juvenile idiopathic arthritis (pJIA), an inflammatory disease that causes pain and swelling in one or more joints.\nRomanian: RoActemra este utilizat pentru tratamentul copiilor cu vârsta de 2 ani şi peste, cu artrită idiopatică juvenilă poliarticulară (AIJp) activă, o boală inflamatorie care cauzează durere şi inflamaţie în una sau mai multe articulaţii.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"disease\" -> \"boală\"\n\"arthritis\" -> \"artrită\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: RoActemra is used for children aged 2 years and over with active polyarticular juvenile idiopathic arthritis (pJIA), an inflammatory disease that causes pain and swelling in one or more joints.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "disease|||boală\tarthritis|||artrită", "en": "RoActemra is used for children aged 2 years and over with active polyarticular juvenile idiopathic arthritis (pJIA), an inflammatory disease that causes pain and swelling in one or more joints.", "ro": "RoActemra este utilizat pentru tratamentul copiilor cu vârsta de 2 ani şi peste, cu artrită idiopatică juvenilă poliarticulară (AIJp) activă, o boală inflamatorie care cauzează durere şi inflamaţie în una sau mai multe articulaţii." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.\nRomanian: Dacă aveţi orice întrebări suplimentare cu privire la utilizarea acestui medicament, adresaţi-vă medicului dumneavoastră, farmacistului sau asistentei medicale.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.", "ro": "Dacă aveţi orice întrebări suplimentare cu privire la utilizarea acestui medicament, adresaţi-vă medicului dumneavoastră, farmacistului sau asistentei medicale." } }
{ "translation": { "text": "Glossary:\n\"hypersensitivity\" -> \"hipersensibilitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If an anaphylactic reaction or other serious hypersensitivity reaction occurs, administration of RoActemra should be stopped immediately, appropriate therapy initiated and tocilizumab should be permanently discontinued.\nRomanian: Dacă apare o reacţie anafilactică sau altă reacţie de hipersensibilitate gravă, administrarea de RoActemra trebuie oprită imediat, se iniţiază tratamentul adecvat, iar tratamentul cu tocilizumab se întrerupe definitiv.", "en_prompt": "<|im_start|>user\nGlossary:\n\"hypersensitivity\" -> \"hipersensibilitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If an anaphylactic reaction or other serious hypersensitivity reaction occurs, administration of RoActemra should be stopped immediately, appropriate therapy initiated and tocilizumab should be permanently discontinued.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "hypersensitivity|||hipersensibilitate", "en": "If an anaphylactic reaction or other serious hypersensitivity reaction occurs, administration of RoActemra should be stopped immediately, appropriate therapy initiated and tocilizumab should be permanently discontinued.", "ro": "Dacă apare o reacţie anafilactică sau altă reacţie de hipersensibilitate gravă, administrarea de RoActemra trebuie oprită imediat, se iniţiază tratamentul adecvat, iar tratamentul cu tocilizumab se întrerupe definitiv." } }
{ "translation": { "text": "Glossary:\n\"practice\" -> \"practică\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In sJIA and pJIA patients, neutrophils and platelets should be monitored at the time of second infusion and thereafter according to good clinical practice, see section 4.2.\nRomanian: La pacienţii cu AIJs şi AIJp, neutrofilele şi trombocitele trebuie să fie monitorizate în momentul celei de-a doua perfuzii şi ulterior, conform cu regulile de bună practică în studiul clinic, vezi pct. 4.2.", "en_prompt": "<|im_start|>user\nGlossary:\n\"practice\" -> \"practică\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In sJIA and pJIA patients, neutrophils and platelets should be monitored at the time of second infusion and thereafter according to good clinical practice, see section 4.2.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "practice|||practică", "en": "In sJIA and pJIA patients, neutrophils and platelets should be monitored at the time of second infusion and thereafter according to good clinical practice, see section 4.2.", "ro": "La pacienţii cu AIJs şi AIJp, neutrofilele şi trombocitele trebuie să fie monitorizate în momentul celei de-a doua perfuzii şi ulterior, conform cu regulile de bună practică în studiul clinic, vezi pct. 4.2." } }
{ "translation": { "text": "Glossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the open-label extension of Study II the inhibition of progression of structural joint damage in tocilizumab plus MTX-treated patients was maintained in the second year of treatment.\nRomanian: În perioada de extensie deschisă a Studiului II, inhibarea progresiei distrugerii structurilor articulare la pacienţii trataţi cu tocilizumab în asociere cu MTX a fost menţinută în al doilea an de tratament.", "en_prompt": "<|im_start|>user\nGlossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the open-label extension of Study II the inhibition of progression of structural joint damage in tocilizumab plus MTX-treated patients was maintained in the second year of treatment.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratament", "en": "In the open-label extension of Study II the inhibition of progression of structural joint damage in tocilizumab plus MTX-treated patients was maintained in the second year of treatment.", "ro": "În perioada de extensie deschisă a Studiului II, inhibarea progresiei distrugerii structurilor articulare la pacienţii trataţi cu tocilizumab în asociere cu MTX a fost menţinută în al doilea an de tratament." } }
{ "translation": { "text": "Glossaries:\n\"dosing interval\" -> \"interval\"\n\"interval\" -> \"interval\"\n\"body weight\" -> \"greutate corporală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The half life of tocilizumab in pJIA patients is up to 16 days for the two body weight categories (8 mg/kg for body weight ≥ 30 kg or 10 mg/kg for body weight < 30 kg) during a dosing interval at steady state.\nRomanian: Timpul de înjumătăţire al tocilizumabului la pacienţii cu AIJp este de până la 16 zile pentru cele două categorii de greutate (8 mg/kg pentru o greutate corporală ≥ 30 kg sau 10 mg/kg pentru o greutate corporală < 30 kg), într-un interval de dozare, la starea de echilibru.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dosing interval\" -> \"interval\"\n\"interval\" -> \"interval\"\n\"body weight\" -> \"greutate corporală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The half life of tocilizumab in pJIA patients is up to 16 days for the two body weight categories (8 mg/kg for body weight ≥ 30 kg or 10 mg/kg for body weight < 30 kg) during a dosing interval at steady state.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "dosing interval|||interval\tinterval|||interval\tbody weight|||greutate corporală", "en": "The half life of tocilizumab in pJIA patients is up to 16 days for the two body weight categories (8 mg/kg for body weight ≥ 30 kg or 10 mg/kg for body weight < 30 kg) during a dosing interval at steady state.", "ro": "Timpul de înjumătăţire al tocilizumabului la pacienţii cu AIJp este de până la 16 zile pentru cele două categorii de greutate (8 mg/kg pentru o greutate corporală ≥ 30 kg sau 10 mg/kg pentru o greutate corporală < 30 kg), într-un interval de dozare, la starea de echilibru." } }
{ "translation": { "text": "Glossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: After week 52, all patients could receive open-label treatment with RoActemra 8 mg/kg.\nRomanian: După săptămâna 52, tuturor pacienţilor li s-a putut administra tratament deschis cu RoActemra", "en_prompt": "<|im_start|>user\nGlossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: After week 52, all patients could receive open-label treatment with RoActemra 8 mg/kg.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratament", "en": "After week 52, all patients could receive open-label treatment with RoActemra 8 mg/kg.", "ro": "După săptămâna 52, tuturor pacienţilor li s-a putut administra tratament deschis cu RoActemra" } }
{ "translation": { "text": "Glossary:\n\"monoclonal antibody\" -> \"anticorp monoclonal\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Tocilizumab is a recombinant humanized, anti-human monoclonal antibody of the immunoglobulin G1 (IgG1) sub-class directed against soluble and membrane-bound interleukin 6 receptors.\nRomanian: Tocilizumab este un anticorp monoclonal umanizat recombinat, al subclasei de imunoglobuline G1", "en_prompt": "<|im_start|>user\nGlossary:\n\"monoclonal antibody\" -> \"anticorp monoclonal\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Tocilizumab is a recombinant humanized, anti-human monoclonal antibody of the immunoglobulin G1 (IgG1) sub-class directed against soluble and membrane-bound interleukin 6 receptors.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "monoclonal antibody|||anticorp monoclonal", "en": "Tocilizumab is a recombinant humanized, anti-human monoclonal antibody of the immunoglobulin G1 (IgG1) sub-class directed against soluble and membrane-bound interleukin 6 receptors.", "ro": "Tocilizumab este un anticorp monoclonal umanizat recombinat, al subclasei de imunoglobuline G1" } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Proportion of patients achieving a clinically relevant improvement in HAQ-DI at week 24 (change from baseline of ≥ 0.3 units) was higher for RoActemra subcutaneous every other week (58%) versus placebo\nRomanian: Procentul de pacienţi care au atins o îmbunătăţire relevantă clinic a HAQ-DI la săptămâna 24 (modificare de la momentul iniţial cu ≥ 0,3 unităţi) a fost mai mare în cazul RoActemra administrat subcutanat la interval de 2 săptămâni (58%), comparativ cu placebo (46,8%).", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Proportion of patients achieving a clinically relevant improvement in HAQ-DI at week 24 (change from baseline of ≥ 0.3 units) was higher for RoActemra subcutaneous every other week (58%) versus placebo\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "Proportion of patients achieving a clinically relevant improvement in HAQ-DI at week 24 (change from baseline of ≥ 0.3 units) was higher for RoActemra subcutaneous every other week (58%) versus placebo", "ro": "Procentul de pacienţi care au atins o îmbunătăţire relevantă clinic a HAQ-DI la săptămâna 24 (modificare de la momentul iniţial cu ≥ 0,3 unităţi) a fost mai mare în cazul RoActemra administrat subcutanat la interval de 2 săptămâni (58%), comparativ cu placebo (46,8%)." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Both considerably lower than in the placebo plus 26 weeks and the placebo plus 52 weeks prednisone taper groups, 4023.5 mg and 5389.5 mg respectively.\nRomanian: În ambele grupuri dozele au fost semnificativ mai mici decât în grupul cu administrare de placebo plus prednison în doze scăzute progresiv pe parcursul a 26 de săptămâni şi decât în grupul cu administrare de placebo plus prednison în doze scăzute treptat pe parcursul a 52 de săptămâni, mai precis 4023,5 mg şi, respectiv,", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Both considerably lower than in the placebo plus 26 weeks and the placebo plus 52 weeks prednisone taper groups, 4023.5 mg and 5389.5 mg respectively.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "Both considerably lower than in the placebo plus 26 weeks and the placebo plus 52 weeks prednisone taper groups, 4023.5 mg and 5389.5 mg respectively.", "ro": "În ambele grupuri dozele au fost semnificativ mai mici decât în grupul cu administrare de placebo plus prednison în doze scăzute progresiv pe parcursul a 26 de săptămâni şi decât în grupul cu administrare de placebo plus prednison în doze scăzute treptat pe parcursul a 52 de săptămâni, mai precis 4023,5 mg şi, respectiv," } }
{ "translation": { "text": "Glossary:\n\"hypersensitivity\" -> \"hipersensibilitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If an anaphylactic reaction or other serious hypersensitivity reaction occurs, administration of RoActemra should be stopped immediately, appropriate therapy initiated and RoActemra should be permanently discontinued.\nRomanian: Dacă apare o reacţie anafilactică sau altă reacţie de hipersensibilitate gravă, administrarea de RoActemra trebuie oprită imediat, se iniţiază tratamentul adecvat, iar tratamentul cu RoActemra se întrerupe definitiv.", "en_prompt": "<|im_start|>user\nGlossary:\n\"hypersensitivity\" -> \"hipersensibilitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If an anaphylactic reaction or other serious hypersensitivity reaction occurs, administration of RoActemra should be stopped immediately, appropriate therapy initiated and RoActemra should be permanently discontinued.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "hypersensitivity|||hipersensibilitate", "en": "If an anaphylactic reaction or other serious hypersensitivity reaction occurs, administration of RoActemra should be stopped immediately, appropriate therapy initiated and RoActemra should be permanently discontinued.", "ro": "Dacă apare o reacţie anafilactică sau altă reacţie de hipersensibilitate gravă, administrarea de RoActemra trebuie oprită imediat, se iniţiază tratamentul adecvat, iar tratamentul cu RoActemra se întrerupe definitiv." } }
{ "translation": { "text": "Glossaries:\n\"disease\" -> \"boală\"\n\"arthritis\" -> \"artrită\"\n\"fever\" -> \"febră\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: RoActemra is used for children aged 2 years and over who have active systemic juvenile idiopathic arthritis (sJIA), an inflammatory disease that causes pain and swelling in one or more joints as well as fever and rash.\nRomanian: RoActemra este utilizat pentru tratamentul copiilor cu vârsta de 2 ani şi peste, cu artrită idiopatică juvenilă sistemică (AIJs) activă, o boală inflamatorie care cauzează durere şi inflamaţie în una sau mai multe articulaţii, precum şi febră şi urticarie.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"disease\" -> \"boală\"\n\"arthritis\" -> \"artrită\"\n\"fever\" -> \"febră\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: RoActemra is used for children aged 2 years and over who have active systemic juvenile idiopathic arthritis (sJIA), an inflammatory disease that causes pain and swelling in one or more joints as well as fever and rash.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "disease|||boală\tarthritis|||artrită\tfever|||febră", "en": "RoActemra is used for children aged 2 years and over who have active systemic juvenile idiopathic arthritis (sJIA), an inflammatory disease that causes pain and swelling in one or more joints as well as fever and rash.", "ro": "RoActemra este utilizat pentru tratamentul copiilor cu vârsta de 2 ani şi peste, cu artrită idiopatică juvenilă sistemică (AIJs) activă, o boală inflamatorie care cauzează durere şi inflamaţie în una sau mai multe articulaţii, precum şi febră şi urticarie." } }
{ "translation": { "text": "Glossary:\n\"hypersensitivity\" -> \"hipersensibilitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Serious hypersensitivity reactions have been reported in association with infusion of RoActemra (see section 4.8).\nRomanian: Au fost raportate reacţii de hipersensibilitate grave asociate cu administrarea RoActemra (vezi pct. 4.8).", "en_prompt": "<|im_start|>user\nGlossary:\n\"hypersensitivity\" -> \"hipersensibilitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Serious hypersensitivity reactions have been reported in association with infusion of RoActemra (see section 4.8).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "hypersensitivity|||hipersensibilitate", "en": "Serious hypersensitivity reactions have been reported in association with infusion of RoActemra (see section 4.8).", "ro": "Au fost raportate reacţii de hipersensibilitate grave asociate cu administrarea RoActemra (vezi pct. 4.8)." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: During routine laboratory monitoring in the 12 week controlled phase, a decrease in neutrophil counts below 1 x 109/l occurred in 7% of patients in the tocilizumab group, and no decreases in the placebo group.\nRomanian: În timpul monitorizării obişnuite de laborator în faza controlată a studiului cu durata de 12 săptămâni, a apărut o scădere a numărului de neutrofile sub 1 x 109/l la 7% dintre pacienţii din grupul tratat cu tocilizumab, iar la cei din grupul care a primit placebo nu a apărut nicio scădere.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: During routine laboratory monitoring in the 12 week controlled phase, a decrease in neutrophil counts below 1 x 109/l occurred in 7% of patients in the tocilizumab group, and no decreases in the placebo group.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "During routine laboratory monitoring in the 12 week controlled phase, a decrease in neutrophil counts below 1 x 109/l occurred in 7% of patients in the tocilizumab group, and no decreases in the placebo group.", "ro": "În timpul monitorizării obişnuite de laborator în faza controlată a studiului cu durata de 12 săptămâni, a apărut o scădere a numărului de neutrofile sub 1 x 109/l la 7% dintre pacienţii din grupul tratat cu tocilizumab, iar la cei din grupul care a primit placebo nu a apărut nicio scădere." } }
{ "translation": { "text": "Glossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If an adult with RA or GCA or a child or adolescent with sJIA misses or forgets a dose\nRomanian: Dacă un adult cu PR sau ACG sau un copil sau adolescent cu AIJs omite sau uită o doză Este foarte important să utilizaţi RoActemra exact aşa cum v-a prescris medicul dumneavoastră.", "en_prompt": "<|im_start|>user\nGlossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If an adult with RA or GCA or a child or adolescent with sJIA misses or forgets a dose\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||doză", "en": "If an adult with RA or GCA or a child or adolescent with sJIA misses or forgets a dose", "ro": "Dacă un adult cu PR sau ACG sau un copil sau adolescent cu AIJs omite sau uită o doză Este foarte important să utilizaţi RoActemra exact aşa cum v-a prescris medicul dumneavoastră." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In Study IV, tocilizumab was administered intravenously every 4 weeks in combination with other DMARDs vs. placebo and other DMARDs.\nRomanian: În Studiul IV, tocilizumab a fost administrat intravenos la interval de patru săptămâni în asociere cu alte DMARD, comparativ cu placebo şi alte DMARD.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In Study IV, tocilizumab was administered intravenously every 4 weeks in combination with other DMARDs vs. placebo and other DMARDs.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "In Study IV, tocilizumab was administered intravenously every 4 weeks in combination with other DMARDs vs. placebo and other DMARDs.", "ro": "În Studiul IV, tocilizumab a fost administrat intravenos la interval de patru săptămâni în asociere cu alte DMARD, comparativ cu placebo şi alte DMARD." } }
{ "translation": { "text": "Glossary:\n\"swelling\" -> \"umflare\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • If you experience allergic reactions such as chest tightness, wheezing, severe dizziness or lightheadedness, swelling of the lips, tongue, face or skin itching, hives or rash during or after the injection, then tell your doctor immediately.\nRomanian: • Dacă manifestaţi o reacţie alergică cum ar fi apăsare în zona pieptului, respiraţie şuierătoare, ameţeli severe sau senzaţie de leşin, umflare a buzelor, limbii, feţei sau mâncărimi ale pielii, urticarie sau erupţie trecătoare pe piele, în timpul sau după administrarea injecţiei, spuneţi imediat medicului dumneavoastră.", "en_prompt": "<|im_start|>user\nGlossary:\n\"swelling\" -> \"umflare\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • If you experience allergic reactions such as chest tightness, wheezing, severe dizziness or lightheadedness, swelling of the lips, tongue, face or skin itching, hives or rash during or after the injection, then tell your doctor immediately.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "swelling|||umflare", "en": "• If you experience allergic reactions such as chest tightness, wheezing, severe dizziness or lightheadedness, swelling of the lips, tongue, face or skin itching, hives or rash during or after the injection, then tell your doctor immediately.", "ro": "• Dacă manifestaţi o reacţie alergică cum ar fi apăsare în zona pieptului, respiraţie şuierătoare, ameţeli severe sau senzaţie de leşin, umflare a buzelor, limbii, feţei sau mâncărimi ale pielii, urticarie sau erupţie trecătoare pe piele, în timpul sau după administrarea injecţiei, spuneţi imediat medicului dumneavoastră." } }
{ "translation": { "text": "Glossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In RA and GCA patients, ALT/AST should be monitored every 4 to 8 weeks for the first 6 months of treatment followed by every 12 weeks thereafter.\nRomanian: La pacienţii cu PR, AIJs şi AIJp, ALT/AST trebuie monitorizate la interval de 4 până la 8 săptămâni pentru primele 6 luni de tratament, apoi la interval de 12 săptămâni.", "en_prompt": "<|im_start|>user\nGlossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In RA and GCA patients, ALT/AST should be monitored every 4 to 8 weeks for the first 6 months of treatment followed by every 12 weeks thereafter.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratament", "en": "In RA and GCA patients, ALT/AST should be monitored every 4 to 8 weeks for the first 6 months of treatment followed by every 12 weeks thereafter.", "ro": "La pacienţii cu PR, AIJs şi AIJp, ALT/AST trebuie monitorizate la interval de 4 până la 8 săptămâni pentru primele 6 luni de tratament, apoi la interval de 12 săptămâni." } }
{ "translation": { "text": "Glossary:\n\"infusion\" -> \"perfuzie\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Diluted product: After dilution, the prepared solution for infusion is physically and chemically stable in sodium chloride 9 mg/mL (0.9%) solution for injection at 30ºC for 24 hours.\nRomanian: După diluare în soluţie injectabilă de clorură de sodiu 9 mg/ml (0,9%), soluţia preparată pentru perfuzie este stabilă fizic şi chimic 24 ore la 30ºC .", "en_prompt": "<|im_start|>user\nGlossary:\n\"infusion\" -> \"perfuzie\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Diluted product: After dilution, the prepared solution for infusion is physically and chemically stable in sodium chloride 9 mg/mL (0.9%) solution for injection at 30ºC for 24 hours.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "infusion|||perfuzie", "en": "Diluted product: After dilution, the prepared solution for infusion is physically and chemically stable in sodium chloride 9 mg/mL (0.9%) solution for injection at 30ºC for 24 hours.", "ro": "După diluare în soluţie injectabilă de clorură de sodiu 9 mg/ml (0,9%), soluţia preparată pentru perfuzie este stabilă fizic şi chimic 24 ore la 30ºC ." } }
{ "translation": { "text": "Glossaries:\n\"tuberculosis\" -> \"tuberculoză\"\n\"cough\" -> \"tuse\"\n\"fever\" -> \"febră\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If symptoms of tuberculosis (persistent cough, weight loss, listlessness, mild fever) or any other infection appear during or after therapy tell your doctor immediately.\nRomanian: Dacă pe parcursul tratamentului sau după terminarea acestuia, apar simptome de tuberculoză (tuse persistentă, pierdere în greutate, apatie, febră uşoară) sau orice alte infecţii, comunicaţi imediat acest lucru medicului dumneavoastră.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"tuberculosis\" -> \"tuberculoză\"\n\"cough\" -> \"tuse\"\n\"fever\" -> \"febră\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If symptoms of tuberculosis (persistent cough, weight loss, listlessness, mild fever) or any other infection appear during or after therapy tell your doctor immediately.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "tuberculosis|||tuberculoză\tcough|||tuse\tfever|||febră", "en": "If symptoms of tuberculosis (persistent cough, weight loss, listlessness, mild fever) or any other infection appear during or after therapy tell your doctor immediately.", "ro": "Dacă pe parcursul tratamentului sau după terminarea acestuia, apar simptome de tuberculoză (tuse persistentă, pierdere în greutate, apatie, febră uşoară) sau orice alte infecţii, comunicaţi imediat acest lucru medicului dumneavoastră." } }
{ "translation": { "text": "Glossary:\n\"diarrhoea\" -> \"diaree\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Some side effects were seen more often: inflamed nose and throat, diarrhoea, lower white blood cell counts and higher liver enzymes.\nRomanian: Unele reacţii adverse au fost observate mai frecvent: inflamaţie la nivelul nasului şi gâtului, diaree, număr scăzut de globule albe ale sângelui şi valori crescute ale transaminazelor hepatice.", "en_prompt": "<|im_start|>user\nGlossary:\n\"diarrhoea\" -> \"diaree\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Some side effects were seen more often: inflamed nose and throat, diarrhoea, lower white blood cell counts and higher liver enzymes.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "diarrhoea|||diaree", "en": "Some side effects were seen more often: inflamed nose and throat, diarrhoea, lower white blood cell counts and higher liver enzymes.", "ro": "Unele reacţii adverse au fost observate mai frecvent: inflamaţie la nivelul nasului şi gâtului, diaree, număr scăzut de globule albe ale sângelui şi valori crescute ale transaminazelor hepatice." } }
{ "translation": { "text": "Glossary:\n\"body weight\" -> \"greutate corporală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • If you weigh less than 30 kg: the dose is 12 mg for every kilogram of body weight\nRomanian: • Dacă aveţi greutatea mai mică de 30 kg, doza este de 12 mg pentru fiecare kilogram de greutate corporală", "en_prompt": "<|im_start|>user\nGlossary:\n\"body weight\" -> \"greutate corporală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • If you weigh less than 30 kg: the dose is 12 mg for every kilogram of body weight\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "body weight|||greutate corporală", "en": "• If you weigh less than 30 kg: the dose is 12 mg for every kilogram of body weight", "ro": "• Dacă aveţi greutatea mai mică de 30 kg, doza este de 12 mg pentru fiecare kilogram de greutate corporală" } }
{ "translation": { "text": "Glossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the open-label extension of Study II the inhibition of progression of structural joint damage in RoActemra plus MTX-treated patients was maintained in the second year of treatment.\nRomanian: În perioada de extensie deschisă a Studiului II, inhibarea progresiei distrugerii structurilor articulare la pacienţii trataţi cu RoActemra în asociere cu MTX s-a menţinut în al doilea an de tratament.", "en_prompt": "<|im_start|>user\nGlossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the open-label extension of Study II the inhibition of progression of structural joint damage in RoActemra plus MTX-treated patients was maintained in the second year of treatment.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratament", "en": "In the open-label extension of Study II the inhibition of progression of structural joint damage in RoActemra plus MTX-treated patients was maintained in the second year of treatment.", "ro": "În perioada de extensie deschisă a Studiului II, inhibarea progresiei distrugerii structurilor articulare la pacienţii trataţi cu RoActemra în asociere cu MTX s-a menţinut în al doilea an de tratament." } }
{ "translation": { "text": "Glossary:\n\"package leaflet\" -> \"prospect\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Comprehensive instructions for the administration of RoActemra in a pre-filled pen are given in the package leaflet, see section 6.6.\nRomanian: Instrucţiuni detaliate pentru administrarea RoActemra în stilou injector (pen) preumplut sunt prezentate în prospect, vezi pct. 6.6.", "en_prompt": "<|im_start|>user\nGlossary:\n\"package leaflet\" -> \"prospect\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Comprehensive instructions for the administration of RoActemra in a pre-filled pen are given in the package leaflet, see section 6.6.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "package leaflet|||prospect", "en": "Comprehensive instructions for the administration of RoActemra in a pre-filled pen are given in the package leaflet, see section 6.6.", "ro": "Instrucţiuni detaliate pentru administrarea RoActemra în stilou injector (pen) preumplut sunt prezentate în prospect, vezi pct. 6.6." } }
{ "translation": { "text": "Glossaries:\n\"infusion\" -> \"perfuzie\"\n\"vial\" -> \"flacon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The required amount of RoActemra concentrate (0.4 mL/kg) should be withdrawn from the vial and placed in the 100 mL infusion bag.\nRomanian: Cantitatea necesară de concentrat de RoActemra (0,4 ml/kg) trebuie extrasă din flacon şi introdusă în punga de perfuzie de 100 ml.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"infusion\" -> \"perfuzie\"\n\"vial\" -> \"flacon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The required amount of RoActemra concentrate (0.4 mL/kg) should be withdrawn from the vial and placed in the 100 mL infusion bag.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "infusion|||perfuzie\tvial|||flacon", "en": "The required amount of RoActemra concentrate (0.4 mL/kg) should be withdrawn from the vial and placed in the 100 mL infusion bag.", "ro": "Cantitatea necesară de concentrat de RoActemra (0,4 ml/kg) trebuie extrasă din flacon şi introdusă în punga de perfuzie de 100 ml." } }
{ "translation": { "text": "Glossary:\n\"package leaflet\" -> \"prospect\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Comprehensive instructions for the administration of RoActemra in a pre-filled pen are given in the package leaflet.\nRomanian: Instrucţiuni detaliate privind administrarea RoActemra în stiloul injector (pen) preumplut sunt prezentate în prospect.", "en_prompt": "<|im_start|>user\nGlossary:\n\"package leaflet\" -> \"prospect\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Comprehensive instructions for the administration of RoActemra in a pre-filled pen are given in the package leaflet.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "package leaflet|||prospect", "en": "Comprehensive instructions for the administration of RoActemra in a pre-filled pen are given in the package leaflet.", "ro": "Instrucţiuni detaliate privind administrarea RoActemra în stiloul injector (pen) preumplut sunt prezentate în prospect." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In Study IV, RoActemra was administered intravenously every 4 weeks in combination with other DMARDs vs. placebo and other DMARDs.\nRomanian: În Studiul IV, RoActemra a fost administrat intravenos la interval de patru săptămâni, în asociere cu alte DMARD, comparativ cu placebo şi alte DMARD.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In Study IV, RoActemra was administered intravenously every 4 weeks in combination with other DMARDs vs. placebo and other DMARDs.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "In Study IV, RoActemra was administered intravenously every 4 weeks in combination with other DMARDs vs. placebo and other DMARDs.", "ro": "În Studiul IV, RoActemra a fost administrat intravenos la interval de patru săptămâni, în asociere cu alte DMARD, comparativ cu placebo şi alte DMARD." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: At Week 52, the mean change in HAQ-DI was -0.58 in the RoActemra 8 mg/kg plus MTX group compared with -0.39 in the placebo + MTX group.\nRomanian: La săptămâna 52, modificarea medie a HAQ-DI a fost de -0,58 în grupul tratat cu RoActemra 8 mg/kg în asociere cu MTX, comparativ cu -0,39 în grupul care a primit placebo în asociere cu MTX.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: At Week 52, the mean change in HAQ-DI was -0.58 in the RoActemra 8 mg/kg plus MTX group compared with -0.39 in the placebo + MTX group.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "At Week 52, the mean change in HAQ-DI was -0.58 in the RoActemra 8 mg/kg plus MTX group compared with -0.39 in the placebo + MTX group.", "ro": "La săptămâna 52, modificarea medie a HAQ-DI a fost de -0,58 în grupul tratat cu RoActemra 8 mg/kg în asociere cu MTX, comparativ cu -0,39 în grupul care a primit placebo în asociere cu MTX." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The PCS mean change from baseline to week 52 was higher (showing more improvement) in the RoActemra weekly and every other weekly dose groups [4.10, 2.76, respectively] than in the two placebo groups [placebo plus 26 weeks; -0.28, placebo plus 52 weeks; -1.49], although only the comparison between RoActemra weekly plus 26 weeks prednisone taper group and placebo plus 52 weeks prednisone taper group (5.59, 99% CI: 8.6, 10.32) showed a statistically significant difference (p=0.0024).\nRomanian: Modificările medii ale PCS între momentul iniţial şi săptămâna 52 au fost mai mari (ceea ce arată o îmbunătăţire mai mare) în grupurile cu RoActemra administrat săptămânal şi la interval de 2 săptămâni [4,10 şi, respectiv, 2,76], comparativ cu cele două grupuri cu administrare de placebo [placebo plus prednison cu scăderea progresivă a dozei în decurs de 26 săptămâni; -0,28, placebo plus prednison în doze scăzute treptat pe parcursul a 52 săptămâni; -1.49], cu toate că doar comparaţia dintre RoActemra administrat subcutanat săptămânal plus prednison în doze scăzute treptat pe parcursul a 26 săptămâni şi grupul cu administrare de placebo plus prednison în doze scăzute treptat pe parcursul a 52 săptămâni (5,59, IÎ 99%: 8,6; 10,32) a arătat o diferenţă semnificativă statistic (p=0,0024).", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The PCS mean change from baseline to week 52 was higher (showing more improvement) in the RoActemra weekly and every other weekly dose groups [4.10, 2.76, respectively] than in the two placebo groups [placebo plus 26 weeks; -0.28, placebo plus 52 weeks; -1.49], although only the comparison between RoActemra weekly plus 26 weeks prednisone taper group and placebo plus 52 weeks prednisone taper group (5.59, 99% CI: 8.6, 10.32) showed a statistically significant difference (p=0.0024).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "The PCS mean change from baseline to week 52 was higher (showing more improvement) in the RoActemra weekly and every other weekly dose groups [4.10, 2.76, respectively] than in the two placebo groups [placebo plus 26 weeks; -0.28, placebo plus 52 weeks; -1.49], although only the comparison between RoActemra weekly plus 26 weeks prednisone taper group and placebo plus 52 weeks prednisone taper group (5.59, 99% CI: 8.6, 10.32) showed a statistically significant difference (p=0.0024).", "ro": "Modificările medii ale PCS între momentul iniţial şi săptămâna 52 au fost mai mari (ceea ce arată o îmbunătăţire mai mare) în grupurile cu RoActemra administrat săptămânal şi la interval de 2 săptămâni [4,10 şi, respectiv, 2,76], comparativ cu cele două grupuri cu administrare de placebo [placebo plus prednison cu scăderea progresivă a dozei în decurs de 26 săptămâni; -0,28, placebo plus prednison în doze scăzute treptat pe parcursul a 52 săptămâni; -1.49], cu toate că doar comparaţia dintre RoActemra administrat subcutanat săptămânal plus prednison în doze scăzute treptat pe parcursul a 26 săptămâni şi grupul cu administrare de placebo plus prednison în doze scăzute treptat pe parcursul a 52 săptămâni (5,59, IÎ 99%: 8,6; 10,32) a arătat o diferenţă semnificativă statistic (p=0,0024)." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In Studies II, III and V, tocilizumab was administered intravenously every four weeks in combination with MTX vs. placebo and MTX.\nRomanian: În Studiile II, III şi V, tocilizumab a fost administrat intravenos la interval de patru săptămâni în asociere cu MTX, comparativ cu placebo şi MTX.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In Studies II, III and V, tocilizumab was administered intravenously every four weeks in combination with MTX vs. placebo and MTX.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "In Studies II, III and V, tocilizumab was administered intravenously every four weeks in combination with MTX vs. placebo and MTX.", "ro": "În Studiile II, III şi V, tocilizumab a fost administrat intravenos la interval de patru săptămâni în asociere cu MTX, comparativ cu placebo şi MTX." } }
{ "translation": { "text": "Glossary:\n\"body weight\" -> \"greutate corporală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • If you weigh less than 30 kg: the dose is 10mg for every kilogram of body weight\nRomanian: • Dacă aveţi greutatea mai mică de 30 kg, doza este de 10 mg pentru fiecare kilogram de greutate corporală", "en_prompt": "<|im_start|>user\nGlossary:\n\"body weight\" -> \"greutate corporală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • If you weigh less than 30 kg: the dose is 10mg for every kilogram of body weight\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "body weight|||greutate corporală", "en": "• If you weigh less than 30 kg: the dose is 10mg for every kilogram of body weight", "ro": "• Dacă aveţi greutatea mai mică de 30 kg, doza este de 10 mg pentru fiecare kilogram de greutate corporală" } }
{ "translation": { "text": "Glossary:\n\"package leaflet\" -> \"prospect\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Comprehensive instructions for the administration of RoActemra in a pre-filled syringe are given in the package leaflet.\nRomanian: Instrucţiuni detaliate privind administrarea RoActemra în seringă preumplută sunt prezentate în prospect.", "en_prompt": "<|im_start|>user\nGlossary:\n\"package leaflet\" -> \"prospect\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Comprehensive instructions for the administration of RoActemra in a pre-filled syringe are given in the package leaflet.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "package leaflet|||prospect", "en": "Comprehensive instructions for the administration of RoActemra in a pre-filled syringe are given in the package leaflet.", "ro": "Instrucţiuni detaliate privind administrarea RoActemra în seringă preumplută sunt prezentate în prospect." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: At Week 52, the mean change in HAQ-DI was -0.58 in the tocilizumab 8 mg/kg plus MTX group compared with -0.39 in the placebo + MTX group.\nRomanian: La săptămâna 52, modificarea medie a HAQ-DI a fost de -0,58 în grupul tratat cu tocilizumab 8 mg/kg în asociere cu MTX, comparativ cu -0,39 în grupul care a primit placebo în asociere cu MTX.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: At Week 52, the mean change in HAQ-DI was -0.58 in the tocilizumab 8 mg/kg plus MTX group compared with -0.39 in the placebo + MTX group.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "At Week 52, the mean change in HAQ-DI was -0.58 in the tocilizumab 8 mg/kg plus MTX group compared with -0.39 in the placebo + MTX group.", "ro": "La săptămâna 52, modificarea medie a HAQ-DI a fost de -0,58 în grupul tratat cu tocilizumab 8 mg/kg în asociere cu MTX, comparativ cu -0,39 în grupul care a primit placebo în asociere cu MTX." } }
{ "translation": { "text": "Glossary:\n\"package leaflet\" -> \"prospect\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Comprehensive instructions for the administration of RoActemra in a pre-filled syringe are given in the package leaflet, see section 6.6.\nRomanian: Instrucţiuni detaliate pentru administrarea RoActemra în seringă preumplută sunt prezentate în prospect, vezi pct. 6.6.", "en_prompt": "<|im_start|>user\nGlossary:\n\"package leaflet\" -> \"prospect\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Comprehensive instructions for the administration of RoActemra in a pre-filled syringe are given in the package leaflet, see section 6.6.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "package leaflet|||prospect", "en": "Comprehensive instructions for the administration of RoActemra in a pre-filled syringe are given in the package leaflet, see section 6.6.", "ro": "Instrucţiuni detaliate pentru administrarea RoActemra în seringă preumplută sunt prezentate în prospect, vezi pct. 6.6." } }
{ "translation": { "text": "Glossary:\n\"exposure\" -> \"expunere\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the monotherapy study the rate of serious infections was 3.6 events per 100 patient years of exposure in the tocilizumab group and 1.5 events per 100 patient years of exposure in the MTX group.\nRomanian: În studiul cu administrare în monoterapie, incidenţa infecţiilor grave a fost de 3,6 evenimente per 100 pacienţi-ani expunere în grupul tratat cu tocilizumab şi 1,5 evenimente per 100 pacienţi-ani expunere în grupul tratat cu MTX.", "en_prompt": "<|im_start|>user\nGlossary:\n\"exposure\" -> \"expunere\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the monotherapy study the rate of serious infections was 3.6 events per 100 patient years of exposure in the tocilizumab group and 1.5 events per 100 patient years of exposure in the MTX group.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "exposure|||expunere", "en": "In the monotherapy study the rate of serious infections was 3.6 events per 100 patient years of exposure in the tocilizumab group and 1.5 events per 100 patient years of exposure in the MTX group.", "ro": "În studiul cu administrare în monoterapie, incidenţa infecţiilor grave a fost de 3,6 evenimente per 100 pacienţi-ani expunere în grupul tratat cu tocilizumab şi 1,5 evenimente per 100 pacienţi-ani expunere în grupul tratat cu MTX." } }
{ "translation": { "text": "Glossary:\n\"arthritis\" -> \"artrită\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 1 year of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids.\nRomanian: RoActemra este indicat pentru tratamentul pacienţilor cu vârsta de 1 an şi peste, cu artrită idiopatică juvenilă sistemică (AIJs) activă, care nu au avut un răspuns adecvat la tratamentele anterioare cu AINS şi corticosteroizi sistemici.", "en_prompt": "<|im_start|>user\nGlossary:\n\"arthritis\" -> \"artrită\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 1 year of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "arthritis|||artrită", "en": "RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 1 year of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids.", "ro": "RoActemra este indicat pentru tratamentul pacienţilor cu vârsta de 1 an şi peste, cu artrită idiopatică juvenilă sistemică (AIJs) activă, care nu au avut un răspuns adecvat la tratamentele anterioare cu AINS şi corticosteroizi sistemici." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The primary efficacy endpoint assessed by the proportion of patients achieving steroid free sustained remission at week 52 on RoActemra plus 26 weeks prednisone taper compared with placebo plus 26 weeks prednisone taper, was met (Table 4).\nRomanian: Criteriul principal de eficacitate, evaluat prin proporţia pacienţilor care au obţinut remisiune durabilă fără utilizare de corticosteroizi după 52 de săptămâni de tratament cu RoActemra plus prednison în doze scăzute treptat pe parcursul a 26 de săptămâni, comparativ cu administrarea de placebo plus prednison în doze scăzute treptat pe parcursul a 26 de săptămâni, a fost îndeplinit (Tabelul 4).", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The primary efficacy endpoint assessed by the proportion of patients achieving steroid free sustained remission at week 52 on RoActemra plus 26 weeks prednisone taper compared with placebo plus 26 weeks prednisone taper, was met (Table 4).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "The primary efficacy endpoint assessed by the proportion of patients achieving steroid free sustained remission at week 52 on RoActemra plus 26 weeks prednisone taper compared with placebo plus 26 weeks prednisone taper, was met (Table 4).", "ro": "Criteriul principal de eficacitate, evaluat prin proporţia pacienţilor care au obţinut remisiune durabilă fără utilizare de corticosteroizi după 52 de săptămâni de tratament cu RoActemra plus prednison în doze scăzute treptat pe parcursul a 26 de săptămâni, comparativ cu administrarea de placebo plus prednison în doze scăzute treptat pe parcursul a 26 de săptămâni, a fost îndeplinit (Tabelul 4)." } }
{ "translation": { "text": "Glossary:\n\"body weight\" -> \"greutate corporală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The half life of tocilizumab in sJIA patients is up to 16 days for the two body weight categories (8 mg/kg for body weight ≥ 30 kg or 12 mg/kg for body weight < 30 kg) at week 12.\nRomanian: Timpul de înjumătăţire al tocilizumab la pacienţii cu AIJs este de până la 16 zile la săptămâna 12 pentru ambele categorii de greutate corporală (8 mg/kg pentru pacienţii cu o greutate corporală ≥ 30 kg sau 12 mg/kg pentru pacienţii cu o greutate corporală < 30 kg ).", "en_prompt": "<|im_start|>user\nGlossary:\n\"body weight\" -> \"greutate corporală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The half life of tocilizumab in sJIA patients is up to 16 days for the two body weight categories (8 mg/kg for body weight ≥ 30 kg or 12 mg/kg for body weight < 30 kg) at week 12.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "body weight|||greutate corporală", "en": "The half life of tocilizumab in sJIA patients is up to 16 days for the two body weight categories (8 mg/kg for body weight ≥ 30 kg or 12 mg/kg for body weight < 30 kg) at week 12.", "ro": "Timpul de înjumătăţire al tocilizumab la pacienţii cu AIJs este de până la 16 zile la săptămâna 12 pentru ambele categorii de greutate corporală (8 mg/kg pentru pacienţii cu o greutate corporală ≥ 30 kg sau 12 mg/kg pentru pacienţii cu o greutate corporală < 30 kg )." } }
{ "translation": { "text": "Glossary:\n\"ulcer\" -> \"ulcer\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • stomach ulcer\nRomanian: • ulcer la nivelul stomacului", "en_prompt": "<|im_start|>user\nGlossary:\n\"ulcer\" -> \"ulcer\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • stomach ulcer\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "ulcer|||ulcer", "en": "• stomach ulcer", "ro": "• ulcer la nivelul stomacului" } }
{ "translation": { "text": "Glossary:\n\"exposure\" -> \"expunere\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the monotherapy study the rate of serious infections was 3.6 events per 100 patient years of exposure in the RoActemra group and 1.5 events per 100 patient years of exposure in the MTX group.\nRomanian: În studiul cu administrare în monoterapie, incidenţa infecţiilor grave a fost de 3,6 evenimente per 100 pacienţi-ani expunere în grupul tratat cu RoActemra şi 1,5 evenimente per 100 pacienţi-ani expunere în grupul tratat cu MTX.", "en_prompt": "<|im_start|>user\nGlossary:\n\"exposure\" -> \"expunere\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the monotherapy study the rate of serious infections was 3.6 events per 100 patient years of exposure in the RoActemra group and 1.5 events per 100 patient years of exposure in the MTX group.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "exposure|||expunere", "en": "In the monotherapy study the rate of serious infections was 3.6 events per 100 patient years of exposure in the RoActemra group and 1.5 events per 100 patient years of exposure in the MTX group.", "ro": "În studiul cu administrare în monoterapie, incidenţa infecţiilor grave a fost de 3,6 evenimente per 100 pacienţi-ani expunere în grupul tratat cu RoActemra şi 1,5 evenimente per 100 pacienţi-ani expunere în grupul tratat cu MTX." } }
{ "translation": { "text": "Glossaries:\n\"infusion\" -> \"perfuzie\"\n\"intravenous infusion\" -> \"perfuzie intravenoasă\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Cytokine Release Syndrome (CRS) (adults and paediatrics) The recommended posology for treatment of CRS given as a 60-minute intravenous infusion is 8 mg/kg in patients weighing greater than or equal to 30 kg or 12 mg/kg in patients weighing less than 30 kg. RoActemra can be given alone or in combination with corticosteroids.\nRomanian: Sindromul de eliberare de citokine (SEC) (adulţi şi copii şi adolescenţi) Doza recomandată pentru tratamentul SEC, administrat sub formă de perfuzie intravenoasă pe parcursul a 60 de minute, este de 8 mg/kg la pacienţii cu greutate corporală mai mare de sau egală cu 30 kg sau de 12 mg/kg la pacienţii cu greutate corporală mai mică de 30 kg.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"infusion\" -> \"perfuzie\"\n\"intravenous infusion\" -> \"perfuzie intravenoasă\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Cytokine Release Syndrome (CRS) (adults and paediatrics) The recommended posology for treatment of CRS given as a 60-minute intravenous infusion is 8 mg/kg in patients weighing greater than or equal to 30 kg or 12 mg/kg in patients weighing less than 30 kg. RoActemra can be given alone or in combination with corticosteroids.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "infusion|||perfuzie\tintravenous infusion|||perfuzie intravenoasă", "en": "Cytokine Release Syndrome (CRS) (adults and paediatrics) The recommended posology for treatment of CRS given as a 60-minute intravenous infusion is 8 mg/kg in patients weighing greater than or equal to 30 kg or 12 mg/kg in patients weighing less than 30 kg. RoActemra can be given alone or in combination with corticosteroids.", "ro": "Sindromul de eliberare de citokine (SEC) (adulţi şi copii şi adolescenţi) Doza recomandată pentru tratamentul SEC, administrat sub formă de perfuzie intravenoasă pe parcursul a 60 de minute, este de 8 mg/kg la pacienţii cu greutate corporală mai mare de sau egală cu 30 kg sau de 12 mg/kg la pacienţii cu greutate corporală mai mică de 30 kg." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The mean change in Patient's global VAS from baseline at week 52 was lower (showing greater improvement) in the RoActemra weekly and every other weekly dose groups [-19.0, -25.3, respectively] than in both placebo groups [placebo plus 26 weeks -3.4, placebo plus 52 weeks -7.2], although only the RoActemra every other weekly plus 26 weeks prednisone taper group showed a statistically significant difference compared to placebo [placebo plus 26 weeks taper p=0.0059, and placebo plus 52 weeks taper p=0.0081].\nRomanian: Modificările medii ale SVA între valoarea iniţială şi săptămâna 52 au fost mai mici (ceea ce arată o îmbunătăţire mai mare) în grupurile cu RoActemra administrat subcutanat săptămânal şi la interval de 2 săptămâni [-19,0, -25,3, respectiv], comparativ cu ambele grupuri cu administrare de placebo [placebo plus prednison în doze scăzute treptat pe parcursul a 26 săptămâni -3,4; placebo plus prednison în doze scăzute treptat pe parcursul a 52 săptămâni -7,2%), cu toate că numai grupul cu RoActemra administrat la fiecare 2 săptămâni plus prednison cu scăderea progresivă a dozei în decurs de 26 săptămâni a prezentat o diferenţă semnificativă statistic faţă de placebo [placebo plus prednison în doze scăzute treptat pe parcursul a 26 săptămâni p = 0,0059, şi placebo plus prednison în doze scăzute treptat pe parcursul a 52 săptămâni p = 0,0081].", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The mean change in Patient's global VAS from baseline at week 52 was lower (showing greater improvement) in the RoActemra weekly and every other weekly dose groups [-19.0, -25.3, respectively] than in both placebo groups [placebo plus 26 weeks -3.4, placebo plus 52 weeks -7.2], although only the RoActemra every other weekly plus 26 weeks prednisone taper group showed a statistically significant difference compared to placebo [placebo plus 26 weeks taper p=0.0059, and placebo plus 52 weeks taper p=0.0081].\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "The mean change in Patient's global VAS from baseline at week 52 was lower (showing greater improvement) in the RoActemra weekly and every other weekly dose groups [-19.0, -25.3, respectively] than in both placebo groups [placebo plus 26 weeks -3.4, placebo plus 52 weeks -7.2], although only the RoActemra every other weekly plus 26 weeks prednisone taper group showed a statistically significant difference compared to placebo [placebo plus 26 weeks taper p=0.0059, and placebo plus 52 weeks taper p=0.0081].", "ro": "Modificările medii ale SVA între valoarea iniţială şi săptămâna 52 au fost mai mici (ceea ce arată o îmbunătăţire mai mare) în grupurile cu RoActemra administrat subcutanat săptămânal şi la interval de 2 săptămâni [-19,0, -25,3, respectiv], comparativ cu ambele grupuri cu administrare de placebo [placebo plus prednison în doze scăzute treptat pe parcursul a 26 săptămâni -3,4; placebo plus prednison în doze scăzute treptat pe parcursul a 52 săptămâni -7,2%), cu toate că numai grupul cu RoActemra administrat la fiecare 2 săptămâni plus prednison cu scăderea progresivă a dozei în decurs de 26 săptămâni a prezentat o diferenţă semnificativă statistic faţă de placebo [placebo plus prednison în doze scăzute treptat pe parcursul a 26 săptămâni p = 0,0059, şi placebo plus prednison în doze scăzute treptat pe parcursul a 52 săptămâni p = 0,0081]." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In Studies II, III and V, RoActemra was administered intravenously every four weeks in combination with MTX vs. placebo and MTX.\nRomanian: În Studiile II, III şi V, RoActemra a fost administrat intravenos la interval de patru săptămâni, în asociere cu MTX, comparativ cu placebo şi MTX.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In Studies II, III and V, RoActemra was administered intravenously every four weeks in combination with MTX vs. placebo and MTX.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "In Studies II, III and V, RoActemra was administered intravenously every four weeks in combination with MTX vs. placebo and MTX.", "ro": "În Studiile II, III şi V, RoActemra a fost administrat intravenos la interval de patru săptămâni, în asociere cu MTX, comparativ cu placebo şi MTX." } }
{ "translation": { "text": "Glossaries:\n\"infusion\" -> \"perfuzie\"\n\"vial\" -> \"flacon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The required amount of RoActemra concentrate (0.5 mL/kg) should be withdrawn from the vial and placed in the 50 mL infusion bag.\nRomanian: Cantitatea necesară de concentrat de RoActemra (0,5 ml/kg) trebuie extrasă din flacon şi introdusă în punga de perfuzie de 50 ml.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"infusion\" -> \"perfuzie\"\n\"vial\" -> \"flacon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The required amount of RoActemra concentrate (0.5 mL/kg) should be withdrawn from the vial and placed in the 50 mL infusion bag.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "infusion|||perfuzie\tvial|||flacon", "en": "The required amount of RoActemra concentrate (0.5 mL/kg) should be withdrawn from the vial and placed in the 50 mL infusion bag.", "ro": "Cantitatea necesară de concentrat de RoActemra (0,5 ml/kg) trebuie extrasă din flacon şi introdusă în punga de perfuzie de 50 ml." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Part I consisted of a 16-week active tocilizumab treatment lead-in period (n=188) followed by Part II, a 24-week randomized double-blind placebo-controlled withdrawal period (n=163), followed by Part III, a 64-week open-label period.\nRomanian: placebo controlată, cu durata de 24 de săptămâni (n = 163), urmată apoi de Partea a III-a, o perioadă de studiu deschis cu durata de 64 de săptămâni.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Part I consisted of a 16-week active tocilizumab treatment lead-in period (n=188) followed by Part II, a 24-week randomized double-blind placebo-controlled withdrawal period (n=163), followed by Part III, a 64-week open-label period.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "Part I consisted of a 16-week active tocilizumab treatment lead-in period (n=188) followed by Part II, a 24-week randomized double-blind placebo-controlled withdrawal period (n=163), followed by Part III, a 64-week open-label period.", "ro": "placebo controlată, cu durata de 24 de săptămâni (n = 163), urmată apoi de Partea a III-a, o perioadă de studiu deschis cu durata de 64 de săptămâni." } }
{ "translation": { "text": "Glossaries:\n\"infusion\" -> \"perfuzie\"\n\"vial\" -> \"flacon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The required amount of RoActemra concentrate (0.6 mL/kg) should be withdrawn from the vial and placed in the 50 mL infusion bag.\nRomanian: Cantitatea necesară de concentrat de RoActemra (0,6 ml/kg) trebuie extrasă din flacon şi introdusă în punga de perfuzie de 50 ml.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"infusion\" -> \"perfuzie\"\n\"vial\" -> \"flacon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The required amount of RoActemra concentrate (0.6 mL/kg) should be withdrawn from the vial and placed in the 50 mL infusion bag.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "infusion|||perfuzie\tvial|||flacon", "en": "The required amount of RoActemra concentrate (0.6 mL/kg) should be withdrawn from the vial and placed in the 50 mL infusion bag.", "ro": "Cantitatea necesară de concentrat de RoActemra (0,6 ml/kg) trebuie extrasă din flacon şi introdusă în punga de perfuzie de 50 ml." } }
{ "translation": { "text": "Glossaries:\n\"infusion\" -> \"perfuzie\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Patients in the tocilizumab arm received an intravenous (IV) infusion of tocilizumab (8 mg/kg) every 4 weeks (q4w) and a subcutaneous (SC) placebo injection every 2 weeks (q2w).\nRomanian: Pacienţilor din braţul cu tocilizumab li s-a administrat tocilizumab (8 mg/kg) în perfuzie intravenoasă (i.v.), la interval de 4 săptămâni şi placebo sub formă de injecţie subcutanată (s.c.), la interval de 2 săptămâni.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"infusion\" -> \"perfuzie\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Patients in the tocilizumab arm received an intravenous (IV) infusion of tocilizumab (8 mg/kg) every 4 weeks (q4w) and a subcutaneous (SC) placebo injection every 2 weeks (q2w).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "infusion|||perfuzie\tplacebo|||placebo", "en": "Patients in the tocilizumab arm received an intravenous (IV) infusion of tocilizumab (8 mg/kg) every 4 weeks (q4w) and a subcutaneous (SC) placebo injection every 2 weeks (q2w).", "ro": "Pacienţilor din braţul cu tocilizumab li s-a administrat tocilizumab (8 mg/kg) în perfuzie intravenoasă (i.v.), la interval de 4 săptămâni şi placebo sub formă de injecţie subcutanată (s.c.), la interval de 2 săptămâni." } }
{ "translation": { "text": "Glossaries:\n\"infusion\" -> \"perfuzie\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Patients in the RoActemra arm received an intravenous (IV) infusion of RoActemra (8 mg/kg) every 4 weeks (q4w) and a subcutaneous (SC) placebo injection every 2 weeks (q2w).\nRomanian: Pacienţilor din braţul cu RoActemra li s-a administrat RoActemra (8 mg/kg) în perfuzie intravenoasă (i.v.), la interval de 4 săptămâni şi placebo sub formă de injecţie subcutanată (s.c.), la interval de 2 săptămâni.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"infusion\" -> \"perfuzie\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Patients in the RoActemra arm received an intravenous (IV) infusion of RoActemra (8 mg/kg) every 4 weeks (q4w) and a subcutaneous (SC) placebo injection every 2 weeks (q2w).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "infusion|||perfuzie\tplacebo|||placebo", "en": "Patients in the RoActemra arm received an intravenous (IV) infusion of RoActemra (8 mg/kg) every 4 weeks (q4w) and a subcutaneous (SC) placebo injection every 2 weeks (q2w).", "ro": "Pacienţilor din braţul cu RoActemra li s-a administrat RoActemra (8 mg/kg) în perfuzie intravenoasă (i.v.), la interval de 4 săptămâni şi placebo sub formă de injecţie subcutanată (s.c.), la interval de 2 săptămâni." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The mean change from baseline at week 104 in total Sharp-Genant score was significantly lower for patients randomised to tocilizumab 8 mg/kg plus MTX (p<0.0001) compared with patients who were randomised to placebo plus MTX.\nRomanian: Modificarea medie faţă de momentul iniţial la săptămâna 104 a Scorului Total Sharp-Genant a fost semnificativ mai redusă la pacienţii din grupul de tratament cu tocilizumab 8 mg/kg în asociere cu MTX (p <0,0001), comparativ cu pacienţii din grupul care a primit placebo în asociere cu MTX.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The mean change from baseline at week 104 in total Sharp-Genant score was significantly lower for patients randomised to tocilizumab 8 mg/kg plus MTX (p<0.0001) compared with patients who were randomised to placebo plus MTX.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "The mean change from baseline at week 104 in total Sharp-Genant score was significantly lower for patients randomised to tocilizumab 8 mg/kg plus MTX (p<0.0001) compared with patients who were randomised to placebo plus MTX.", "ro": "Modificarea medie faţă de momentul iniţial la săptămâna 104 a Scorului Total Sharp-Genant a fost semnificativ mai redusă la pacienţii din grupul de tratament cu tocilizumab 8 mg/kg în asociere cu MTX (p <0,0001), comparativ cu pacienţii din grupul care a primit placebo în asociere cu MTX." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The mean change from baseline at week 104 in total Sharp-Genant score was significantly lower for patients randomised to RoActemra 8 mg/kg plus MTX (p<0.0001) compared with patients who were randomised to placebo plus MTX.\nRomanian: Modificarea medie faţă de momentul iniţial la săptămâna 104 a Scorului Total Sharp-Genant a fost semnificativ mai redusă la pacienţii din grupul de tratament cu RoActemra 8 mg/kg în asociere cu MTX (p <0,0001), comparativ cu pacienţii din grupul care a primit placebo în asociere cu MTX.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The mean change from baseline at week 104 in total Sharp-Genant score was significantly lower for patients randomised to RoActemra 8 mg/kg plus MTX (p<0.0001) compared with patients who were randomised to placebo plus MTX.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "The mean change from baseline at week 104 in total Sharp-Genant score was significantly lower for patients randomised to RoActemra 8 mg/kg plus MTX (p<0.0001) compared with patients who were randomised to placebo plus MTX.", "ro": "Modificarea medie faţă de momentul iniţial la săptămâna 104 a Scorului Total Sharp-Genant a fost semnificativ mai redusă la pacienţii din grupul de tratament cu RoActemra 8 mg/kg în asociere cu MTX (p <0,0001), comparativ cu pacienţii din grupul care a primit placebo în asociere cu MTX." } }
{ "translation": { "text": "Glossary:\n\"vial\" -> \"flacon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Excipients with known effects Each 80 mg vial contains 0.10 mmol (2.21 mg) sodium.\nRomanian: Fiecare flacon a 80 mg conţine sodiu 0,10 mmoli (2,21 mg).", "en_prompt": "<|im_start|>user\nGlossary:\n\"vial\" -> \"flacon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Excipients with known effects Each 80 mg vial contains 0.10 mmol (2.21 mg) sodium.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "vial|||flacon", "en": "Excipients with known effects Each 80 mg vial contains 0.10 mmol (2.21 mg) sodium.", "ro": "Fiecare flacon a 80 mg conţine sodiu 0,10 mmoli (2,21 mg)." } }
{ "translation": { "text": "Glossary:\n\"tuberculosis\" -> \"tuberculoză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Your doctor will check for signs and symptoms of tuberculosis before starting RoActemra.\nRomanian: Înainte de a începe tratamentul cu RoActemra, medicul dumneavoastră va verifica dacă există semne şi simptome de tuberculoză.", "en_prompt": "<|im_start|>user\nGlossary:\n\"tuberculosis\" -> \"tuberculoză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Your doctor will check for signs and symptoms of tuberculosis before starting RoActemra.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "tuberculosis|||tuberculoză", "en": "Your doctor will check for signs and symptoms of tuberculosis before starting RoActemra.", "ro": "Înainte de a începe tratamentul cu RoActemra, medicul dumneavoastră va verifica dacă există semne şi simptome de tuberculoză." } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"doză\"\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: This medicine contains 26.55 mg sodium per maximum dose of 1200 mg. Take this into account if you are on a low-sodium diet.\nRomanian: RoActemra conţine sodiu Acest medicament conţine 26,55 mg sodiu pentru o doză maximă de 1200 mg.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"doză\"\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: This medicine contains 26.55 mg sodium per maximum dose of 1200 mg. Take this into account if you are on a low-sodium diet.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||doză\tmedicine|||medicament", "en": "This medicine contains 26.55 mg sodium per maximum dose of 1200 mg. Take this into account if you are on a low-sodium diet.", "ro": "RoActemra conţine sodiu Acest medicament conţine 26,55 mg sodiu pentru o doză maximă de 1200 mg." } }
{ "translation": { "text": "Glossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • Do not take the next dose until you have informed your doctor AND your doctor has told you to take the next dose if you have experienced any allergic reaction symptoms after RoActemra administration.\nRomanian: • Dacă manifestaţi orice simptome caracteristice unei reacţii alergice după administrarea de RoActemra, nu vă administraţi doza următoare decât dacă v-aţi informat medicul despre aceasta şi medicul dumneavoastră v-a spus să vă administraţi următoarea doză.", "en_prompt": "<|im_start|>user\nGlossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • Do not take the next dose until you have informed your doctor AND your doctor has told you to take the next dose if you have experienced any allergic reaction symptoms after RoActemra administration.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||doză", "en": "• Do not take the next dose until you have informed your doctor AND your doctor has told you to take the next dose if you have experienced any allergic reaction symptoms after RoActemra administration.", "ro": "• Dacă manifestaţi orice simptome caracteristice unei reacţii alergice după administrarea de RoActemra, nu vă administraţi doza următoare decât dacă v-aţi informat medicul despre aceasta şi medicul dumneavoastră v-a spus să vă administraţi următoarea doză." } }
{ "translation": { "text": "Glossaries:\n\"treatment\" -> \"tratament\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: A statistically significant superior treatment effect was seen in favour of RoActemra over placebo in achieving steroid-free sustained remission at week 52 on RoActemra plus 26 weeks prednisone taper compared with placebo plus 26 weeks prednisone taper and with placebo plus 52 weeks prednisone taper.\nRomanian: A fost observat un efect superior, semnificativ statistic, al tratamentului cu RoActemra, faţă de placebo, în obţinerea unei remisiuni durabile fără utilizare de corticosteroizi la săptămâna 52 de tratament cu RoActemra plus prednison în doze scăzute treptat pe parcursul a 26 săptămâni,", "en_prompt": "<|im_start|>user\nGlossaries:\n\"treatment\" -> \"tratament\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: A statistically significant superior treatment effect was seen in favour of RoActemra over placebo in achieving steroid-free sustained remission at week 52 on RoActemra plus 26 weeks prednisone taper compared with placebo plus 26 weeks prednisone taper and with placebo plus 52 weeks prednisone taper.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratament\tplacebo|||placebo", "en": "A statistically significant superior treatment effect was seen in favour of RoActemra over placebo in achieving steroid-free sustained remission at week 52 on RoActemra plus 26 weeks prednisone taper compared with placebo plus 26 weeks prednisone taper and with placebo plus 52 weeks prednisone taper.", "ro": "A fost observat un efect superior, semnificativ statistic, al tratamentului cu RoActemra, faţă de placebo, în obţinerea unei remisiuni durabile fără utilizare de corticosteroizi la săptămâna 52 de tratament cu RoActemra plus prednison în doze scăzute treptat pe parcursul a 26 săptămâni," } }
{ "translation": { "text": "Glossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the 12 week double-blind, controlled phase, 75 patients received treatment with tocilizumab (8 mg/kg or 12 mg/kg based upon body weight).\nRomanian: unui număr de 75 de pacienţi li s-a administrat tratament cu tocilizumab (8 mg/kg sau 12 mg/kg în funcţie de greutatea corporală).", "en_prompt": "<|im_start|>user\nGlossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the 12 week double-blind, controlled phase, 75 patients received treatment with tocilizumab (8 mg/kg or 12 mg/kg based upon body weight).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratament", "en": "In the 12 week double-blind, controlled phase, 75 patients received treatment with tocilizumab (8 mg/kg or 12 mg/kg based upon body weight).", "ro": "unui număr de 75 de pacienţi li s-a administrat tratament cu tocilizumab (8 mg/kg sau 12 mg/kg în funcţie de greutatea corporală)." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: During the 6-month controlled trials transient elevations in ALT/AST > 3 x ULN were observed in 2.1% of patients on RoActemra 8 mg/kg compared to 4.9% of patients on MTX and in 6.5% of patients who received 8 mg/kg RoActemra plus DMARDs compared to 1.5% of patients on placebo plus DMARDs.\nRomanian: În cadrul studiilor clinice controlate cu durata de 6 luni, creşteri tranzitorii ale ALT/AST la valori > 3 x LSN au fost observate la 2,1% dintre pacienţii trataţi cu RoActemra 8 mg/kg, comparativ cu 4,9% dintre pacienţii trataţi cu MTX şi la 6,5% dintre pacienţii trataţi cu RoActemra 8 mg/kg şi DMARD, comparativ cu 1,5% dintre pacienţii cărora li s-a administrat placebo şi DMARD.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: During the 6-month controlled trials transient elevations in ALT/AST > 3 x ULN were observed in 2.1% of patients on RoActemra 8 mg/kg compared to 4.9% of patients on MTX and in 6.5% of patients who received 8 mg/kg RoActemra plus DMARDs compared to 1.5% of patients on placebo plus DMARDs.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "During the 6-month controlled trials transient elevations in ALT/AST > 3 x ULN were observed in 2.1% of patients on RoActemra 8 mg/kg compared to 4.9% of patients on MTX and in 6.5% of patients who received 8 mg/kg RoActemra plus DMARDs compared to 1.5% of patients on placebo plus DMARDs.", "ro": "În cadrul studiilor clinice controlate cu durata de 6 luni, creşteri tranzitorii ale ALT/AST la valori > 3 x LSN au fost observate la 2,1% dintre pacienţii trataţi cu RoActemra 8 mg/kg, comparativ cu 4,9% dintre pacienţii trataţi cu MTX şi la 6,5% dintre pacienţii trataţi cu RoActemra 8 mg/kg şi DMARD, comparativ cu 1,5% dintre pacienţii cărora li s-a administrat placebo şi DMARD." } }
{ "translation": { "text": "Glossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If a child or adolescent with pJIA misses or forgets a dose\nRomanian: Dacă un copil sau un adolescent cu AIJp omite sau uită o doză Este foarte important să utilizaţi RoActemra exact aşa cum a prescris medicul.", "en_prompt": "<|im_start|>user\nGlossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If a child or adolescent with pJIA misses or forgets a dose\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||doză", "en": "If a child or adolescent with pJIA misses or forgets a dose", "ro": "Dacă un copil sau un adolescent cu AIJp omite sau uită o doză Este foarte important să utilizaţi RoActemra exact aşa cum a prescris medicul." } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"doză\"\n\"AUC\" -> \"aria de sub curbă\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The following parameters (predicted mean ± SD) were estimated for a dose of 8 mg/kg RoActemra given every 4 weeks: steady-state area under curve (AUC) = 38000 ± 13000 h µg/mL, trough concentration (Cmin) = 15.9 ± 13.1 µg/mL and maximum concentration (Cmax) = 182 ± 50.4 µg/mL, and.\nRomanian: Pentru o doză de 8 mg/kg de RoActemra, administrată la interval de 4 săptămâni, au fost estimaţi următorii parametri (media estimată ± DS): aria de sub curbă (ASC) la starea de echilibru = 38000 ± 13000 h µg/ml, concentraţia minimă (Cmin) = 15,9 ± 13,1 µg/ml şi concentraţia maximă", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"doză\"\n\"AUC\" -> \"aria de sub curbă\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The following parameters (predicted mean ± SD) were estimated for a dose of 8 mg/kg RoActemra given every 4 weeks: steady-state area under curve (AUC) = 38000 ± 13000 h µg/mL, trough concentration (Cmin) = 15.9 ± 13.1 µg/mL and maximum concentration (Cmax) = 182 ± 50.4 µg/mL, and.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||doză\tAUC|||aria de sub curbă", "en": "The following parameters (predicted mean ± SD) were estimated for a dose of 8 mg/kg RoActemra given every 4 weeks: steady-state area under curve (AUC) = 38000 ± 13000 h µg/mL, trough concentration (Cmin) = 15.9 ± 13.1 µg/mL and maximum concentration (Cmax) = 182 ± 50.4 µg/mL, and.", "ro": "Pentru o doză de 8 mg/kg de RoActemra, administrată la interval de 4 săptămâni, au fost estimaţi următorii parametri (media estimată ± DS): aria de sub curbă (ASC) la starea de echilibru = 38000 ± 13000 h µg/ml, concentraţia minimă (Cmin) = 15,9 ± 13,1 µg/ml şi concentraţia maximă" } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The assessment of the time to first GCA flare showed a significantly lower risk of flare for the RoActemra subcutaneous weekly group compared to placebo plus 26 weeks prednisone and placebo plus 52 weeks prednisone taper groups and for the RoActemra subcutaneous every other weekly group compared to placebo plus 26 weeks prednisone (when compared at a 0.01 significance level).\nRomanian: Evaluarea intervalului de timp până la primul episod de acutizare a ACG a evidenţiat un risc de acutizare semnificativ mai scăzut pentru grupul cu RoActemra administrat subcutanat în fiecare săptămână, comparativ cu grupurile cu administrare de placebo plus prednison în doze scăzute treptat pe parcursul a 26 săptămâni şi administrare de placebo plus prednison în doze scăzute treptat pe parcursul a 52 săptămâni şi pentru grupul cu RoActemra administrat subcutanat la interval de 2", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The assessment of the time to first GCA flare showed a significantly lower risk of flare for the RoActemra subcutaneous weekly group compared to placebo plus 26 weeks prednisone and placebo plus 52 weeks prednisone taper groups and for the RoActemra subcutaneous every other weekly group compared to placebo plus 26 weeks prednisone (when compared at a 0.01 significance level).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "The assessment of the time to first GCA flare showed a significantly lower risk of flare for the RoActemra subcutaneous weekly group compared to placebo plus 26 weeks prednisone and placebo plus 52 weeks prednisone taper groups and for the RoActemra subcutaneous every other weekly group compared to placebo plus 26 weeks prednisone (when compared at a 0.01 significance level).", "ro": "Evaluarea intervalului de timp până la primul episod de acutizare a ACG a evidenţiat un risc de acutizare semnificativ mai scăzut pentru grupul cu RoActemra administrat subcutanat în fiecare săptămână, comparativ cu grupurile cu administrare de placebo plus prednison în doze scăzute treptat pe parcursul a 26 săptămâni şi administrare de placebo plus prednison în doze scăzute treptat pe parcursul a 52 săptămâni şi pentru grupul cu RoActemra administrat subcutanat la interval de 2" } }
{ "translation": { "text": "Glossary:\n\"elimination\" -> \"eliminare\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Given its long elimination half-life (t1/2), the effect of RoActemra on CYP450 enzyme activity may persist for several weeks after stopping therapy.\nRomanian: Efectul RoActemra asupra activităţii CYP450 poate persista timp de câteva săptămâni după oprirea tratamentului, din cauza timpului de înjumătăţire (t1/2) prin eliminare lung.", "en_prompt": "<|im_start|>user\nGlossary:\n\"elimination\" -> \"eliminare\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Given its long elimination half-life (t1/2), the effect of RoActemra on CYP450 enzyme activity may persist for several weeks after stopping therapy.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "elimination|||eliminare", "en": "Given its long elimination half-life (t1/2), the effect of RoActemra on CYP450 enzyme activity may persist for several weeks after stopping therapy.", "ro": "Efectul RoActemra asupra activităţii CYP450 poate persista timp de câteva săptămâni după oprirea tratamentului, din cauza timpului de înjumătăţire (t1/2) prin eliminare lung." } }
{ "translation": { "text": "Glossary:\n\"body weight\" -> \"greutate corporală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Eligible patients received tocilizumab dosed according to body weight (BW), with patients weighing ≥30 kg (n = 25) dosed with 162 mg of RoActemra every 2 weeks (Q2W) and patients weighing below 30 kg (n = 27) dosed with 162 mg of RoActemra every 3 weeks (Q3W) for 52 weeks.\nRomanian: Pacienţii eligibili au fost tratați cu tocilizumab în doze stabilite în funcţie de greutatea corporală (GC), pacienţii cu o greutate corporală de 30 kg sau peste (n = 25) fiind trataţi cu doze de 162 mg de RoActemra la fiecare 2 săptămâni, iar pacienţii cu greutatea corporală mai mică de 30 kg (n =27) fiind trataţi cu doze de 162 mg de RoActemra o dată la 3 săptămâni, timp de 52 de săptămâni.", "en_prompt": "<|im_start|>user\nGlossary:\n\"body weight\" -> \"greutate corporală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Eligible patients received tocilizumab dosed according to body weight (BW), with patients weighing ≥30 kg (n = 25) dosed with 162 mg of RoActemra every 2 weeks (Q2W) and patients weighing below 30 kg (n = 27) dosed with 162 mg of RoActemra every 3 weeks (Q3W) for 52 weeks.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "body weight|||greutate corporală", "en": "Eligible patients received tocilizumab dosed according to body weight (BW), with patients weighing ≥30 kg (n = 25) dosed with 162 mg of RoActemra every 2 weeks (Q2W) and patients weighing below 30 kg (n = 27) dosed with 162 mg of RoActemra every 3 weeks (Q3W) for 52 weeks.", "ro": "Pacienţii eligibili au fost tratați cu tocilizumab în doze stabilite în funcţie de greutatea corporală (GC), pacienţii cu o greutate corporală de 30 kg sau peste (n = 25) fiind trataţi cu doze de 162 mg de RoActemra la fiecare 2 săptămâni, iar pacienţii cu greutatea corporală mai mică de 30 kg (n =27) fiind trataţi cu doze de 162 mg de RoActemra o dată la 3 săptămâni, timp de 52 de săptămâni." } }
{ "translation": { "text": "Glossary:\n\"body weight\" -> \"greutate corporală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: For the 162 mg every week dosing regimen, the steady-state Cavg was 51% higher in patients with body weight less than 60 kg compared to patients weighing between 60 to 100 kg. For the 162 mg every other week regimen, the steady-state Cavg was 129% higher in patients with body weight less than 60 kg compared to patients weighing between 60 to 100 kg.\nRomanian: În cazul schemei de dozare de 162 mg în fiecare săptămână, Cmedie la starea de echilibru a fost cu 51% mai mare la pacienţii cu greutate corporală mai mică de 60 kg, comparativ cu pacienţii care cântăreau între 60 şi 100 kg.", "en_prompt": "<|im_start|>user\nGlossary:\n\"body weight\" -> \"greutate corporală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: For the 162 mg every week dosing regimen, the steady-state Cavg was 51% higher in patients with body weight less than 60 kg compared to patients weighing between 60 to 100 kg. For the 162 mg every other week regimen, the steady-state Cavg was 129% higher in patients with body weight less than 60 kg compared to patients weighing between 60 to 100 kg.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "body weight|||greutate corporală", "en": "For the 162 mg every week dosing regimen, the steady-state Cavg was 51% higher in patients with body weight less than 60 kg compared to patients weighing between 60 to 100 kg. For the 162 mg every other week regimen, the steady-state Cavg was 129% higher in patients with body weight less than 60 kg compared to patients weighing between 60 to 100 kg.", "ro": "În cazul schemei de dozare de 162 mg în fiecare săptămână, Cmedie la starea de echilibru a fost cu 51% mai mare la pacienţii cu greutate corporală mai mică de 60 kg, comparativ cu pacienţii care cântăreau între 60 şi 100 kg." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Doses of 8 mg/kg tocilizumab or placebo were given every four weeks in combination with stable DMARDs.\nRomanian: Au fost administrate doze de tocilizumab de 8 mg/kg sau placebo, la interval de patru săptămâni, în asociere cu doza stabilă de DMARD.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Doses of 8 mg/kg tocilizumab or placebo were given every four weeks in combination with stable DMARDs.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "Doses of 8 mg/kg tocilizumab or placebo were given every four weeks in combination with stable DMARDs.", "ro": "Au fost administrate doze de tocilizumab de 8 mg/kg sau placebo, la interval de patru săptămâni, în asociere cu doza stabilă de DMARD." } }
{ "translation": { "text": "Glossary:\n\"hypersensitivity\" -> \"hipersensibilitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Clinically significant hypersensitivity reactions associated with RoActemra and requiring treatment discontinuation were reported in a total of 56 out of 4,009 patients (1.4%) treated with RoActemra during the controlled and open label clinical studies.\nRomanian: În timpul studiilor clinice deschise şi controlate au fost raportate reacţii de hipersensibilitate semnificative clinic asociate cu administrarea RoActemra şi care au necesitat întreruperea tratamentului la un total de 56 de pacienţi (1,4%) din cei 4009 pacienţi trataţi cu RoActemra.", "en_prompt": "<|im_start|>user\nGlossary:\n\"hypersensitivity\" -> \"hipersensibilitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Clinically significant hypersensitivity reactions associated with RoActemra and requiring treatment discontinuation were reported in a total of 56 out of 4,009 patients (1.4%) treated with RoActemra during the controlled and open label clinical studies.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "hypersensitivity|||hipersensibilitate", "en": "Clinically significant hypersensitivity reactions associated with RoActemra and requiring treatment discontinuation were reported in a total of 56 out of 4,009 patients (1.4%) treated with RoActemra during the controlled and open label clinical studies.", "ro": "În timpul studiilor clinice deschise şi controlate au fost raportate reacţii de hipersensibilitate semnificative clinic asociate cu administrarea RoActemra şi care au necesitat întreruperea tratamentului la un total de 56 de pacienţi (1,4%) din cei 4009 pacienţi trataţi cu RoActemra." } }
{ "translation": { "text": "Glossaries:\n\"pharmacokinetics\" -> \"farmacocinetică\"\n\"body weight\" -> \"greutate corporală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The pharmacokinetics of tocilizumab were determined using a population pharmacokinetic analysis on a database composed of 140 sJIA patients treated with 8 mg/kg IV every 2 weeks (patients with a body weight ≥ 30 kg ) 12 mg/kg IV every 2 weeks (patients with a body weight < 30 kg), 162 mg SC every week (patients weighing ≥ 30 kg), 162 mg SC every 10 days or every 2 weeks (patients weighing below 30 kg).\nRomanian: Farmacocinetica tocilizumabului a fost determinată folosind analiza farmacocinetică a populaţiei pe o bază de date compusă din 140 de pacienţi cu AIJs trataţi cu 8 mg/kg IV la fiecare 2 săptămâni (pacienţi cu o greutate corporală ≥ 30 kg ), 12 mg/kg IV la fiecare 2 săptămâni (pacienţi cu o greutate corporală < 30 kg) 162 mg subcutanat în fiecare săptămână (pacienți cu o greutate ≥ 30 kg), 162 mg subcutanat la fiecare 10 zile sau la fiecare 2 săptămâni (pacienți cu o greutate mai mică de 30 kg).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"pharmacokinetics\" -> \"farmacocinetică\"\n\"body weight\" -> \"greutate corporală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The pharmacokinetics of tocilizumab were determined using a population pharmacokinetic analysis on a database composed of 140 sJIA patients treated with 8 mg/kg IV every 2 weeks (patients with a body weight ≥ 30 kg ) 12 mg/kg IV every 2 weeks (patients with a body weight < 30 kg), 162 mg SC every week (patients weighing ≥ 30 kg), 162 mg SC every 10 days or every 2 weeks (patients weighing below 30 kg).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "pharmacokinetics|||farmacocinetică\tbody weight|||greutate corporală", "en": "The pharmacokinetics of tocilizumab were determined using a population pharmacokinetic analysis on a database composed of 140 sJIA patients treated with 8 mg/kg IV every 2 weeks (patients with a body weight ≥ 30 kg ) 12 mg/kg IV every 2 weeks (patients with a body weight < 30 kg), 162 mg SC every week (patients weighing ≥ 30 kg), 162 mg SC every 10 days or every 2 weeks (patients weighing below 30 kg).", "ro": "Farmacocinetica tocilizumabului a fost determinată folosind analiza farmacocinetică a populaţiei pe o bază de date compusă din 140 de pacienţi cu AIJs trataţi cu 8 mg/kg IV la fiecare 2 săptămâni (pacienţi cu o greutate corporală ≥ 30 kg ), 12 mg/kg IV la fiecare 2 săptămâni (pacienţi cu o greutate corporală < 30 kg) 162 mg subcutanat în fiecare săptămână (pacienți cu o greutate ≥ 30 kg), 162 mg subcutanat la fiecare 10 zile sau la fiecare 2 săptămâni (pacienți cu o greutate mai mică de 30 kg)." } }
{ "translation": { "text": "Glossary:\n\"elimination\" -> \"eliminare\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Given its long elimination half-life (t1/2), the effect of tocilizumab on CYP450 enzyme activity may persist for several weeks after stopping therapy.\nRomanian: Efectul tocilizumab asupra activităţii CYP450 poate persista timp de câteva săptămâni după oprirea tratamentului, din cauza timpului de înjumătăţire (t1/2) prin eliminare lung.", "en_prompt": "<|im_start|>user\nGlossary:\n\"elimination\" -> \"eliminare\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Given its long elimination half-life (t1/2), the effect of tocilizumab on CYP450 enzyme activity may persist for several weeks after stopping therapy.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "elimination|||eliminare", "en": "Given its long elimination half-life (t1/2), the effect of tocilizumab on CYP450 enzyme activity may persist for several weeks after stopping therapy.", "ro": "Efectul tocilizumab asupra activităţii CYP450 poate persista timp de câteva săptămâni după oprirea tratamentului, din cauza timpului de înjumătăţire (t1/2) prin eliminare lung." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: RoActemra subcutaneous weekly dose also showed a clinically meaningful decrease in the risk for flare compared to placebo plus 26 weeks prednisone in patients who entered the trial with relapsing GCA as well as those with new-onset disease (Table 4).\nRomanian: Doza de RoActemra administrată subcutanat în fiecare săptămână a fost asociată, de asemenea, cu o scădere semnificativă clinic a riscului de acutizare, comparativ cu administrarea de placebo plus prednison în doze scăzute treptat pe parcursul a 26 de săptămâni la pacienţii care, la intrarea în studiu, prezentau ACG recurentă,", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: RoActemra subcutaneous weekly dose also showed a clinically meaningful decrease in the risk for flare compared to placebo plus 26 weeks prednisone in patients who entered the trial with relapsing GCA as well as those with new-onset disease (Table 4).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "RoActemra subcutaneous weekly dose also showed a clinically meaningful decrease in the risk for flare compared to placebo plus 26 weeks prednisone in patients who entered the trial with relapsing GCA as well as those with new-onset disease (Table 4).", "ro": "Doza de RoActemra administrată subcutanat în fiecare săptămână a fost asociată, de asemenea, cu o scădere semnificativă clinic a riscului de acutizare, comparativ cu administrarea de placebo plus prednison în doze scăzute treptat pe parcursul a 26 de săptămâni la pacienţii care, la intrarea în studiu, prezentau ACG recurentă," } }
{ "translation": { "text": "Glossary:\n\"hypersensitivity\" -> \"hipersensibilitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Clinically significant hypersensitivity reactions associated with tocilizumab and requiring treatment discontinuation were reported in a total of 56 out of 4,009 patients (1.4%) treated with tocilizumab during the controlled and open label clinical studies.\nRomanian: În timpul studiilor clinice deschise şi controlate au fost raportate reacţii de hipersensibilitate semnificative clinic asociate cu administrarea de tocilizumab şi care au necesitat întreruperea tratamentului la un total de 56 de pacienţi (1,4%) din cei 4009 pacienţi trataţi cu tocilizumab.", "en_prompt": "<|im_start|>user\nGlossary:\n\"hypersensitivity\" -> \"hipersensibilitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Clinically significant hypersensitivity reactions associated with tocilizumab and requiring treatment discontinuation were reported in a total of 56 out of 4,009 patients (1.4%) treated with tocilizumab during the controlled and open label clinical studies.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "hypersensitivity|||hipersensibilitate", "en": "Clinically significant hypersensitivity reactions associated with tocilizumab and requiring treatment discontinuation were reported in a total of 56 out of 4,009 patients (1.4%) treated with tocilizumab during the controlled and open label clinical studies.", "ro": "În timpul studiilor clinice deschise şi controlate au fost raportate reacţii de hipersensibilitate semnificative clinic asociate cu administrarea de tocilizumab şi care au necesitat întreruperea tratamentului la un total de 56 de pacienţi (1,4%) din cei 4009 pacienţi trataţi cu tocilizumab." } }
{ "translation": { "text": "Glossaries:\n\"infusion\" -> \"perfuzie\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Patients in the adalimumab arm received an adalimumab SC injection (40 mg) q2w plus an IV placebo infusion q4w.\nRomanian: Pacienţilor din braţul cu adalimumab li s-a administrat adalimumab (40 mg) sub formă de injecţie s.c. la interval de 2 săptămâni plus placebo în perfuzie i.v. la interval de 4 săptămâni.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"infusion\" -> \"perfuzie\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Patients in the adalimumab arm received an adalimumab SC injection (40 mg) q2w plus an IV placebo infusion q4w.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "infusion|||perfuzie\tplacebo|||placebo", "en": "Patients in the adalimumab arm received an adalimumab SC injection (40 mg) q2w plus an IV placebo infusion q4w.", "ro": "Pacienţilor din braţul cu adalimumab li s-a administrat adalimumab (40 mg) sub formă de injecţie s.c. la interval de 2 săptămâni plus placebo în perfuzie i.v. la interval de 4 săptămâni." } }
{ "translation": { "text": "Glossaries:\n\"infusion\" -> \"perfuzie\"\n\"intravenous infusion\" -> \"perfuzie intravenoasă\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: METHOD AND ROUTE(S) OF ADMINISTRATION For intravenous infusion after dilution The diluted product should be used immediately Read the package leaflet before use\nRomanian: MODUL ŞI CALEA(CĂILE) DE ADMINISTRARE Pentru perfuzie intravenoasă după diluare", "en_prompt": "<|im_start|>user\nGlossaries:\n\"infusion\" -> \"perfuzie\"\n\"intravenous infusion\" -> \"perfuzie intravenoasă\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: METHOD AND ROUTE(S) OF ADMINISTRATION For intravenous infusion after dilution The diluted product should be used immediately Read the package leaflet before use\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "infusion|||perfuzie\tintravenous infusion|||perfuzie intravenoasă", "en": "METHOD AND ROUTE(S) OF ADMINISTRATION For intravenous infusion after dilution The diluted product should be used immediately Read the package leaflet before use", "ro": "MODUL ŞI CALEA(CĂILE) DE ADMINISTRARE Pentru perfuzie intravenoasă după diluare" } }
{ "translation": { "text": "Glossary:\n\"cough\" -> \"tuse\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Patients should be advised to seek medical advice if signs/symptoms (e.g., persistent cough, wasting/weight loss, low grade (fever) suggestive of a tuberculosis infection occur during or after therapy with RoActemra.\nRomanian: Pacienţii trebuie sfătuiţi să solicite asistenţă medicală dacă în timpul sau după tratamentul cu RoActemra apar semne/simptome care sugerează infecţia tuberculoasă (de exemplu tuse persistentă, astenie/scădere ponderală, subfebrilitate).", "en_prompt": "<|im_start|>user\nGlossary:\n\"cough\" -> \"tuse\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Patients should be advised to seek medical advice if signs/symptoms (e.g., persistent cough, wasting/weight loss, low grade (fever) suggestive of a tuberculosis infection occur during or after therapy with RoActemra.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "cough|||tuse", "en": "Patients should be advised to seek medical advice if signs/symptoms (e.g., persistent cough, wasting/weight loss, low grade (fever) suggestive of a tuberculosis infection occur during or after therapy with RoActemra.", "ro": "Pacienţii trebuie sfătuiţi să solicite asistenţă medicală dacă în timpul sau după tratamentul cu RoActemra apar semne/simptome care sugerează infecţia tuberculoasă (de exemplu tuse persistentă, astenie/scădere ponderală, subfebrilitate)." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The mean [SD] change scores were as follows: RoActemra weekly plus 26 weeks 5.61 [10.115], RoActemra every other weekly plus 26 weeks 1.81 [8.836], placebo plus 26 weeks 0.26 [10.702], and placebo plus 52 weeks -1.63 [6.753].\nRomanian: 26 săptămâni, 1,81 [8,836] pentru RoActemra administrat la interval de două săptămâni plus prednison în doze scăzute treptat pe parcursul a 26 săptămâni, 0,26 [10,702] pentru placebo plus prednison în doze scăzute treptat pe parcursul a 26 săptămâni şi -1,63 [ 6,753] pentru placebo plus prednison în doze scăzute treptat pe parcursul a 52 săptămâni.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The mean [SD] change scores were as follows: RoActemra weekly plus 26 weeks 5.61 [10.115], RoActemra every other weekly plus 26 weeks 1.81 [8.836], placebo plus 26 weeks 0.26 [10.702], and placebo plus 52 weeks -1.63 [6.753].\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "The mean [SD] change scores were as follows: RoActemra weekly plus 26 weeks 5.61 [10.115], RoActemra every other weekly plus 26 weeks 1.81 [8.836], placebo plus 26 weeks 0.26 [10.702], and placebo plus 52 weeks -1.63 [6.753].", "ro": "26 săptămâni, 1,81 [8,836] pentru RoActemra administrat la interval de două săptămâni plus prednison în doze scăzute treptat pe parcursul a 26 săptămâni, 0,26 [10,702] pentru placebo plus prednison în doze scăzute treptat pe parcursul a 26 săptămâni şi -1,63 [ 6,753] pentru placebo plus prednison în doze scăzute treptat pe parcursul a 52 săptămâni." } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"doză\"\n\"AUC\" -> \"aria de sub curbă\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The following parameters (predicted mean ± SD) were estimated for a dose of 8 mg/kg tocilizumab given every 4 weeks: steady-state area under curve (AUC) = 38000 ± 13000 h µg/mL, trough concentration (Cmin) = 15.9 ± 13.1 µg/mL and maximum concentration (Cmax) = 182 ± 50.4 µg/mL, and the accumulation ratios for AUC and Cmax were small, 1.32 and 1.09, respectively.\nRomanian: Pentru o doză de 8 mg/kg de tocilizumab, administrată la interval de 4 săptămâni, au fost estimaţi următorii parametri (media estimată ± DS): aria de sub curbă (ASC) la starea de echilibru = 38000 ± 13000 h µg/ml, concentraţia minimă (Cmin) = 15,9 ± 13,1 µg/ml şi concentraţia maximă", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"doză\"\n\"AUC\" -> \"aria de sub curbă\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The following parameters (predicted mean ± SD) were estimated for a dose of 8 mg/kg tocilizumab given every 4 weeks: steady-state area under curve (AUC) = 38000 ± 13000 h µg/mL, trough concentration (Cmin) = 15.9 ± 13.1 µg/mL and maximum concentration (Cmax) = 182 ± 50.4 µg/mL, and the accumulation ratios for AUC and Cmax were small, 1.32 and 1.09, respectively.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||doză\tAUC|||aria de sub curbă", "en": "The following parameters (predicted mean ± SD) were estimated for a dose of 8 mg/kg tocilizumab given every 4 weeks: steady-state area under curve (AUC) = 38000 ± 13000 h µg/mL, trough concentration (Cmin) = 15.9 ± 13.1 µg/mL and maximum concentration (Cmax) = 182 ± 50.4 µg/mL, and the accumulation ratios for AUC and Cmax were small, 1.32 and 1.09, respectively.", "ro": "Pentru o doză de 8 mg/kg de tocilizumab, administrată la interval de 4 săptămâni, au fost estimaţi următorii parametri (media estimată ± DS): aria de sub curbă (ASC) la starea de echilibru = 38000 ± 13000 h µg/ml, concentraţia minimă (Cmin) = 15,9 ± 13,1 µg/ml şi concentraţia maximă" } }
{ "translation": { "text": "Glossary:\n\"bilirubin\" -> \"bilirubină\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: During the double-blind controlled period, the incidence of indirect bilirubin greater than the upper limit of normal, collected as a routine laboratory parameter, is 6.2% in patients treated with 8 mg/kg tocilizumab + DMARD.\nRomanian: În timpul perioadei controlate dublu-orb, la pacienţii trataţi cu doze de tocilizumab de 8 mg/kg + DMARD, incidenţa unor concentraţii de bilirubină indirectă mai mari decât limita superioară a valorilor normale, înregistrată ca un parametru obişnuit de laborator, este de 6,2%.", "en_prompt": "<|im_start|>user\nGlossary:\n\"bilirubin\" -> \"bilirubină\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: During the double-blind controlled period, the incidence of indirect bilirubin greater than the upper limit of normal, collected as a routine laboratory parameter, is 6.2% in patients treated with 8 mg/kg tocilizumab + DMARD.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "bilirubin|||bilirubină", "en": "During the double-blind controlled period, the incidence of indirect bilirubin greater than the upper limit of normal, collected as a routine laboratory parameter, is 6.2% in patients treated with 8 mg/kg tocilizumab + DMARD.", "ro": "În timpul perioadei controlate dublu-orb, la pacienţii trataţi cu doze de tocilizumab de 8 mg/kg + DMARD, incidenţa unor concentraţii de bilirubină indirectă mai mari decât limita superioară a valorilor normale, înregistrată ca un parametru obişnuit de laborator, este de 6,2%." } }
{ "translation": { "text": "Glossary:\n\"vial\" -> \"flacon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Each 10 mL vial contains 200 mg tocilizumab (20 mg/mL).\nRomanian: Fiecare flacon a 10 ml conţine tocilizumab 200 mg (20 mg/ml).", "en_prompt": "<|im_start|>user\nGlossary:\n\"vial\" -> \"flacon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Each 10 mL vial contains 200 mg tocilizumab (20 mg/mL).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "vial|||flacon", "en": "Each 10 mL vial contains 200 mg tocilizumab (20 mg/mL).", "ro": "Fiecare flacon a 10 ml conţine tocilizumab 200 mg (20 mg/ml)." } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"doză\"\n\"medicinal product\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: This medicinal product contains 1.17 mmol (or 26.55 mg) sodium per maximum dose of 1200 mg. To be taken into consideration by patients on a controlled sodium diet. Doses below 1025 mg of this medicinal product contain less than 1 mmol sodium (23 mg), i.e. essentially ‘sodium free'.\nRomanian: Acest medicament conţine 1,17 mmoli (sau 26,55 mg) sodiu pentru o doză maximă de 1200 mg.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"doză\"\n\"medicinal product\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: This medicinal product contains 1.17 mmol (or 26.55 mg) sodium per maximum dose of 1200 mg. To be taken into consideration by patients on a controlled sodium diet. Doses below 1025 mg of this medicinal product contain less than 1 mmol sodium (23 mg), i.e. essentially ‘sodium free'.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||doză\tmedicinal product|||medicament", "en": "This medicinal product contains 1.17 mmol (or 26.55 mg) sodium per maximum dose of 1200 mg. To be taken into consideration by patients on a controlled sodium diet. Doses below 1025 mg of this medicinal product contain less than 1 mmol sodium (23 mg), i.e. essentially ‘sodium free'.", "ro": "Acest medicament conţine 1,17 mmoli (sau 26,55 mg) sodiu pentru o doză maximă de 1200 mg." } }
{ "translation": { "text": "Glossaries:\n\"exposure\" -> \"expunere\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In 6-month controlled clinical studies, the rate of serious infections with tocilizumab 8 mg/kg plus DMARDs was 5.3 events per 100 patient years exposure compared to 3.9 events per 100 patient years exposure in the placebo plus DMARD group.\nRomanian: În studiile clinice controlate cu durata de 6 luni, incidenţa infecţiilor grave raportate în grupul tratat cu tocilizumab 8 mg/kg şi DMARD a fost de 5,3 evenimente per 100 pacienţi-ani expunere, comparativ cu 3,9 evenimente per 100 pacienţi-ani expunere în grupul tratat cu placebo şi DMARD.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"exposure\" -> \"expunere\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In 6-month controlled clinical studies, the rate of serious infections with tocilizumab 8 mg/kg plus DMARDs was 5.3 events per 100 patient years exposure compared to 3.9 events per 100 patient years exposure in the placebo plus DMARD group.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "exposure|||expunere\tplacebo|||placebo", "en": "In 6-month controlled clinical studies, the rate of serious infections with tocilizumab 8 mg/kg plus DMARDs was 5.3 events per 100 patient years exposure compared to 3.9 events per 100 patient years exposure in the placebo plus DMARD group.", "ro": "În studiile clinice controlate cu durata de 6 luni, incidenţa infecţiilor grave raportate în grupul tratat cu tocilizumab 8 mg/kg şi DMARD a fost de 5,3 evenimente per 100 pacienţi-ani expunere, comparativ cu 3,9 evenimente per 100 pacienţi-ani expunere în grupul tratat cu placebo şi DMARD." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the 6-month controlled studies the rate of all infections reported with tocilizumab 8 mg/kg plus DMARD treatment was 127 events per 100 patient years compared to 112 events per 100 patient years in the placebo plus DMARD group.\nRomanian: În studiile clinice controlate cu durata de 6 luni, incidenţa tuturor infecţiilor raportate în grupul tratat cu tocilizumab 8 mg/kg şi DMARD a fost de 127 evenimente per 100 pacienţi-ani, comparativ cu 112 evenimente per 100 pacienţi-ani în grupul tratat cu placebo şi DMARD.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the 6-month controlled studies the rate of all infections reported with tocilizumab 8 mg/kg plus DMARD treatment was 127 events per 100 patient years compared to 112 events per 100 patient years in the placebo plus DMARD group.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "In the 6-month controlled studies the rate of all infections reported with tocilizumab 8 mg/kg plus DMARD treatment was 127 events per 100 patient years compared to 112 events per 100 patient years in the placebo plus DMARD group.", "ro": "În studiile clinice controlate cu durata de 6 luni, incidenţa tuturor infecţiilor raportate în grupul tratat cu tocilizumab 8 mg/kg şi DMARD a fost de 127 evenimente per 100 pacienţi-ani, comparativ cu 112 evenimente per 100 pacienţi-ani în grupul tratat cu placebo şi DMARD." } }
{ "translation": { "text": "Glossaries:\n\"placebo\" -> \"placebo\"\n\"physician\" -> \"medic\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The physician's global assessment of disease activity, as measured on a 0-100 mm scale, showed a greater reduction in disease activity for tocilizumab compared to placebo (adjusted mean changes of -45.2 mm vs -35.2 mm, p=0.0031).\nRomanian: Evaluarea globală a activităţii bolii efectuată de către medic, pe o scală de la 0-100 mm, a arătat o reducere mai mare a activităţii bolii în cazul tratamentului cu tocilizumab, comparativ cu placebo", "en_prompt": "<|im_start|>user\nGlossaries:\n\"placebo\" -> \"placebo\"\n\"physician\" -> \"medic\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The physician's global assessment of disease activity, as measured on a 0-100 mm scale, showed a greater reduction in disease activity for tocilizumab compared to placebo (adjusted mean changes of -45.2 mm vs -35.2 mm, p=0.0031).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo\tphysician|||medic", "en": "The physician's global assessment of disease activity, as measured on a 0-100 mm scale, showed a greater reduction in disease activity for tocilizumab compared to placebo (adjusted mean changes of -45.2 mm vs -35.2 mm, p=0.0031).", "ro": "Evaluarea globală a activităţii bolii efectuată de către medic, pe o scală de la 0-100 mm, a arătat o reducere mai mare a activităţii bolii în cazul tratamentului cu tocilizumab, comparativ cu placebo" } }
{ "translation": { "text": "Glossary:\n\"immunisation\" -> \"imunizare\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: It is recommended that all patients, particularly sJIA and pJIA patients, be brought up to date with all immunisations in agreement with current immunisation guidelines prior to initiating RoActemra therapy.\nRomanian: Înainte de iniţierea tratamentului cu RoActemra, se recomandă ca toţi pacienţii, în special pacienţii cu AIJs şi AIJp, să fie aduşi la zi cu toate imunizările în conformitate cu ghidurile de imunizare actuale.", "en_prompt": "<|im_start|>user\nGlossary:\n\"immunisation\" -> \"imunizare\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: It is recommended that all patients, particularly sJIA and pJIA patients, be brought up to date with all immunisations in agreement with current immunisation guidelines prior to initiating RoActemra therapy.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "immunisation|||imunizare", "en": "It is recommended that all patients, particularly sJIA and pJIA patients, be brought up to date with all immunisations in agreement with current immunisation guidelines prior to initiating RoActemra therapy.", "ro": "Înainte de iniţierea tratamentului cu RoActemra, se recomandă ca toţi pacienţii, în special pacienţii cu AIJs şi AIJp, să fie aduşi la zi cu toate imunizările în conformitate cu ghidurile de imunizare actuale." } }
{ "translation": { "text": "Glossaries:\n\"dosing interval\" -> \"interval\"\n\"interval\" -> \"interval\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Following subcutaneous administration, the effective t1/2 of RoActemra in sJIA patients is up to 14 days for both the 162 mg QW and Q2W regimens during a dosing interval at steady state.\nRomanian: După administrarea subcutanată, t1/2 efectiv al RoActemra la pacienții cu AIJs este de până la 14 zile, pentru ambele scheme de 162 mg în fiecare săptămână și la interval de două săptămâni pe durata unui interval de dozare în starea de echilibru.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dosing interval\" -> \"interval\"\n\"interval\" -> \"interval\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Following subcutaneous administration, the effective t1/2 of RoActemra in sJIA patients is up to 14 days for both the 162 mg QW and Q2W regimens during a dosing interval at steady state.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "dosing interval|||interval\tinterval|||interval", "en": "Following subcutaneous administration, the effective t1/2 of RoActemra in sJIA patients is up to 14 days for both the 162 mg QW and Q2W regimens during a dosing interval at steady state.", "ro": "După administrarea subcutanată, t1/2 efectiv al RoActemra la pacienții cu AIJs este de până la 14 zile, pentru ambele scheme de 162 mg în fiecare săptămână și la interval de două săptămâni pe durata unui interval de dozare în starea de echilibru." } }
{ "translation": { "text": "Glossary:\n\"immunisation\" -> \"imunizare\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: It is recommended that all patients particularly elderly patients, be brought up to date with all immunisations in agreement with current immunisation guidelines prior to initiating RoActemra therapy.\nRomanian: Înainte de iniţierea tratamentului cu RoActemra, se recomandă ca toţi pacienţii, în special pacienţii vârstnici, să fie aduşi la zi cu toate imunizările în conformitate cu ghidurile de imunizare actuale.", "en_prompt": "<|im_start|>user\nGlossary:\n\"immunisation\" -> \"imunizare\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: It is recommended that all patients particularly elderly patients, be brought up to date with all immunisations in agreement with current immunisation guidelines prior to initiating RoActemra therapy.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "immunisation|||imunizare", "en": "It is recommended that all patients particularly elderly patients, be brought up to date with all immunisations in agreement with current immunisation guidelines prior to initiating RoActemra therapy.", "ro": "Înainte de iniţierea tratamentului cu RoActemra, se recomandă ca toţi pacienţii, în special pacienţii vârstnici, să fie aduşi la zi cu toate imunizările în conformitate cu ghidurile de imunizare actuale." } }
{ "translation": { "text": "Glossaries:\n\"exposure\" -> \"expunere\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In 6-month controlled clinical studies, the rate of serious infections with RoActemra 8 mg/kg plus DMARDs was 5.3 events per 100 patient years exposure compared to 3.9 events per 100 patient years exposure in the placebo plus DMARD group.\nRomanian: În studiile clinice controlate cu durata de 6 luni, incidenţa infecţiilor grave raportate în grupul tratat cu RoActemra 8 mg/kg şi DMARD a fost de 5,3 evenimente per 100 pacienţi-ani expunere, comparativ cu 3,9 evenimente per 100 pacienţi-ani expunere în grupul tratat cu placebo şi DMARD.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"exposure\" -> \"expunere\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In 6-month controlled clinical studies, the rate of serious infections with RoActemra 8 mg/kg plus DMARDs was 5.3 events per 100 patient years exposure compared to 3.9 events per 100 patient years exposure in the placebo plus DMARD group.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "exposure|||expunere\tplacebo|||placebo", "en": "In 6-month controlled clinical studies, the rate of serious infections with RoActemra 8 mg/kg plus DMARDs was 5.3 events per 100 patient years exposure compared to 3.9 events per 100 patient years exposure in the placebo plus DMARD group.", "ro": "În studiile clinice controlate cu durata de 6 luni, incidenţa infecţiilor grave raportate în grupul tratat cu RoActemra 8 mg/kg şi DMARD a fost de 5,3 evenimente per 100 pacienţi-ani expunere, comparativ cu 3,9 evenimente per 100 pacienţi-ani expunere în grupul tratat cu placebo şi DMARD." } }
{ "translation": { "text": "Glossary:\n\"clearance\" -> \"clearance\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The total clearance of RoActemra was concentration-dependent and is the sum of the linear clearance and the nonlinear clearance.\nRomanian: Clearance-ul total al RoActemra a fost dependent de concentraţie şi este suma clearance-ului linear şi a clearance-ului non-linear.", "en_prompt": "<|im_start|>user\nGlossary:\n\"clearance\" -> \"clearance\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The total clearance of RoActemra was concentration-dependent and is the sum of the linear clearance and the nonlinear clearance.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "clearance|||clearance", "en": "The total clearance of RoActemra was concentration-dependent and is the sum of the linear clearance and the nonlinear clearance.", "ro": "Clearance-ul total al RoActemra a fost dependent de concentraţie şi este suma clearance-ului linear şi a clearance-ului non-linear." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the 6-month controlled studies the rate of all infections reported with RoActemra 8 mg/kg plus DMARD treatment was 127 events per 100 patient years compared to 112 events per 100 patient years in the placebo plus DMARD group.\nRomanian: În studiile clinice controlate cu durata de 6 luni, incidenţa tuturor infecţiilor raportate în grupul tratat cu RoActemra 8 mg/kg şi DMARD a fost de 127 evenimente per 100 pacienţi-ani, comparativ cu 112 evenimente per 100 pacienţi-ani în grupul tratat cu placebo şi DMARD.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the 6-month controlled studies the rate of all infections reported with RoActemra 8 mg/kg plus DMARD treatment was 127 events per 100 patient years compared to 112 events per 100 patient years in the placebo plus DMARD group.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "In the 6-month controlled studies the rate of all infections reported with RoActemra 8 mg/kg plus DMARD treatment was 127 events per 100 patient years compared to 112 events per 100 patient years in the placebo plus DMARD group.", "ro": "În studiile clinice controlate cu durata de 6 luni, incidenţa tuturor infecţiilor raportate în grupul tratat cu RoActemra 8 mg/kg şi DMARD a fost de 127 evenimente per 100 pacienţi-ani, comparativ cu 112 evenimente per 100 pacienţi-ani în grupul tratat cu placebo şi DMARD." } }
{ "translation": { "text": "Glossary:\n\"cough\" -> \"tuse\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • upper respiratory tract infections with typical symptoms such as cough, blocked nose, runny nose, sore throat and headache,\nRomanian: • infecţii ale tractului respirator superior cu simptome caracteristice, cum ar fi tuse, nas înfundat,", "en_prompt": "<|im_start|>user\nGlossary:\n\"cough\" -> \"tuse\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • upper respiratory tract infections with typical symptoms such as cough, blocked nose, runny nose, sore throat and headache,\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "cough|||tuse", "en": "• upper respiratory tract infections with typical symptoms such as cough, blocked nose, runny nose, sore throat and headache,", "ro": "• infecţii ale tractului respirator superior cu simptome caracteristice, cum ar fi tuse, nas înfundat," } }
{ "translation": { "text": "Glossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Following 1 year of treatment with tocilizumab plus MTX, 85% of patients (n=348) had no progression of structural joint damage, as defined by a change in the Total Sharp Score of zero or less, compared with 67% of placebo plus MTX-treated patients (n=290) (p ≤ 0.001).\nRomanian: După un an de tratament cu tocilizumab în asociere cu MTX, 85% dintre pacienţi (n=348) nu au prezentat progresia distrugerii structurilor articulare, evaluată prin modificarea Scorului Total", "en_prompt": "<|im_start|>user\nGlossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Following 1 year of treatment with tocilizumab plus MTX, 85% of patients (n=348) had no progression of structural joint damage, as defined by a change in the Total Sharp Score of zero or less, compared with 67% of placebo plus MTX-treated patients (n=290) (p ≤ 0.001).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratament", "en": "Following 1 year of treatment with tocilizumab plus MTX, 85% of patients (n=348) had no progression of structural joint damage, as defined by a change in the Total Sharp Score of zero or less, compared with 67% of placebo plus MTX-treated patients (n=290) (p ≤ 0.001).", "ro": "După un an de tratament cu tocilizumab în asociere cu MTX, 85% dintre pacienţi (n=348) nu au prezentat progresia distrugerii structurilor articulare, evaluată prin modificarea Scorului Total" } }
{ "translation": { "text": "Glossaries:\n\"infusion\" -> \"perfuzie\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the 6-month controlled trials adverse events associated with infusion (selected events occurring during or within 24 hours of infusion) were reported by 6.9% of patients in the RoActemra 8 mg/kg plus DMARD group and 5.1% of patients in the placebo plus DMARD group.\nRomanian: În cadrul studiilor clinice controlate cu durata de 6 luni, au fost raportate evenimente adverse asociate perfuziei (evenimente apărute în timpul perfuziei sau până în 24 de ore de la perfuzie) la 6,9% din pacienţii din grupul tratat cu RoActemra 8 mg/kg şi DMARD şi la 5,1% din pacienţii din grupul tratat cu placebo şi DMARD.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"infusion\" -> \"perfuzie\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the 6-month controlled trials adverse events associated with infusion (selected events occurring during or within 24 hours of infusion) were reported by 6.9% of patients in the RoActemra 8 mg/kg plus DMARD group and 5.1% of patients in the placebo plus DMARD group.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "infusion|||perfuzie\tplacebo|||placebo", "en": "In the 6-month controlled trials adverse events associated with infusion (selected events occurring during or within 24 hours of infusion) were reported by 6.9% of patients in the RoActemra 8 mg/kg plus DMARD group and 5.1% of patients in the placebo plus DMARD group.", "ro": "În cadrul studiilor clinice controlate cu durata de 6 luni, au fost raportate evenimente adverse asociate perfuziei (evenimente apărute în timpul perfuziei sau până în 24 de ore de la perfuzie) la 6,9% din pacienţii din grupul tratat cu RoActemra 8 mg/kg şi DMARD şi la 5,1% din pacienţii din grupul tratat cu placebo şi DMARD." } }
{ "translation": { "text": "Glossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: With routine laboratory monitoring it was seen that approximately 24% of patients receiving RoActemra in clinical trials experienced sustained elevations in total cholesterol ≥ 6.2 mmol/ l, with 15% experiencing a sustained increase in LDL to ≥ 4.1 mmol/ l. Elevations in lipid parameters responded to treatment with lipid-lowering agents.\nRomanian: În cadrul monitorizării obişnuite de laborator, s-a observat că aproximativ 24% din pacienţii care au urmat în studiile clinice tratament cu RoActemra au prezentat creşteri de durată ale colesterolului total ≥ 6,2 mmol/l, iar 15% dintre pacienţi au prezentat creşteri de durată ale LDL ≥ 4,1 mmol/l.", "en_prompt": "<|im_start|>user\nGlossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: With routine laboratory monitoring it was seen that approximately 24% of patients receiving RoActemra in clinical trials experienced sustained elevations in total cholesterol ≥ 6.2 mmol/ l, with 15% experiencing a sustained increase in LDL to ≥ 4.1 mmol/ l. Elevations in lipid parameters responded to treatment with lipid-lowering agents.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratament", "en": "With routine laboratory monitoring it was seen that approximately 24% of patients receiving RoActemra in clinical trials experienced sustained elevations in total cholesterol ≥ 6.2 mmol/ l, with 15% experiencing a sustained increase in LDL to ≥ 4.1 mmol/ l. Elevations in lipid parameters responded to treatment with lipid-lowering agents.", "ro": "În cadrul monitorizării obişnuite de laborator, s-a observat că aproximativ 24% din pacienţii care au urmat în studiile clinice tratament cu RoActemra au prezentat creşteri de durată ale colesterolului total ≥ 6,2 mmol/l, iar 15% dintre pacienţi au prezentat creşteri de durată ale LDL ≥ 4,1 mmol/l." } }
{ "translation": { "text": "Glossary:\n\"vial\" -> \"flacon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Each 4 mL vial contains 80 mg tocilizumab (20 mg/mL).\nRomanian: Fiecare flacon a 4 ml conţine tocilizumab 80 mg (20 mg/ml).", "en_prompt": "<|im_start|>user\nGlossary:\n\"vial\" -> \"flacon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Each 4 mL vial contains 80 mg tocilizumab (20 mg/mL).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "vial|||flacon", "en": "Each 4 mL vial contains 80 mg tocilizumab (20 mg/mL).", "ro": "Fiecare flacon a 4 ml conţine tocilizumab 80 mg (20 mg/ml)." } }
{ "translation": { "text": "Glossaries:\n\"infusion\" -> \"perfuzie\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the 6-month controlled trials adverse events associated with infusion (selected events occurring during or within 24 hours of infusion) were reported by 6.9% of patients in the tocilizumab 8 mg/kg plus DMARD group and 5.1% of patients in the placebo plus DMARD group.\nRomanian: În cadrul studiilor clinice controlate cu durata de 6 luni, au fost raportate evenimente adverse asociate perfuziei (evenimente apărute în timpul perfuziei sau până în 24 de ore de la perfuzie) la 6,9% din pacienţii din grupul tratat cu tocilizumab 8 mg/kg şi DMARD şi la 5,1% din pacienţii din grupul tratat cu placebo şi DMARD.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"infusion\" -> \"perfuzie\"\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the 6-month controlled trials adverse events associated with infusion (selected events occurring during or within 24 hours of infusion) were reported by 6.9% of patients in the tocilizumab 8 mg/kg plus DMARD group and 5.1% of patients in the placebo plus DMARD group.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "infusion|||perfuzie\tplacebo|||placebo", "en": "In the 6-month controlled trials adverse events associated with infusion (selected events occurring during or within 24 hours of infusion) were reported by 6.9% of patients in the tocilizumab 8 mg/kg plus DMARD group and 5.1% of patients in the placebo plus DMARD group.", "ro": "În cadrul studiilor clinice controlate cu durata de 6 luni, au fost raportate evenimente adverse asociate perfuziei (evenimente apărute în timpul perfuziei sau până în 24 de ore de la perfuzie) la 6,9% din pacienţii din grupul tratat cu tocilizumab 8 mg/kg şi DMARD şi la 5,1% din pacienţii din grupul tratat cu placebo şi DMARD." } }
{ "translation": { "text": "Glossary:\n\"clearance\" -> \"clearance\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The total clearance of tocilizumab was concentration-dependent and is the sum of the linear clearance and the nonlinear clearance.\nRomanian: Clearance-ul total al tocilizumab a fost dependent de concentraţie şi este suma clearance-ului linear şi a clearance-ului non-linear.", "en_prompt": "<|im_start|>user\nGlossary:\n\"clearance\" -> \"clearance\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The total clearance of tocilizumab was concentration-dependent and is the sum of the linear clearance and the nonlinear clearance.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "clearance|||clearance", "en": "The total clearance of tocilizumab was concentration-dependent and is the sum of the linear clearance and the nonlinear clearance.", "ro": "Clearance-ul total al tocilizumab a fost dependent de concentraţie şi este suma clearance-ului linear şi a clearance-ului non-linear." } }
{ "translation": { "text": "Glossaries:\n\"pharmacokinetics\" -> \"farmacocinetică\"\n\"infusion\" -> \"perfuzie\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The pharmacokinetics of tocilizumab were determined using a population pharmacokinetic analysis on a database composed of 3552 RA patients treated with a one-hour infusion of 4 or 8 mg/kg tocilizumab every 4 weeks for 24 weeks or with 162 mg tocilizumab given subcutaneously either once a week or every other week for 24 weeks.\nRomanian: Farmacocinetica tocilizumabului a fost determinată utilizând analiza farmacocinetică a populaţiei pe o bază de date compusă din 3552 pacienţi cu PR trataţi cu o doză de 4 sau 8 mg/kg tocilizumab, administrată în perfuzie în decurs de o oră, la interval de 4 săptămâni, pe o perioadă de 24 săptămâni sau cu o doză de 162 mg tocilizumab administrată subcutanat fie o dată pe săptămână, fie o dată la interval de două săptămâni, pe o perioadă de 24 săptămâni.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"pharmacokinetics\" -> \"farmacocinetică\"\n\"infusion\" -> \"perfuzie\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The pharmacokinetics of tocilizumab were determined using a population pharmacokinetic analysis on a database composed of 3552 RA patients treated with a one-hour infusion of 4 or 8 mg/kg tocilizumab every 4 weeks for 24 weeks or with 162 mg tocilizumab given subcutaneously either once a week or every other week for 24 weeks.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "pharmacokinetics|||farmacocinetică\tinfusion|||perfuzie", "en": "The pharmacokinetics of tocilizumab were determined using a population pharmacokinetic analysis on a database composed of 3552 RA patients treated with a one-hour infusion of 4 or 8 mg/kg tocilizumab every 4 weeks for 24 weeks or with 162 mg tocilizumab given subcutaneously either once a week or every other week for 24 weeks.", "ro": "Farmacocinetica tocilizumabului a fost determinată utilizând analiza farmacocinetică a populaţiei pe o bază de date compusă din 3552 pacienţi cu PR trataţi cu o doză de 4 sau 8 mg/kg tocilizumab, administrată în perfuzie în decurs de o oră, la interval de 4 săptămâni, pe o perioadă de 24 săptămâni sau cu o doză de 162 mg tocilizumab administrată subcutanat fie o dată pe săptămână, fie o dată la interval de două săptămâni, pe o perioadă de 24 săptămâni." } }
{ "translation": { "text": "Glossary:\n\"body weight\" -> \"greutate corporală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The dose is 12 mg for every kg of body weight if you weigh less than 30 kg. RoActemra can be given alone or in combination with corticosteroids.\nRomanian: Doza este de 12 mg pentru fiecare kg de greutate corporală, în cazul în care aceasta este mai mică de 30 kg.", "en_prompt": "<|im_start|>user\nGlossary:\n\"body weight\" -> \"greutate corporală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The dose is 12 mg for every kg of body weight if you weigh less than 30 kg. RoActemra can be given alone or in combination with corticosteroids.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "body weight|||greutate corporală", "en": "The dose is 12 mg for every kg of body weight if you weigh less than 30 kg. RoActemra can be given alone or in combination with corticosteroids.", "ro": "Doza este de 12 mg pentru fiecare kg de greutate corporală, în cazul în care aceasta este mai mică de 30 kg." } }
{ "translation": { "text": "Glossary:\n\"vial\" -> \"flacon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Each 20 mL vial contains 400 mg tocilizumab (20 mg/mL).\nRomanian: Fiecare flacon a 20 ml conţine tocilizumab 400 mg (20 mg/ml).", "en_prompt": "<|im_start|>user\nGlossary:\n\"vial\" -> \"flacon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Each 20 mL vial contains 400 mg tocilizumab (20 mg/mL).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "vial|||flacon", "en": "Each 20 mL vial contains 400 mg tocilizumab (20 mg/mL).", "ro": "Fiecare flacon a 20 ml conţine tocilizumab 400 mg (20 mg/ml)." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: ALT ≥3 x ULN occurred in 3% of patients in the RoActemra subcutaneous weekly group compared to 2% in the placebo plus 52 week prednisone taper group and none in the placebo plus 26 week prednisone taper group.\nRomanian: comparativ cu 2% în grupul cu administrare de placebo plus prednison în doze scăzute treptat pe parcursul a 52 săptămâni şi la niciun pacient din grupul cu administrare de placebo plus prednison în doze scăzute treptat pe parcursul a 26 săptămâni.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: ALT ≥3 x ULN occurred in 3% of patients in the RoActemra subcutaneous weekly group compared to 2% in the placebo plus 52 week prednisone taper group and none in the placebo plus 26 week prednisone taper group.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "ALT ≥3 x ULN occurred in 3% of patients in the RoActemra subcutaneous weekly group compared to 2% in the placebo plus 52 week prednisone taper group and none in the placebo plus 26 week prednisone taper group.", "ro": "comparativ cu 2% în grupul cu administrare de placebo plus prednison în doze scăzute treptat pe parcursul a 52 săptămâni şi la niciun pacient din grupul cu administrare de placebo plus prednison în doze scăzute treptat pe parcursul a 26 săptămâni." } }
{ "translation": { "text": "Glossary:\n\"arthritis\" -> \"artrită\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids.\nRomanian: RoActemra este indicat pentru tratamentul pacienţilor cu vârsta de 2 ani şi peste, cu artrită idiopatică juvenilă sistemică (AIJs) activă, care nu au avut un răspuns adecvat la tratamentele anterioare cu AINS", "en_prompt": "<|im_start|>user\nGlossary:\n\"arthritis\" -> \"artrită\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "arthritis|||artrită", "en": "RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids.", "ro": "RoActemra este indicat pentru tratamentul pacienţilor cu vârsta de 2 ani şi peste, cu artrită idiopatică juvenilă sistemică (AIJs) activă, care nu au avut un răspuns adecvat la tratamentele anterioare cu AINS" } }
{ "translation": { "text": "Glossary:\n\"vial\" -> \"flacon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Each vial contains 200 mg of tocilizumab* in 10 mL (20 mg/mL).\nRomanian: Fiecare flacon conţine tocilizumab* 200 mg în 10 ml (20 mg/ml).", "en_prompt": "<|im_start|>user\nGlossary:\n\"vial\" -> \"flacon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Each vial contains 200 mg of tocilizumab* in 10 mL (20 mg/mL).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "vial|||flacon", "en": "Each vial contains 200 mg of tocilizumab* in 10 mL (20 mg/mL).", "ro": "Fiecare flacon conţine tocilizumab* 200 mg în 10 ml (20 mg/ml)." } }
{ "translation": { "text": "Glossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If a patient misses a subcutaneous once every 2 week injection of RoActemra within 7 days of the scheduled dose, he/she should be instructed to take the missed dose immediately and the next dose on the next scheduled day.\nRomanian: Dacă un pacient omite administrarea unei injecții subcutanate de RoActemra o dată la fiecare 2 săptămâni într-un interval de 7 zile de la doza programată, el/ea ar trebui îndrumat/ă să ia doza omisă imediat, iar umătoarea doză în următoarea zi programată.", "en_prompt": "<|im_start|>user\nGlossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If a patient misses a subcutaneous once every 2 week injection of RoActemra within 7 days of the scheduled dose, he/she should be instructed to take the missed dose immediately and the next dose on the next scheduled day.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||doză", "en": "If a patient misses a subcutaneous once every 2 week injection of RoActemra within 7 days of the scheduled dose, he/she should be instructed to take the missed dose immediately and the next dose on the next scheduled day.", "ro": "Dacă un pacient omite administrarea unei injecții subcutanate de RoActemra o dată la fiecare 2 săptămâni într-un interval de 7 zile de la doza programată, el/ea ar trebui îndrumat/ă să ia doza omisă imediat, iar umătoarea doză în următoarea zi programată." } }
{ "translation": { "text": "Glossary:\n\"clearance\" -> \"clearance\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The total clearance of RoActemra was concentration-dependent and is the sum of the linear and non-linear clearance.\nRomanian: Clearence-ul total al RoActemra este dependent de concentraţie şi este suma clearance-ului linear şi non-linear.", "en_prompt": "<|im_start|>user\nGlossary:\n\"clearance\" -> \"clearance\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The total clearance of RoActemra was concentration-dependent and is the sum of the linear and non-linear clearance.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "clearance|||clearance", "en": "The total clearance of RoActemra was concentration-dependent and is the sum of the linear and non-linear clearance.", "ro": "Clearence-ul total al RoActemra este dependent de concentraţie şi este suma clearance-ului linear şi non-linear." } }
{ "translation": { "text": "Glossary:\n\"vial\" -> \"flacon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Each vial contains 80 mg of tocilizumab* in 4 mL (20 mg/mL).\nRomanian: Fiecare flacon conţine tocilizumab* 80 mg în 4 ml (20 mg/ml).", "en_prompt": "<|im_start|>user\nGlossary:\n\"vial\" -> \"flacon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Each vial contains 80 mg of tocilizumab* in 4 mL (20 mg/mL).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "vial|||flacon", "en": "Each vial contains 80 mg of tocilizumab* in 4 mL (20 mg/mL).", "ro": "Fiecare flacon conţine tocilizumab* 80 mg în 4 ml (20 mg/ml)." } }
{ "translation": { "text": "Glossary:\n\"infusion\" -> \"perfuzie\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Therefore, RoActemra doses exceeding 800 mg per infusion are not recommended (see section 4.2).\nRomanian: RoActemra mai mari de 800 mg per perfuzie (vezi pct. 4.2).", "en_prompt": "<|im_start|>user\nGlossary:\n\"infusion\" -> \"perfuzie\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Therefore, RoActemra doses exceeding 800 mg per infusion are not recommended (see section 4.2).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "infusion|||perfuzie", "en": "Therefore, RoActemra doses exceeding 800 mg per infusion are not recommended (see section 4.2).", "ro": "RoActemra mai mari de 800 mg per perfuzie (vezi pct. 4.2)." } }
{ "translation": { "text": "Glossary:\n\"exposure\" -> \"expunere\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: During the double-blind controlled period and with long-term exposure, the pattern and incidence of decreases in neutrophil counts remained consistent with what was seen in the 6-month controlled clinical trials.\nRomanian: În timpul perioadei controlate dublu-orb şi cu expunere pe termen lung, caracterul şi incidenţa scăderii numărului de neutrofile au rămas în concordanţă cu cele observate în cadrul studiilor clinice controlate cu durata de 6 luni.", "en_prompt": "<|im_start|>user\nGlossary:\n\"exposure\" -> \"expunere\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: During the double-blind controlled period and with long-term exposure, the pattern and incidence of decreases in neutrophil counts remained consistent with what was seen in the 6-month controlled clinical trials.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "exposure|||expunere", "en": "During the double-blind controlled period and with long-term exposure, the pattern and incidence of decreases in neutrophil counts remained consistent with what was seen in the 6-month controlled clinical trials.", "ro": "În timpul perioadei controlate dublu-orb şi cu expunere pe termen lung, caracterul şi incidenţa scăderii numărului de neutrofile au rămas în concordanţă cu cele observate în cadrul studiilor clinice controlate cu durata de 6 luni." } }
{ "translation": { "text": "Glossary:\n\"immunisation\" -> \"imunizare\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: It is recommended that all patients particularly paediatric or elderly patients, be brought up to date with all immunisations in agreement with current immunisation guidelines prior to initiating RoActemra therapy.\nRomanian: Înainte de iniţierea tratamentului cu RoActemra, se recomandă ca toţi pacienţii, în special pacienţii copii şi adolescenţi sau cei vârstnici, să fie aduşi la zi cu toate imunizările în conformitate cu ghidurile de imunizare actuale.", "en_prompt": "<|im_start|>user\nGlossary:\n\"immunisation\" -> \"imunizare\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: It is recommended that all patients particularly paediatric or elderly patients, be brought up to date with all immunisations in agreement with current immunisation guidelines prior to initiating RoActemra therapy.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "immunisation|||imunizare", "en": "It is recommended that all patients particularly paediatric or elderly patients, be brought up to date with all immunisations in agreement with current immunisation guidelines prior to initiating RoActemra therapy.", "ro": "Înainte de iniţierea tratamentului cu RoActemra, se recomandă ca toţi pacienţii, în special pacienţii copii şi adolescenţi sau cei vârstnici, să fie aduşi la zi cu toate imunizările în conformitate cu ghidurile de imunizare actuale." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the 6-month controlled trials decreases in neutrophil counts below 1 x 109/ L occurred in 3.4% of patients on RoActemra 8 mg/kg plus DMARDs compared to < 0.1% of patients on placebo plus DMARDs.\nRomanian: În cadrul studiilor clinice controlate cu durata de 6 luni, scăderea numărului de neutrofile sub 1 x 109/l a apărut la 3,4% dintre pacienţii trataţi cu RoActemra 8 mg/kg şi DMARD, comparativ cu < 0,1% dintre pacienţii trataţi cu placebo şi DMARD.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the 6-month controlled trials decreases in neutrophil counts below 1 x 109/ L occurred in 3.4% of patients on RoActemra 8 mg/kg plus DMARDs compared to < 0.1% of patients on placebo plus DMARDs.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "In the 6-month controlled trials decreases in neutrophil counts below 1 x 109/ L occurred in 3.4% of patients on RoActemra 8 mg/kg plus DMARDs compared to < 0.1% of patients on placebo plus DMARDs.", "ro": "În cadrul studiilor clinice controlate cu durata de 6 luni, scăderea numărului de neutrofile sub 1 x 109/l a apărut la 3,4% dintre pacienţii trataţi cu RoActemra 8 mg/kg şi DMARD, comparativ cu < 0,1% dintre pacienţii trataţi cu placebo şi DMARD." } }
{ "translation": { "text": "Glossary:\n\"vial\" -> \"flacon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Each vial contains 400 mg of tocilizumab* in 20 mL (20 mg/mL).\nRomanian: Fiecare flacon conţine tocilizumab* 400 mg în 20 ml (20 mg/ml).", "en_prompt": "<|im_start|>user\nGlossary:\n\"vial\" -> \"flacon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Each vial contains 400 mg of tocilizumab* in 20 mL (20 mg/mL).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "vial|||flacon", "en": "Each vial contains 400 mg of tocilizumab* in 20 mL (20 mg/mL).", "ro": "Fiecare flacon conţine tocilizumab* 400 mg în 20 ml (20 mg/ml)." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the 6-month controlled trials decreases in neutrophil counts below 1 x 109/ l occurred in 3.4% of patients on tocilizumab 8 mg/kg plus DMARDs compared to < 0.1% of patients on placebo plus DMARDs.\nRomanian: În cadrul studiilor clinice controlate cu durata de 6 luni, scăderea numărului de neutrofile sub 1 x 109/l a apărut la 3,4% dintre pacienţii trataţi cu tocilizumab 8 mg/kg şi DMARD, comparativ cu < 0,1% dintre pacienţii trataţi cu placebo şi DMARD.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the 6-month controlled trials decreases in neutrophil counts below 1 x 109/ l occurred in 3.4% of patients on tocilizumab 8 mg/kg plus DMARDs compared to < 0.1% of patients on placebo plus DMARDs.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "In the 6-month controlled trials decreases in neutrophil counts below 1 x 109/ l occurred in 3.4% of patients on tocilizumab 8 mg/kg plus DMARDs compared to < 0.1% of patients on placebo plus DMARDs.", "ro": "În cadrul studiilor clinice controlate cu durata de 6 luni, scăderea numărului de neutrofile sub 1 x 109/l a apărut la 3,4% dintre pacienţii trataţi cu tocilizumab 8 mg/kg şi DMARD, comparativ cu < 0,1% dintre pacienţii trataţi cu placebo şi DMARD." } }
{ "translation": { "text": "Glossary:\n\"clearance\" -> \"clearance\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The total clearance of tocilizumab was concentrationdependent and is the sum of the linear and non-linear clearance.\nRomanian: Clearence-ul total al tocilizumabului a fost dependent de concentraţie şi este suma clearance-ului linear şi non-linear.", "en_prompt": "<|im_start|>user\nGlossary:\n\"clearance\" -> \"clearance\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The total clearance of tocilizumab was concentrationdependent and is the sum of the linear and non-linear clearance.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "clearance|||clearance", "en": "The total clearance of tocilizumab was concentrationdependent and is the sum of the linear and non-linear clearance.", "ro": "Clearence-ul total al tocilizumabului a fost dependent de concentraţie şi este suma clearance-ului linear şi non-linear." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Doses of 4 or 8 mg/kg of RoActemraor placebo were given every four weeks as blinded therapy for 52 weeks in combination with stable MTX (10 mg to 25 mg weekly).\nRomanian: Au fost administrate doze de RoActemra 4 sau 8 mg/kg sau placebo la interval de patru săptămâni ca tratament orb timp de 52 de săptămâni, în asociere cu doza stabilă de MTX (10 mg până la 25 mg săptămânal).", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Doses of 4 or 8 mg/kg of RoActemraor placebo were given every four weeks as blinded therapy for 52 weeks in combination with stable MTX (10 mg to 25 mg weekly).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "Doses of 4 or 8 mg/kg of RoActemraor placebo were given every four weeks as blinded therapy for 52 weeks in combination with stable MTX (10 mg to 25 mg weekly).", "ro": "Au fost administrate doze de RoActemra 4 sau 8 mg/kg sau placebo la interval de patru săptămâni ca tratament orb timp de 52 de săptămâni, în asociere cu doza stabilă de MTX (10 mg până la 25 mg săptămânal)." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Doses of 4 or 8 mg/kg of tocilizumab or placebo were given every four weeks as blinded therapy for 52 weeks in combination with stable MTX (10 mg to 25 mg weekly).\nRomanian: Au fost administrate doze de 4 sau 8 mg/kg de tocilizumab sau placebo la interval de patru săptămâni ca tratament orb pentru 52 de săptămâni, în asociere cu doza stabilită de MTX (10 mg până la 25 mg săptămânal).", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Doses of 4 or 8 mg/kg of tocilizumab or placebo were given every four weeks as blinded therapy for 52 weeks in combination with stable MTX (10 mg to 25 mg weekly).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "Doses of 4 or 8 mg/kg of tocilizumab or placebo were given every four weeks as blinded therapy for 52 weeks in combination with stable MTX (10 mg to 25 mg weekly).", "ro": "Au fost administrate doze de 4 sau 8 mg/kg de tocilizumab sau placebo la interval de patru săptămâni ca tratament orb pentru 52 de săptămâni, în asociere cu doza stabilită de MTX (10 mg până la 25 mg săptămânal)." } }
{ "translation": { "text": "Glossary:\n\"pharmacokinetics\" -> \"farmacocinetică\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The pharmacokinetics of RoActemra in pJIA patients was characterized by a population pharmacokinetic analysis which included 237 patients who were treated with 8 mg/kg IV every 4 weeks (patients weighing ≥ 30 kg), 10 mg/kg IV every 4 weeks (patients weighing below 30 kg), 162\nRomanian: Farmacocinetica RoActemra la pacienţii cu AIJp a fost caracterizată prin analiza farmacocinetică a populaţiei care a cuprins 237 pacienți tratați cu 8 mg/kg IV la fiecare 4 săptămâni (pacienții cu o greutate ≥ 30 kg), 10 mg/kg IV la fiecare 4 săptămâni (pacienții cu o greutate sub 30 kg), 162 mg SC la fiecare 2 săptămâni (pacienții cu o greutate ≥ 30 kg) sau 162 mg SC la fiecare 3 săptămâni (pacienții cu o greutate sub 30 kg).", "en_prompt": "<|im_start|>user\nGlossary:\n\"pharmacokinetics\" -> \"farmacocinetică\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The pharmacokinetics of RoActemra in pJIA patients was characterized by a population pharmacokinetic analysis which included 237 patients who were treated with 8 mg/kg IV every 4 weeks (patients weighing ≥ 30 kg), 10 mg/kg IV every 4 weeks (patients weighing below 30 kg), 162\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "pharmacokinetics|||farmacocinetică", "en": "The pharmacokinetics of RoActemra in pJIA patients was characterized by a population pharmacokinetic analysis which included 237 patients who were treated with 8 mg/kg IV every 4 weeks (patients weighing ≥ 30 kg), 10 mg/kg IV every 4 weeks (patients weighing below 30 kg), 162", "ro": "Farmacocinetica RoActemra la pacienţii cu AIJp a fost caracterizată prin analiza farmacocinetică a populaţiei care a cuprins 237 pacienți tratați cu 8 mg/kg IV la fiecare 4 săptămâni (pacienții cu o greutate ≥ 30 kg), 10 mg/kg IV la fiecare 4 săptămâni (pacienții cu o greutate sub 30 kg), 162 mg SC la fiecare 2 săptămâni (pacienții cu o greutate ≥ 30 kg) sau 162 mg SC la fiecare 3 săptămâni (pacienții cu o greutate sub 30 kg)." } }
{ "translation": { "text": "Glossary:\n\"pharmacokinetics\" -> \"farmacocinetică\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The pharmacokinetics of RoActemra were determined using a population pharmacokinetic analysis on a database composed of 3552 RA patients treated with 162 mg subcutaneous every week, 162 mg subcutaneous every other week, and or 4 or 8 mg/kg intravenous every 4 weeks for 24 weeks.\nRomanian: Farmacocinetica RoActemra a fost determinată utilizând analiza farmacocinetică a populaţiei pe o bază de date compusă din 3552 de pacienţi cu PR trataţi cu o doză de 162 mg administrată subcutanat, o dată pe săpămână, cu o doză de 162 mg administrată subcutanat o dată la interval de 2 săptămâni sau cu o doză de 4mg/kg sau 8 mg/kg administrată intravenos la interval de 4 săptămâni, pe o perioadă de 24 de săptămâni.", "en_prompt": "<|im_start|>user\nGlossary:\n\"pharmacokinetics\" -> \"farmacocinetică\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The pharmacokinetics of RoActemra were determined using a population pharmacokinetic analysis on a database composed of 3552 RA patients treated with 162 mg subcutaneous every week, 162 mg subcutaneous every other week, and or 4 or 8 mg/kg intravenous every 4 weeks for 24 weeks.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "pharmacokinetics|||farmacocinetică", "en": "The pharmacokinetics of RoActemra were determined using a population pharmacokinetic analysis on a database composed of 3552 RA patients treated with 162 mg subcutaneous every week, 162 mg subcutaneous every other week, and or 4 or 8 mg/kg intravenous every 4 weeks for 24 weeks.", "ro": "Farmacocinetica RoActemra a fost determinată utilizând analiza farmacocinetică a populaţiei pe o bază de date compusă din 3552 de pacienţi cu PR trataţi cu o doză de 162 mg administrată subcutanat, o dată pe săpămână, cu o doză de 162 mg administrată subcutanat o dată la interval de 2 săptămâni sau cu o doză de 4mg/kg sau 8 mg/kg administrată intravenos la interval de 4 săptămâni, pe o perioadă de 24 de săptămâni." } }
{ "translation": { "text": "Glossary:\n\"exposure\" -> \"expunere\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: During the double-blind controlled period and with long-term exposure, the pattern and incidence of elevation in ALT/AST remained consistent with what was seen in the 6-month controlled clinical trials.\nRomanian: În timpul perioadei controlate dublu-orb şi cu expunere pe termen lung, caracterul şi incidenţa creşterilor ALT/AST au rămas în concordanţă cu cele observate în cadrul studiilor clinice controlate cu durata de 6 luni.", "en_prompt": "<|im_start|>user\nGlossary:\n\"exposure\" -> \"expunere\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: During the double-blind controlled period and with long-term exposure, the pattern and incidence of elevation in ALT/AST remained consistent with what was seen in the 6-month controlled clinical trials.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "exposure|||expunere", "en": "During the double-blind controlled period and with long-term exposure, the pattern and incidence of elevation in ALT/AST remained consistent with what was seen in the 6-month controlled clinical trials.", "ro": "În timpul perioadei controlate dublu-orb şi cu expunere pe termen lung, caracterul şi incidenţa creşterilor ALT/AST au rămas în concordanţă cu cele observate în cadrul studiilor clinice controlate cu durata de 6 luni." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: At week 24, inhibition of structural damage was shown, with significantly less radiographic progression in patients receiving RoActemra subcutaneous compared to placebo (mean mTSS of 0.62 vs. 1.23, p=0.0149 (van Elteren).\nRomanian: comparativ cu placebo (valoarea medie a mTSS de 0,062 comparativ cu 1,23, p=0,0149 (van Elteren)).", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: At week 24, inhibition of structural damage was shown, with significantly less radiographic progression in patients receiving RoActemra subcutaneous compared to placebo (mean mTSS of 0.62 vs. 1.23, p=0.0149 (van Elteren).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "At week 24, inhibition of structural damage was shown, with significantly less radiographic progression in patients receiving RoActemra subcutaneous compared to placebo (mean mTSS of 0.62 vs. 1.23, p=0.0149 (van Elteren).", "ro": "comparativ cu placebo (valoarea medie a mTSS de 0,062 comparativ cu 1,23, p=0,0149 (van Elteren))." } }
{ "translation": { "text": "Glossaries:\n\"pharmacokinetics\" -> \"farmacocinetică\"\n\"infusion\" -> \"perfuzie\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The pharmacokinetics of RoActemra were determined using a population pharmacokinetic analysis on a database composed of 3552 RA patients treated with a one-hour infusion of 4 or 8 mg/kg RoActemra every 4 weeks for 24 weeks or with 162 mg tocilizumab given subcutaneously either once a week or every other week for 24 weeks.\nRomanian: Farmacocinetica RoActemra a fost determinată utilizând analiza farmacocinetică a populaţiei pe o bază de date compusă din 3552 de pacienţi cu PR trataţi cu o doză de 4 sau 8 mg/kg RoActemra, administrată în perfuzie în decurs de o oră, la interval de 4 săptămâni, pe o perioadă de 24 de săptămâni sau cu o doză de 162 mg tocilizumab administrată subcutanat, o dată pe săptămână sau o dată la interval de două săptămâni, pe o perioadă de 24 de săptămâni.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"pharmacokinetics\" -> \"farmacocinetică\"\n\"infusion\" -> \"perfuzie\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The pharmacokinetics of RoActemra were determined using a population pharmacokinetic analysis on a database composed of 3552 RA patients treated with a one-hour infusion of 4 or 8 mg/kg RoActemra every 4 weeks for 24 weeks or with 162 mg tocilizumab given subcutaneously either once a week or every other week for 24 weeks.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "pharmacokinetics|||farmacocinetică\tinfusion|||perfuzie", "en": "The pharmacokinetics of RoActemra were determined using a population pharmacokinetic analysis on a database composed of 3552 RA patients treated with a one-hour infusion of 4 or 8 mg/kg RoActemra every 4 weeks for 24 weeks or with 162 mg tocilizumab given subcutaneously either once a week or every other week for 24 weeks.", "ro": "Farmacocinetica RoActemra a fost determinată utilizând analiza farmacocinetică a populaţiei pe o bază de date compusă din 3552 de pacienţi cu PR trataţi cu o doză de 4 sau 8 mg/kg RoActemra, administrată în perfuzie în decurs de o oră, la interval de 4 săptămâni, pe o perioadă de 24 de săptămâni sau cu o doză de 162 mg tocilizumab administrată subcutanat, o dată pe săptămână sau o dată la interval de două săptămâni, pe o perioadă de 24 de săptămâni." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Change in EQ5D scores from baseline to week 52 were RoActemra weekly plus 26 weeks 0.10 [0.198], RoActemra every other weekly plus 26 weeks 0.05 [0.215], placebo plus 26 weeks 0.07 [0.293], and placebo plus 52 weeks -0.02 [0.159].\nRomanian: 0,05 [0,215] pentru RoActemra administrat la interval de două săptămâni plus prednison în doze scăzute treptat pe parcursul a 26 săptămâni, 0,07 [0,293] pentru placebo plus prednison în doze scăzute treptat pe parcursul a 26 săptămâni şi de -0,02 [0,159] pentru placebo plus prednison cu scăderea progresivă a dozei în decurs de 52 săptămâni.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Change in EQ5D scores from baseline to week 52 were RoActemra weekly plus 26 weeks 0.10 [0.198], RoActemra every other weekly plus 26 weeks 0.05 [0.215], placebo plus 26 weeks 0.07 [0.293], and placebo plus 52 weeks -0.02 [0.159].\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "Change in EQ5D scores from baseline to week 52 were RoActemra weekly plus 26 weeks 0.10 [0.198], RoActemra every other weekly plus 26 weeks 0.05 [0.215], placebo plus 26 weeks 0.07 [0.293], and placebo plus 52 weeks -0.02 [0.159].", "ro": "0,05 [0,215] pentru RoActemra administrat la interval de două săptămâni plus prednison în doze scăzute treptat pe parcursul a 26 săptămâni, 0,07 [0,293] pentru placebo plus prednison în doze scăzute treptat pe parcursul a 26 săptămâni şi de -0,02 [0,159] pentru placebo plus prednison cu scăderea progresivă a dozei în decurs de 52 săptămâni." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Platelets During routine laboratory monitoring in the 12 week controlled phase, 3% of patients in the placebo group and 1% in the tocilizumab group had a decrease in platelet count to ≤ 100 x 103/µl.\nRomanian: În timpul monitorizării obişnuite de laborator în faza controlată a studiului cu durata de 12 săptămâni, reducerea numărului de trombocite la valori ≤ 100 x 103 /μl a apărut la 3% dintre pacienţii care au primit placebo şi la 1% dintre pacienţii trataţi cu tocilizumab.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Platelets During routine laboratory monitoring in the 12 week controlled phase, 3% of patients in the placebo group and 1% in the tocilizumab group had a decrease in platelet count to ≤ 100 x 103/µl.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "Platelets During routine laboratory monitoring in the 12 week controlled phase, 3% of patients in the placebo group and 1% in the tocilizumab group had a decrease in platelet count to ≤ 100 x 103/µl.", "ro": "În timpul monitorizării obişnuite de laborator în faza controlată a studiului cu durata de 12 săptămâni, reducerea numărului de trombocite la valori ≤ 100 x 103 /μl a apărut la 3% dintre pacienţii care au primit placebo şi la 1% dintre pacienţii trataţi cu tocilizumab." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In SCII, 656 patients were randomized 2:1 to RoActemra subcutaneous 162 mg every other week or placebo, in combination with non-biologic DMARD(s).\nRomanian: RoActemra subcutanat 162 mg sau placebo, în asociere cu DMARD non-biologice.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In SCII, 656 patients were randomized 2:1 to RoActemra subcutaneous 162 mg every other week or placebo, in combination with non-biologic DMARD(s).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "In SCII, 656 patients were randomized 2:1 to RoActemra subcutaneous 162 mg every other week or placebo, in combination with non-biologic DMARD(s).", "ro": "RoActemra subcutanat 162 mg sau placebo, în asociere cu DMARD non-biologice." } }
{ "translation": { "text": "Glossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Following 1 year of treatment with RoActemra plus MTX, 85% of patients(n=348) had no progression of structural joint damage, as defined by a change in the Total Sharp Score of zero or less, compared with 67% of placebo plus MTX-treated patients(n=290) (p ≤ 0.001).\nRomanian: PBO + MTX După un an de tratament cu RoActemra în asociere cu MTX, 85% dintre pacienţi (n=348) nu au prezentat progresia distrugerii structurilor articulare, evaluată prin modificarea Scorului Total", "en_prompt": "<|im_start|>user\nGlossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Following 1 year of treatment with RoActemra plus MTX, 85% of patients(n=348) had no progression of structural joint damage, as defined by a change in the Total Sharp Score of zero or less, compared with 67% of placebo plus MTX-treated patients(n=290) (p ≤ 0.001).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratament", "en": "Following 1 year of treatment with RoActemra plus MTX, 85% of patients(n=348) had no progression of structural joint damage, as defined by a change in the Total Sharp Score of zero or less, compared with 67% of placebo plus MTX-treated patients(n=290) (p ≤ 0.001).", "ro": "PBO + MTX După un an de tratament cu RoActemra în asociere cu MTX, 85% dintre pacienţi (n=348) nu au prezentat progresia distrugerii structurilor articulare, evaluată prin modificarea Scorului Total" } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the 6-month controlled trials decreases in platelet counts below 100 x 103/ μL occurred in 1.7% of patients on RoActemra 8 mg/kg plus DMARDs compared to < 1% on placebo plus DMARDs.\nRomanian: În cadrul studiilor clinice controlate cu durata de 6 luni, reducerea numărului de trombocite la valori sub 100 x 103 /μl a apărut la 1,7% dintre pacienţii trataţi cu RoActemra 8 mg/kg şi DMARD, comparativ cu < 1% dintre pacienţii trataţi cu placebo şi DMARD.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the 6-month controlled trials decreases in platelet counts below 100 x 103/ μL occurred in 1.7% of patients on RoActemra 8 mg/kg plus DMARDs compared to < 1% on placebo plus DMARDs.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "In the 6-month controlled trials decreases in platelet counts below 100 x 103/ μL occurred in 1.7% of patients on RoActemra 8 mg/kg plus DMARDs compared to < 1% on placebo plus DMARDs.", "ro": "În cadrul studiilor clinice controlate cu durata de 6 luni, reducerea numărului de trombocite la valori sub 100 x 103 /μl a apărut la 1,7% dintre pacienţii trataţi cu RoActemra 8 mg/kg şi DMARD, comparativ cu < 1% dintre pacienţii trataţi cu placebo şi DMARD." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the 6-month controlled trials decreases in platelet counts below 100 x 103/ μL occurred in 1.7% of patients on tocilizumab 8 mg/kg plus DMARDs compared to < 1% on placebo plus DMARDs.\nRomanian: Trombocite În cadrul studiilor clinice controlate cu durata de 6 luni, reducerea numărului de trombocite la valori sub 100 x 103 /μl a apărut la 1,7% dintre pacienţii trataţi cu tocilizumab 8 mg/kg şi DMARD, comparativ cu < 1% dintre pacienţii trataţi cu placebo şi DMARD.", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the 6-month controlled trials decreases in platelet counts below 100 x 103/ μL occurred in 1.7% of patients on tocilizumab 8 mg/kg plus DMARDs compared to < 1% on placebo plus DMARDs.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "In the 6-month controlled trials decreases in platelet counts below 100 x 103/ μL occurred in 1.7% of patients on tocilizumab 8 mg/kg plus DMARDs compared to < 1% on placebo plus DMARDs.", "ro": "Trombocite În cadrul studiilor clinice controlate cu durata de 6 luni, reducerea numărului de trombocite la valori sub 100 x 103 /μl a apărut la 1,7% dintre pacienţii trataţi cu tocilizumab 8 mg/kg şi DMARD, comparativ cu < 1% dintre pacienţii trataţi cu placebo şi DMARD." } }
{ "translation": { "text": "Glossary:\n\"exposure\" -> \"expunere\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: During the double-blind controlled period and with long-term exposure, the pattern and incidence of decreases in platelet counts remained consistent with what was seen in the 6-month controlled clinical trials.\nRomanian: În timpul perioadei controlate dublu-orb şi cu expunere pe termen lung, caracterul şi incidenţa scăderii numărului de trombocite au rămas în concordanţă cu cele observate în cadrul studiilor clinice controlate cu durata de 6 luni.", "en_prompt": "<|im_start|>user\nGlossary:\n\"exposure\" -> \"expunere\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: During the double-blind controlled period and with long-term exposure, the pattern and incidence of decreases in platelet counts remained consistent with what was seen in the 6-month controlled clinical trials.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "exposure|||expunere", "en": "During the double-blind controlled period and with long-term exposure, the pattern and incidence of decreases in platelet counts remained consistent with what was seen in the 6-month controlled clinical trials.", "ro": "În timpul perioadei controlate dublu-orb şi cu expunere pe termen lung, caracterul şi incidenţa scăderii numărului de trombocite au rămas în concordanţă cu cele observate în cadrul studiilor clinice controlate cu durata de 6 luni." } }
{ "translation": { "text": "Glossary:\n\"infusion\" -> \"perfuzie\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Withdraw a volume of sterile, non-pyrogenic sodium chloride 9 mg/mL (0.9%) solution for injection from a 100 mL infusion bag, equal to the volume of RoActemra concentrate required for the patients dose, under aseptic conditions.\nRomanian: Dintr-o pungă de perfuzie de 100 ml se extrage, în condiţii aseptice, un volum de soluţie injectabilă sterilă, apirogenă de clorură de sodiu 9 mg/ml (0,9%) egal cu volumul de concentrat de RoActemra necesar pentru doza pacientului.", "en_prompt": "<|im_start|>user\nGlossary:\n\"infusion\" -> \"perfuzie\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Withdraw a volume of sterile, non-pyrogenic sodium chloride 9 mg/mL (0.9%) solution for injection from a 100 mL infusion bag, equal to the volume of RoActemra concentrate required for the patients dose, under aseptic conditions.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "infusion|||perfuzie", "en": "Withdraw a volume of sterile, non-pyrogenic sodium chloride 9 mg/mL (0.9%) solution for injection from a 100 mL infusion bag, equal to the volume of RoActemra concentrate required for the patients dose, under aseptic conditions.", "ro": "Dintr-o pungă de perfuzie de 100 ml se extrage, în condiţii aseptice, un volum de soluţie injectabilă sterilă, apirogenă de clorură de sodiu 9 mg/ml (0,9%) egal cu volumul de concentrat de RoActemra necesar pentru doza pacientului." } }
{ "translation": { "text": "Glossary:\n\"exposure\" -> \"expunere\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: During the double-blind controlled period and with long-term exposure, the pattern and incidence of elevations in lipid parameters remained consistent with what was seen in the 6-month controlled trials.\nRomanian: În timpul perioadei controlate dublu-orb şi cu expunere pe termen lung, caracterul şi incidenţa creşterii parametrilor lipidici au rămas în concordanţă cu cele observate în cadrul studiilor clinice controlate cu durata de 6 luni.", "en_prompt": "<|im_start|>user\nGlossary:\n\"exposure\" -> \"expunere\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: During the double-blind controlled period and with long-term exposure, the pattern and incidence of elevations in lipid parameters remained consistent with what was seen in the 6-month controlled trials.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "exposure|||expunere", "en": "During the double-blind controlled period and with long-term exposure, the pattern and incidence of elevations in lipid parameters remained consistent with what was seen in the 6-month controlled trials.", "ro": "În timpul perioadei controlate dublu-orb şi cu expunere pe termen lung, caracterul şi incidenţa creşterii parametrilor lipidici au rămas în concordanţă cu cele observate în cadrul studiilor clinice controlate cu durata de 6 luni." } }
{ "translation": { "text": "Glossary:\n\"bilirubin\" -> \"bilirubină\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: During the double-blind controlled period, the incidence of indirect bilirubin greater than the upper limit of normal, collected as a routine laboratory parameter, is 6.2% in patients treated with 8 mg/kg RoActemra + DMARD.\nRomanian: 8 mg/kg + DMARD, incidenţa unor concentraţii de bilirubină indirectă mai mari decât limita superioară a valorilor normale, înregistrată ca un parametru obişnuit de laborator, este de 6,2%.", "en_prompt": "<|im_start|>user\nGlossary:\n\"bilirubin\" -> \"bilirubină\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: During the double-blind controlled period, the incidence of indirect bilirubin greater than the upper limit of normal, collected as a routine laboratory parameter, is 6.2% in patients treated with 8 mg/kg RoActemra + DMARD.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "bilirubin|||bilirubină", "en": "During the double-blind controlled period, the incidence of indirect bilirubin greater than the upper limit of normal, collected as a routine laboratory parameter, is 6.2% in patients treated with 8 mg/kg RoActemra + DMARD.", "ro": "8 mg/kg + DMARD, incidenţa unor concentraţii de bilirubină indirectă mai mari decât limita superioară a valorilor normale, înregistrată ca un parametru obişnuit de laborator, este de 6,2%." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Doses of 4 or 8 mg/kg RoActemra or placebo were given every four weeks in combination with stable MTX (10 mg to 25 mg weekly).\nRomanian: Au fost administrate doze de RoActemra de 4 sau 8 mg/kg sau placebo la interval de patru săptămâni, în asociere cu doza stabilă de MTX (10 mg până la 25 mg săptămânal).", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Doses of 4 or 8 mg/kg RoActemra or placebo were given every four weeks in combination with stable MTX (10 mg to 25 mg weekly).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "Doses of 4 or 8 mg/kg RoActemra or placebo were given every four weeks in combination with stable MTX (10 mg to 25 mg weekly).", "ro": "Au fost administrate doze de RoActemra de 4 sau 8 mg/kg sau placebo la interval de patru săptămâni, în asociere cu doza stabilă de MTX (10 mg până la 25 mg săptămânal)." } }
{ "translation": { "text": "Glossary:\n\"vial\" -> \"flacon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: STATEMENT OF ACTIVE SUBSTANCE(S) 1 vial contains 400 mg tocilizumab.\nRomanian: 1 flacon conţine tocilizumab 400 mg.", "en_prompt": "<|im_start|>user\nGlossary:\n\"vial\" -> \"flacon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: STATEMENT OF ACTIVE SUBSTANCE(S) 1 vial contains 400 mg tocilizumab.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "vial|||flacon", "en": "STATEMENT OF ACTIVE SUBSTANCE(S) 1 vial contains 400 mg tocilizumab.", "ro": "1 flacon conţine tocilizumab 400 mg." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Doses of 4 or 8 mg/kg tocilizumab or placebo were given every four weeks in combination with stable MTX (10 mg to 25 mg weekly).\nRomanian: Au fost administrate doze de tocilizumab de 4 sau 8 mg/kg sau placebo la interval de patru săptămâni, în asociere cu doza stabilă de MTX (10 mg până la 25 mg săptămânal).", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Doses of 4 or 8 mg/kg tocilizumab or placebo were given every four weeks in combination with stable MTX (10 mg to 25 mg weekly).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "Doses of 4 or 8 mg/kg tocilizumab or placebo were given every four weeks in combination with stable MTX (10 mg to 25 mg weekly).", "ro": "Au fost administrate doze de tocilizumab de 4 sau 8 mg/kg sau placebo la interval de patru săptămâni, în asociere cu doza stabilă de MTX (10 mg până la 25 mg săptămânal)." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Doses of 4 or 8 mg/kg RoActemra or placebo were given every four weeks, in combination with stable MTX (10 mg to 25 mg weekly).\nRomanian: Au fost administrate doze de RoActemra de 4 sau 8 mg/kg, sau placebo, la interval de patru săptămâni, în asociere cu doza stabilă de MTX (10 mg până la 25 mg săptămânal).", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Doses of 4 or 8 mg/kg RoActemra or placebo were given every four weeks, in combination with stable MTX (10 mg to 25 mg weekly).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "Doses of 4 or 8 mg/kg RoActemra or placebo were given every four weeks, in combination with stable MTX (10 mg to 25 mg weekly).", "ro": "Au fost administrate doze de RoActemra de 4 sau 8 mg/kg, sau placebo, la interval de patru săptămâni, în asociere cu doza stabilă de MTX (10 mg până la 25 mg săptămânal)." } }
{ "translation": { "text": "Glossary:\n\"fever\" -> \"febră\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • body aches, fever, chills\nRomanian: • dureri la nivelul întregului corp, febră, frisoane", "en_prompt": "<|im_start|>user\nGlossary:\n\"fever\" -> \"febră\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • body aches, fever, chills\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "fever|||febră", "en": "• body aches, fever, chills", "ro": "• dureri la nivelul întregului corp, febră, frisoane" } }
{ "translation": { "text": "Glossary:\n\"vial\" -> \"flacon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: STATEMENT OF ACTIVE SUBSTANCE(S) 1 vial contains 80 mg tocilizumab.\nRomanian: 1 flacon conţine tocilizumab 80 mg.", "en_prompt": "<|im_start|>user\nGlossary:\n\"vial\" -> \"flacon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: STATEMENT OF ACTIVE SUBSTANCE(S) 1 vial contains 80 mg tocilizumab.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "vial|||flacon", "en": "STATEMENT OF ACTIVE SUBSTANCE(S) 1 vial contains 80 mg tocilizumab.", "ro": "1 flacon conţine tocilizumab 80 mg." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Of 100 women who take this medicine approximately 2 will become pregnant.\nRomanian: Din 100 de femei care iau acest medicament, aproximativ 2 vor rămâne gravide.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Of 100 women who take this medicine approximately 2 will become pregnant.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "Of 100 women who take this medicine approximately 2 will become pregnant.", "ro": "Din 100 de femei care iau acest medicament, aproximativ 2 vor rămâne gravide." } }
{ "translation": { "text": "Glossary:\n\"test\" -> \"test\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: You should do a pregnancy test right away.\nRomanian: Trebuie să efectuaţi imediat un test de sarcină.", "en_prompt": "<|im_start|>user\nGlossary:\n\"test\" -> \"test\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: You should do a pregnancy test right away.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "test|||test", "en": "You should do a pregnancy test right away.", "ro": "Trebuie să efectuaţi imediat un test de sarcină." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: NS: non statistically significant †: compared to placebo\nRomanian: NS: nesemnificativ statistic †: în comparaţie cu placebo", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: NS: non statistically significant †: compared to placebo\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "NS: non statistically significant †: compared to placebo", "ro": "NS: nesemnificativ statistic †: în comparaţie cu placebo" } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder\nRomanian: Pentru orice informaţii referitoare la acest medicament, vă rugăm să contactaţi reprezentanţa locală a deţinătorului autorizaţiei de punere pe piaţă", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder", "ro": "Pentru orice informaţii referitoare la acest medicament, vă rugăm să contactaţi reprezentanţa locală a deţinătorului autorizaţiei de punere pe piaţă" } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: This medicine will not affect your future fertility.\nRomanian: Acest medicament nu va afecta fertilitatea dumneavoastră viitoare.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: This medicine will not affect your future fertility.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "This medicine will not affect your future fertility.", "ro": "Acest medicament nu va afecta fertilitatea dumneavoastră viitoare." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: As a result, this medicine works by postponing ovulation.\nRomanian: Drept urmare, acest medicament acţionează prin amânarea ovulaţiei.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: As a result, this medicine works by postponing ovulation.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "As a result, this medicine works by postponing ovulation.", "ro": "Drept urmare, acest medicament acţionează prin amânarea ovulaţiei." } }
{ "translation": { "text": "Glossaries:\n\"medicinal product\" -> \"medicament\"\n\"submission\" -> \"transmitere\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines webportal.\nRomanian: Cerințele pentru depunerea rapoartelor periodice actualizate privind siguranţa pentru acest medicament sunt prezentate în lista de date de referință și frecvențe de transmitere la nivelul Uniunii (lista EURD), menţionată la articolul 107c alineatul (7) din Directiva 2001/83/CE şi orice actualizări ulterioare ale acesteia publicată pe portalul web european privind medicamentele.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"medicinal product\" -> \"medicament\"\n\"submission\" -> \"transmitere\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines webportal.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicinal product|||medicament\tsubmission|||transmitere", "en": "The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines webportal.", "ro": "Cerințele pentru depunerea rapoartelor periodice actualizate privind siguranţa pentru acest medicament sunt prezentate în lista de date de referință și frecvențe de transmitere la nivelul Uniunii (lista EURD), menţionată la articolul 107c alineatul (7) din Directiva 2001/83/CE şi orice actualizări ulterioare ale acesteia publicată pe portalul web european privind medicamentele." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Do not use this medicine after the expiry date which is on the carton and on the blister after EXP.\nRomanian: Nu utilizaţi acest medicament după data de expirare înscrisă pe cutie şi pe blister după EXP.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Do not use this medicine after the expiry date which is on the carton and on the blister after EXP.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "Do not use this medicine after the expiry date which is on the carton and on the blister after EXP.", "ro": "Nu utilizaţi acest medicament după data de expirare înscrisă pe cutie şi pe blister după EXP." } }
{ "translation": { "text": "Glossary:\n\"BMI\" -> \"IMC\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Therefore, ellaOne is still recommended for all women regardless of their weight or BMI.\nRomanian: Ca urmare, ellaOne este recomandat în continuare tuturor femeilor, indiferent de greutatea lor corporală sau IMC.", "en_prompt": "<|im_start|>user\nGlossary:\n\"BMI\" -> \"IMC\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Therefore, ellaOne is still recommended for all women regardless of their weight or BMI.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "BMI|||IMC", "en": "Therefore, ellaOne is still recommended for all women regardless of their weight or BMI.", "ro": "Ca urmare, ellaOne este recomandat în continuare tuturor femeilor, indiferent de greutatea lor corporală sau IMC." } }
{ "translation": { "text": "Glossary:\n\"toxicity\" -> \"toxicitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Information from reproductive toxicity studies is limited due to the absence of exposure measurement in these studies.\nRomanian: Informaţiile din studii de toxicitate asupra funcţiei de reproducere sunt limitate ca urmare a absenţei măsurării expunerii în aceste studii.", "en_prompt": "<|im_start|>user\nGlossary:\n\"toxicity\" -> \"toxicitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Information from reproductive toxicity studies is limited due to the absence of exposure measurement in these studies.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "toxicity|||toxicitate", "en": "Information from reproductive toxicity studies is limited due to the absence of exposure measurement in these studies.", "ro": "Informaţiile din studii de toxicitate asupra funcţiei de reproducere sunt limitate ca urmare a absenţei măsurării expunerii în aceste studii." } }
{ "translation": { "text": "Glossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the phase III studies, 82 women entered a study more than once and therefore received more than one dose of ellaOne (73 women enrolled twice and 9 enrolled three times).\nRomanian: În studiile de fază III, 82 de femei au fost incluse într-un studiu mai mult de o dată şi, prin urmare, li s-a administrat mai mult de o doză de ellaOne (73 dintre femei s-au înrolat de două ori şi 9 femei de trei ori).", "en_prompt": "<|im_start|>user\nGlossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the phase III studies, 82 women entered a study more than once and therefore received more than one dose of ellaOne (73 women enrolled twice and 9 enrolled three times).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||doză", "en": "In the phase III studies, 82 women entered a study more than once and therefore received more than one dose of ellaOne (73 women enrolled twice and 9 enrolled three times).", "ro": "În studiile de fază III, 82 de femei au fost incluse într-un studiu mai mult de o dată şi, prin urmare, li s-a administrat mai mult de o doză de ellaOne (73 dintre femei s-au înrolat de două ori şi 9 femei de trei ori)." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can provide more information on the safety of this medicine.\nRomanian: De asemenea, puteţi raporta reacţiile adverse direct prin intermediul sistemului naţional de raportare, aşa cum este menţionat în Anexa V. Raportând reacţiile adverse, puteţi contribui la furnizarea de informaţii suplimentare privind siguranţa acestui medicament.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can provide more information on the safety of this medicine.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can provide more information on the safety of this medicine.", "ro": "De asemenea, puteţi raporta reacţiile adverse direct prin intermediul sistemului naţional de raportare, aşa cum este menţionat în Anexa V. Raportând reacţiile adverse, puteţi contribui la furnizarea de informaţii suplimentare privind siguranţa acestui medicament." } }
{ "translation": { "text": "Glossaries:\n\"BMI\" -> \"IMC\"\n\"body mass index\" -> \"IMC\"\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: There is some evidence that this medicine may be less effective with increasing body weight or body mass index (BMI), but these data were limited and inconclusive.\nRomanian: Există unele dovezi că acest medicament poate fi mai puţin eficace odată cu creşterea în greutate sau a indicelui de masă corporală (IMC), dar aceste date sunt limitate şi neconcludente.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"BMI\" -> \"IMC\"\n\"body mass index\" -> \"IMC\"\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: There is some evidence that this medicine may be less effective with increasing body weight or body mass index (BMI), but these data were limited and inconclusive.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "BMI|||IMC\tbody mass index|||IMC\tmedicine|||medicament", "en": "There is some evidence that this medicine may be less effective with increasing body weight or body mass index (BMI), but these data were limited and inconclusive.", "ro": "Există unele dovezi că acest medicament poate fi mai puţin eficace odată cu creşterea în greutate sau a indicelui de masă corporală (IMC), dar aceste date sunt limitate şi neconcludente." } }
{ "translation": { "text": "Glossary:\n\"ritonavir\" -> \"ritonavir\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In such cases ritonavir might reduce plasma concentrations of ulipristal acetate.\nRomanian: În astfel de cazuri, ritonavir ar putea reduce concentraţiile plasmatice de ulipristal acetat.", "en_prompt": "<|im_start|>user\nGlossary:\n\"ritonavir\" -> \"ritonavir\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In such cases ritonavir might reduce plasma concentrations of ulipristal acetate.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "ritonavir|||ritonavir", "en": "In such cases ritonavir might reduce plasma concentrations of ulipristal acetate.", "ro": "În astfel de cazuri, ritonavir ar putea reduce concentraţiile plasmatice de ulipristal acetat." } }
{ "translation": { "text": "Glossaries:\n\"toxicity\" -> \"toxicitate\"\n\"genotoxicity\" -> \"genotoxicitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, and genotoxicity.\nRomanian: Datele non-clinice nu au evidenţiat niciun risc special pentru om pe baza studiilor convenţionale farmacologice privind evaluarea siguranţei, toxicitate după doze repetate sau genotoxicitate.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"toxicity\" -> \"toxicitate\"\n\"genotoxicity\" -> \"genotoxicitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, and genotoxicity.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "toxicity|||toxicitate\tgenotoxicity|||genotoxicitate", "en": "Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, and genotoxicity.", "ro": "Datele non-clinice nu au evidenţiat niciun risc special pentru om pe baza studiilor convenţionale farmacologice privind evaluarea siguranţei, toxicitate după doze repetate sau genotoxicitate." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: This medicine is suitable for any woman of childbearing age, including adolescents.\nRomanian: Acest medicament este adecvat pentru orice femeie aflată la vârsta fertilă, inclusiv adolescente.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: This medicine is suitable for any woman of childbearing age, including adolescents.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "This medicine is suitable for any woman of childbearing age, including adolescents.", "ro": "Acest medicament este adecvat pentru orice femeie aflată la vârsta fertilă, inclusiv adolescente." } }
{ "translation": { "text": "Glossary:\n\"medicinal product\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.\nRomanian: Pacientele cu afecţiuni ereditare rare de intoleranţă la galactoză, deficit de lactază (Lapp) sau sindrom de malabsorbţie la glucoză-galactoză nu trebuie să utilizeze acest medicament.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicinal product\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicinal product|||medicament", "en": "Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.", "ro": "Pacientele cu afecţiuni ereditare rare de intoleranţă la galactoză, deficit de lactază (Lapp) sau sindrom de malabsorbţie la glucoză-galactoză nu trebuie să utilizeze acest medicament." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: This medicine is a contraceptive used to prevent a pregnancy from starting.\nRomanian: Acest medicament este un contraceptiv utilizat pentru a preveni instalarea unei sarcini.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: This medicine is a contraceptive used to prevent a pregnancy from starting.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "This medicine is a contraceptive used to prevent a pregnancy from starting.", "ro": "Acest medicament este un contraceptiv utilizat pentru a preveni instalarea unei sarcini." } }
{ "translation": { "text": "Glossary:\n\"elimination\" -> \"eliminare\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Biotransformation/elimination\nRomanian: Metabolizare/eliminare", "en_prompt": "<|im_start|>user\nGlossary:\n\"elimination\" -> \"eliminare\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Biotransformation/elimination\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "elimination|||eliminare", "en": "Biotransformation/elimination", "ro": "Metabolizare/eliminare" } }
{ "translation": { "text": "Glossary:\n\"asthma\" -> \"astm\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Use in women with severe asthma treated by oral glucocorticoid is not recommended.\nRomanian: Utilizarea la femei cu astm sever tratate cu glucocorticoizi orali nu este recomandată.", "en_prompt": "<|im_start|>user\nGlossary:\n\"asthma\" -> \"astm\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Use in women with severe asthma treated by oral glucocorticoid is not recommended.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "asthma|||astm", "en": "Use in women with severe asthma treated by oral glucocorticoid is not recommended.", "ro": "Utilizarea la femei cu astm sever tratate cu glucocorticoizi orali nu este recomandată." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If you have been told by your doctor or other healthcare professional that you have an intolerance to some sugars, tell your pharmacist before taking this medicine.\nRomanian: Dacă medicul dumneavoastră sau personalul medical v-a atenţionat că aveţi intoleranţă la unele categorii de glucide, spuneţi-i farmacistului înainte de a lua acest medicament.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If you have been told by your doctor or other healthcare professional that you have an intolerance to some sugars, tell your pharmacist before taking this medicine.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "If you have been told by your doctor or other healthcare professional that you have an intolerance to some sugars, tell your pharmacist before taking this medicine.", "ro": "Dacă medicul dumneavoastră sau personalul medical v-a atenţionat că aveţi intoleranţă la unele categorii de glucide, spuneţi-i farmacistului înainte de a lua acest medicament." } }
{ "translation": { "text": "Glossary:\n\"ritonavir\" -> \"ritonavir\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The CYP3A4 inhibitor ritonavir can also have an inducing effect on CYP3A4 when ritonavir is used for a longer period.\nRomanian: Inhibitorul CYP3A4 ritonavir poate avea, de asemenea, un efect inductor asupra CYP3A4 atunci când ritonavir se utilizează o perioadă mai lungă de timp.", "en_prompt": "<|im_start|>user\nGlossary:\n\"ritonavir\" -> \"ritonavir\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The CYP3A4 inhibitor ritonavir can also have an inducing effect on CYP3A4 when ritonavir is used for a longer period.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "ritonavir|||ritonavir", "en": "The CYP3A4 inhibitor ritonavir can also have an inducing effect on CYP3A4 when ritonavir is used for a longer period.", "ro": "Inhibitorul CYP3A4 ritonavir poate avea, de asemenea, un efect inductor asupra CYP3A4 atunci când ritonavir se utilizează o perioadă mai lungă de timp." } }
{ "translation": { "text": "Glossary:\n\"clearance\" -> \"clearance\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Thus, administration of ulipristal acetate is unlikely to alter the clearance of medicinal products that are metabolised by these enzymes.\nRomanian: Astfel, administrarea de ulipristal acetat este puţin probabil să modifice clearance-ul medicamentelor care sunt metabolizate pe calea acestor izoenzime.", "en_prompt": "<|im_start|>user\nGlossary:\n\"clearance\" -> \"clearance\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Thus, administration of ulipristal acetate is unlikely to alter the clearance of medicinal products that are metabolised by these enzymes.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "clearance|||clearance", "en": "Thus, administration of ulipristal acetate is unlikely to alter the clearance of medicinal products that are metabolised by these enzymes.", "ro": "Astfel, administrarea de ulipristal acetat este puţin probabil să modifice clearance-ul medicamentelor care sunt metabolizate pe calea acestor izoenzime." } }
{ "translation": { "text": "Glossaries:\n\"activity\" -> \"activitate\"\n\"modulator\" -> \"modulator\"\n\"toxicity\" -> \"toxicitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Most findings in general toxicity studies were related to its mechanism of action as a modulator of progesterone and glucocorticoid receptors, with antiprogesterone activity observed at exposures similar to therapeutic levels.\nRomanian: Cele mai multe constatări din studiile de toxicitate generală au fost legate de mecanismul de acţiune ca modulator al receptorilor pentru progesteron şi glucocorticoizi, cu activitate antiprogesteronică observată la expunere similară cu cea obţinută în cazul dozelor terapeutice.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"activity\" -> \"activitate\"\n\"modulator\" -> \"modulator\"\n\"toxicity\" -> \"toxicitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Most findings in general toxicity studies were related to its mechanism of action as a modulator of progesterone and glucocorticoid receptors, with antiprogesterone activity observed at exposures similar to therapeutic levels.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "activity|||activitate\tmodulator|||modulator\ttoxicity|||toxicitate", "en": "Most findings in general toxicity studies were related to its mechanism of action as a modulator of progesterone and glucocorticoid receptors, with antiprogesterone activity observed at exposures similar to therapeutic levels.", "ro": "Cele mai multe constatări din studiile de toxicitate generală au fost legate de mecanismul de acţiune ca modulator al receptorilor pentru progesteron şi glucocorticoizi, cu activitate antiprogesteronică observată la expunere similară cu cea obţinută în cazul dozelor terapeutice." } }
{ "translation": { "text": "Glossaries:\n\"dose\" -> \"doză\"\n\"single dose\" -> \"doză unică\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The clinical relevance of this interaction for single dose administration of ulipristal acetate as emergency contraception is not known.\nRomanian: Relevanţa clinică a acestei interacţiuni pentru administrarea în doză unică a ulipristal acetat ca metodă contraceptivă de urgenţă nu este cunoscută.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"dose\" -> \"doză\"\n\"single dose\" -> \"doză unică\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The clinical relevance of this interaction for single dose administration of ulipristal acetate as emergency contraception is not known.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||doză\tsingle dose|||doză unică", "en": "The clinical relevance of this interaction for single dose administration of ulipristal acetate as emergency contraception is not known.", "ro": "Relevanţa clinică a acestei interacţiuni pentru administrarea în doză unică a ulipristal acetat ca metodă contraceptivă de urgenţă nu este cunoscută." } }
{ "translation": { "text": "Glossaries:\n\"syphilis\" -> \"sifilis\"\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: This medicine will not protect you against HIV infection or any other sexually transmitted diseases (e.g. chlamydia, genital herpes, genital warts, gonorrhoea, hepatitis B and syphilis).\nRomanian: Acest medicament nu vă va proteja împotriva infecţiei cu virusul HIV sau a oricăror altor boli cu transmitere sexuală (de exemplu, chlamydia, herpes genital, condiloame genitale, gonoree, hepatită B şi sifilis).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"syphilis\" -> \"sifilis\"\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: This medicine will not protect you against HIV infection or any other sexually transmitted diseases (e.g. chlamydia, genital herpes, genital warts, gonorrhoea, hepatitis B and syphilis).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "syphilis|||sifilis\tmedicine|||medicament", "en": "This medicine will not protect you against HIV infection or any other sexually transmitted diseases (e.g. chlamydia, genital herpes, genital warts, gonorrhoea, hepatitis B and syphilis).", "ro": "Acest medicament nu vă va proteja împotriva infecţiei cu virusul HIV sau a oricăror altor boli cu transmitere sexuală (de exemplu, chlamydia, herpes genital, condiloame genitale, gonoree, hepatită B şi sifilis)." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: - if you are allergic to ulipristal acetate or any of the other ingredients of this medicine (listed in section 6).\nRomanian: - dacă sunteţi alergică la ulipristal acetat sau la oricare dintre celelalte componente ale acestui medicament (enumerate la pct. 6).", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: - if you are allergic to ulipristal acetate or any of the other ingredients of this medicine (listed in section 6).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "- if you are allergic to ulipristal acetate or any of the other ingredients of this medicine (listed in section 6).", "ro": "- dacă sunteţi alergică la ulipristal acetat sau la oricare dintre celelalte componente ale acestui medicament (enumerate la pct. 6)." } }
{ "translation": { "text": "Glossaries:\n\"glycoprotein\" -> \"glicoproteină\"\n\"albumin\" -> \"albumină\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Ulipristal acetate is highly bound (>98%) to plasma proteins, including albumin, alpha-l-acid glycoprotein, and high density lipoprotein.\nRomanian: Ulipristal acetat este legat în proporţie mare (> 98%) de proteinele plasmatice, inclusiv albumină, alfa-l-acid glicoproteină şi lipoproteina cu densitate mare.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"glycoprotein\" -> \"glicoproteină\"\n\"albumin\" -> \"albumină\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Ulipristal acetate is highly bound (>98%) to plasma proteins, including albumin, alpha-l-acid glycoprotein, and high density lipoprotein.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "glycoprotein|||glicoproteină\talbumin|||albumină", "en": "Ulipristal acetate is highly bound (>98%) to plasma proteins, including albumin, alpha-l-acid glycoprotein, and high density lipoprotein.", "ro": "Ulipristal acetat este legat în proporţie mare (> 98%) de proteinele plasmatice, inclusiv albumină, alfa-l-acid glicoproteină şi lipoproteina cu densitate mare." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Always take this medicine exactly as described in this leaflet or as your pharmacist, doctor or other healthcare professional has told you.\nRomanian: Luați întotdeauna acest medicament exact aşa cum este descris în acest prospect sau aşa cum v-a spus farmacistul, medicul dumneavoastră sau personalul medical.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Always take this medicine exactly as described in this leaflet or as your pharmacist, doctor or other healthcare professional has told you.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "Always take this medicine exactly as described in this leaflet or as your pharmacist, doctor or other healthcare professional has told you.", "ro": "Luați întotdeauna acest medicament exact aşa cum este descris în acest prospect sau aşa cum v-a spus farmacistul, medicul dumneavoastră sau personalul medical." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If you take this medicine while you are breast-feeding a baby, do not breast-feed for one week after taking this medicine.\nRomanian: Dacă luaţi acest medicament în timp ce alăptaţi, opriţi alăptarea timp de o săptămână după ce aţi luat acest medicament.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If you take this medicine while you are breast-feeding a baby, do not breast-feed for one week after taking this medicine.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "If you take this medicine while you are breast-feeding a baby, do not breast-feed for one week after taking this medicine.", "ro": "Dacă luaţi acest medicament în timp ce alăptaţi, opriţi alăptarea timp de o săptămână după ce aţi luat acest medicament." } }
{ "translation": { "text": "Glossaries:\n\"test\" -> \"test\"\n\"character\" -> \"caracter\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In case the next menstrual period is more than 7 days late, if the menstrual period is abnormal in character or if there are symptoms suggestive of pregnancy or in case of doubt, a pregnancy test should be performed.\nRomanian: În cazul în care următoarea menstruaţie întârzie cu mai mult de 7 zile, dacă menstruaţia are un caracter anormal sau dacă există simptome care să sugereze o sarcină sau în cazul în care există dubii, trebuie efectuat un test de sarcină.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"test\" -> \"test\"\n\"character\" -> \"caracter\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In case the next menstrual period is more than 7 days late, if the menstrual period is abnormal in character or if there are symptoms suggestive of pregnancy or in case of doubt, a pregnancy test should be performed.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "test|||test\tcharacter|||caracter", "en": "In case the next menstrual period is more than 7 days late, if the menstrual period is abnormal in character or if there are symptoms suggestive of pregnancy or in case of doubt, a pregnancy test should be performed.", "ro": "În cazul în care următoarea menstruaţie întârzie cu mai mult de 7 zile, dacă menstruaţia are un caracter anormal sau dacă există simptome care să sugereze o sarcină sau în cazul în care există dubii, trebuie efectuat un test de sarcină." } }
{ "translation": { "text": "Glossaries:\n\"medicine\" -> \"medicament\"\n\"test\" -> \"test\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Before taking this medicine, if your period is late, tell your pharmacist, doctor or other healthcare professional, or do a pregnancy test in order to make sure you are not already pregnant (see section “Warning and precautions”).\nRomanian: Înainte de a lua acest medicament, dacă menstruaţia dumneavoastră a întârziat, adresaţi-vă farmacistului, medicului dumneavoastră sau personalului medical sau efectuaţi un test de sarcină, pentru a vă asigura că nu sunteţi deja gravidă (vezi pct. „Atenţionări şi precauţii”).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"medicine\" -> \"medicament\"\n\"test\" -> \"test\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Before taking this medicine, if your period is late, tell your pharmacist, doctor or other healthcare professional, or do a pregnancy test in order to make sure you are not already pregnant (see section “Warning and precautions”).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament\ttest|||test", "en": "Before taking this medicine, if your period is late, tell your pharmacist, doctor or other healthcare professional, or do a pregnancy test in order to make sure you are not already pregnant (see section “Warning and precautions”).", "ro": "Înainte de a lua acest medicament, dacă menstruaţia dumneavoastră a întârziat, adresaţi-vă farmacistului, medicului dumneavoastră sau personalului medical sau efectuaţi un test de sarcină, pentru a vă asigura că nu sunteţi deja gravidă (vezi pct. „Atenţionări şi precauţii”)." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Do not take this medicine together with another emergency contraceptive pill that contains levonorgestrel.\nRomanian: Nu luați acest medicament împreună cu o altă pilulă contraceptivă de urgenţă care conţine levonorgestrel.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Do not take this medicine together with another emergency contraceptive pill that contains levonorgestrel.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "Do not take this medicine together with another emergency contraceptive pill that contains levonorgestrel.", "ro": "Nu luați acest medicament împreună cu o altă pilulă contraceptivă de urgenţă care conţine levonorgestrel." } }
{ "translation": { "text": "Glossary:\n\"BMI\" -> \"IMC\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In all women, emergency contraception should be taken as soon as possible after unprotected intercourse, regardless of the woman's body weight or BMI.\nRomanian: La toate femeile, contracepţia de urgenţă trebuie luată la cât mai scurt timp după actul sexual neprotejat, indiferent de greutatea corporală sau de valoarea IMC a femeii.", "en_prompt": "<|im_start|>user\nGlossary:\n\"BMI\" -> \"IMC\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In all women, emergency contraception should be taken as soon as possible after unprotected intercourse, regardless of the woman's body weight or BMI.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "BMI|||IMC", "en": "In all women, emergency contraception should be taken as soon as possible after unprotected intercourse, regardless of the woman's body weight or BMI.", "ro": "La toate femeile, contracepţia de urgenţă trebuie luată la cât mai scurt timp după actul sexual neprotejat, indiferent de greutatea corporală sau de valoarea IMC a femeii." } }
{ "translation": { "text": "Glossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Pharmacodynamic data show that even when taken immediately before ovulation is scheduled to occur (when LH has already started to rise), ulipristal acetate is able to postpone follicular rupture for at least 5 days in 78.6% of cases (p<0.005 vs. levonorgestrel and vs. placebo)\nRomanian: Datele farmacodinamice arată că şi în cazul administrării imediat înainte de data aşteptată a ovulaţiei (când LH a început deja să crească), ulipristal acetat este capabil să amâne ruptura foliculară timp de cel puţin 5 zile în 78,6% din cazuri (p<0,005 faţă de levonorgestrel şi faţă de placebo) (vezi tabelul).", "en_prompt": "<|im_start|>user\nGlossary:\n\"placebo\" -> \"placebo\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Pharmacodynamic data show that even when taken immediately before ovulation is scheduled to occur (when LH has already started to rise), ulipristal acetate is able to postpone follicular rupture for at least 5 days in 78.6% of cases (p<0.005 vs. levonorgestrel and vs. placebo)\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "placebo|||placebo", "en": "Pharmacodynamic data show that even when taken immediately before ovulation is scheduled to occur (when LH has already started to rise), ulipristal acetate is able to postpone follicular rupture for at least 5 days in 78.6% of cases (p<0.005 vs. levonorgestrel and vs. placebo)", "ro": "Datele farmacodinamice arată că şi în cazul administrării imediat înainte de data aşteptată a ovulaţiei (când LH a început deja să crească), ulipristal acetat este capabil să amâne ruptura foliculară timp de cel puţin 5 zile în 78,6% din cazuri (p<0,005 faţă de levonorgestrel şi faţă de placebo) (vezi tabelul)." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If you wish to start or continue with a regular method of contraception after using this medicine, you can do so but you should also use condoms until your next period.\nRomanian: Dacă doriţi să începeţi sau să continuaţi o metodă de contracepţie regulată după utilizarea acestui medicament, puteţi face acest lucru, dar trebuie, de asemenea, să utilizaţi prezervative până la următoarea dumneavoastră menstruaţie.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If you wish to start or continue with a regular method of contraception after using this medicine, you can do so but you should also use condoms until your next period.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "If you wish to start or continue with a regular method of contraception after using this medicine, you can do so but you should also use condoms until your next period.", "ro": "Dacă doriţi să începeţi sau să continuaţi o metodă de contracepţie regulată după utilizarea acestui medicament, puteţi face acest lucru, dar trebuie, de asemenea, să utilizaţi prezervative până la următoarea dumneavoastră menstruaţie." } }
{ "translation": { "text": "Glossary:\n\"modulator\" -> \"modulator\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Ulipristal acetate is an orally-active synthetic selective progesterone receptor modulator which acts via high-affinity binding to the human progesterone receptor.\nRomanian: Ulipristal acetat este un modulator selectiv al receptorilor pentru progesteron, obţinut prin sinteză, activ pe cale orală, care acţionează prin legarea cu afinitate mare de receptorul uman pentru progesteron.", "en_prompt": "<|im_start|>user\nGlossary:\n\"modulator\" -> \"modulator\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Ulipristal acetate is an orally-active synthetic selective progesterone receptor modulator which acts via high-affinity binding to the human progesterone receptor.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "modulator|||modulator", "en": "Ulipristal acetate is an orally-active synthetic selective progesterone receptor modulator which acts via high-affinity binding to the human progesterone receptor.", "ro": "Ulipristal acetat este un modulator selectiv al receptorilor pentru progesteron, obţinut prin sinteză, activ pe cale orală, care acţionează prin legarea cu afinitate mare de receptorul uman pentru progesteron." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If you become pregnant despite taking this medicine, there is no evidence that it will affect your pregnancy.\nRomanian: Dacă rămâneţi gravidă în pofida faptului că luaţi acest medicament, nu există dovezi că vă va afecta sarcina.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If you become pregnant despite taking this medicine, there is no evidence that it will affect your pregnancy.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "If you become pregnant despite taking this medicine, there is no evidence that it will affect your pregnancy.", "ro": "Dacă rămâneţi gravidă în pofida faptului că luaţi acest medicament, nu există dovezi că vă va afecta sarcina." } }
{ "translation": { "text": "Glossary:\n\"doctor\" -> \"medic\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: When your period is late or when you have symptoms of pregnancy (heavy breasts, morning sickness) you should consult a doctor or other healthcare professional before taking the tablet.\nRomanian: Când menstruaţia dumneavoastră a întârziat sau când aveţi simptome de sarcină (sâni grei, greaţă de dimineaţă), trebuie să consultaţi un medic sau personalul medical înainte de a lua comprimatul.", "en_prompt": "<|im_start|>user\nGlossary:\n\"doctor\" -> \"medic\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: When your period is late or when you have symptoms of pregnancy (heavy breasts, morning sickness) you should consult a doctor or other healthcare professional before taking the tablet.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "doctor|||medic", "en": "When your period is late or when you have symptoms of pregnancy (heavy breasts, morning sickness) you should consult a doctor or other healthcare professional before taking the tablet.", "ro": "Când menstruaţia dumneavoastră a întârziat sau când aveţi simptome de sarcină (sâni grei, greaţă de dimineaţă), trebuie să consultaţi un medic sau personalul medical înainte de a lua comprimatul." } }
{ "translation": { "text": "Glossary:\n\"BMI\" -> \"IMC\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Limited and inconclusive data from clinical trials suggest a possible trend for a reduced contraceptive efficacy of ulipristal acetate with high body weight or BMI (see section 4.4).\nRomanian: Date limitate şi neconcludente din studiile clinice sugerează o posibilă tendinţă de reducere a eficacităţii contraceptive a ulipristal acetat în cazul unei greutăţi corporale ridicate sau al unui IMC ridicat (vezi pct. 4.4).", "en_prompt": "<|im_start|>user\nGlossary:\n\"BMI\" -> \"IMC\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Limited and inconclusive data from clinical trials suggest a possible trend for a reduced contraceptive efficacy of ulipristal acetate with high body weight or BMI (see section 4.4).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "BMI|||IMC", "en": "Limited and inconclusive data from clinical trials suggest a possible trend for a reduced contraceptive efficacy of ulipristal acetate with high body weight or BMI (see section 4.4).", "ro": "Date limitate şi neconcludente din studiile clinice sugerează o posibilă tendinţă de reducere a eficacităţii contraceptive a ulipristal acetat în cazul unei greutăţi corporale ridicate sau al unui IMC ridicat (vezi pct. 4.4)." } }
{ "translation": { "text": "Glossary:\n\"film-coated tablet\" -> \"comprimat filmat\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: ellaOne is available in a carton containing one blister of 1 film-coated tablet.\nRomanian: ellaOne este disponibil în cutie conţinând un blister cu 1 comprimat filmat.", "en_prompt": "<|im_start|>user\nGlossary:\n\"film-coated tablet\" -> \"comprimat filmat\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: ellaOne is available in a carton containing one blister of 1 film-coated tablet.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "film-coated tablet|||comprimat filmat", "en": "ellaOne is available in a carton containing one blister of 1 film-coated tablet.", "ro": "ellaOne este disponibil în cutie conţinând un blister cu 1 comprimat filmat." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu/.\nRomanian: Informaţii detaliate privind acest medicament sunt disponibile pe site-ul Agenţiei Europene pentru Medicamente: http://www.ema.europa.eu/.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu/.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu/.", "ro": "Informaţii detaliate privind acest medicament sunt disponibile pe site-ul Agenţiei Europene pentru Medicamente: http://www.ema.europa.eu/." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: This medicine may make regular hormonal contraceptives, like pills and patches, temporarily less effective.\nRomanian: Acest medicament poate scădea temporar eficacitatea contraceptivelor hormonale uzuale, precum comprimatele şi plasturii.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: This medicine may make regular hormonal contraceptives, like pills and patches, temporarily less effective.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "This medicine may make regular hormonal contraceptives, like pills and patches, temporarily less effective.", "ro": "Acest medicament poate scădea temporar eficacitatea contraceptivelor hormonale uzuale, precum comprimatele şi plasturii." } }
{ "translation": { "text": "Glossary:\n\"clearance\" -> \"clearance\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The terminal half-life of ulipristal acetate in plasma following a single 30 mg dose is estimated to 32.4 ± 6.3 hours, with a mean oral clearance (CL/F) of 76.8 ± 64.0 L/h.\nRomanian: Timpul de înjumătăţire plasmatică prin eliminare a ulipristal acetat după administrarea unei doze unice de 30 mg este estimat la 32,4 ± 6,3 ore, cu o medie a clearance-ului oral (CL/F) de 76,8 ± 64,0 l/oră.", "en_prompt": "<|im_start|>user\nGlossary:\n\"clearance\" -> \"clearance\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The terminal half-life of ulipristal acetate in plasma following a single 30 mg dose is estimated to 32.4 ± 6.3 hours, with a mean oral clearance (CL/F) of 76.8 ± 64.0 L/h.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "clearance|||clearance", "en": "The terminal half-life of ulipristal acetate in plasma following a single 30 mg dose is estimated to 32.4 ± 6.3 hours, with a mean oral clearance (CL/F) of 76.8 ± 64.0 L/h.", "ro": "Timpul de înjumătăţire plasmatică prin eliminare a ulipristal acetat după administrarea unei doze unice de 30 mg este estimat la 32,4 ± 6,3 ore, cu o medie a clearance-ului oral (CL/F) de 76,8 ± 64,0 l/oră." } }
{ "translation": { "text": "Glossaries:\n\"BMI\" -> \"IMC\"\n\"body mass index\" -> \"IMC\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Limited and inconclusive data suggest that there may be reduced efficacy of ellaOne with increasing body weight or body mass index (BMI) (see section 5.1).\nRomanian: Date limitate şi neconcludente sugerează că ar putea exista o eficacitate redusă a ellaOne în cazul unei greutăţi corporale mai mari sau al unui indice de masă corporală (IMC) mai mare (vezi pct.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"BMI\" -> \"IMC\"\n\"body mass index\" -> \"IMC\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Limited and inconclusive data suggest that there may be reduced efficacy of ellaOne with increasing body weight or body mass index (BMI) (see section 5.1).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "BMI|||IMC\tbody mass index|||IMC", "en": "Limited and inconclusive data suggest that there may be reduced efficacy of ellaOne with increasing body weight or body mass index (BMI) (see section 5.1).", "ro": "Date limitate şi neconcludente sugerează că ar putea exista o eficacitate redusă a ellaOne în cazul unei greutăţi corporale mai mari sau al unui indice de masă corporală (IMC) mai mare (vezi pct." } }
{ "translation": { "text": "Glossaries:\n\"ritonavir\" -> \"ritonavir\"\n\"treatment\" -> \"tratament\"\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: fosphenytoine, carbamazepine, oxcarbazepine and barbiturates) - medicines used to treat tuberculosis (for example, rifampicin, rifabutin) - a treatment for HIV (ritonavir, efavirenz, nevirapine) - a medicine used to treat fungal infections (griseofulvin) - herbal remedies containing St John's wort (Hypericum perforatum).\nRomanian: fosfenitoină, carbamazepină, oxcarbazepină şi barbiturice) - medicamente utilizate în tratamentul tuberculozei (de exemplu, rifampicină, rifabutină) - un tratament pentru infecţia cu virusul HIV (ritonavir, efavirenz, nevirapină) - un medicament utilizat în tratamentul infecţiilor fungice (griseofulvină) - remedii pe bază de plante care conțin sunătoare (Hypericum perforatum).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"ritonavir\" -> \"ritonavir\"\n\"treatment\" -> \"tratament\"\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: fosphenytoine, carbamazepine, oxcarbazepine and barbiturates) - medicines used to treat tuberculosis (for example, rifampicin, rifabutin) - a treatment for HIV (ritonavir, efavirenz, nevirapine) - a medicine used to treat fungal infections (griseofulvin) - herbal remedies containing St John's wort (Hypericum perforatum).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "ritonavir|||ritonavir\ttreatment|||tratament\tmedicine|||medicament", "en": "fosphenytoine, carbamazepine, oxcarbazepine and barbiturates) - medicines used to treat tuberculosis (for example, rifampicin, rifabutin) - a treatment for HIV (ritonavir, efavirenz, nevirapine) - a medicine used to treat fungal infections (griseofulvin) - herbal remedies containing St John's wort (Hypericum perforatum).", "ro": "fosfenitoină, carbamazepină, oxcarbazepină şi barbiturice) - medicamente utilizate în tratamentul tuberculozei (de exemplu, rifampicină, rifabutină) - un tratament pentru infecţia cu virusul HIV (ritonavir, efavirenz, nevirapină) - un medicament utilizat în tratamentul infecţiilor fungice (griseofulvină) - remedii pe bază de plante care conțin sunătoare (Hypericum perforatum)." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: You must take this medicine within 120 hours (5 days) of unprotected sex or contraceptive failure.\nRomanian: Trebuie să luaţi acest medicament în decurs de 120 de ore (5 zile) de la actul sexual neprotejat sau ineficienţa metodei contraceptive.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: You must take this medicine within 120 hours (5 days) of unprotected sex or contraceptive failure.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "You must take this medicine within 120 hours (5 days) of unprotected sex or contraceptive failure.", "ro": "Trebuie să luaţi acest medicament în decurs de 120 de ore (5 zile) de la actul sexual neprotejat sau ineficienţa metodei contraceptive." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If you have any further questions on the use of this medicine, ask your pharmacist, doctor or other healthcare professional.\nRomanian: Dacă aveţi orice întrebări suplimentare cu privire la acest medicament, adresaţi-vă farmacistului, medicului dumneavoastră sau personalului medical.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If you have any further questions on the use of this medicine, ask your pharmacist, doctor or other healthcare professional.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "If you have any further questions on the use of this medicine, ask your pharmacist, doctor or other healthcare professional.", "ro": "Dacă aveţi orice întrebări suplimentare cu privire la acest medicament, adresaţi-vă farmacistului, medicului dumneavoastră sau personalului medical." } }
{ "translation": { "text": "Glossary:\n\"film-coated tablet\" -> \"comprimat filmat\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: What ellaOne looks like and contents of the pack ellaOne is a golden film-coated tablet of shield shape (around 10.8 mm diameter) with “ella” engraved on both sides.\nRomanian: Cum arată ellaOne şi conţinutul ambalajului ellaOne este un comprimat filmat de culoare aurie, în formă de scut (diamentru aproximativ 10,8 mm) inscripţionat cu “ella” pe ambele feţe.", "en_prompt": "<|im_start|>user\nGlossary:\n\"film-coated tablet\" -> \"comprimat filmat\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: What ellaOne looks like and contents of the pack ellaOne is a golden film-coated tablet of shield shape (around 10.8 mm diameter) with “ella” engraved on both sides.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "film-coated tablet|||comprimat filmat", "en": "What ellaOne looks like and contents of the pack ellaOne is a golden film-coated tablet of shield shape (around 10.8 mm diameter) with “ella” engraved on both sides.", "ro": "Cum arată ellaOne şi conţinutul ambalajului ellaOne este un comprimat filmat de culoare aurie, în formă de scut (diamentru aproximativ 10,8 mm) inscripţionat cu “ella” pe ambele feţe." } }
{ "translation": { "text": "Glossary:\n\"test\" -> \"test\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If you miss your period and experience such symptoms after taking ellaOne, you should do a pregnancy test (see section 2 “Pregnancy, breastfeeding and fertility”).\nRomanian: Dacă menstruaţia nu vine şi prezentaţi astfel de simptome după ce aţi luat ellaOne, trebuie să efectuaţi un test de sarcină (vezi pct. 2 „Sarcina, alăptarea şi fertilitatea”).", "en_prompt": "<|im_start|>user\nGlossary:\n\"test\" -> \"test\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If you miss your period and experience such symptoms after taking ellaOne, you should do a pregnancy test (see section 2 “Pregnancy, breastfeeding and fertility”).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "test|||test", "en": "If you miss your period and experience such symptoms after taking ellaOne, you should do a pregnancy test (see section 2 “Pregnancy, breastfeeding and fertility”).", "ro": "Dacă menstruaţia nu vine şi prezentaţi astfel de simptome după ce aţi luat ellaOne, trebuie să efectuaţi un test de sarcină (vezi pct. 2 „Sarcina, alăptarea şi fertilitatea”)." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Talk to your pharmacist, doctor or other healthcare professional before taking this medicine - if your period is late or you have symptoms of pregnancy (heavy breasts, morning sickness), as you may already be pregnant (see section “Pregnancy, breast-feeding and fertility”); - if you suffer from severe asthma; - if you suffer from severe liver disease.\nRomanian: Înainte să luaţi acest medicament, adresaţi-vă farmacistului, medicului dumneavoastră sau personalului medical - dacă menstruaţia dumneavoastră a întârziat sau aveţi simptome de sarcină (sâni grei, greaţă de dimineaţă), deoarece este posibil să fiţi deja gravidă (vezi pct. „Sarcina, alăptarea şi fertilitatea”);", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Talk to your pharmacist, doctor or other healthcare professional before taking this medicine - if your period is late or you have symptoms of pregnancy (heavy breasts, morning sickness), as you may already be pregnant (see section “Pregnancy, breast-feeding and fertility”); - if you suffer from severe asthma; - if you suffer from severe liver disease.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "Talk to your pharmacist, doctor or other healthcare professional before taking this medicine - if your period is late or you have symptoms of pregnancy (heavy breasts, morning sickness), as you may already be pregnant (see section “Pregnancy, breast-feeding and fertility”); - if you suffer from severe asthma; - if you suffer from severe liver disease.", "ro": "Înainte să luaţi acest medicament, adresaţi-vă farmacistului, medicului dumneavoastră sau personalului medical - dacă menstruaţia dumneavoastră a întârziat sau aveţi simptome de sarcină (sâni grei, greaţă de dimineaţă), deoarece este posibil să fiţi deja gravidă (vezi pct. „Sarcina, alăptarea şi fertilitatea”);" } }
{ "translation": { "text": "Glossary:\n\"ritonavir\" -> \"ritonavir\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Concomitant use of ellaOne with CYP3A4 inducers is not recommended due to interaction (e.g. barbiturates (including primidone and phenobarbital), phenytoin, fosphenytoin, carbamazepine, oxcarbazepine, herbal medicinal products containing Hypericum perforatum (St. John's wort), rifampicin, rifabutin, griseofulvin, efavirenz, nevirapine and long term use of ritonavir).\nRomanian: Utilizarea concomitentă a ellaOne cu inductori ai izoenzimei CYP3A4 nu este recomandată din cauza interacţiunii (de exemplu, barbiturice (inclusiv primidonă și fenobarbital), fenitoină, fosfenitoină, carbamazepină, oxcarbazepină, medicamente pe bază de plante care conţin Hypericum perforatum (sunătoare), rifampicină, rifabutină, griseofulvină, efavirenz, nevirapină și utilizarea îndelungată de ritonavir).", "en_prompt": "<|im_start|>user\nGlossary:\n\"ritonavir\" -> \"ritonavir\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Concomitant use of ellaOne with CYP3A4 inducers is not recommended due to interaction (e.g. barbiturates (including primidone and phenobarbital), phenytoin, fosphenytoin, carbamazepine, oxcarbazepine, herbal medicinal products containing Hypericum perforatum (St. John's wort), rifampicin, rifabutin, griseofulvin, efavirenz, nevirapine and long term use of ritonavir).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "ritonavir|||ritonavir", "en": "Concomitant use of ellaOne with CYP3A4 inducers is not recommended due to interaction (e.g. barbiturates (including primidone and phenobarbital), phenytoin, fosphenytoin, carbamazepine, oxcarbazepine, herbal medicinal products containing Hypericum perforatum (St. John's wort), rifampicin, rifabutin, griseofulvin, efavirenz, nevirapine and long term use of ritonavir).", "ro": "Utilizarea concomitentă a ellaOne cu inductori ai izoenzimei CYP3A4 nu este recomandată din cauza interacţiunii (de exemplu, barbiturice (inclusiv primidonă și fenobarbital), fenitoină, fosfenitoină, carbamazepină, oxcarbazepină, medicamente pe bază de plante care conţin Hypericum perforatum (sunătoare), rifampicină, rifabutină, griseofulvină, efavirenz, nevirapină și utilizarea îndelungată de ritonavir)." } }
{ "translation": { "text": "Glossary:\n\"test\" -> \"test\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If you miss your period and experience such symptoms after taking ellaOne, you should do a pregnancy test (See section “Pregnancy, breastfeeding and fertility”).\nRomanian: Dacă menstruaţia nu vine şi prezentaţi astfel de simptome după ce aţi luat ellaOne, trebuie să efectuaţi un test de sarcină (Vezi pct. „Sarcina, alăptarea şi fertilitatea”).", "en_prompt": "<|im_start|>user\nGlossary:\n\"test\" -> \"test\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If you miss your period and experience such symptoms after taking ellaOne, you should do a pregnancy test (See section “Pregnancy, breastfeeding and fertility”).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "test|||test", "en": "If you miss your period and experience such symptoms after taking ellaOne, you should do a pregnancy test (See section “Pregnancy, breastfeeding and fertility”).", "ro": "Dacă menstruaţia nu vine şi prezentaţi astfel de simptome după ce aţi luat ellaOne, trebuie să efectuaţi un test de sarcină (Vezi pct. „Sarcina, alăptarea şi fertilitatea”)." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If you are currently taking hormonal contraception, continue to use it as usual after taking this medicine, but be sure to use condoms every time you have sex until your next period.\nRomanian: Dacă luaţi în prezent contracepţie hormonală, continuaţi să o utilizaţi ca de obicei după ce luaţi acest medicament, dar aveţi grijă să utilizaţi prezervative de fiecare dată când întreţineţi raporturi sexuale până la următoarea dumneavoastră menstruaţie.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If you are currently taking hormonal contraception, continue to use it as usual after taking this medicine, but be sure to use condoms every time you have sex until your next period.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "If you are currently taking hormonal contraception, continue to use it as usual after taking this medicine, but be sure to use condoms every time you have sex until your next period.", "ro": "Dacă luaţi în prezent contracepţie hormonală, continuaţi să o utilizaţi ca de obicei după ce luaţi acest medicament, dar aveţi grijă să utilizaţi prezervative de fiecare dată când întreţineţi raporturi sexuale până la următoarea dumneavoastră menstruaţie." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If you become pregnant despite taking this medicine, it is important that you see your doctor.\nRomanian: Dacă rămâneţi gravidă în pofida faptului că aţi luat acest medicament, este important să vă consultaţi medicul.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If you become pregnant despite taking this medicine, it is important that you see your doctor.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "If you become pregnant despite taking this medicine, it is important that you see your doctor.", "ro": "Dacă rămâneţi gravidă în pofida faptului că aţi luat acest medicament, este important să vă consultaţi medicul." } }
{ "translation": { "text": "Glossary:\n\"diarrhoea\" -> \"diaree\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: - diarrhoea, heartburn, wind, dry mouth - unusual or irregular vaginal bleeding, heavy/prolonged periods premenstrual syndrome, vaginal irritation or discharge, lesser or greater sex drive - hot flushes - appetite changes, emotional disorders, anxiety, agitation, trouble sleeping, sleepiness, migraine visual disturbances - influenza - acne, skin lesions, itching - fever, chills, malaise\nRomanian: - diaree, senzaţie de arsură în capul pieptului, flatulenţă, uscăciune a gurii - sângerări vaginale neobişnuite sau neregulate, menstruaţie abundentă/prelungită, sindrom premenstrual, iritaţie sau secreţii vaginale, apetit sexual scăzut sau crescut - bufeuri - modificări ale poftei de mâncare, tulburări emoţionale, anxietate, agitaţie, tulburări ale somnului,", "en_prompt": "<|im_start|>user\nGlossary:\n\"diarrhoea\" -> \"diaree\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: - diarrhoea, heartburn, wind, dry mouth - unusual or irregular vaginal bleeding, heavy/prolonged periods premenstrual syndrome, vaginal irritation or discharge, lesser or greater sex drive - hot flushes - appetite changes, emotional disorders, anxiety, agitation, trouble sleeping, sleepiness, migraine visual disturbances - influenza - acne, skin lesions, itching - fever, chills, malaise\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "diarrhoea|||diaree", "en": "- diarrhoea, heartburn, wind, dry mouth - unusual or irregular vaginal bleeding, heavy/prolonged periods premenstrual syndrome, vaginal irritation or discharge, lesser or greater sex drive - hot flushes - appetite changes, emotional disorders, anxiety, agitation, trouble sleeping, sleepiness, migraine visual disturbances - influenza - acne, skin lesions, itching - fever, chills, malaise", "ro": "- diaree, senzaţie de arsură în capul pieptului, flatulenţă, uscăciune a gurii - sângerări vaginale neobişnuite sau neregulate, menstruaţie abundentă/prelungită, sindrom premenstrual, iritaţie sau secreţii vaginale, apetit sexual scăzut sau crescut - bufeuri - modificări ale poftei de mâncare, tulburări emoţionale, anxietate, agitaţie, tulburări ale somnului," } }
{ "translation": { "text": "Glossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The treatment consists of one tablet to be taken orally as soon as possible, but no later than 120 hours (5 days) after unprotected intercourse or contraceptive failure.\nRomanian: Acest tratament constă într-un comprimat cu administrare orală, ce se va administra cât mai repede cu putinţă, dar nu mai târziu de 120 de ore (5 zile) de la contactul sexual neprotejat sau nefuncţionarea metodei contraceptive utilizate.", "en_prompt": "<|im_start|>user\nGlossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The treatment consists of one tablet to be taken orally as soon as possible, but no later than 120 hours (5 days) after unprotected intercourse or contraceptive failure.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratament", "en": "The treatment consists of one tablet to be taken orally as soon as possible, but no later than 120 hours (5 days) after unprotected intercourse or contraceptive failure.", "ro": "Acest tratament constă într-un comprimat cu administrare orală, ce se va administra cât mai repede cu putinţă, dar nu mai târziu de 120 de ore (5 zile) de la contactul sexual neprotejat sau nefuncţionarea metodei contraceptive utilizate." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The effect of breast-feeding your baby in the week after taking this medicine is not known.\nRomanian: Nu se cunoaşte efectul alăptării în săptămâna următoarea administrării acestui medicament.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The effect of breast-feeding your baby in the week after taking this medicine is not known.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "The effect of breast-feeding your baby in the week after taking this medicine is not known.", "ro": "Nu se cunoaşte efectul alăptării în săptămâna următoarea administrării acestui medicament." } }
{ "translation": { "text": "Glossary:\n\"film-coated tablet\" -> \"comprimat filmat\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: ellaOne 30 mg film-coated tablet Ulipristal acetate\nRomanian: ellaOne 30 mg comprimat filmat Ulipristal acetat", "en_prompt": "<|im_start|>user\nGlossary:\n\"film-coated tablet\" -> \"comprimat filmat\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: ellaOne 30 mg film-coated tablet Ulipristal acetate\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "film-coated tablet|||comprimat filmat", "en": "ellaOne 30 mg film-coated tablet Ulipristal acetate", "ro": "ellaOne 30 mg comprimat filmat Ulipristal acetat" } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If you have unprotected sex after taking this medicine, it will not stop you from becoming pregnant.\nRomanian: Dacă aveţi raporturi sexuale neprotejate după ce aţi luat acest medicament, medicamentul nu va preveni o eventuală sarcină.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If you have unprotected sex after taking this medicine, it will not stop you from becoming pregnant.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "If you have unprotected sex after taking this medicine, it will not stop you from becoming pregnant.", "ro": "Dacă aveţi raporturi sexuale neprotejate după ce aţi luat acest medicament, medicamentul nu va preveni o eventuală sarcină." } }
{ "translation": { "text": "Glossary:\n\"film-coated tablet\" -> \"comprimat filmat\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: 1 film-coated tablet.\nRomanian: FORMA FARMACEUTICĂ ŞI CONŢINUTUL 1 comprimat filmat.", "en_prompt": "<|im_start|>user\nGlossary:\n\"film-coated tablet\" -> \"comprimat filmat\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: 1 film-coated tablet.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "film-coated tablet|||comprimat filmat", "en": "1 film-coated tablet.", "ro": "FORMA FARMACEUTICĂ ŞI CONŢINUTUL 1 comprimat filmat." } }
{ "translation": { "text": "Glossary:\n\"sensitivity\" -> \"sensibilitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: - genital pain or itching, pain during sex, rupture of an ovarian cyst, unusually light period - loss of concentration, vertigo, shaking, disorientation, fainting - unusual sensation in eye, red eye, sensitivity to light - dry throat, disturbance in taste - hives (itchy rash), feeling thirsty\nRomanian: menstruaţie neobişnuit de redusă cantitativ - pierderea capacităţii de concentrare, vertij, tremurături, dezorientare, leşin - senzaţie neobişnuită la nivelul ochilor, ochi roşii, sensibilitate la lumină - gât uscat, tulburări ale simţului gustativ - urticarie (erupţie pe piele cu mâncărime), senzaţie de sete", "en_prompt": "<|im_start|>user\nGlossary:\n\"sensitivity\" -> \"sensibilitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: - genital pain or itching, pain during sex, rupture of an ovarian cyst, unusually light period - loss of concentration, vertigo, shaking, disorientation, fainting - unusual sensation in eye, red eye, sensitivity to light - dry throat, disturbance in taste - hives (itchy rash), feeling thirsty\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "sensitivity|||sensibilitate", "en": "- genital pain or itching, pain during sex, rupture of an ovarian cyst, unusually light period - loss of concentration, vertigo, shaking, disorientation, fainting - unusual sensation in eye, red eye, sensitivity to light - dry throat, disturbance in taste - hives (itchy rash), feeling thirsty", "ro": "menstruaţie neobişnuit de redusă cantitativ - pierderea capacităţii de concentrare, vertij, tremurături, dezorientare, leşin - senzaţie neobişnuită la nivelul ochilor, ochi roşii, sensibilitate la lumină - gât uscat, tulburări ale simţului gustativ - urticarie (erupţie pe piele cu mâncărime), senzaţie de sete" } }
{ "translation": { "text": "Glossary:\n\"package leaflet\" -> \"prospect\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: QR code linking to package leaflet to be included Package leaflet online at\nRomanian: Se va include linkul cu codul QR către prospect", "en_prompt": "<|im_start|>user\nGlossary:\n\"package leaflet\" -> \"prospect\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: QR code linking to package leaflet to be included Package leaflet online at\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "package leaflet|||prospect", "en": "QR code linking to package leaflet to be included Package leaflet online at", "ro": "Se va include linkul cu codul QR către prospect" } }
{ "translation": { "text": "Glossary:\n\"film-coated tablet\" -> \"comprimat filmat\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Package leaflet: Information for the user ellaOne 30 mg film-coated tablet\nRomanian: Prospect: Informaţii pentru utilizator ellaOne 30 mg comprimat filmat Ulipristal acetat", "en_prompt": "<|im_start|>user\nGlossary:\n\"film-coated tablet\" -> \"comprimat filmat\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Package leaflet: Information for the user ellaOne 30 mg film-coated tablet\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "film-coated tablet|||comprimat filmat", "en": "Package leaflet: Information for the user ellaOne 30 mg film-coated tablet", "ro": "Prospect: Informaţii pentru utilizator ellaOne 30 mg comprimat filmat Ulipristal acetat" } }
{ "translation": { "text": "Glossary:\n\"film-coated tablet\" -> \"comprimat filmat\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: ellaOne film-coated tablet\nRomanian: INFORMAŢII ÎN BRAILLE ellaOne comprimat filmat", "en_prompt": "<|im_start|>user\nGlossary:\n\"film-coated tablet\" -> \"comprimat filmat\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: ellaOne film-coated tablet\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "film-coated tablet|||comprimat filmat", "en": "ellaOne film-coated tablet", "ro": "INFORMAŢII ÎN BRAILLE ellaOne comprimat filmat" } }
{ "translation": { "text": "Glossary:\n\"film-coated tablet\" -> \"comprimat filmat\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Each film-coated tablet contains 30 mg ulipristal acetate\nRomanian: Fiecare comprimat filmat conţine ulipristal acetat", "en_prompt": "<|im_start|>user\nGlossary:\n\"film-coated tablet\" -> \"comprimat filmat\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Each film-coated tablet contains 30 mg ulipristal acetate\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "film-coated tablet|||comprimat filmat", "en": "Each film-coated tablet contains 30 mg ulipristal acetate", "ro": "Fiecare comprimat filmat conţine ulipristal acetat" } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: There have been no reports of harmful effects from taking a higher dose than recommended of this medicine However do ask your pharmacist, doctor or other healthcare professional for advice.\nRomanian: Nu s-au raportat reacţii adverse ca urmare a administrării unei doze mai mari din acest medicament decât cea recomandată.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: There have been no reports of harmful effects from taking a higher dose than recommended of this medicine However do ask your pharmacist, doctor or other healthcare professional for advice.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "There have been no reports of harmful effects from taking a higher dose than recommended of this medicine However do ask your pharmacist, doctor or other healthcare professional for advice.", "ro": "Nu s-au raportat reacţii adverse ca urmare a administrării unei doze mai mari din acest medicament decât cea recomandată." } }
{ "translation": { "text": "Glossary:\n\"film-coated tablet\" -> \"comprimat filmat\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: ellaOne 30 mg film-coated tablet\nRomanian: DENUMIREA COMERCIALĂ A MEDICAMENTULUI ellaOne 30 mg comprimat filmat", "en_prompt": "<|im_start|>user\nGlossary:\n\"film-coated tablet\" -> \"comprimat filmat\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: ellaOne 30 mg film-coated tablet\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "film-coated tablet|||comprimat filmat", "en": "ellaOne 30 mg film-coated tablet", "ro": "DENUMIREA COMERCIALĂ A MEDICAMENTULUI ellaOne 30 mg comprimat filmat" } }
{ "translation": { "text": "Glossary:\n\"active substance\" -> \"substanță activă\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: (Two medicines are bioequivalent when they produce the same levels of the active substance in the body.)\nRomanian: (Două medicamente sunt considerate bioechivalente dacă produc în organism aceleași niveluri de substanță activă.", "en_prompt": "<|im_start|>user\nGlossary:\n\"active substance\" -> \"substanță activă\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: (Two medicines are bioequivalent when they produce the same levels of the active substance in the body.)\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "active substance|||substanță activă", "en": "(Two medicines are bioequivalent when they produce the same levels of the active substance in the body.)", "ro": "(Două medicamente sunt considerate bioechivalente dacă produc în organism aceleași niveluri de substanță activă." } }
{ "translation": { "text": "Glossaries:\n\"CHMP\" -> \"Comitetul pentru medicamente de uz uman\"\n\"Committee for Medicinal Products for Human Use\" -> \"Comitetul pentru medicamente de uz uman\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: On 6 June 2016, Sun Pharmaceutical Industries Europe B.V. officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Docetaxel Sun, for the treatment of various types of cancer.\nRomanian: La data de 6 iunie 2016, Sun Pharmaceutical Industries Europe B.V. a informat oficial Comitetul pentru medicamente de uz uman (CHMP) că dorește să își retragă cererea de autorizare de introducere pe piață pentru Docetaxel Sun, pentru tratarea mai multor tipuri de cancer.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"CHMP\" -> \"Comitetul pentru medicamente de uz uman\"\n\"Committee for Medicinal Products for Human Use\" -> \"Comitetul pentru medicamente de uz uman\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: On 6 June 2016, Sun Pharmaceutical Industries Europe B.V. officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Docetaxel Sun, for the treatment of various types of cancer.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "CHMP|||Comitetul pentru medicamente de uz uman\tCommittee for Medicinal Products for Human Use|||Comitetul pentru medicamente de uz uman", "en": "On 6 June 2016, Sun Pharmaceutical Industries Europe B.V. officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Docetaxel Sun, for the treatment of various types of cancer.", "ro": "La data de 6 iunie 2016, Sun Pharmaceutical Industries Europe B.V. a informat oficial Comitetul pentru medicamente de uz uman (CHMP) că dorește să își retragă cererea de autorizare de introducere pe piață pentru Docetaxel Sun, pentru tratarea mai multor tipuri de cancer." } }
{ "translation": { "text": "Glossaries:\n\"generic\" -> \"medicament generic\"\n\"medicine\" -> \"medicament\"\n\"generic medicine\" -> \"medicament generic\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Docetaxel Sun was developed as a ‘generic medicine'.\nRomanian: Docetaxel Sun a fost dezvoltat ca „medicament generic”.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"generic\" -> \"medicament generic\"\n\"medicine\" -> \"medicament\"\n\"generic medicine\" -> \"medicament generic\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Docetaxel Sun was developed as a ‘generic medicine'.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "generic|||medicament generic\tmedicine|||medicament\tgeneric medicine|||medicament generic", "en": "Docetaxel Sun was developed as a ‘generic medicine'.", "ro": "Docetaxel Sun a fost dezvoltat ca „medicament generic”." } }
{ "translation": { "text": "Glossaries:\n\"generic\" -> \"medicament generic\"\n\"medicine\" -> \"medicament\"\n\"generic medicine\" -> \"medicament generic\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Because Docetaxel Sun was developed as a generic medicine, the company presented the results of studies from the literature, and studies to show the quality of the medicine.\nRomanian: Deoarece Docetaxel Sun a fost dezvoltat ca medicament generic, compania a prezentat rezultatele studiilor din literatura de specialitate și ale studiilor efectuate pentru a demonstra calitatea medicamentului.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"generic\" -> \"medicament generic\"\n\"medicine\" -> \"medicament\"\n\"generic medicine\" -> \"medicament generic\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Because Docetaxel Sun was developed as a generic medicine, the company presented the results of studies from the literature, and studies to show the quality of the medicine.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "generic|||medicament generic\tmedicine|||medicament\tgeneric medicine|||medicament generic", "en": "Because Docetaxel Sun was developed as a generic medicine, the company presented the results of studies from the literature, and studies to show the quality of the medicine.", "ro": "Deoarece Docetaxel Sun a fost dezvoltat ca medicament generic, compania a prezentat rezultatele studiilor din literatura de specialitate și ale studiilor efectuate pentru a demonstra calitatea medicamentului." } }
{ "translation": { "text": "Glossaries:\n\"medicine\" -> \"medicament\"\n\"reference medicine\" -> \"medicament de referință\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: This means that Docetaxel Sun was intended to be similar to a ‘reference medicine' already authorised in the European Union called Taxotere.\nRomanian: Aceasta înseamnă că Docetaxel Sun trebuia să fie similar cu un „medicament de referință” deja autorizat în Uniunea Europeană (UE), denumit Taxotere.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"medicine\" -> \"medicament\"\n\"reference medicine\" -> \"medicament de referință\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: This means that Docetaxel Sun was intended to be similar to a ‘reference medicine' already authorised in the European Union called Taxotere.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament\treference medicine|||medicament de referință", "en": "This means that Docetaxel Sun was intended to be similar to a ‘reference medicine' already authorised in the European Union called Taxotere.", "ro": "Aceasta înseamnă că Docetaxel Sun trebuia să fie similar cu un „medicament de referință” deja autorizat în Uniunea Europeană (UE), denumit Taxotere." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Docetaxel Sun is a medicine that contains the active substance docetaxel.\nRomanian: Docetaxel Sun este un medicament care conține substanța activă docetaxel.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Docetaxel Sun is a medicine that contains the active substance docetaxel.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "Docetaxel Sun is a medicine that contains the active substance docetaxel.", "ro": "Docetaxel Sun este un medicament care conține substanța activă docetaxel." } }
{ "translation": { "text": "Glossaries:\n\"generic\" -> \"medicament generic\"\n\"medicine\" -> \"medicament\"\n\"infusion\" -> \"perfuzie\"\n\"active substance\" -> \"substanță activă\"\n\"generic medicine\" -> \"medicament generic\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: No further studies were carried out because Docetaxel Sun is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Taxotere.\nRomanian: Nu au fost efectuate studii suplimentare, deoarece Docetaxel Sun este un medicament generic administrat prin perfuzie și conține aceeași substanță activă ca medicamentul de referință, Taxotere.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"generic\" -> \"medicament generic\"\n\"medicine\" -> \"medicament\"\n\"infusion\" -> \"perfuzie\"\n\"active substance\" -> \"substanță activă\"\n\"generic medicine\" -> \"medicament generic\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: No further studies were carried out because Docetaxel Sun is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Taxotere.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "generic|||medicament generic\tmedicine|||medicament\tinfusion|||perfuzie\tactive substance|||substanță activă\tgeneric medicine|||medicament generic", "en": "No further studies were carried out because Docetaxel Sun is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Taxotere.", "ro": "Nu au fost efectuate studii suplimentare, deoarece Docetaxel Sun este un medicament generic administrat prin perfuzie și conține aceeași substanță activă ca medicamentul de referință, Taxotere." } }
{ "translation": { "text": "Glossary:\n\"solution for infusion\" -> \"soluție perfuzabilă\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: It was to be available as a concentrate to make a solution for infusion (drip) into a vein.\nRomanian: Medicamentul urma să fie disponibil sub formă de concentrat din care se prepară o soluție perfuzabilă (picurare în venă).", "en_prompt": "<|im_start|>user\nGlossary:\n\"solution for infusion\" -> \"soluție perfuzabilă\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: It was to be available as a concentrate to make a solution for infusion (drip) into a vein.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "solution for infusion|||soluție perfuzabilă", "en": "It was to be available as a concentrate to make a solution for infusion (drip) into a vein.", "ro": "Medicamentul urma să fie disponibil sub formă de concentrat din care se prepară o soluție perfuzabilă (picurare în venă)." } }
{ "translation": { "text": "Glossary:\n\"bioequivalence\" -> \"bioechivalență\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: However, solutions containing micelles may behave differently from one another, and the CHMP considered that more information was needed to show that the Docetaxel Sun solution was similar enough in its composition and behaviour to Taxotere solution to allow a bioequivalence study to be omitted.\nRomanian: Cu toate acestea, soluțiile care conțin micele pot prezenta un comportament diferit una față de cealaltă și CHMP a considerat că, pentru a permite omiterea studiului de bioechivalență, sunt necesare mai multe informații care să demonstreze că soluția obținută din Docetaxel Sun este suficient de asemănătoare cu soluția obținută din Taxotere.", "en_prompt": "<|im_start|>user\nGlossary:\n\"bioequivalence\" -> \"bioechivalență\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: However, solutions containing micelles may behave differently from one another, and the CHMP considered that more information was needed to show that the Docetaxel Sun solution was similar enough in its composition and behaviour to Taxotere solution to allow a bioequivalence study to be omitted.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "bioequivalence|||bioechivalență", "en": "However, solutions containing micelles may behave differently from one another, and the CHMP considered that more information was needed to show that the Docetaxel Sun solution was similar enough in its composition and behaviour to Taxotere solution to allow a bioequivalence study to be omitted.", "ro": "Cu toate acestea, soluțiile care conțin micele pot prezenta un comportament diferit una față de cealaltă și CHMP a considerat că, pentru a permite omiterea studiului de bioechivalență, sunt necesare mai multe informații care să demonstreze că soluția obținută din Docetaxel Sun este suficient de asemănătoare cu soluția obținută din Taxotere." } }
{ "translation": { "text": "Glossary:\n\"EMA\" -> \"EMA\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Withdrawal of the marketing authorisation application for Docetaxel Sun (docetaxel) EMA/396891/2016\nRomanian: EMA/396891/2016", "en_prompt": "<|im_start|>user\nGlossary:\n\"EMA\" -> \"EMA\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Withdrawal of the marketing authorisation application for Docetaxel Sun (docetaxel) EMA/396891/2016\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "EMA|||EMA", "en": "Withdrawal of the marketing authorisation application for Docetaxel Sun (docetaxel) EMA/396891/2016", "ro": "EMA/396891/2016" } }
{ "translation": { "text": "Glossary:\n\"active substance\" -> \"substanță activă\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Two medicines are bioequivalent when they produce the same levels of the active substance in the body.\nRomanian: Două medicamente sunt considerate bioechivalente dacă produc aceleași niveluri de substanță activă în organism.", "en_prompt": "<|im_start|>user\nGlossary:\n\"active substance\" -> \"substanță activă\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Two medicines are bioequivalent when they produce the same levels of the active substance in the body.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "active substance|||substanță activă", "en": "Two medicines are bioequivalent when they produce the same levels of the active substance in the body.", "ro": "Două medicamente sunt considerate bioechivalente dacă produc aceleași niveluri de substanță activă în organism." } }
{ "translation": { "text": "Glossary:\n\"compassionate use\" -> \"uz compasional\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: What consequences does this withdrawal have for patients in clinical trials or compassionate use programmes?\nRomanian: Care sunt consecințele retragerii cererii pentru pacienții implicați în studii clinice sau în programe de uz compasional?", "en_prompt": "<|im_start|>user\nGlossary:\n\"compassionate use\" -> \"uz compasional\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: What consequences does this withdrawal have for patients in clinical trials or compassionate use programmes?\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "compassionate use|||uz compasional", "en": "What consequences does this withdrawal have for patients in clinical trials or compassionate use programmes?", "ro": "Care sunt consecințele retragerii cererii pentru pacienții implicați în studii clinice sau în programe de uz compasional?" } }
{ "translation": { "text": "Glossaries:\n\"generic\" -> \"medicament generic\"\n\"medicine\" -> \"medicament\"\n\"generic medicine\" -> \"medicament generic\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Aripiprazole Mylan was developed as a ‘generic medicine'.\nRomanian: Aripiprazole Mylan a fost dezvoltat ca „medicament generic”.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"generic\" -> \"medicament generic\"\n\"medicine\" -> \"medicament\"\n\"generic medicine\" -> \"medicament generic\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Aripiprazole Mylan was developed as a ‘generic medicine'.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "generic|||medicament generic\tmedicine|||medicament\tgeneric medicine|||medicament generic", "en": "Aripiprazole Mylan was developed as a ‘generic medicine'.", "ro": "Aripiprazole Mylan a fost dezvoltat ca „medicament generic”." } }
{ "translation": { "text": "Glossary:\n\"bioequivalence\" -> \"bioechivalență\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The biowaiver removes the need to repeat bioequivalence studies for all the other strengths of Aripiprazole Mylan tablets.\nRomanian: Acordarea bioderogării elimină necesitatea repetării studiilor de bioechivalență pentru toate celelalte concentrații ale comprimatelor de Aripiprazole Mylan.", "en_prompt": "<|im_start|>user\nGlossary:\n\"bioequivalence\" -> \"bioechivalență\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The biowaiver removes the need to repeat bioequivalence studies for all the other strengths of Aripiprazole Mylan tablets.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "bioequivalence|||bioechivalență", "en": "The biowaiver removes the need to repeat bioequivalence studies for all the other strengths of Aripiprazole Mylan tablets.", "ro": "Acordarea bioderogării elimină necesitatea repetării studiilor de bioechivalență pentru toate celelalte concentrații ale comprimatelor de Aripiprazole Mylan." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: It was also expected to be used to treat moderate to severe manic episodes and to prevent new manic episodes in adults with bipolar I disorder who have responded to the medicine in the past, and for up to 12 weeks to treat moderate to severe manic episodes in patients aged 13 years or over with bipolar I disorder.\nRomanian: De asemenea, medicamentul ar fi trebuit să se utilizeze pentru tratarea episoadelor maniacale moderate până la severe și pentru prevenirea episoadelor maniacale noi la adulții cu tulburare bipolară de tip I care au răspuns anterior la acest medicament; de asemenea, ar fi trebuit să se utilizeze timp de până la 12 săptămâni pentru tratarea episoadelor maniacale moderate până la severe la pacienții cu vârsta de cel puțin 13 ani diagnosticați cu tulburare bipolară de tip I.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: It was also expected to be used to treat moderate to severe manic episodes and to prevent new manic episodes in adults with bipolar I disorder who have responded to the medicine in the past, and for up to 12 weeks to treat moderate to severe manic episodes in patients aged 13 years or over with bipolar I disorder.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "It was also expected to be used to treat moderate to severe manic episodes and to prevent new manic episodes in adults with bipolar I disorder who have responded to the medicine in the past, and for up to 12 weeks to treat moderate to severe manic episodes in patients aged 13 years or over with bipolar I disorder.", "ro": "De asemenea, medicamentul ar fi trebuit să se utilizeze pentru tratarea episoadelor maniacale moderate până la severe și pentru prevenirea episoadelor maniacale noi la adulții cu tulburare bipolară de tip I care au răspuns anterior la acest medicament; de asemenea, ar fi trebuit să se utilizeze timp de până la 12 săptămâni pentru tratarea episoadelor maniacale moderate până la severe la pacienții cu vârsta de cel puțin 13 ani diagnosticați cu tulburare bipolară de tip I." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Aripiprazole Mylan is a medicine that contains the active substance aripiprazole.\nRomanian: Aripiprazole Mylan este un medicament care conține substanța activă aripiprazol.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Aripiprazole Mylan is a medicine that contains the active substance aripiprazole.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "Aripiprazole Mylan is a medicine that contains the active substance aripiprazole.", "ro": "Aripiprazole Mylan este un medicament care conține substanța activă aripiprazol." } }
{ "translation": { "text": "Glossaries:\n\"generic\" -> \"medicament generic\"\n\"medicine\" -> \"medicament\"\n\"generic medicine\" -> \"medicament generic\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Because Aripiprazole Mylan is a generic medicine, the company had presented results of studies in volunteers to show that Aripiprazole Mylan 10-mg tablet and the 10-mg orodispersible tablet were bioequivalent to the corresponding tablets of the reference medicine, Abilify.\nRomanian: Având în vedere că Aripiprazole Mylan este un medicament generic, compania a prezentat rezultatele studiilor efectuate pe voluntari pentru a demonstra că Aripiprazole Mylan comprimate de 10 mg și comprimate orodispersabile de 10 mg sunt bioechivalente cu comprimatele corespunzătoare ale medicamentului de referință, Abilify.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"generic\" -> \"medicament generic\"\n\"medicine\" -> \"medicament\"\n\"generic medicine\" -> \"medicament generic\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Because Aripiprazole Mylan is a generic medicine, the company had presented results of studies in volunteers to show that Aripiprazole Mylan 10-mg tablet and the 10-mg orodispersible tablet were bioequivalent to the corresponding tablets of the reference medicine, Abilify.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "generic|||medicament generic\tmedicine|||medicament\tgeneric medicine|||medicament generic", "en": "Because Aripiprazole Mylan is a generic medicine, the company had presented results of studies in volunteers to show that Aripiprazole Mylan 10-mg tablet and the 10-mg orodispersible tablet were bioequivalent to the corresponding tablets of the reference medicine, Abilify.", "ro": "Având în vedere că Aripiprazole Mylan este un medicament generic, compania a prezentat rezultatele studiilor efectuate pe voluntari pentru a demonstra că Aripiprazole Mylan comprimate de 10 mg și comprimate orodispersabile de 10 mg sunt bioechivalente cu comprimatele corespunzătoare ale medicamentului de referință, Abilify." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The active substance in Aripiprazole Mylan, aripiprazole, is an antipsychotic medicine.\nRomanian: Substanța activă din Aripiprazole Mylan, aripiprazolul, este un medicament antipsihotic.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The active substance in Aripiprazole Mylan, aripiprazole, is an antipsychotic medicine.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "The active substance in Aripiprazole Mylan, aripiprazole, is an antipsychotic medicine.", "ro": "Substanța activă din Aripiprazole Mylan, aripiprazolul, este un medicament antipsihotic." } }
{ "translation": { "text": "Glossaries:\n\"serotonin\" -> \"serotonină\"\n\"5-hydroxytryptamine\" -> \"serotonină\"\n\"agonist\" -> \"agonist\"\n\"dopamine\" -> \"dopamină\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: agonist' on the receptors for the neurotransmitters dopamine and 5-hydroxytryptamine (also called serotonin).\nRomanian: Aripiprazolul se consideră a fi un „agonist parțial” al receptorilor pentru neurotransmițătorii dopamină și 5-hidroxitriptamină (numit și serotonină).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"serotonin\" -> \"serotonină\"\n\"5-hydroxytryptamine\" -> \"serotonină\"\n\"agonist\" -> \"agonist\"\n\"dopamine\" -> \"dopamină\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: agonist' on the receptors for the neurotransmitters dopamine and 5-hydroxytryptamine (also called serotonin).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "serotonin|||serotonină\t5-hydroxytryptamine|||serotonină\tagonist|||agonist\tdopamine|||dopamină", "en": "agonist' on the receptors for the neurotransmitters dopamine and 5-hydroxytryptamine (also called serotonin).", "ro": "Aripiprazolul se consideră a fi un „agonist parțial” al receptorilor pentru neurotransmițătorii dopamină și 5-hidroxitriptamină (numit și serotonină)." } }
{ "translation": { "text": "Glossaries:\n\"CHMP\" -> \"Comitetul pentru medicamente de uz uman\"\n\"Committee for Medicinal Products for Human Use\" -> \"Comitetul pentru medicamente de uz uman\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Aripiprazole Mylan, for the treatment of schizophrenia and the treatment and prevention of manic episodes in patients with bipolar I disorder.\nRomanian: La data de 8 ianuarie 2016, Mylan S.A.S. a informat oficial Comitetul pentru medicamente de uz uman (CHMP) că dorește să își retragă cererea de autorizare de introducere pe piață pentru Aripiprazole Mylan, pentru tratamentul schizofreniei și pentru tratamentul și prevenirea episoadelor maniacale la pacienții cu tulburare bipolară de tip I.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"CHMP\" -> \"Comitetul pentru medicamente de uz uman\"\n\"Committee for Medicinal Products for Human Use\" -> \"Comitetul pentru medicamente de uz uman\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Aripiprazole Mylan, for the treatment of schizophrenia and the treatment and prevention of manic episodes in patients with bipolar I disorder.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "CHMP|||Comitetul pentru medicamente de uz uman\tCommittee for Medicinal Products for Human Use|||Comitetul pentru medicamente de uz uman", "en": "officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Aripiprazole Mylan, for the treatment of schizophrenia and the treatment and prevention of manic episodes in patients with bipolar I disorder.", "ro": "La data de 8 ianuarie 2016, Mylan S.A.S. a informat oficial Comitetul pentru medicamente de uz uman (CHMP) că dorește să își retragă cererea de autorizare de introducere pe piață pentru Aripiprazole Mylan, pentru tratamentul schizofreniei și pentru tratamentul și prevenirea episoadelor maniacale la pacienții cu tulburare bipolară de tip I." } }
{ "translation": { "text": "Glossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: These clinical signs disappear within 7 days without any particular treatment.\nRomanian: Aceste semne clinice dispar în decurs de 7 zile, fără să necesite vreun tratament.", "en_prompt": "<|im_start|>user\nGlossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: These clinical signs disappear within 7 days without any particular treatment.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratament", "en": "These clinical signs disappear within 7 days without any particular treatment.", "ro": "Aceste semne clinice dispar în decurs de 7 zile, fără să necesite vreun tratament." } }
{ "translation": { "text": "Glossary:\n\"immunity\" -> \"imunitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: b) the disease to which the veterinary medicinal product is intended to confer immunity is largely absent from the territory.\nRomanian: b) boala pentru care produsul medicinal veterinar este destinat a conferi imunitate este, în mare măsură, absentă în teritoriu.", "en_prompt": "<|im_start|>user\nGlossary:\n\"immunity\" -> \"imunitate\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: b) the disease to which the veterinary medicinal product is intended to confer immunity is largely absent from the territory.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "immunity|||imunitate", "en": "b) the disease to which the veterinary medicinal product is intended to confer immunity is largely absent from the territory.", "ro": "b) boala pentru care produsul medicinal veterinar este destinat a conferi imunitate este, în mare măsură, absentă în teritoriu." } }
{ "translation": { "text": "Glossary:\n\"interferon\" -> \"interferon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Such side effects have been described after multiple and long-term administration of type I interferon in man.\nRomanian: Asemenea efecte secundare au fost descrise în urma unor administrări multiple şi pe termen lung de interferon de tip I la om.", "en_prompt": "<|im_start|>user\nGlossary:\n\"interferon\" -> \"interferon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Such side effects have been described after multiple and long-term administration of type I interferon in man.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "interferon|||interferon", "en": "Such side effects have been described after multiple and long-term administration of type I interferon in man.", "ro": "Asemenea efecte secundare au fost descrise în urma unor administrări multiple şi pe termen lung de interferon de tip I la om." } }
{ "translation": { "text": "Glossary:\n\"eradication\" -> \"eradicare\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: a) the administration of the veterinary medicinal product to animals will interfere with the implementation of national programmes for the diagnosis, control and eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.\nRomanian: a) administrarea produsului medicinal veterinar la animale va interfera cu implementarea programelor naţionale pentru diagnostic, control şi eradicare a bolilor la animale sau va provoca dificultăţi în certificarea absenţei contaminării la animalele vii sau în alimente ori alte produse obţinute de la animalele tratate.", "en_prompt": "<|im_start|>user\nGlossary:\n\"eradication\" -> \"eradicare\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: a) the administration of the veterinary medicinal product to animals will interfere with the implementation of national programmes for the diagnosis, control and eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "eradication|||eradicare", "en": "a) the administration of the veterinary medicinal product to animals will interfere with the implementation of national programmes for the diagnosis, control and eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.", "ro": "a) administrarea produsului medicinal veterinar la animale va interfera cu implementarea programelor naţionale pentru diagnostic, control şi eradicare a bolilor la animale sau va provoca dificultăţi în certificarea absenţei contaminării la animalele vii sau în alimente ori alte produse obţinute de la animalele tratate." } }
{ "translation": { "text": "Glossary:\n\"vaccine\" -> \"vaccin\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: No information is available on the safety and efficacy from the concurrent use of this product with any vaccine.\nRomanian: Nu sunt disponibile informaţii în legătură cu siguranţa şi eficacitatea utilizării acestui produs în mod concomitent cu orice vaccin.", "en_prompt": "<|im_start|>user\nGlossary:\n\"vaccine\" -> \"vaccin\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: No information is available on the safety and efficacy from the concurrent use of this product with any vaccine.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "vaccine|||vaccin", "en": "No information is available on the safety and efficacy from the concurrent use of this product with any vaccine.", "ro": "Nu sunt disponibile informaţii în legătură cu siguranţa şi eficacitatea utilizării acestui produs în mod concomitent cu orice vaccin." } }
{ "translation": { "text": "Glossary:\n\"vaccination\" -> \"vaccinare\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Any person intending to import, sell, supply and/or use VIRBAGEN OMEGA must consult the relevant Member State's competent authority on the current vaccination policies prior to the import, sale, supply and/or use.\nRomanian: Orice persoană care intenţionează să importe, să vândă, să elibereze şi/sau să utilizeze VIRBAGEN OMEGA trebuie să consulte autoritatea competentă în domeniu a Statului Membru respectiv, referitor la politicile de vaccinare existente, înainte de a efectua importul, vânzarea, utilizarea şi/sau furnizarea.", "en_prompt": "<|im_start|>user\nGlossary:\n\"vaccination\" -> \"vaccinare\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Any person intending to import, sell, supply and/or use VIRBAGEN OMEGA must consult the relevant Member State's competent authority on the current vaccination policies prior to the import, sale, supply and/or use.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "vaccination|||vaccinare", "en": "Any person intending to import, sell, supply and/or use VIRBAGEN OMEGA must consult the relevant Member State's competent authority on the current vaccination policies prior to the import, sale, supply and/or use.", "ro": "Orice persoană care intenţionează să importe, să vândă, să elibereze şi/sau să utilizeze VIRBAGEN OMEGA trebuie să consulte autoritatea competentă în domeniu a Statului Membru respectiv, referitor la politicile de vaccinare existente, înainte de a efectua importul, vânzarea, utilizarea şi/sau furnizarea." } }
{ "translation": { "text": "Glossary:\n\"interferon\" -> \"interferon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • in anaemic cats, mortality rate of about 60% at 4, 6, 9 and 12 months was reduced by approximately 30% following treatment with interferon.\nRomanian: • rata mortalităţii pentru pisicile anemice, de aproximativ 60% la 4, 6, 9 şi 12 luni, a fost redusă cu aproximativ 30% în urma tratamentului cu interferon.", "en_prompt": "<|im_start|>user\nGlossary:\n\"interferon\" -> \"interferon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • in anaemic cats, mortality rate of about 60% at 4, 6, 9 and 12 months was reduced by approximately 30% following treatment with interferon.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "interferon|||interferon", "en": "• in anaemic cats, mortality rate of about 60% at 4, 6, 9 and 12 months was reduced by approximately 30% following treatment with interferon.", "ro": "• rata mortalităţii pentru pisicile anemice, de aproximativ 60% la 4, 6, 9 şi 12 luni, a fost redusă cu aproximativ 30% în urma tratamentului cu interferon." } }
{ "translation": { "text": "Glossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In cats infected by FIV, mortality was low (5%) and was not influenced by the treatment.\nRomanian: In cazul pisicilor infectate cu FIV, rata mortalităţii a fost mică (5%) şi nu a fost influenţată de tratament.", "en_prompt": "<|im_start|>user\nGlossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In cats infected by FIV, mortality was low (5%) and was not influenced by the treatment.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratament", "en": "In cats infected by FIV, mortality was low (5%) and was not influenced by the treatment.", "ro": "In cazul pisicilor infectate cu FIV, rata mortalităţii a fost mică (5%) şi nu a fost influenţată de tratament." } }
{ "translation": { "text": "Glossary:\n\"virus\" -> \"virus\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: It is mainly in cells infected by virus that the mechanism of replication is stopped both by destruction of mRNA and by inactivation of translation proteins (2'5' oligo-adenylate synthetase activation).\nRomanian: Mecanismul de replicare este oprit în principal la nivelul celulelor infectate de virus, atât prin distrugerea ARNm cât şi prin inactivarea proteinelor de translaţie (activarea 2'5' oligo-adenilat sintetazei).", "en_prompt": "<|im_start|>user\nGlossary:\n\"virus\" -> \"virus\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: It is mainly in cells infected by virus that the mechanism of replication is stopped both by destruction of mRNA and by inactivation of translation proteins (2'5' oligo-adenylate synthetase activation).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "virus|||virus", "en": "It is mainly in cells infected by virus that the mechanism of replication is stopped both by destruction of mRNA and by inactivation of translation proteins (2'5' oligo-adenylate synthetase activation).", "ro": "Mecanismul de replicare este oprit în principal la nivelul celulelor infectate de virus, atât prin distrugerea ARNm cât şi prin inactivarea proteinelor de translaţie (activarea 2'5' oligo-adenilat sintetazei)." } }
{ "translation": { "text": "Glossary:\n\"reconstitution\" -> \"reconstituire\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The product should be used immediately after reconstitution.\nRomanian: Produsul trebuie utilizat imediat după reconstituire.", "en_prompt": "<|im_start|>user\nGlossary:\n\"reconstitution\" -> \"reconstituire\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The product should be used immediately after reconstitution.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "reconstitution|||reconstituire", "en": "The product should be used immediately after reconstitution.", "ro": "Produsul trebuie utilizat imediat după reconstituire." } }
{ "translation": { "text": "Glossaries:\n\"intravenous administration\" -> \"administrare intravenoasă\"\n\"anorexia\" -> \"anorexie\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the case of intravenous administration in cats, increased adverse reactions may be seen, e.g. hyperthermia, soft faeces, anorexia, decreased drinking or collapse.\nRomanian: În caz de administrare intravenoasă la pisici, pot fi observate reacţii adverse crescute, de exemplu hipertermie, scaun moale, anorexie, scăderea cantităţii de lichide băute sau colaps.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"intravenous administration\" -> \"administrare intravenoasă\"\n\"anorexia\" -> \"anorexie\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the case of intravenous administration in cats, increased adverse reactions may be seen, e.g. hyperthermia, soft faeces, anorexia, decreased drinking or collapse.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "intravenous administration|||administrare intravenoasă\tanorexia|||anorexie", "en": "In the case of intravenous administration in cats, increased adverse reactions may be seen, e.g. hyperthermia, soft faeces, anorexia, decreased drinking or collapse.", "ro": "În caz de administrare intravenoasă la pisici, pot fi observate reacţii adverse crescute, de exemplu hipertermie, scaun moale, anorexie, scăderea cantităţii de lichide băute sau colaps." } }
{ "translation": { "text": "Glossary:\n\"reconstitution\" -> \"reconstituire\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Shelf life after reconstitution according to directions: use immediately.\nRomanian: Perioada de valabilitate după reconstituire conform indicaţiilor: se va utiliza imediat.", "en_prompt": "<|im_start|>user\nGlossary:\n\"reconstitution\" -> \"reconstituire\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Shelf life after reconstitution according to directions: use immediately.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "reconstitution|||reconstituire", "en": "Shelf life after reconstitution according to directions: use immediately.", "ro": "Perioada de valabilitate după reconstituire conform indicaţiilor: se va utiliza imediat." } }
{ "translation": { "text": "Glossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: STATEMENT OF ACTIVE SUBSTANCES Each dose of 1 ml contains:\nRomanian: DECLARAREA SUBSTANŢELOR ACTIVE Fiecare doză de 1 ml conține:", "en_prompt": "<|im_start|>user\nGlossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: STATEMENT OF ACTIVE SUBSTANCES Each dose of 1 ml contains:\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||doză", "en": "STATEMENT OF ACTIVE SUBSTANCES Each dose of 1 ml contains:", "ro": "DECLARAREA SUBSTANŢELOR ACTIVE Fiecare doză de 1 ml conține:" } }
{ "translation": { "text": "Glossary:\n\"interferon\" -> \"interferon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • in non-anaemic cats, mortality rate of 50 % in cats infected by FeLV was reduced by 20% following treatment with interferon.\nRomanian: • rata mortalităţii pentru pisicile ne-anemice, de 50 % la pisicile infectate cu FeLV, a fost redusă cu 20% în urma tratamentului cu interferon.", "en_prompt": "<|im_start|>user\nGlossary:\n\"interferon\" -> \"interferon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • in non-anaemic cats, mortality rate of 50 % in cats infected by FeLV was reduced by 20% following treatment with interferon.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "interferon|||interferon", "en": "• in non-anaemic cats, mortality rate of 50 % in cats infected by FeLV was reduced by 20% following treatment with interferon.", "ro": "• rata mortalităţii pentru pisicile ne-anemice, de 50 % la pisicile infectate cu FeLV, a fost redusă cu 20% în urma tratamentului cu interferon." } }
{ "translation": { "text": "Glossary:\n\"interferon\" -> \"interferon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Omega interferon of feline origin, produced by genetic engineering, is a type Ι interferon closely related to alpha interferon.\nRomanian: 5.1 Proprietăţi farmacodinamice Interferonul omega de origine felină, obţinut prin inginerie genetică, este un interferon de tip I, înrudit îndeaproape cu interferonul alfa.", "en_prompt": "<|im_start|>user\nGlossary:\n\"interferon\" -> \"interferon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Omega interferon of feline origin, produced by genetic engineering, is a type Ι interferon closely related to alpha interferon.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "interferon|||interferon", "en": "Omega interferon of feline origin, produced by genetic engineering, is a type Ι interferon closely related to alpha interferon.", "ro": "5.1 Proprietăţi farmacodinamice Interferonul omega de origine felină, obţinut prin inginerie genetică, este un interferon de tip I, înrudit îndeaproape cu interferonul alfa." } }
{ "translation": { "text": "Glossaries:\n\"lethargy\" -> \"letargie\"\n\"diarrhoea\" -> \"diaree\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Slight and transient clinical signs such as hyperthermia (3-6 hours after injection) lethargy and digestive signs (vomiting and soft faeces to mild diarrhoea, in cats only. )\nRomanian: În studiile de siguranță s-au observat foarte frecvent semne ușoare și trecătoare cum este hipertermia (la 3-6 ore după injecţie), letargie și semne digestive (vomă și fecale moi până la diaree, doar la pisici).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"lethargy\" -> \"letargie\"\n\"diarrhoea\" -> \"diaree\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Slight and transient clinical signs such as hyperthermia (3-6 hours after injection) lethargy and digestive signs (vomiting and soft faeces to mild diarrhoea, in cats only. )\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "lethargy|||letargie\tdiarrhoea|||diaree", "en": "Slight and transient clinical signs such as hyperthermia (3-6 hours after injection) lethargy and digestive signs (vomiting and soft faeces to mild diarrhoea, in cats only. )", "ro": "În studiile de siguranță s-au observat foarte frecvent semne ușoare și trecătoare cum este hipertermia (la 3-6 ore după injecţie), letargie și semne digestive (vomă și fecale moi până la diaree, doar la pisici)." } }
{ "translation": { "text": "Glossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Each dose of 1 ml contains:\nRomanian: Fiecare doză de 1 ml conține:", "en_prompt": "<|im_start|>user\nGlossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Each dose of 1 ml contains:\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||doză", "en": "Each dose of 1 ml contains:", "ro": "Fiecare doză de 1 ml conține:" } }
{ "translation": { "text": "Glossary:\n\"species\" -> \"specie\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: 4.4 Special warnings for each target species\nRomanian: 4.4 Atenţionări speciale pentru fiecare specie țintă", "en_prompt": "<|im_start|>user\nGlossary:\n\"species\" -> \"specie\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: 4.4 Special warnings for each target species\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "species|||specie", "en": "4.4 Special warnings for each target species", "ro": "4.4 Atenţionări speciale pentru fiecare specie țintă" } }
{ "translation": { "text": "Glossaries:\n\"diluent\" -> \"diluant\"\n\"interferon\" -> \"interferon\"\n\"recombinant\" -> \"recombinant\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The freeze-dried fraction must be reconstituted with 1 ml of the specific diluent to obtain, depending on the presentation, a limpid and colourless suspension containing 5 MU or 10 MU of recombinant interferon.\nRomanian: Fracţia liofilizată trebuie reconstituită cu 1 ml de diluant specific pentru a obţine, în funcţie de prezentarea farmaceutică, o suspensie limpede și incoloră ce conţine 5 MU sau 10 MU de interferon recombinant.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"diluent\" -> \"diluant\"\n\"interferon\" -> \"interferon\"\n\"recombinant\" -> \"recombinant\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The freeze-dried fraction must be reconstituted with 1 ml of the specific diluent to obtain, depending on the presentation, a limpid and colourless suspension containing 5 MU or 10 MU of recombinant interferon.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "diluent|||diluant\tinterferon|||interferon\trecombinant|||recombinant", "en": "The freeze-dried fraction must be reconstituted with 1 ml of the specific diluent to obtain, depending on the presentation, a limpid and colourless suspension containing 5 MU or 10 MU of recombinant interferon.", "ro": "Fracţia liofilizată trebuie reconstituită cu 1 ml de diluant specific pentru a obţine, în funcţie de prezentarea farmaceutică, o suspensie limpede și incoloră ce conţine 5 MU sau 10 MU de interferon recombinant." } }
{ "translation": { "text": "Glossary:\n\"lethargy\" -> \"letargie\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • mild lethargy and drowsiness\nRomanian: • uşoară letargie şi somnolenţă", "en_prompt": "<|im_start|>user\nGlossary:\n\"lethargy\" -> \"letargie\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • mild lethargy and drowsiness\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "lethargy|||letargie", "en": "• mild lethargy and drowsiness", "ro": "• uşoară letargie şi somnolenţă" } }
{ "translation": { "text": "Glossaries:\n\"diluent\" -> \"diluant\"\n\"interferon\" -> \"interferon\"\n\"recombinant\" -> \"recombinant\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The freeze-dried fraction must be reconstituted with 1 ml of the specific diluent to obtain a suspension containing 5 MU of recombinant interferon.\nRomanian: Fracţia liofilizată trebuie reconstituită cu 1 ml de diluant specific pentru a obţine o suspensie ce conţine 5 MU de interferon recombinant.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"diluent\" -> \"diluant\"\n\"interferon\" -> \"interferon\"\n\"recombinant\" -> \"recombinant\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The freeze-dried fraction must be reconstituted with 1 ml of the specific diluent to obtain a suspension containing 5 MU of recombinant interferon.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "diluent|||diluant\tinterferon|||interferon\trecombinant|||recombinant", "en": "The freeze-dried fraction must be reconstituted with 1 ml of the specific diluent to obtain a suspension containing 5 MU of recombinant interferon.", "ro": "Fracţia liofilizată trebuie reconstituită cu 1 ml de diluant specific pentru a obţine o suspensie ce conţine 5 MU de interferon recombinant." } }
{ "translation": { "text": "Glossaries:\n\"diluent\" -> \"diluant\"\n\"interferon\" -> \"interferon\"\n\"recombinant\" -> \"recombinant\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The freeze-dried fraction must be reconstituted with 1 ml of the specific diluent to obtain a solution containing 10 MU of recombinant interferon.\nRomanian: Fracţia liofilizată trebuie reconstituită cu 1 ml de diluant specific pentru a obţine o suspensie ce conţine 10 MU de interferon recombinant.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"diluent\" -> \"diluant\"\n\"interferon\" -> \"interferon\"\n\"recombinant\" -> \"recombinant\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: The freeze-dried fraction must be reconstituted with 1 ml of the specific diluent to obtain a solution containing 10 MU of recombinant interferon.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "diluent|||diluant\tinterferon|||interferon\trecombinant|||recombinant", "en": "The freeze-dried fraction must be reconstituted with 1 ml of the specific diluent to obtain a solution containing 10 MU of recombinant interferon.", "ro": "Fracţia liofilizată trebuie reconstituită cu 1 ml de diluant specific pentru a obţine o suspensie ce conţine 10 MU de interferon recombinant." } }
{ "translation": { "text": "Glossary:\n\"species\" -> \"specie\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: SPECIAL WARNING(S) Special warnings for each target species\nRomanian: Atenţionări speciale pentru fiecare specie țintă", "en_prompt": "<|im_start|>user\nGlossary:\n\"species\" -> \"specie\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: SPECIAL WARNING(S) Special warnings for each target species\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "species|||specie", "en": "SPECIAL WARNING(S) Special warnings for each target species", "ro": "Atenţionări speciale pentru fiecare specie țintă" } }
{ "translation": { "text": "Glossary:\n\"vial\" -> \"flacon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Box containing 1 vial of lyophilisate and 1 vial with 1 ml of solvent.\nRomanian: Cutie conţinând 1 flacon de liofilizat şi 1 flacon cu 1 ml de solvent.", "en_prompt": "<|im_start|>user\nGlossary:\n\"vial\" -> \"flacon\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Box containing 1 vial of lyophilisate and 1 vial with 1 ml of solvent.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "vial|||flacon", "en": "Box containing 1 vial of lyophilisate and 1 vial with 1 ml of solvent.", "ro": "Cutie conţinând 1 flacon de liofilizat şi 1 flacon cu 1 ml de solvent." } }
{ "translation": { "text": "Glossary:\n\"vaccine\" -> \"vaccin\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: IDflu is a vaccine.\nRomanian: IDflu este un vaccin.", "en_prompt": "<|im_start|>user\nGlossary:\n\"vaccine\" -> \"vaccin\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: IDflu is a vaccine.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "vaccine|||vaccin", "en": "IDflu is a vaccine.", "ro": "IDflu este un vaccin." } }
{ "translation": { "text": "Glossary:\n\"subtype\" -> \"subtip\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: IDflu contains 15 micrograms of each of three different strains (varieties) of influenza virus (an H1N1 subtype, A/California/7/2009, NYMC X-179A; an H3N2 subtype, A/Hong Kong/4801/2014, NYMC X-263B; and a type B, B/Brisbane/60/2008, wild type).\nRomanian: IDflu conține 15 micrograme din fiecare din cele trei tulpini (varietăți) ale virusului gripal (un subtip al H1N1, A/California/7/2009, NYMC X-179A, un subtip al H3N2, A/Hong Kong/4801/2014, NYMC X-263B și un tip B, B/Brisbane/60/2008, de tip sălbatic).", "en_prompt": "<|im_start|>user\nGlossary:\n\"subtype\" -> \"subtip\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: IDflu contains 15 micrograms of each of three different strains (varieties) of influenza virus (an H1N1 subtype, A/California/7/2009, NYMC X-179A; an H3N2 subtype, A/Hong Kong/4801/2014, NYMC X-263B; and a type B, B/Brisbane/60/2008, wild type).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "subtype|||subtip", "en": "IDflu contains 15 micrograms of each of three different strains (varieties) of influenza virus (an H1N1 subtype, A/California/7/2009, NYMC X-179A; an H3N2 subtype, A/Hong Kong/4801/2014, NYMC X-263B; and a type B, B/Brisbane/60/2008, wild type).", "ro": "IDflu conține 15 micrograme din fiecare din cele trei tulpini (varietăți) ale virusului gripal (un subtip al H1N1, A/California/7/2009, NYMC X-179A, un subtip al H3N2, A/Hong Kong/4801/2014, NYMC X-263B și un tip B, B/Brisbane/60/2008, de tip sălbatic)." } }
{ "translation": { "text": "Glossary:\n\"virus\" -> \"virus\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the future, the immune system will be able to produce antibodies more quickly when it is exposed to any of these virus strains.\nRomanian: În viitor, sistemul imunitar va fi capabil să producă mai repede anticorpi când este expus la una dintre aceste tulpini de virus.", "en_prompt": "<|im_start|>user\nGlossary:\n\"virus\" -> \"virus\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In the future, the immune system will be able to produce antibodies more quickly when it is exposed to any of these virus strains.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "virus|||virus", "en": "In the future, the immune system will be able to produce antibodies more quickly when it is exposed to any of these virus strains.", "ro": "În viitor, sistemul imunitar va fi capabil să producă mai repede anticorpi când este expus la una dintre aceste tulpini de virus." } }
{ "translation": { "text": "Glossary:\n\"virus\" -> \"virus\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: When a person is given the vaccine, the immune system recognises the virus fragments as ‘foreign' and makes antibodies against them.\nRomanian: Când unei persoane i se administrează vaccinul, sistemul imunitar recunoaște fragmentele de virus ca fiind „străine” și produce anticorpi împotriva lor.", "en_prompt": "<|im_start|>user\nGlossary:\n\"virus\" -> \"virus\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: When a person is given the vaccine, the immune system recognises the virus fragments as ‘foreign' and makes antibodies against them.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "virus|||virus", "en": "When a person is given the vaccine, the immune system recognises the virus fragments as ‘foreign' and makes antibodies against them.", "ro": "Când unei persoane i se administrează vaccinul, sistemul imunitar recunoaște fragmentele de virus ca fiind „străine” și produce anticorpi împotriva lor." } }
{ "translation": { "text": "Glossaries:\n\"CHMP\" -> \"Comitetul pentru medicamente de uz uman\"\n\"Committee for Medicinal Products for Human Use\" -> \"Comitetul pentru medicamente de uz uman\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for\nRomanian: Documentul explică modul în care Comitetul pentru medicamente de uz uman (CHMP) a evaluat medicamentul, pentru a emite avizul în favoarea acordării autorizației de punere pe piață și recomandările privind condițiile de utilizare pentru IDflu.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"CHMP\" -> \"Comitetul pentru medicamente de uz uman\"\n\"Committee for Medicinal Products for Human Use\" -> \"Comitetul pentru medicamente de uz uman\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "CHMP|||Comitetul pentru medicamente de uz uman\tCommittee for Medicinal Products for Human Use|||Comitetul pentru medicamente de uz uman", "en": "It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for", "ro": "Documentul explică modul în care Comitetul pentru medicamente de uz uman (CHMP) a evaluat medicamentul, pentru a emite avizul în favoarea acordării autorizației de punere pe piață și recomandările privind condițiile de utilizare pentru IDflu." } }
{ "translation": { "text": "Glossaries:\n\"WHO\" -> \"OMS\"\n\"World Health Organization\" -> \"OMS\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Each year, the World Health Organization (WHO) makes recommendations on which flu strains should be included in vaccines for the upcoming flu season.\nRomanian: În fiecare an, Organizația Mondială a Sănătății (OMS) emite recomandări privind tulpinile gripale care trebuie introduse în vaccinurile pentru sezonul gripal următor.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"WHO\" -> \"OMS\"\n\"World Health Organization\" -> \"OMS\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Each year, the World Health Organization (WHO) makes recommendations on which flu strains should be included in vaccines for the upcoming flu season.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "WHO|||OMS\tWorld Health Organization|||OMS", "en": "Each year, the World Health Organization (WHO) makes recommendations on which flu strains should be included in vaccines for the upcoming flu season.", "ro": "În fiecare an, Organizația Mondială a Sănătății (OMS) emite recomandări privind tulpinile gripale care trebuie introduse în vaccinurile pentru sezonul gripal următor." } }
{ "translation": { "text": "Glossary:\n\"virus\" -> \"virus\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: IDflu contains fragments from three different strains of flu virus.\nRomanian: IDflu conține fragmente a trei tulpini diferite de virus gripal.", "en_prompt": "<|im_start|>user\nGlossary:\n\"virus\" -> \"virus\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: IDflu contains fragments from three different strains of flu virus.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "virus|||virus", "en": "IDflu contains fragments from three different strains of flu virus.", "ro": "IDflu conține fragmente a trei tulpini diferite de virus gripal." } }
{ "translation": { "text": "Glossary:\n\"fever\" -> \"febră\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: People who have fever or an acute (short-lived) infection should not receive the vaccine until they have recovered.\nRomanian: Persoanelor care prezintă febră sau o infecție acută (de scurtă durată) nu trebuie să li se administreze vaccinul decât după vindecare.", "en_prompt": "<|im_start|>user\nGlossary:\n\"fever\" -> \"febră\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: People who have fever or an acute (short-lived) infection should not receive the vaccine until they have recovered.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "fever|||febră", "en": "People who have fever or an acute (short-lived) infection should not receive the vaccine until they have recovered.", "ro": "Persoanelor care prezintă febră sau o infecție acută (de scurtă durată) nu trebuie să li se administreze vaccinul decât după vindecare." } }
{ "translation": { "text": "Glossaries:\n\"adjuvant\" -> \"adjuvant\"\n\"vaccine\" -> \"vaccin\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In one study in people aged 60 years and over, IDflu was compared with a flu vaccine containing an adjuvant (a compound added to enhance the immune response).\nRomanian: Într-un studiu efectuat pe persoane cu vârsta de 60 de ani și peste, IDflu a fost comparat cu un vaccin antigripal care conține un adjuvant (un compus care se adaugă pentru intensificarea răspunsului imunitar).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"adjuvant\" -> \"adjuvant\"\n\"vaccine\" -> \"vaccin\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In one study in people aged 60 years and over, IDflu was compared with a flu vaccine containing an adjuvant (a compound added to enhance the immune response).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "adjuvant|||adjuvant\tvaccine|||vaccin", "en": "In one study in people aged 60 years and over, IDflu was compared with a flu vaccine containing an adjuvant (a compound added to enhance the immune response).", "ro": "Într-un studiu efectuat pe persoane cu vârsta de 60 de ani și peste, IDflu a fost comparat cu un vaccin antigripal care conține un adjuvant (un compus care se adaugă pentru intensificarea răspunsului imunitar)." } }
{ "translation": { "text": "Glossary:\n\"system\" -> \"sistem\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: IDflu is given as one ‘intradermal' injection into the upper layer of the skin, using a special micro-injection system.\nRomanian: IDflu se administrează o singură dată, sub formă de injecție „intradermică” în stratul superior al pielii, cu ajutorul unui sistem special de microinjectare.", "en_prompt": "<|im_start|>user\nGlossary:\n\"system\" -> \"sistem\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: IDflu is given as one ‘intradermal' injection into the upper layer of the skin, using a special micro-injection system.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "system|||sistem", "en": "IDflu is given as one ‘intradermal' injection into the upper layer of the skin, using a special micro-injection system.", "ro": "IDflu se administrează o singură dată, sub formă de injecție „intradermică” în stratul superior al pielii, cu ajutorul unui sistem special de microinjectare." } }
{ "translation": { "text": "Glossary:\n\"vaccine\" -> \"vaccin\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: IDflu is a vaccine, which is available as a suspension for injection in a pre-filled syringe.\nRomanian: IDflu este un vaccin disponibil sub formă de suspensie injectabilă într-o seringă preumplută.", "en_prompt": "<|im_start|>user\nGlossary:\n\"vaccine\" -> \"vaccin\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: IDflu is a vaccine, which is available as a suspension for injection in a pre-filled syringe.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "vaccine|||vaccin", "en": "IDflu is a vaccine, which is available as a suspension for injection in a pre-filled syringe.", "ro": "IDflu este un vaccin disponibil sub formă de suspensie injectabilă într-o seringă preumplută." } }
{ "translation": { "text": "Glossary:\n\"vaccine\" -> \"vaccin\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In all studies, IDflu was compared with another flu vaccine given by injection into a muscle.\nRomanian: În toate studiile, IDflu a fost comparat cu un alt vaccin antigripal care se administrează prin injecție intramusculară.", "en_prompt": "<|im_start|>user\nGlossary:\n\"vaccine\" -> \"vaccin\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In all studies, IDflu was compared with another flu vaccine given by injection into a muscle.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "vaccine|||vaccin", "en": "In all studies, IDflu was compared with another flu vaccine given by injection into a muscle.", "ro": "În toate studiile, IDflu a fost comparat cu un alt vaccin antigripal care se administrează prin injecție intramusculară." } }
{ "translation": { "text": "Glossary:\n\"vaccine\" -> \"vaccin\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Later seasonal formulations of IDflu have been shown to bring about similar antibody responses against the three flu strains included in the vaccine to those seen in the main studies.\nRomanian: Formulele ulterioare sezoniere ale IDflu au dovedit că declanșează reacții similare cu cele observate în studiile principale în ceea ce privește producerea de anticorpi pentru protejarea împotriva celor trei tulpini de virus gripal conținute de vaccin.", "en_prompt": "<|im_start|>user\nGlossary:\n\"vaccine\" -> \"vaccin\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Later seasonal formulations of IDflu have been shown to bring about similar antibody responses against the three flu strains included in the vaccine to those seen in the main studies.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "vaccine|||vaccin", "en": "Later seasonal formulations of IDflu have been shown to bring about similar antibody responses against the three flu strains included in the vaccine to those seen in the main studies.", "ro": "Formulele ulterioare sezoniere ale IDflu au dovedit că declanșează reacții similare cu cele observate în studiile principale în ceea ce privește producerea de anticorpi pentru protejarea împotriva celor trei tulpini de virus gripal conținute de vaccin." } }
{ "translation": { "text": "Glossary:\n\"package leaflet\" -> \"prospect\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of IDflu have been included in the summary of product characteristics and the package leaflet.\nRomanian: În Rezumatul caracteristicilor produsului și în prospect au fost incluse recomandări și măsuri de precauție pentru utilizarea sigură și eficace a IDflu, care trebuie respectate de personalul medical și de", "en_prompt": "<|im_start|>user\nGlossary:\n\"package leaflet\" -> \"prospect\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of IDflu have been included in the summary of product characteristics and the package leaflet.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "package leaflet|||prospect", "en": "Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of IDflu have been included in the summary of product characteristics and the package leaflet.", "ro": "În Rezumatul caracteristicilor produsului și în prospect au fost incluse recomandări și măsuri de precauție pentru utilizarea sigură și eficace a IDflu, care trebuie respectate de personalul medical și de" } }
{ "translation": { "text": "Glossaries:\n\"virus\" -> \"virus\"\n\"WHO\" -> \"OMS\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Fragments of the virus strains that are expected to cause flu in the upcoming season, according to the recommendations from the WHO for the northern hemisphere and from the European Union (EU), need to be included in IDflu before the\nRomanian: Înainte ca vaccinul să poată fi utilizat, trebuie introduse în vaccin fragmente ale tulpinilor de virus despre care se presupune că vor cauza gripa în sezonul următor, conform recomandărilor OMS pentru emisfera nordică și conform recomandărilor Uniunii Europene (UE).", "en_prompt": "<|im_start|>user\nGlossaries:\n\"virus\" -> \"virus\"\n\"WHO\" -> \"OMS\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Fragments of the virus strains that are expected to cause flu in the upcoming season, according to the recommendations from the WHO for the northern hemisphere and from the European Union (EU), need to be included in IDflu before the\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "virus|||virus\tWHO|||OMS", "en": "Fragments of the virus strains that are expected to cause flu in the upcoming season, according to the recommendations from the WHO for the northern hemisphere and from the European Union (EU), need to be included in IDflu before the", "ro": "Înainte ca vaccinul să poată fi utilizat, trebuie introduse în vaccin fragmente ale tulpinilor de virus despre care se presupune că vor cauza gripa în sezonul următor, conform recomandărilor OMS pentru emisfera nordică și conform recomandărilor Uniunii Europene (UE)." } }
{ "translation": { "text": "Glossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: You may need urgent treatment.\nRomanian: S-ar putea să aveţi nevoie de tratament medical de urgenţă.", "en_prompt": "<|im_start|>user\nGlossary:\n\"treatment\" -> \"tratament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: You may need urgent treatment.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "treatment|||tratament", "en": "You may need urgent treatment.", "ro": "S-ar putea să aveţi nevoie de tratament medical de urgenţă." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • Take this medicine once daily about the same time each day.\nRomanian: • Luaţi acest medicament o dată pe zi, la aproximativ aceeaşi oră, în fiecare zi.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • Take this medicine once daily about the same time each day.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "• Take this medicine once daily about the same time each day.", "ro": "• Luaţi acest medicament o dată pe zi, la aproximativ aceeaşi oră, în fiecare zi." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: This makes it easier to remember to take this medicine.\nRomanian: În acest fel vă amintiţi mai uşor să luaţi acest medicament.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: This makes it easier to remember to take this medicine.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "This makes it easier to remember to take this medicine.", "ro": "În acest fel vă amintiţi mai uşor să luaţi acest medicament." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • Take this medicine at least 1 hour before eating, or\nRomanian: • Luaţi acest medicament cu cel puţin o oră înainte de a mânca, sau", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • Take this medicine at least 1 hour before eating, or\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "• Take this medicine at least 1 hour before eating, or", "ro": "• Luaţi acest medicament cu cel puţin o oră înainte de a mânca, sau" } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • If you have already eaten, wait at least 3 hours before taking this medicine.\nRomanian: • Dacă aţi mâncat deja, aşteptaţi cel puţin 3 ore înainte de a lua acest medicament.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • If you have already eaten, wait at least 3 hours before taking this medicine.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "• If you have already eaten, wait at least 3 hours before taking this medicine.", "ro": "• Dacă aţi mâncat deja, aşteptaţi cel puţin 3 ore înainte de a lua acest medicament." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If you do not take this medicine as prescribed by your doctor your cancer may grow again.\nRomanian: Dacă nu luaţi acest medicament aşa cum v-a fost prescris de medicul dumneavoastră cancerul dumneavoastră poate creşte din nou.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If you do not take this medicine as prescribed by your doctor your cancer may grow again.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "If you do not take this medicine as prescribed by your doctor your cancer may grow again.", "ro": "Dacă nu luaţi acest medicament aşa cum v-a fost prescris de medicul dumneavoastră cancerul dumneavoastră poate creşte din nou." } }
{ "translation": { "text": "Glossaries:\n\"antidote\" -> \"antidot\"\n\"medicinal product\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: There is no specific antidote for overdose with this medicinal product.\nRomanian: Nu există un antidot specific pentru supradozajul cu acest medicament.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"antidote\" -> \"antidot\"\n\"medicinal product\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: There is no specific antidote for overdose with this medicinal product.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "antidote|||antidot\tmedicinal product|||medicament", "en": "There is no specific antidote for overdose with this medicinal product.", "ro": "Nu există un antidot specific pentru supradozajul cu acest medicament." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: It is important to take this medicine every day, as long as your doctor prescribes it for you.\nRomanian: Este important să luaţi acest medicament în fiecare zi, atât timp cât vă este prescris de medicul dumneavoastră.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: It is important to take this medicine every day, as long as your doctor prescribes it for you.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "It is important to take this medicine every day, as long as your doctor prescribes it for you.", "ro": "Este important să luaţi acest medicament în fiecare zi, atât timp cât vă este prescris de medicul dumneavoastră." } }
{ "translation": { "text": "Glossary:\n\"body weight\" -> \"greutate corporală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • if you are female, have a low body weight of less than 50 kg or have kidney problems.\nRomanian: • dacă sunteţi femeie, aveţi o greutate corporală mai mică de 50 kg sau aveţi probleme cu rinichii.", "en_prompt": "<|im_start|>user\nGlossary:\n\"body weight\" -> \"greutate corporală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • if you are female, have a low body weight of less than 50 kg or have kidney problems.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "body weight|||greutate corporală", "en": "• if you are female, have a low body weight of less than 50 kg or have kidney problems.", "ro": "• dacă sunteţi femeie, aveţi o greutate corporală mai mică de 50 kg sau aveţi probleme cu rinichii." } }
{ "translation": { "text": "Glossary:\n\"medicinal product\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Therefore, this medicinal product is unlikely to interact with other medicines that modulate or are metabolised by CYP enzymes.\nRomanian: Prin urmare, este puţin probabil ca acest medicament să interacţioneze cu alte medicamente care modulează sau sunt metabolizate de enzimele CYP.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicinal product\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Therefore, this medicinal product is unlikely to interact with other medicines that modulate or are metabolised by CYP enzymes.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicinal product|||medicament", "en": "Therefore, this medicinal product is unlikely to interact with other medicines that modulate or are metabolised by CYP enzymes.", "ro": "Prin urmare, este puţin probabil ca acest medicament să interacţioneze cu alte medicamente care modulează sau sunt metabolizate de enzimele CYP." } }
{ "translation": { "text": "Glossary:\n\"medicinal product\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Treatment with this medicinal product should be interrupted pending investigation of these symptoms.\nRomanian: Tratamentul cu acest medicament trebuie întrerupt până la investigarea acestor simptome.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicinal product\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Treatment with this medicinal product should be interrupted pending investigation of these symptoms.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicinal product|||medicament", "en": "Treatment with this medicinal product should be interrupted pending investigation of these symptoms.", "ro": "Tratamentul cu acest medicament trebuie întrerupt până la investigarea acestor simptome." } }
{ "translation": { "text": "Glossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If a dose is missed, it should be taken within the same day as soon as the patient remembers.\nRomanian: În cazul în care este omisă o doză, aceasta trebuie administrată în aceeaşi zi, imediat ce pacientul îşi aminteşte.", "en_prompt": "<|im_start|>user\nGlossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If a dose is missed, it should be taken within the same day as soon as the patient remembers.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||doză", "en": "If a dose is missed, it should be taken within the same day as soon as the patient remembers.", "ro": "În cazul în care este omisă o doză, aceasta trebuie administrată în aceeaşi zi, imediat ce pacientul îşi aminteşte." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Do not use this medicine after the expiry date which is stated on the carton, the pouch and the blister after EXP.\nRomanian: Nu utilizaţi acest medicament după data de expirare înscrisă pe cutia de carton, pungă şi blister după EXP.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Do not use this medicine after the expiry date which is stated on the carton, the pouch and the blister after EXP.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "Do not use this medicine after the expiry date which is stated on the carton, the pouch and the blister after EXP.", "ro": "Nu utilizaţi acest medicament după data de expirare înscrisă pe cutia de carton, pungă şi blister după EXP." } }
{ "translation": { "text": "Glossaries:\n\"disease\" -> \"boală\"\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Treatment with this medicine is not recommended if you have a severe liver disease.\nRomanian: Nu este recomandat tratamentul cu acest medicament dacă aveţi o boală severă de ficat.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"disease\" -> \"boală\"\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Treatment with this medicine is not recommended if you have a severe liver disease.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "disease|||boală\tmedicine|||medicament", "en": "Treatment with this medicine is not recommended if you have a severe liver disease.", "ro": "Nu este recomandat tratamentul cu acest medicament dacă aveţi o boală severă de ficat." } }
{ "translation": { "text": "Glossary:\n\"tacrolimus\" -> \"tacrolimus\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • Cyclosporine A, tacrolimus - medicines that affect your immune system.\nRomanian: • Ciclosporina A, tacrolimus - medicamente care afectează sistemul imunitar.", "en_prompt": "<|im_start|>user\nGlossary:\n\"tacrolimus\" -> \"tacrolimus\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: • Cyclosporine A, tacrolimus - medicines that affect your immune system.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "tacrolimus|||tacrolimus", "en": "• Cyclosporine A, tacrolimus - medicines that affect your immune system.", "ro": "• Ciclosporina A, tacrolimus - medicamente care afectează sistemul imunitar." } }
{ "translation": { "text": "Glossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Do not take a double dose (two tablets instead of one at the same time) to make up for a missed dose.\nRomanian: Nu luaţi o doză dublă (două comprimate o dată în loc de unul) pentru a compensa doza uitată.", "en_prompt": "<|im_start|>user\nGlossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Do not take a double dose (two tablets instead of one at the same time) to make up for a missed dose.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||doză", "en": "Do not take a double dose (two tablets instead of one at the same time) to make up for a missed dose.", "ro": "Nu luaţi o doză dublă (două comprimate o dată în loc de unul) pentru a compensa doza uitată." } }
{ "translation": { "text": "Glossary:\n\"drinking water\" -> \"apă de băut\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If swallowing of whole tablets is not possible, these can be dispersed in approximately 100 ml of non-carbonated drinking water.\nRomanian: Dacă nu este posibilă înghiţirea comprimatelor întregi, acestea pot fi dizolvate în aproximativ 100 ml de apă de băut necarbogazoasă.", "en_prompt": "<|im_start|>user\nGlossary:\n\"drinking water\" -> \"apă de băut\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If swallowing of whole tablets is not possible, these can be dispersed in approximately 100 ml of non-carbonated drinking water.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "drinking water|||apă de băut", "en": "If swallowing of whole tablets is not possible, these can be dispersed in approximately 100 ml of non-carbonated drinking water.", "ro": "Dacă nu este posibilă înghiţirea comprimatelor întregi, acestea pot fi dizolvate în aproximativ 100 ml de apă de băut necarbogazoasă." } }
{ "translation": { "text": "Glossary:\n\"subtype\" -> \"subtip\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Mutation in EGFR defines a distinct molecular subtype of lung cancer.\nRomanian: Mutaţiile EGFR definesc un subtip molecular distinct de cancer pulmonar.", "en_prompt": "<|im_start|>user\nGlossary:\n\"subtype\" -> \"subtip\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Mutation in EGFR defines a distinct molecular subtype of lung cancer.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "subtype|||subtip", "en": "Mutation in EGFR defines a distinct molecular subtype of lung cancer.", "ro": "Mutaţiile EGFR definesc un subtip molecular distinct de cancer pulmonar." } }
{ "translation": { "text": "Glossary:\n\"toxicology\" -> \"toxicologie\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Available non-clinical toxicology data have shown effects on reproductive organs at higher doses.\nRomanian: Datele de toxicologie nonclinică disponibile au arătat efecte asupra organelor de reproducere la doze mai mari.", "en_prompt": "<|im_start|>user\nGlossary:\n\"toxicology\" -> \"toxicologie\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Available non-clinical toxicology data have shown effects on reproductive organs at higher doses.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "toxicology|||toxicologie", "en": "Available non-clinical toxicology data have shown effects on reproductive organs at higher doses.", "ro": "Datele de toxicologie nonclinică disponibile au arătat efecte asupra organelor de reproducere la doze mai mari." } }
{ "translation": { "text": "Glossary:\n\"medicinal product\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Based on the available clinical trial data, there is no suggestion that this medicinal product causes an adverse reaction on cardiac contractility.\nRomanian: Pe baza datelor disponibile din studiile clinice, nu se sugerează că acest medicament produce o reacţie adversă asupra contractilităţii cardiace.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicinal product\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Based on the available clinical trial data, there is no suggestion that this medicinal product causes an adverse reaction on cardiac contractility.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicinal product|||medicament", "en": "Based on the available clinical trial data, there is no suggestion that this medicinal product causes an adverse reaction on cardiac contractility.", "ro": "Pe baza datelor disponibile din studiile clinice, nu se sugerează că acest medicament produce o reacţie adversă asupra contractilităţii cardiace." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Do not give this medicine to children or adolescents under the age of 18 years.\nRomanian: Nu se recomandă administrarea acestui medicament la copii sau adolescenţi cu vârsta sub 18 ani.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Do not give this medicine to children or adolescents under the age of 18 years.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "Do not give this medicine to children or adolescents under the age of 18 years.", "ro": "Nu se recomandă administrarea acestui medicament la copii sau adolescenţi cu vârsta sub 18 ani." } }
{ "translation": { "text": "Glossary:\n\"diarrhoea\" -> \"diaree\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: At the first signs of diarrhoea drink plenty of fluids.\nRomanian: La primele semne de diaree trebuie să beţi multe lichide.", "en_prompt": "<|im_start|>user\nGlossary:\n\"diarrhoea\" -> \"diaree\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: At the first signs of diarrhoea drink plenty of fluids.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "diarrhoea|||diaree", "en": "At the first signs of diarrhoea drink plenty of fluids.", "ro": "La primele semne de diaree trebuie să beţi multe lichide." } }
{ "translation": { "text": "Glossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Antidiarrhoeal medicinal products (e.g. loperamide) should be used and if necessary their dose should be escalated to the highest recommended approved dose.\nRomanian: Trebuie utilizate medicamente antidiareice (de exemplu loperamidă) şi, dacă este necesar, doza acestora trebuie crescută până la cea mai mare doză recomandată aprobată.", "en_prompt": "<|im_start|>user\nGlossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Antidiarrhoeal medicinal products (e.g. loperamide) should be used and if necessary their dose should be escalated to the highest recommended approved dose.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||doză", "en": "Antidiarrhoeal medicinal products (e.g. loperamide) should be used and if necessary their dose should be escalated to the highest recommended approved dose.", "ro": "Trebuie utilizate medicamente antidiareice (de exemplu loperamidă) şi, dacă este necesar, doza acestora trebuie crescută până la cea mai mare doză recomandată aprobată." } }
{ "translation": { "text": "Glossaries:\n\"adverse effect\" -> \"efect advers\"\n\"medicinal product\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Therefore, an adverse effect of this medicinal product on human fertility cannot be excluded.\nRomanian: Prin urmare, nu poate fi exclus un efect advers al tratamentului cu acest medicament asupra fertilităţii la om.", "en_prompt": "<|im_start|>user\nGlossaries:\n\"adverse effect\" -> \"efect advers\"\n\"medicinal product\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Therefore, an adverse effect of this medicinal product on human fertility cannot be excluded.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "adverse effect|||efect advers\tmedicinal product|||medicament", "en": "Therefore, an adverse effect of this medicinal product on human fertility cannot be excluded.", "ro": "Prin urmare, nu poate fi exclus un efect advers al tratamentului cu acest medicament asupra fertilităţii la om." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: This medicine is used on its own to treat adult patients with a specific type of cancer of the lung (non-small cell lung cancer):\nRomanian: Acest medicament este utilizat de unul singur pentru tratamentul pacienţilor adulţi cu un tip specific de cancer al plămânilor (cu alt fel de celule decât celule mici):", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: This medicine is used on its own to treat adult patients with a specific type of cancer of the lung (non-small cell lung cancer):\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "This medicine is used on its own to treat adult patients with a specific type of cancer of the lung (non-small cell lung cancer):", "ro": "Acest medicament este utilizat de unul singur pentru tratamentul pacienţilor adulţi cu un tip specific de cancer al plămânilor (cu alt fel de celule decât celule mici):" } }
{ "translation": { "text": "Glossary:\n\"medicinal product\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: This medicinal product should be administered without food (see sections 4.2 and 5.2).\nRomanian: Acest medicament trebuie administrat fără alimente (vezi pct. 4.2 şi 5.2).", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicinal product\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: This medicinal product should be administered without food (see sections 4.2 and 5.2).\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicinal product|||medicament", "en": "This medicinal product should be administered without food (see sections 4.2 and 5.2).", "ro": "Acest medicament trebuie administrat fără alimente (vezi pct. 4.2 şi 5.2)." } }
{ "translation": { "text": "Glossary:\n\"disease\" -> \"boală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In these patients, confounding factors have included pre-existing liver disease and/or comorbidities associated with progression of underlying malignancy.\nRomanian: La aceşti pacienţi, factorii de risc au inclus boală hepatică preexistentă şi/sau comorbidităţi asociate cu progresia malignităţii preexistente.", "en_prompt": "<|im_start|>user\nGlossary:\n\"disease\" -> \"boală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: In these patients, confounding factors have included pre-existing liver disease and/or comorbidities associated with progression of underlying malignancy.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "disease|||boală", "en": "In these patients, confounding factors have included pre-existing liver disease and/or comorbidities associated with progression of underlying malignancy.", "ro": "La aceşti pacienţi, factorii de risc au inclus boală hepatică preexistentă şi/sau comorbidităţi asociate cu progresia malignităţii preexistente." } }
{ "translation": { "text": "Glossary:\n\"physician\" -> \"medic\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Treatment with GIOTRIF should be initiated and supervised by a physician experienced in the use of anticancer therapies.\nRomanian: Tratamentul cu GIOTRIF trebuie iniţiat şi supravegheat de către un medic cu experienţă în efectuarea tratamentelor antineoplazice.", "en_prompt": "<|im_start|>user\nGlossary:\n\"physician\" -> \"medic\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Treatment with GIOTRIF should be initiated and supervised by a physician experienced in the use of anticancer therapies.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "physician|||medic", "en": "Treatment with GIOTRIF should be initiated and supervised by a physician experienced in the use of anticancer therapies.", "ro": "Tratamentul cu GIOTRIF trebuie iniţiat şi supravegheat de către un medic cu experienţă în efectuarea tratamentelor antineoplazice." } }
{ "translation": { "text": "Glossary:\n\"disease\" -> \"boală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: These could be symptoms of an inflammation of the lungs (interstitial lung disease) and can be lifethreatening.\nRomanian: Acestea pot fi simptome de inflamaţie a plămânilor (boală pulmonară interstiţială) şi pot pune viaţa în pericol.", "en_prompt": "<|im_start|>user\nGlossary:\n\"disease\" -> \"boală\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: These could be symptoms of an inflammation of the lungs (interstitial lung disease) and can be lifethreatening.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "disease|||boală", "en": "These could be symptoms of an inflammation of the lungs (interstitial lung disease) and can be lifethreatening.", "ro": "Acestea pot fi simptome de inflamaţie a plămânilor (boală pulmonară interstiţială) şi pot pune viaţa în pericol." } }
{ "translation": { "text": "Glossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.\nRomanian: Dacă sunteţi gravidă sau alăptaţi, credeţi că aţi putea fi gravidă sau intenţionaţi să ramâneţi gravidă, adresaţi-vă medicului dumneavoastră sau farmacistului pentru recomandări înainte de a lua acest medicament.", "en_prompt": "<|im_start|>user\nGlossary:\n\"medicine\" -> \"medicament\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "medicine|||medicament", "en": "If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.", "ro": "Dacă sunteţi gravidă sau alăptaţi, credeţi că aţi putea fi gravidă sau intenţionaţi să ramâneţi gravidă, adresaţi-vă medicului dumneavoastră sau farmacistului pentru recomandări înainte de a lua acest medicament." } }
{ "translation": { "text": "Glossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Following administration of an oral solution of 15 mg afatinib, 85.4% of the dose was recovered in the faeces and 4.3% in urine.\nRomanian: După administrarea orală a unei soluţii de afatinib 15 mg, 85,4% din doză a fost regăsită în materiile fecale şi 4,3% în urină.", "en_prompt": "<|im_start|>user\nGlossary:\n\"dose\" -> \"doză\"\nTranslate the source text from English to Romanian following the provided translation glossaries.\nEnglish: Following administration of an oral solution of 15 mg afatinib, 85.4% of the dose was recovered in the faeces and 4.3% in urine.\nRomanian:<|im_end|>\n<|im_start|>assistant\n", "terms": "dose|||doză", "en": "Following administration of an oral solution of 15 mg afatinib, 85.4% of the dose was recovered in the faeces and 4.3% in urine.", "ro": "După administrarea orală a unei soluţii de afatinib 15 mg, 85,4% din doză a fost regăsită în materiile fecale şi 4,3% în urină." } }
